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Abstract 
Respiratory Syncytial Virus (RSV), which is the principal etiological cause of LRTIs (Low 
Respiratory Tract Infections) worldwide, and the virus members of the enterovirus genus, 
causing a wide range of diseases, ranging from enteric or respiratory infections to hand-
foot-and-mouth disease and acute flaccid paralysis, are associated with severe treats for 
public health. Currently, there are no effective small-molecule antiviral on the market for the 
treatment or prevention of these viral infections. 
In the first part of the project about RSV, the N and F proteins were chosen as targets for 
the identification of new anti-RSV agents. On the RSV N protein, different computer-aided 
techniques were used for structure-based virtual screenings, of commercially available 
drug-like compounds. The two most potent hits were chosen as a starting point for further 
investigations. A series of analogues were synthesised and evaluated for anti-RSV activity 
in a virus-cell-based assay. Computer-aided techniques were also used for the rational 
-helix mimics, able to inhibit the protein-protein interactions between the trimeric 
inner coiled- -helixes of the F protein. The most promising compound 
and a series of analogues were synthesised and evaluated for their anti-RSV activities in a 
virus-cell-based assay. 
For the second part of the project on enterovirus, the highly conserved 2C protein among 
the enterovirus species was investigated. Starting from fluoxetine, which has been identified 
to inhibit viral replication by targeting 2C protein, and the new resolved EVA 71 2C crystal 
structure was used to investigate and to elucidate the binding mechanism of fluoxetine, 
using molecular modelling methodologies. The gained data were used to design, synthesise 
and evaluate new antiviral agents. Also, different molecular modelling techniques were used 
to perform a virtual screening in order to identify new potential inhibitors of the ATPase 
pocket of the 2C protein. 
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1.1 Viruses 
A virus is an infectious non-living entity. It is small, sophisticated, but not able to replicate 
without a host cell and evolve by natural selection. Generally, a complete virus particle 
called virion is composed of the nucleic acid which is the viral genome and the essential 
infective agent. The genome can be associated with viral proteins called nucleoproteins. 
The viral genome enclosed in the capsid which, is formed by proteins encoded in the viral 
genome. The function of the capsid is to protect the viral genome from the intercellular 
environment. Viruses can also have an envelope which, is a lipid bilayer formed by the host 
cell membrane.  
Since the first observation of an unfilterable pathogen agent infecting tobacco plants by 
Dmitri Ivanovsky in 1892 and the discovery of the Tabacco Mosaic Virus by Martinus 
Beijerinck in 1898, 5560 viral species were identified.1,2 Following the discovery in 1901 of 
the first identified human-infecting virus, yellow fever virus, the development in virus 
discovery technologies lead to the identification of 219 virus species able to infect humans, 
and the number is rising with a rate of 3-4 new species per year.3,4 This increasing number 
of the discovered human-infecting virus is reflecting the social and economic impact on 
society. Over the centuries of human history, empires and civilisations have been affected 
by infectious pathogens. Among these pathogens, viruses were the leading cause of 
epidemics and pandemics events able to change the course of history, affect the global 
economy, affecting trades, people movements across the countries and even social 
behaviours.5-7  
 
Virus classification 
The increasing number of viruses led to the need for a classification method. For this 
reason, in 1966 the International Committee on Taxonomy of Viruses (ICTV) was created 
to standardising the classification of viruses.8 The viruses are classified based on the 
Linnaean hierarchical system, initially proposed in 1962 by Lwoff, Robert W. Horne, and 
Paul Tournier.9 Currently, the taxonomic system is grouping the viruses based on their 
shared properties and the viral genome, with the following structure:1 
· One Phylum (-viricota) 
· Two Subphylum (-viricotina) 
· Six Class (-viricetes) 
· 14 Order (-virales) 
· Five Suborder (-virineae) 
· 150 Family (-viridae) 
· 79 Subfamily (-virinae) 
· 1021 Genus (-virus) 
Part I: Introduction 
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· 5560 Species 
 
Another type of classification is the Baltimore classification, introduced in 1971 by the Nobel 
prize winner David Baltimore.10 All the viruses are divided into groups based on the viral 
genome and the viral replication method. Based on the viral genome we can identify three 
significant classes of viruses: DNA viruses, RNA viruses and Retro-transcribing viruses. 
These viruses are divided into seven groups in the Baltimore classification (see Figure 1). 
 
  
Figure 1. Baltimore classification. Representation of the Baltimore classification. In 
Baltimore classification viruses are divided into three big classes on the base of their 
genome: DNA viruses, RNA viruses and retro-transcribing Viruses. Each class is further 
divided into groups, based on if the genome is a double stranded or single stranded. ds = 
double stranded. ss = single stranded. (+) = positive. (-) = negative. RT = Reverse 
Transcriptase. 
 
DNA viruses are classified into two groups. The group I is composed of the double strand 
DNA (dsDNA) viruses (e.g. Adenoviruses, Herpesviruses, Poxviruses). On the other hand, 
group II represent the viruses having a + single-stranded DNA genome (+ssDNA); for 
example, the Parvoviruses are part of this group. The RNA viruses are divided into three 
groups, called group III, group IV and group V. The group III are the double-stranded RNA 
(dsRNA) viruses, such Reoviruses. The group IV is formed by positive single-stranded RNA 
(+ssRNA) viruses (e.g. Picornaviruses, Togaviruses). Finally, the group V is formed by the 
negative single-stranded RNA (-ssRNA) viruses, the Orthomyxoviruses and Rhabdoviruses 
are members of this group.  
The last two groups, group VI and group VII, in the Baltimore classification are the groups 
composed by the retro-transcribing viruses. The group VI is composed by the positive 
single-stranded RNA viruses which, are using the reverse transcriptase to synthesise a 
DNA intermediate. This group include the retroviruses class. The last group, group VII, is 
formed by those viruses, such the Hepatitis B virus, which have a double-stranded DNA 
genome, and which are using an RNA intermediate as a template for the reverse 
transcriptase for the synthesis of viral DNA. 
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Viral life cycle 
The different species of viruses need a host cell to replicate themselves, to evolve and to 
be able to infect other hosts. The different viruses shared a typical life cycle process which, 
can be divided into three stages: viral entry, viral replication, viral shedding.11  
The first stage, the viral entry, starts when the virus attaches to the cell. This attachment is 
mediated by the interaction of specific viral protein on the virion surface and receptors on 
the host cell membrane. Once the virus is attached to the host cell membrane, the virus 
must enter the cell to be able to release the viral genome to infect the host cell. This entry 
stage could occur by membrane fusion, typical of enveloped viruses, and by endocytosis.  
All viruses need a further step to release the viral genome inside the cell, called uncoating. 
Through this process, the proteinaceous shell protecting the viral genome, capsid or core, 
is disassembled and the viral genome delivery in the host cell.12,13 
The viral genome, now inside the host cell, contains the information needed by the virus to 
produce proteins that are necessary for the assembly of the functional and infective copy of 
the virus. Viruses, like all biological system, are subjected to the Central Dogma of 
Molecular Biology proposed by Crick in 1958.14,15 The information contained in the DNA 
Nucleic acid sequence is transfer into protein, through the synthesis of RNA nucleic 
sequence. The step of RNA production from the DNA is called transcription, and the one in 
which the RNA produces proteins is called translation (see figure 2). 
 
Figure 2. Central Dogma of Molecular Biology. Schematic representation of the central 
dogma of molecular biology proposed by Crick. The information contained in the DNA 
sequence is transferred in the proteins through the RNA. 
 
In contrast to the living cells genome, viral genomes are not encoding the complex 
machinery for the translation process, the ribosomes. For this reason, all viruses need to 
synthesise mRNA that will be translated into protein by the host cell ribosomes. For 
convention, this mRNA is called +mRNA.  
The different groups of viruses in the Baltimore classification, undergo different transcription 
steps to produce +mRNA. The difference is based on the type of genome information 
carried by the infecting virus, as shown in figure 3. The viral +mRNA produced, by the viral 
genome, will be translated into viral protein components by the host cell ribosome 
machinery. The viral components can be classified as structural proteins and non-structural 
proteins. The structural proteins are those that are going to forming the viral particle. The 
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non-structural are those viral proteins which, are not going to be present inside the virion. 
The non-structural proteins are mainly proteins needed by the virus for the genome 
replication. 
 
 
Figure 3. Replication in the different Baltimore classification groups. Schematic 
representation of the different replication strategies for the different Baltimore virus groups. 
ds = double stranded. ss = single stranded. (+) = positive. (-) = negative. RT = Reverse 
Transcriptase. 
 
The general viral replication process diverges for different type of viruses. For example, 
RNA viruses replicate in the host cell cytoplasm. Instead, DNA viruses and retroviruses 
need to reach the nucleus to perform DNA synthesis. The different types of virus can use 
different host cellular organelles during the replication process, like endoplasmic reticulum 
or the Golgi apparatus.16-18 
Once the viral components are inside the host cell, and the virus has started the genome 
replication, the new copies of the virus start to be assembled for the final release of the new 
virions, the viral shedding. The viral shedding can occur via three different processes: 1) 
budding, 2) exocytosis, 3) via apoptosis. The shedding process depends on the type of 
virus. The enveloped ones are mainly released from the infected cell via the budding 
process, in which the virus is forming the viral envelope from the host cell membrane.19-20 
The non-enveloped virion is instead released from the infected cell or by exocytosis or by 
apoptosis of the infected cell.11,21 
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1.2 Antiviral therapies 
Virus-Related infections are a major global threat to human health worldwide. The 
development of successful antiviral treatment was achieved only for 10 of the 219 human-
infecting viruses. Among them, the Human immunodeficiency virus (HIV) has a devasting 
impact on public health. The virus, which was identified in 1983, infected 76 million people 
worldwide, and 35 million people died because of the virus-related acquired 
immunodeficiency syndrome (AIDS).22 In 2017, 1.8 million people contracted the virus, and 
1 million people died from AIDS-related issue.23-25 Another virus that has a huge public 
health impact is the Hepatitis C virus (HCV). The virus is the etiological cause of Hepatitis 
C, a liver-affecting disease. It is estimated that 71 million people are infected worldwide, 
and 80% of them have a higher risk to develop cirrhosis or liver cancer.26-27 Also, Respiratory 
virus, causing influenza-like illness, are infecting between 25 and 50 million people every 
year and during the epidemics of influenza viruses, three to five millions of people are 
estimated to develop a severe illness, and influenza virus-related death is 290000 to 
650000.28-30  
Ninety-six is the number of antiviral drugs approved so far since the commercialisation of 
the first antiviral drug in 1963, the Idoxuridine.31-33 These drugs have been approved and 
can be found in the 179 antiviral medications on the market.34  
 
 
Figure 4. Idoxuridine. 
 
De Clercq and Li, in 2016, reviewed the history of the approved drugs during the last 50 
years of the antiviral drug discovery field. As can be seen in Table 1, other than the 
approved drugs for the treatment of the retrovirus HIV, several other drugs have been 
approved for the treatment of six DNA viruses, Hepatitis B virus (HBV), varicella zoster virus 
(VZV), human cytomegalovirus (HCMV), herpes simplex virus (HSV), human 
papillomavirus (HPV), Variola Virus. On the other hand, among the RNA viruses, treatment 
is currently available only for hepatitis C virus (HCV), Respiratory Syncytial virus (RSV) and 
Influenza virus.35 
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Table 1. Viruses for which antiviral drugs are approved. For each Baltimore virus group 
are reported the virus families, the human viruses name, the year of discovery, the number 
of antiviral drugs and their molecular targets. 
 
 
The ninety-six approved drugs can be divided, on the base of the drug target, into eight 
classes. The first class is composed of all the approved drugs that are (i) targeting the viral 
DNA polymerase. These approved drugs can be further divided into five sub-groups based 
on the type of chemical structure, nucleoside analogues, 5-substituted 2’-deoxyuridine 
analogues, acyclic guanosine analogues, acyclic nucleoside phosphonate (ANP) 
analogues and (nonnucleoside) pyrophosphate analogues. 
The (ii) hepatitis C virus (HCV) NS5A and NS5B inhibitors compose the second class, and 
they are targeting the HCV replication. One of the approved NS5B drug, sofosbuvir, is a 
nucleoside analogue. The class of (iii) reverse transcriptase (RT) inhibitors for the treatment 
of HIV, can be divided into nucleoside RT inhibitors (NRTIs) and nonnucleoside Rt inhibitors 
(NNRTIs). The (iv) protease inhibitors (PIs) are targeting the viral protease during the virion 
assembly. (v) Integrase inhibitors are blocking the viral genome integration of HIV. The last 
three classes are the (vi) entry inhibitors blocking the viral attachment to the cell, (vii) the 
influenza virus inhibitors which are approved for the treatment of the influenza virus 
infection, and the (viii) immunostimulators, interferons, oligonucleotides, and antimitotic 
inhibitors, this class of drugs are targeting host-cell protein target crucial for the viral 
replication. 
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Figure 5. Representation of the viral life-cycle stages targeted by the approval drugs 
classes 
 
Eleven of the approved drugs are approved for the treatment of different viruses. One 
example is the Ribavirin drug, which is approved for the treatment of the RNA viruses HCV, 
RSV, and influenza virus. The drug inhibits the viral replication by targeting the RNA-
Dependent-RNA polymerase, which is a typical crucial stage in the viral life cycle for the 
RNA viruses. 
 
Figure 6. Ribavirin. 
 
Another example is the approved drugs of the acyclic nucleoside phosphonate (ANP) 
analogues class, were used off-label for the treatment of different DNA virus-related 
infections.36  
Despite the enormous efforts, which have been put in the antiviral drug development and 
the achievement that has been made in the last decades in this field, viral infections remain 
a significant threat for human health worldwide. Besides, the threats caused by emerging 
drug-resistant viruses, antiviral drugs or vaccine against emerging and re-emerging viruses 
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such Ebola virus, Zika virus, severe acute respiratory syndrome (SARS) and the Middle 
East respiratory syndrome (MERS) coronaviruses, are not available, pushing the need for 
the development of new antiviral drugs.37-39 
 
1.3 Drug discovery and development process 
The drug discovery and development process to bring new molecular entities (NMEs) 
successfully in the market, is a very long and expensive process, which was estimated to 
be above $2.5 billion cost.40,41 The process is generally considered to be 10 to 15 years 
long, but it might take longer due to the increasing complexity required for drug approval 
from the regulatory agencies, like the Food and Drug Administration (FDA) in the US or the 
European Medicines Agency (EMA) in Europe.42,43 Each therapeutic area has its 
challenges. In the case of the antiviral drug development, the long time required for the 
approval of a new drug might be a problem in the cases of life-threating infections caused 
by emerging or re-emerging viruses, due to the lack of commercially available treatments. 
Also, most of this virus is affecting developing countries, reducing the interest of 
pharmaceutical companies for investment in this therapeutic area. 
The development pipeline for bringing the NME into the market generally can be divided 
into six steps (see figure 7), drug discovery, pre-clinical studies, three phases of clinical 
trials and the pharmacovigilance.44-46 
 
 
Figure 7. Drug discovery and development process. 
 
In the case of the therapeutic area of antiviral drugs, the discovery step starts with the 
identification and the validation of a molecular target, which it can be a viral target, or a host 
cell target essential for the viral replication. Drugs that target a viral protein are related to 
high specificity and reduced side-effect. The drawbacks of targeting a viral protein are that 
drug resistant-mutants can emerge after the administration of this drugs and that the drug 
spectrum of activity is related to how much the protein is conserved among the different 
serotype inside a family.42 After the identification of a druggable target, the development of 
assays is required to start screening chemical libraries for hit molecule identification. 
Commonly these screening are performed using High throughput screening (HTS) method, 
in which thousands of compounds are tested in a short time.47 Different antiviral assays are 
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developed to confirm the activity of the hit molecules and to understand the mode of action. 
The identified hits are then optimised to obtain lead compounds, with enhanced potency 
and selectivity in vitro and proven efficacy in animal models. Before reaching the preclinical 
stage of the development pipeline, the lead compounds are further optimised to enhance 
the pharmacokinetic properties of the molecules. The candidate compounds, during the 
preclinical step, are extensively evaluated in vitro and animal models for their safety, before 
reaching the clinical trials, in which the candidates are tested on humans. The clinical trials 
are composed of three phases, in which during the phase I, the drug candidates are 
evaluated on a small group of healthy volunteers to evaluate the safety and the tolerability 
of the drug candidate. Then, the drug candidate is administered to evaluate the efficacy in 
a group of patients during phase II of the clinical trials. Finally, the drug candidate is 
administered to a larger group of patients during phase III of the clinical trials. The drug 
candidate, once it is safety and efficacy are proven and confirmed in human, it can reach 
the market, but it is continuously under observation for a side effect that was not observed 
during the clinical trials (pharmacovigilance).48 
During the last decades, several new technique and technologies were developed to assist, 
and more importantly, to reduce time and costs of the process of drug discovery and 
development. The boom of the computational power, in the last decades, gave to scientist 
the opportunity to handle a significant amount of data and to simulate complex systems, 
using tools developed by the computer science field. Nowadays, in the field of the drug 
discovery, several in silico techniques are used both in academia and in pharmaceutical 
companies, by chemist and biologist to assist them during the research process. 
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1.4 Molecular modelling 
Computational techniques have become a powerful ally of the medicinal chemistry during 
the drug discovery and development process.49 The advances in computer hardware and 
softwares in the last decades, are helping to handle and process the big amount of data 
generated during R&D in pharmaceutical field. The software and algorithms are helping to 
process the data into information and the information into knowledge. Computational 
methods are widely used worldwide to speed-up, reduce time and costs R&D processes.50  
The term “Molecular modelling“, which is today largely used in the drug design process, 
refer to all the computational techniques, such as quantum mechanics, molecular 
mechanics, energy minimisation, generation of conformations and other computational 
methods to model, simulate and generate data related to the structure and property of bio-
molecular systems.51 
The structural information of small molecules and protein are very important, this because 
the effect of molecules on specific protein targets are related to specific interactions that the 
molecules establish, through a series of chemical features with the protein, and they are 
closely dependent on the 3D structures of the molecules, called also conformations.52 Each 
molecule can assume different conformation on the base of the number of rotatable bonds 
and each conformation is associated with a specific energy. For this reason, during the 
modelling process, the prediction of the energies of a possible conformation of the 
molecules has a central role. Several computational methods were developed to address 
the calculation of these energies, and among them the quantum mechanics and the 
molecular mechanics are two widely used methods.53  
 
1.4.1 Quantum mechanics, molecular mechanics and force fields 
The quantum mechanics methods are the most precise methods for the calculation of 
molecular energies. These methods are calculating the physicochemical properties of a 
molecule at a quantum chemistry level, taking in consideration both the nuclei of the atoms 
and the electrons and for this reason, the method is extremely time-consuming, and the 
calculation can be performed on a small number of atoms. The quantum mechanics 
methods are mainly used for the calculations of molecular properties like the electrostatic 
potentials, the energy of the molecular orbitals and the calculations of partial atomic 
charges.54  
On the other hand, energy minimisation and generation of molecules conformations, are 
common tasks carried out in molecular modelling using molecular mechanics methods. In 
Molecular mechanics, the molecules are considered more straightforwardly compared to 
quantum mechanics. In fact, each atom is considered as one particle with an assigned 
radius and the bond between the different type atoms are considered as a spring, this 
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makes it possible to perform the calculations not only on small molecules but also on more 
complex systems, like proteins, in a relatively short period of time compared to the quantum 
mechanics calculations.53  
The energy related to a specific conformation of a molecule is calculated, in molecular 
mechanics, using a force field. The term force field refers to the equation and the 
parametrised value of the different atoms used to calculate the energy. In all the force fields, 
the calculated energy is the result of the contributions of bonded or covalent terms and non-
bonds on non-covalent terms. The bonded or covalent terms are the stretching of the bond 
between two atoms, the angle and the torsional rotation between atoms. The non-bonded 
or non-covalent terms are the electrostatic interaction and the van der Waals interactions. 
Some force fields are also considering other contribution terms and different 
parametrisation of the atoms and they are optimised for a different set of molecules.51 
AMBER force field is optimised for proteins and nucleic acids, while the MMFF94 is a force 
field commonly used for small molecules.55,56 The licensed Schrodinger suite software has 
its force filed, the OPLS2005 and the last version OPLS3, which are optimised for the 
medicinal chemistry research both for small molecules and proteins.57,58 
 
1.4.2 Energy minimisation and conformational search  
The energy minimisation is an important task performed during molecular modelling, 
especially when, for example, small molecules, are converted from 2D structures into 3D 
structures, with the aim of identified conformations of these molecules related with a 
minimum of potential energy. The energy minimisation became a complicated task when it 
is applied to molecules with more than one rotatable bound. The term “energy surface” of a 
molecule refers in molecular modelling to how the potential energy reacts to a change in 
the conformation of the molecule. The energy surface of a molecule has different points of 
minimum energy. In those points, any further change of the 3D structure will be related to 
an increase in the potential energy. The minimisation methods are using an algorithm to 
find a modification of the conformations related to lower potential energy compared to the 
initial confirmation. The only drawback is that the process is going “downhill”, and the 
minimum energy found, could be a local minimum and not a global minimum.51  
One of the applications of the minimisation methods is the conformational search, in which 
all the minimum-energy conformations are generated for a specific molecule. The 
conformational search is essential when the molecular modelling techniques are applied to 
the drug design process. In fact, in the modern molecular modelling software, the 
conformational search is used for the generation of databases (DB) containing the different 
conformations of a specific set of molecules, which are used in different computer-aided 
drug design techniques for the identification of biologically active compounds.59  
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1.5 Computer-Aided Drug Design 
Computer-aided drug design (CADD) comprises a series of molecular modelling 
methodologies applied to rational drug design of biologically active small molecules. 
Commonly the drug discovery and development process, begin with the identification of hit 
molecules. The HTS technique is widely used in the pharmaceutical industry for the 
identification of hit molecules, but this technique is related to high operational costs. Once 
the hit molecule is confirmed, the chemical structure hit is further derivatised in the process 
called hit-to-lead, followed by the lead optimisation process. In recent years, CADD 
methodologies are commonly used for the rational drug design, as useful tools to speed up 
and reduce costs of the hit-to-lead and lead optimisation processes.60,61 
CADD can be split into two main groups, the Structure-based CADD (SB-CADD) and the 
Ligand-based CADD (LB-CADD). In the Structure-based CADD (SB-CADD), the 3D 
information of the biological target is used as a starting point to find new or optimise active 
molecules. In Ligand-based CADD (LB-CADD), only the information related to the 
biologically active compounds on a specific target is used for the identification of new 
biologically active compounds.62 
 
1.5.1 Structure-based CADD (SB-CADD) 
The structure-based CADD are all the techniques applied to rational drug design where the 
structures, of the ligand and of target protein, are known. The structure of a protein can be 
coming from different sources.49 The Protein Data Bank (PDB) is the biggest public archive 
of macromolecules (protein, RNA and DNA) structures, and since the announcement in 
1971 the archive contains today 152500 structures.63 These structures are the result of X-
ray crystallography, NMR and cryo-electron microscopy (EM).64 Another source of protein 
structure is the homology modelling technique. The unknown 3D structure of a target protein 
is built starting from a known 3D protein structure (template), knowing only the amino acid 
sequence of the last one. To obtain a good homology model to be used in SB-CADD, the 
sequence of the template must have more than 50% of similarity with the target sequence. 
The homology model protocol consists of the following steps: 1) sequence alignment, 2) 
Model building, 3) model optimisation 4) model validation. All these steps for the generation 
of homology model are now incorporated in different softwares.65 
Another source of protein structure is molecular dynamics (MD) simulations. The MD 
simulations are used with different scopes, like binding energy analysis, molecular 
interaction analysis, but also to obtain an ensemble of conformations of the protein that can 
be used in computer-aided drug design. In fact, the MD is using the Newton’s second law 
to study the movement and the interactions of atoms over time. The integration of the 
second-order differential equations, showed in figure 8, provide a series of configurations 
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of the molecular system during the time of the simulations. These configurations represent 
the trajectories of the simulations, in which the atoms position and their velocities over time 
are stored.66 
 
Figure 8: Newton’s second law. fi, net force on the atom; mi, mass of the atom; ai(t), 
acceleration of the atom; x(t), vector describing the special position of the interacting atoms; 
V(x), force field 
 
The SB-CADD can be divided into the de novo approach and the virtual screening (VS) 
approach, and both approaches rely on molecular docking methods. In the first one, 
molecular docking methods are used to identify fragments able to interact in the binding 
site, and then the fragment are linked together to give novel ligand.67 The virtual screening 
approach, instead, is used to evaluate the interaction of a high number of compounds in the 
binding site. This method is very useful to reduce the number of compounds to be screened 
with more sophisticated docking analyses.68 Another method that can be used for virtual 
screening is the structure-based pharmacophore search. In this method, the analysis of the 
receptor-ligand interactions is used to define a set of essential 3D features of the ligand 
(pharmacophore model) for the interaction with the receptor. The resulting pharmacophore 
model will be used to search a 3D database for similar compounds, before using more 
sophisticated docking analysis methods.69,70 
As was said before, both SB-CADD approaches relay on molecular docking. Molecular 
docking is a method in which the interactions between a ligand and a binding site of a protein 
is predicted. In fact, the basic hypothesis for the docking method is that the ability of a ligand 
to affect a target protein, which has a biological effect, is related to its binding mode with 
the protein. A compound that has a similar binding mode and shares a similar interaction 
with the ligand will have similar biological effects.71 
Nowadays, several molecular docking programs are available, and these programs are 
characterised by different scoring functions, which evaluate the interaction of the ligand with 
the binding site. The different scoring functions are calculating the free binding energy as a 
result of different energy contributions, which differ between the different molecular docking 
programs.50,72  
In general, the scoring function is calculating the free binding energy (ΔGbind) of the ligand 
to the protein by the following form: 
 
ΔGbind = ΔGsolvent + ΔGconf + ΔGint + ΔGrot + ΔGt/r + ΔGvib 
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ΔGsolvent is the solvent contributions to the free binding energy. ΔGconf represents the 
contribution of the ligand and protein conformational changes. ΔGint represents the 
contribution of the noncovalent interactions, electrostatic and van der Waals forces, 
between the protein and the ligand. ΔGrot represents the free energy penalty related to the 
loss of rotational freedom of the bond. ΔGt/r represents the free energy penalty related to 
the loss of translational and rotational of freedom. ΔGvib is the free energy related to the 
vibrational modes. 
When dealing with a high number of docked compounds, different programs with different 
scoring functions can be used to evaluate the compounds, and the scoring results of each 
program can be combined together (consensus scoring), this was demonstrated to increase 
the accuracy of the scoring and ranking.73,74 
 
1.5.2 Ligand-based CADD (LB-CADD) 
The ligand-based approaches are the ones that rely only on a set of ligands active on a 
specific target, this because similar compounds can evoke similar biological effect and 
interact with the target protein. One of the most common ligand-based approaches is the 
pharmacophore methods. The core concept of the pharmacophore methods is that the 
biological activity of a ligand is related with the 3D orientation of a specific set of structural 
features, associated to pharmacophore features that include positively and negatively 
ionized areas, hydrogen bond donors, hydrogen bond acceptors and hydrophobic features. 
One ligand or a set of active ligands can be used to generate a pharmacophore model. This 
model can be further used to screen a DB, containing a large number of compounds, to find 
new molecules presenting the same set of features of the model (pharmacophore search).75 
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1.6 Project aims 
In this drug discovery project, several techniques were applied to different viral targets to 
identify small molecules as potential anti-RSV and anti-enterovirus agents. 
Among the RSV viral protein, the N protein and the F protein have been chosen as targets 
for the identification of new viral replication inhibitors.  
The N protein, which is part of the ribonucleocapsid complex (RNP), plays a key role in virus 
replication, acting as a template for transcription and replication, performed by the RdRp 
(RNA-dependent RNA polymerase). Interactions between the RNP and P protein, which is 
part of the RdRp, have been reported to be fundamental for viral RNA synthesis.  
The F protein is the viral protein responsible the fusion of the viral and cell membranes. 
During this project, on both the RSV protein targets, the following activities were performed: 
· molecular modelling techniques for the identification of new potential inhibitors; 
· synthesis of several compounds for Structure-Activity Relationships (SARs) 
exploration of the most promising hits; 
· Biological evaluation of the synthesised compounds. 
For the enterovirus part of the project, the non-structural 2C protein was chosen as a target 
for the identification of small molecules as anti-enterovirus agents. The 2C protein is highly 
conserved 2C protein among the enterovirus species and play a crucial role during the viral 
replication. In this part of the project the following activities were performed: 
· molecular modelling techniques used to elucidate the binding mechanism of 
fluoxetine to the non-structural 2C protein; 
· SAR exploration of fluoxetine, through the synthesis of a series of fluoxetine 
fragments and fluoxetine analogues; 
· design and synthesis of novel anti-enterovirus agents; 
· biological evaluation of the synthesised compounds; 
· molecular modelling techniques for the identification of new potential inhibitors of 
the ATPase pocket. 
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2.1 Respiratory Syncytial Virus (RSV) 
RSV (Respiratory syncytial virus) represents a worldwide health problem. It is the principal 
etiological cause of LRTIs (Low Respiratory Tract Infections) such as Pneumonia and 
Bronchiolitis. 
RSV is estimated to cause 33 million of LRTIs in children under 5 years of age in 2005, of 
which 3.4 million were hospitalized (in the first two years of life).1-2 The estimated mortality 
related to RSV was 66.000-199.000 in 2005, of which 99% in developing countries.3 
Furthermore, RSV LTRIs are a risk factor in HIV infected patients, immune compromised 
patients and in elderly people. 
 
 
 
Figure 1. Burden of disease. Representation of information related with RSV low 
respiratory tract infections (LRTIs), RSV mortality and risk factors.  
 
From a study of hospitalization cost related to bronchiolitis infection in children, the cost in 
2002 was estimated to be more than $500 million per year.4 (Fig.1) The high cost of the 
hospitalization and the lack of an effective cure against the virus make RSV an interesting 
target for drug discovery. The only approved drug is inhaled Ribavirin, but its use is no 
longer recommended by the 2014 AAP guidelines for RSV infection due to the 
ineffectiveness of the treatment.5 Another treatment available on the market is a humanized 
monoclonal antibody, Palivizumab, but due to its high cost it is used only prophylactically in 
high risk hospitalized children.6 
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Figure 2. Available Drugs against RSV. representation of RSV drugs available on the 
market and drugs which are currently in clinical trial (phase I-III) 
 
At the moment 8 antiviral drug candidates (Fig 2) and 4 immunoglobulins are in clinical 
trials.2,7-8 
The current protocol in case of severe bronchiolitis is to administer oxygen and intravenous 
fluids, due to the fact that in 90% of cases the disease is estimated to resolve after 21 days 
from the first symptoms.5,9 
As reported above, RSV is the most common etiological agent for LRTIs, such Bronchiolitis 
and Pneumonia (Bronchiolitis is the infection of the bronchioles, Pneumonia is the infection 
of the lung). 
RSV infections in the North-Hemisphere occurred during the winter and the transmission is 
through person to person contact. The incubation period is 2-8 days and the shedding is 
approximately 8 days, but it may be 3 weeks in immunocompetent individuals or few months 
in immunocompromised patient.  
RSV infection starts in the nasopharyngeal epithelium and then rapidly spreads to terminal 
bronchioles thanks to intercellular transmission. A LRTI can lead to formation of edema in 
the lungs, increased mucus production and epithelial cells necrosis. Necrosis of epithelial 
cells is followed by regeneration of the tissue that causes swelling and consequently 
obstruction of the small airways. The symptom of this obstruction is wheezing (a rapid and 
noisy breath).10 
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In 2010 a cohort study, a correlation between severe RSV infections in first years of life and 
development of long term respiratory diseases (i.e. allergic asthma and airways 
remodelling) in adulthood was suggested.11 This remodelling was observed to be related 
not to the virus but to a strong immune response, that could be destructive for infected and 
neighbour tissues.12 
RSV belongs to the Paramyxoviridae family, Mononegavirales order.13 RSV was classified 
as part of the Pneumovirinae subfamily.14 RSV is similar to the other viruses of the 
Paramyxovirinae subfamily, but its genome does not express any HN proteins 
(Hemagglutinin-Neuraminidase), and the mRNA of accessory proteins is transcripted by 
ORFs (Open Reading Frames) and is present at 3’ terminus, differently from 
Paramyxoviridae.15 (Fig. 3) 
 
 
 
Figure 3. RSV taxonomy tree. Visual representation of the Pneumovirinae subfamily, 
inside the Mononegavirales order 
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2.1.1 RSV Virion 
RSV is an enveloped (-) ssRNA virus and takes its name from the fact that it causes the 
formation of syncytia between infected cell membranes. The virus exists in a single serotype 
with 2 subgroups, strain A and strain B, which differ in the hypervariable G protein, while 
the F protein is antigenically similar. Strain A seems to be related to a more severe RSV 
disease.16 
 
 
 
Figure 4. RSV Virion. protein composition of the virion. inside the virion the proteins can 
be divided into different types: envelope spikes (F, G, SH) proteins, inner envelope face (M, 
M2) proteins, ribonucleocapsid proteins (N, P, L, M2) proteins. The N and P proteins are 
essential for the encapsidation of the viral RNA and together with the L and the M2 proteins 
are taking part in the RNA replication and transcription process. 
 
Only 8 of the 11 proteins encoded by the genome are present in the virion. (Fig. 4) There 
are 3 membrane proteins, which are considered as envelope spikes: F (fusion), G (major 
surface glycoprotein) and SH (small hydrophobic protein). Under the phospholipidic bilayer 
there are the M proteins (matrix), which form the inner envelope face. The M protein seems 
to bind the RNP complex (Ribonucleoprotein complex).17 RNP is a complex of (-) ssRNA 
and N proteins, that are important for the encapsidation of the viral genome; this complex 
forms flexible left-handed helix.18 RdRp (RNA-dependent-RNA polymerase) is composed 
by the L (Large polymerase) protein, and two important co-factors, the P protein 
(phosphoprotein) and the M2-1 protein: they form the machine necessary for the 
transcription and replication of the viral RNA. These 8 proteins are necessary for starting 
the infection.  
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Two of the remaining proteins are non-structural proteins (NS1 and NS2), important to 
counteract the IFN innate immune response. The final protein is M2-2, which is synthetized 
from the viral mRNA of the second ORF of M2 gene, and is a co-factor leads the switch 
from transcription to replication in the RSV viral life-cycle. With 11 proteins the RSV is the 
more complex virus among the Paramyxoviridae. 
From tomography analysis was observed that virion morphology ranges from filamentous 
to spherical, with intermediate form and the dimension are 200 nm to 2 µm length for 
filamentous virion. The width was also variable and was observed to be between 70 nm to 
190 nm, with an average of 120 nm.18 (Fig. 5) 
 
 
 
 
 
 
 
a) b) 
 
Figure 5. Virion morphology. a) filamentous shape; b) spherical shape. The 
pleomorphicity of the virion was linked to the amount of M proteins on the inner layer. 
Filamentous virions have up to 85% of the inner membrane surface covered by M proteins 
and the spherical virion, the M proteins inner layer is covering only the 24% of the surface. 
 
This pleomorphicity of virion was linked to the amount of M proteins in the inner layer. For 
spherical virion, the M proteins inner layer is covering only the 24% of the surface. Whilst 
the filamentous virions have up to 85% of the inner membrane surface covered by M 
proteins.17 
The reason for this pleomorphicity, is still unknown for RSV. Some studies suggest that this 
kind of difference in the virion morphology is a strategy of the virus to bluff the immune 
system, like Archetti bodies produced during influenza A infection.19 Another hypothesis, is 
that the host cells can affect the budding process, which lead to difference in morphology 
in harvested virion, like was observed at the beginning and late in Sendai virus infection.20 
Underneath the layer of M proteins there is a second layer composed of M2-1 proteins. The 
RNP complex runs parallel to the membrane in each virion morphology type and interacts 
with the M protein layer and M2-1 proteins.17 M2-1 proteins seem to interact, other than with 
the RNP complex, with P (Phosphoprotein) protein, and with the N-TD (N Terminal Domain) 
of the M (Matrix protein). 
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2.1.2 RSV genome organisation 
The RSV genome is 15.2 kb, single stranded, non-segmented, negative sense RNA and 
contains 10 genes that encode for 11 viral proteins, in order 3’-NS1-NS2-N-P-M-SH-G-F-
M2-L-5’. Each virion may contain from 1 to 9 copies of the viral genome, with an average of 
1.8 copies per virion.  
In comparison with other viruses of the Paramyxovirinae subfamily, RSV shows a more 
complex genome, as shown in Figure 6 with two non-structural genes in the 3’ terminus of 
the genome and a gene that encodes for SH (Small Hydrophobic) protein. 
 
 
 
Figure 6. Genome comparison between RSV and other Paramyxovirinae. visual 
comparison between the RSV, Measles virus, Sendai virus and Mumps virus genomes, 
RSV has a more complex viral genome compared to other Paramyxoviruses. 
 
The RSV genome is transcribed in 10 different viral mRNAs, each encoding for a single 
protein. The only exception is the viral RNA of the M2 gene, which contains two ORFs 
(Open Reading Frames), the first one that is the upstream ORF encodes for the M2-1, 
meanwhile the other downstream encodes for M2-2 protein. The M2-1 is already present 
inside the virion, while the M2-2 is synthetized later in the infection. 
 
 
Figure 7. RSV genome. more detailed refiguration of the RSV genome and the relative 
protein primary sequence mRNA length. aa = amino acids, nt = nucleotides. 
 
A peculiarity of the RSV genome is that there is only one promotor for the transcription and 
it is localized at 3’ terminus which lies in the leader (Le) extragenic region and it is composed 
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of 44 nt. Another extragenic region is present at the 5’ terminus; it is called trailer (Tr) and 
is formed by 155 nt.21 (Fig. 7) 
Each gene contains a conserved gene-start (GS), a gene-end (GE) and an intergenic 
sequence (IS), which directs the polymerase during transcription process.22-23 (Fig. 8) 
 
 
 
Figure 8. Gene structure. simplified refiguration of the viral RSV gene structure. Gene 
contains a gene-start (GS) sequence, a gene-end (GE) sequence and an intergenic 
sequence (IS). These sequences direct the polymerase during transcription process. 
 
The viral polymerase has the tendency to dissociate at gene junctions, and for the reason 
that is present only promotor at 3’ terminus, there is a gradient expression.24-25 For these 
reason the viral genome during evolution has put the protein required in large amount more 
at the beginning of the genome like for NS1 and NS2, these are important counter agent 
against innate immune defence of host cells.26 
  
Part II: RSV 
34 
2.1.3 RSV Life Cycle 
RSV virus life cycle (Fig 9) occurs in the cytoplasm and can be summarized in three big 
steps:  
1) Attachment and entry; 
2) Transcription, translation and replication; 
3) Assembly and budding. 
 
 
Figure 9. RSV Life cycle. The RSV life cycle can be divided into three steps: 1) Attachment 
and entry, 2) Transcription, translation and replication, 3) Assembly and budding. During 
the first step, the F, G and SH proteins are responsible for the virion attachment to the host 
cell and the fusion between the membranes. The fusion between the viral and the host cell 
membranes, assure the release pf the ribonucleocomplex inside the host cell cytoplasm. 
During the second step of the viral replication life cycle, the RNA-dependent RNA 
polymerase (L protein) together with the P protein and the M2-1 and M2-2 co-factor, is 
responsible for the transcription, translation and replication of the viral elements necessary 
for the release of new viral copies. Once the viral elements and the newly synthetised viral 
genome are accumulated in the host cell, the new virion are assembled and released by 
budding process. 
 
Attachment and entry 
In each step of the viral life cycle, different proteins are covering different roles. For the 
attachment and entry stage, the main role is played by the envelope spikes, G, F and SH 
proteins. RSV infects specifically only ciliated epithelial cells of airways. These cells are 
polarized and have two different types of cell surface; the first one is called apical; it is 
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ciliated and exposed to the lumen. The second one is called basolateral and it is exposed 
to the basement membrane, which is in contact with underlying tissue. RSV entry and 
budding happen exclusively from the apical surface of epithelial cells.12 
This specificity of the RSV infection is related to the viral membrane glycoproteins and their 
ability to bind to glycosaminoglycans (GAGs). This binding was reported to be the first step 
of the viral infection and was reported that RSV bind especially with HS (heparan sulfate) 
and CS-B (chondroitin dermatan sulfate). These two types of GAGs were found on the lung 
cells. GAGs are unbranched polymers of disaccharide units of glucuronic acid or iduronic 
acid, linked to glucosamine or galactosamine. GAGs can be modified, such as by sulfation. 
GAGs can be linked to core proteins via an O-glycosidic bond. HS consists of glucuronic 
acid or iduronic acid linked to N-acetylglucosamine, instead CS-B contains iduronic acid 
linked to N-acetylgalactosamine modified by sulfation on C4. The specificity in the binding 
of RSV to cell surface GAGs seems to be based on GAG structural configuration instead of 
a simple charge interaction of the virus and sulfate groups.27-28 
There is a change in the percentage, during life, from CS-B to CS-C in the lungs.29 This 
change can be related with the fact that most severe RSV LRTIs affect infants.  
At the beginning, the G protein was believed to be the principal protein involved in RSV 
attachment to the cell membrane30, but experiment on RSV mutant lacking of G, SH or both, 
showed that the virus is still able to infect cells.30-31 This demonstrates that the F protein, 
which is responsible for membrane fusion, is able to bind receptors on the cell surface. 
The G protein, unique among the paramyxovirus, is a heavily glycosylated type II 
transmembrane protein, which seems to bind carbohydrate receptors on cell surfaces.  
The F protein is responsible for the fusion between the virion and the host cell membranes. 
It is highly conserved in the Paramyxoviridae family.32 The F protein is necessary for RSV 
to enter the cell. The F protein is a homotrimer expressed on the virion envelope. It is 
expressed as a metastable conformation, which is called pre-fusion conformation. After 
binding of the virion on the cell surface, the F protein undergoes a series of conformational 
changes that end with the final stable conformation, called post-fusion.33-36 
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Figure 10. Fusion process. schematic representation of the fusion process performed by 
the F protein. HRA region is represented in blue is anchored to the viral membrane. HRB 
region is represented in red and it is responsible for the attachment to the cell membrane.  
 
The F protein is characterized by three regions. HRA (heptad repeat A) at the N-TD, HRB 
(heptad repeat B) at the C-TD, and head of the protein in between HRA and HRB. 
As shown in Figure 10, the F protein is anchored to the virion membrane through a 
transmembrane domain at the N-TD in proximity to HRA. The HRA (blue) is a region formed 
by three α-helices of the three F protein monomers. In the pre-fusion conformation, the three 
α-helices that form HRB are attached to the head of the F protein (I). After the attachment 
to the HRB region is subjected to a process of refolding, which leads to the formation of a 
“long trimeric coiled coil” that is able to anchor to the cell membrane (red). This conformation 
of the F protein is called “pre-hairpin intermediate” (II). This intermediate is highly unstable, 
and its collapsing is responsible for the membrane’s fusion (III). The final conformation, 
called post-fusion, is related with the formation of the pore between the viral and cell 
membranes, is possibly due to the formation of a structure called 6-HB (six helix bundle) 
also known as hairpin structure (IV). This structure is made by an inner core of HRA 
surrounded by the three α-helices of HRB. The process of fusion seems to be the results of 
a cooperation of more than one F proteins.37 
The last protein that plays an unclear role in the attachment and entry process is the SH 
protein. Once the fusion of the virion is completed and its content is inside the host cell, the 
second stage of RSV life cycle can start. 
 
Transcription, translation and replication 
With the transcription, translation and replication stage the virus produces all the elements 
for the production of new complete virions. Genome encapsidates in the RNP complex (viral 
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RNA and N proteins) as a flexible left-handed helix is the template for the viral RNA-
dependent-RNA polymerase (RdRp) which is composed by L, P, M2-1 proteins. 
RSV genome has some peculiarities in comparison with other viruses of the 
Paramyxovirinae subfamily: 
· It has 10 genes that encode for 11 proteins, subject to a Gradient expression;  
· It has a Le (Leader) extragenic region of 44 nt at the 3’ terminus and a Tr (Trailer) 
extragenic region of 155 nt at the 5’ terminus;21,38 
· Each gene presents a conserved gene-start (GS), gene-end (GE) and an intergenic 
sequence between genes;39-40 
· It has only one promotor for transcription, which is contained in the Le sequence. 
 
 
 
Figure 11. RSV genome transcription and replication. schematic representation of the 
viral genome transcription and replication performed by the RNA-dependent RNA 
polymerase. The antigenome is essential for the viral genome replication. The viral genome 
directly transcripted into mRNAs which are translated into viral proteins. 
 
The viral genome is subject to two different processes by the RdRp: transcription and 
replication (Fig. 11).  
The transcription is the process that the virus uses to produce viral mRNAs. These mRNAs 
are naked, capped and polyadenylated by the viral polymerase and they are translated by 
the host cell machinery. 
The replication process can be split into two sub-process, the synthesis of an antigenome 
as template and the replication of the viral genome. Both antigenome and genome are not 
naked. Viral mRNAs are produced from the promoter on the Le region at 3’, with a start and 
stop synthesis by the polymerase, which is moving along the genes from the 3’ to the 5’ 
terminus. The genome is used by the RdRp as a template for both transcription and 
replication.  
The polymerase has to bind to the RNP, at the promotor region to be functional. Two 
possible modes have been postulated. In the first one, the 3’ terminus and the Nucleocapsid 
bind to the promotor and generate a structure specific for the polymerase assembly. In the 
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second mode of action, the polymerase binds to the Nucleocapsid and is able to displace 
two N proteins from the 3’ terminus and interact directly with the promoter.22 
First of all, the virus needs to synthetize all the proteins of the genome. The viral polymerase 
starts to produce viral sub-genomic RNA starting from the promotor leader region. As was 
said before the RSV genome present a gradient expression which produce a difference in 
amount of viral mRNAs produced.  
The process of transcription consists in the production of ten mono-cistronic viral mRNAs, 
which are capped, methylated at the 5’ terminus and polyadenylated at the 3’ terminus. 
These mRNAs are then translated from the host cell translation system. 
The translation begins from the promotor and then continues through the RNA. Once the 
polymerase reaches the GE sequence, the newly synthetized mRNA is polyadenylated and 
released from the polymerase. At this point the polymerase reinitiates the translation of the 
next gene from the next GS sequence.  
To start RSV translation, the viral genome needs three elements: 
· A region at the 3’ terminus of Le for the recruitment of the polymerase; 
· A U rich sequence at the end of the Le; 
· The first GS sequence. 
The GS (CCCCGUUUAU) sequence is highly conserved in all RSV genes, except for the 
GS of L gene.39-40 The putative function of the GS sequence is to keep the polymerase 
bonded for enough time to allow the nucleotide to reach the binding site of the polymerase.22 
The GE sequence is a conserved sequence which is followed by a U rich tract, this last one 
being responsible for the polyadenylation of the nascent mRNA and seems to be related to 
the process of releasing of the mRNAs from the polymerase.41 After mRNA releasing, the 
active site of polymerase is empty and is able to reinitiate the RNA synthesis from the next 
GS sequence. 
The cycle of gene translation is repeated along the entire genome. Each de novo 
synthetized mRNA is translated by the host cell apparatus, which leads to the accumulation 
of the viral proteins in the host cell. 
Once the viral mRNAs are produced, they are translated by the host cell ribosomes in the 
Endoplasmic reticulum. The envelope proteins (G, F and SH), are processed during a 
passage in the Golgi complex, which allows proteins to be located on the cell membrane. 
During the infection, there is an increased production of the M2-2 protein. This protein is the 
co-factor that promotes anti-genome and genome production and inhibit viral mRNA 
synthesis. 
Since RSV genome is negative sense, for its replication the virus needs an anti-genome as 
template for the genome replication for the new viral progeny.  
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RSV needs to synthetize a positive-sense genome, called antigenome, to replicate its 
negative-sense genome. The polymerase is recruited at the promoter in the 3’ terminus Le 
region. Once bonded to the genome, it starts the synthesis along the template, producing a 
complete positive-sense RNA complement to the RSV genome. 
The antigenome has at the 3’ terminus the complementary sequence of the Tr, which is 
155nt. This sequence contains the promoter for the synthesis of new complete viral 
genomes and has a higher level of replication than the Le region, producing more replicated 
genomes than antigenomes.22,42 The antigenome is used as template for the synthesis of 
new copies of the viral genome. 
The antigenome and the new copies of the genome are immediately encapsidates. The N 
protein is able to bind unspecifically to the viral RNA, and protein-protein interactions (PPIs) 
between N proteins are sufficient for the RNP assembly.43-44 
 
Assembly and budding 
After the virus enters the host cell, replicates its genome and produces all the proteins for 
the new progeny, new virions are created by budding from the plasma membrane. 
During the infection, the formation of Inclusion Bodies (IBs) in the cytoplasm has been 
observed: these bodies are made by accumulation of viral polymerase and other viral 
proteins, such as N protein, M protein and non-structural proteins (NS1 and NS2).45-47 These 
IBs are associated with lipid-raft structures, which are micro-domains in the plasma 
membrane with high amount of cholesterol and sphingolipids. These lipid rafts seem to be 
important in the RSV life cycle. All the life cycle seems to turn around this host membrane 
domain.48 
RSV virions bind and bud from the apical membrane of polarized epithelial cells of airways 
tissues; for this reason, RSV infection remain localised in the low respiratory tract. From 
mutant RSV virions lacking the F and G membrane glycoproteins, the only protein 
responsible for the specific budding on the apical surface has been identified as the matrix 
protein (M).49-50 The M protein later in the infection, interact with the cytoplasmic domain of 
F and G, but this interaction in not responsible for the M protein specificity for the apical 
membrane. The M protein is believed to bind a specific zone in the plasma membrane which 
is called lipid rift. This is a microdomain in the lipid bilayer enriched of cholesterol and 
sphingolipid and seems to be important for the accumulation of viral proteins necessary for 
viral budding.51-54 
This leads to the formation of a layer of M proteins that are the anchor point for the 
encapsidated viral genome (RNP). On the RNP is present L, which is attached to L through 
the P and M2-1 protein. Once the assembly process is finished and all the required proteins 
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are located near the membrane, the new virus can bud from the cell surface. This process 
seems to be carried out by the M protein inner layer.55 
After the assembly of the viral proteins on the inner space of the plasma membrane, the 
budding is probably triggered by a rearrangement of the M proteins inner layer, such as for 
the budding of Ebola virus.56 
 
2.2 Viral proteins 
Envelope spikes 
G protein 
The G protein is a unique binding protein, different from Hemagglutinins and Hemagglutinin-
Neuraminidase among other Paramyxoviruses. 
The G protein is a 298 aa long type II glycoprotein with a transmembrane sequence at the 
N-TD (N terminal domain). The G protein ectodomain is post-translationally glycosylated, 
for the majority with O-oligosaccharide and a small amount of N- oligosaccharide.57 
In addition, a soluble form of the G protein (GS) is released form infected cells: this seems 
to be the product of a second highly conserved AUG codon on the G ORF, with the 
transmembrane domain proteolytically removed.58 The function of this soluble form of the 
G protein is to inhibit the inflammatory cytokines process at the first stage of the infection 
and as “antigen decoy” to help the virus escaping the immune system.59-60 
 
SH protein 
The SH protein is a 65 aa long protein, which forms a transmembrane homopentamer. This 
protein has a channel function that enables ions and small compounds to pass through the 
membranes. The SH protein has been found on the plasma membrane and in the Golgi 
complex.61-62 These evidences allows the SH protein to be classified as a viroporin. The SH 
function is unknown but it is believed to cause the alteration of ionic homeostasis and 
depolarization of the host cell membranes.63 
 
F protein 
The RSV F protein is a type I glycoprotein and is produced as a 574 aa precursor (F0), 
which is cleaved twice by furin in the process of transportation on the plasma membrane. 
After the cleavage two proteins are generated, F2 and F1, connected by two disulfide 
bonds. This cleavage is important to allow the F protein to fuse with the cell membrane. The 
active F protein, ready for fusion, is a homotrimer of the processed F0.37 
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Ribonucleocapsid 
N protein 
The entire viral genome is coated by N proteins called Ribonucleoprotein (RNP), and it 
remains coated during transcription and replication, meaning that the RNP is the template 
for the RdRp. The RNP forms a left handed helix, which is extremely flexible; this flexibility 
might allow the RNP to be read from the large RdRp, without necessary removing the N 
protein from the viral genome.43 This strategy avoids the formation of secondary RNA 
structures and the possibility to form dsRNA, which could trigger the innate immune 
response. 
 
RNA-dependent-RNA polymerase 
L protein 
The polymerase machine is made by the L protein. In the infected cell, the virus needs to 
interact with other viral and host proteins, for an efficient and complete RNA synthesis 
activity.64-65 
The L protein is a 2165 aa long multifunctional protein, with different enzymatic domains. 
This protein is able to identify the promotor sequence, perform RNA synthesis, perform 
capping and methylation of the 5’ terminus of mRNAs and polyadenylate them at 3’ 
terminus. Six conserved regions (I-IV) are postulated to perform the enzymatic activities of 
the L protein. Some of these regions are connected to specific activities. Regions II and III 
are believed to form the polymerization domain.66-67 
The region V is supposed to be responsible for the guanylyl transferase activity and region 
IV is believed to have methyltransferase activity.68-69 
 
P protein 
The P protein, is a 241 aa long protein, which forms homotetramers in solution and is 
classified as an intrinsically disordered protein (IDP).70 This protein is essential for the 
correct function of the RdRp activities, and it is responsible for the ability of the polymerase 
to bind to RNP and move along the encapsidates genome.71-76 The P tetramer has a central 
core of four-helix bundle tetramerization (119−160 aa), a C-TD (161−241 aa) and a N-TD 
(1-103 aa). These last two are intrinsically disordered regions and are responsible for the 
binding to other viral proteins.77 
 
M2-1 protein 
M2-1 is a 194 aa long, basic protein that forms homotetramers in solution.78 M2-1 is 
considered a transcriptase processivity factor that is able to inhibit the termination on 
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intragenic sequence, helping the polymerase to read the GE and reducing the transcription 
gradient.79-81 
Studies on intracellular levels of M2-1 showed that M2-1 is not involved in the switch of the 
polymerase from the translation process to the replication process.82-83 The M2-1 interacts 
with the P protein and binds specifically to RNA sequences at the Le region, proving that it 
is loaded on the RNA during the initiation of the transcription process.84-85 
 
M2-2 protein 
The M2-2 protein is a 90 aa long protein, which is translated from the second ORF of the 
M2 gene. This is the co-factor responsible for the switch of the polymerase activity. It has a 
potent inhibition effect on the RSV RNA translation, possibly explaining the fact that this 
protein is not present in the virion and is not present in the first stage of the infection.86-88 
 
M protein 
The RSV M protein is 250 aa long, and forms homodimers in solution89, which represent 
the active functional proteins for the assembly and the budding process.56 The M protein is 
expressed in high amount in the infected cell and it is able to act as linker between the other 
proteins necessary for new virions. The Paramyxovirus Matrix protein has also been 
observed in the nucleus of the infected cells early in the infection, while later the protein is 
detectable in the cytoplasm.90-91 The transient localization of the Matrix protein in the 
nucleus is believed to be related with the inhibition of nuclear processes or with the 
prevention of budding of uncomplete virions in early stages of the infection.92 Late during 
the infection a high amount of M protein is required for assembly and budding 
processes.55,93 
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2.3 Project aims 
Two main targets among RSV proteins have been chosen to identify new inhibitors of the 
viral replication: 
· N protein; 
· F protein; 
The N protein, which is part of the ribonucleocapsid complex (RNP), plays a key role in virus 
replication, acting as a template for transcription and replication, performed by the RdRp 
(RNA-dependent RNA polymerase). Interactions between the RNP and P protein, which is 
part of the RdRp, have been reported to be fundamental for viral RNA synthesis. 
For the N protein, the aim is to design a novel series of anti-RSV compounds using different 
in silico approaches. The attention has been focused on a druggable pocket in the N protein 
involved in PPIs (protein-protein interaction) with the C-TND of the P protein.94, several 
computer-aided drug design methodologies will be applied to identify and synthesise small 
molecule as potential anti-RSV agents.  
Below, the activities performed during the project on the RSV N protein: 
· starting from five available X-ray structures of this protein with the respective ligands 
molecular modelling techniques were used for the identification of new potential 
inhibitors; 
· Several compounds were identified as potential viral inhibitors through the molecular 
modelling techniques  
· Among the identified compounds, four hits were confirmed in antiviral assays; 
· several analogues of the two most potent hits were synthesised for Structure-Activity 
Relationships (SARs) exploration; 
· The synthesised analogues were biologically evaluated. 
 
In the case of the F protein, which is the viral protein responsible the fusion of the viral and 
cell membranes, the objective was to design α-helix mimics of the HRB. The α-helix mimics 
compounds are designed to inhibit the assembly of the 6-HB (6-helix-bundle), an important 
step in the fusion mechanism of the virus for the infection of the cell. 
Below, the activities performed during the project on the RSV F protein: 
· starting from five available X-ray structure of the F protein in the post-fusion 
conformation, different cheminformatics tools and molecular modelling techniques 
were used to design, evaluate and select an α-helix mimic; 
· The selected α-helix mimic was synthetised and the optimised synthetic route was 
used to synthesise a restricted number of analogues. 
· All the synthesised compounds and the key intermediates were biologically 
evaluated. 
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Chapter 3: N protein 
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3.1 N protein 
RSV N protein is responsible for the encapsidation of the viral genome: it acts as RNP 
complex, which forms a left-handed helix, which is the template for RNA transcription and 
replication (Fig. 12). Both these steps need the polymerase to bind to the RNP; this 
interaction is mediated by the action of the Phosphoprotein (P), binds to N proteins of RNP 
by the CTD of the P protein. On the other hand, each N protein is organized in four subunits, 
two NTDs (31 to 252 aa) and CTDs (253 to 360 aa) globular domains and two NTD (31 to 
252 aa) and CTD (362 to 391 aa) extensions. The N-P interaction is critical for the viral 
transcription and replication. 
 
Figure 12. RNP resolved structure. ribbon representation of the ribonucleoprotein (RNP) 
complex. The N-NTDs are represented as blue ribbons and the N-CTDs are represented 
as red ribbons. The viral RNA is represented as a yellow ribbon.  (Pdb: 4BKK) 
 
In 2012 a pocket was discovered on the N-NTD that is responsible for the interaction with 
the P-CTD. This pocket is a hydrophobic site surrounded by positively charged residues. 
From mutagenic analyses, 10 residues were identified as important in the N-P PPI (protein-
protein interaction): K46, M50, E128, S131, R132, Y135, K136, R150, H151 and D152. 
Furthermore, four critical residues of P-CTD were identified as important for the N-P PPI: 
L238, E239, D240 and F241.95 
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Figure 13. Binding pocket on N-NTD. On the left side, ribbon representation of the N-NTD 
in complex with the N-P interaction inhibitor M76, with 1-benzyl-1H- pyrazole-3,5-
dicarboxylate (BPdC) scaffold (Pdb: 4UCC). On the right side of the figure, a more detailed 
view of the binding pocket  
 
This information has been confirmed by the resolution of the X-ray crystal structure of N-
NTD:P-CTD interaction (Pdb: 4UC8 and 4UC9); only the dipeptide D240-F241 of P-CTD is 
responsible for the binding with the N-NTD. In particular, residue F241 has a key role in the 
interaction.94 Five compounds with a common 1-benzyl-1H- pyrazole-3,5-dicarboxylate 
(BPdC) scaffold were found active to inhibit the N-P interaction and to inhibit the RSV viral 
infection in a cell-based assay (Fig. 13). For three of them a crystal structure in complex 
with the protein has been resolved (Pdb: 4UCC, 4UCD and 4UCE). All this information was 
used as a starting point for computer-aided techniques aiming the identification of potential 
new inhibitors of the N-P interaction. 
 
3.1.1 Structure-based virtual screening 
Starting from the crystal structure of N-NTD with the most active compound of the BPdC 
series (Pdb: 4UCC), a structure-based virtual screening was performed. 
Docking of the co-crystallised ligand was performed using Glide SP.96-98 The docked ligand 
shows the same orientation inside the pocket found in the crystal, with a RMSD (Root-
mean-square deviation) of 0.769 Å. This result validates this program for performing a 
virtual screening. 
For the virtual screening (VS), the SPECS library of 342047 commercially available 
compounds was used.99 The VS algorithm (Schrodinger Maestro) generated 906454 poses, 
from which the top scored 20% of them (181290 poses) were docked using Glide SP. 
515038 poses were obtained, which were then rescored using Glide XP, Plants and FlexX.  
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After combining the results of the rescoring (consensus scoring, see Experimental), the 
poses with the highest ranking were selected and 4481 compounds were then clustered 
using MACCS Fingerprints and Tanimoto similarity matrix in MOE. In this way, the more 
dissimilar compound structures were selected, obtaining 2705 compounds, which were 
analysed through a visual inspection of their predicted binding mode. 24 compounds were 
finally selected based on their ability to bind deeply inside the hydrophobic pocket and on 
the basis of the number of interactions (Fig. 14). The selected compounds were bought 
from the SPECS company and sent for testing in cell-based assays. The compounds 
structures are showed in Table 1 in the appendix. 
 
 
 
Figure 14. vHTS workflow and docked pose of a selected compound. Different 
molecular modelling techniques were employed during the virtual high throughput screening 
(vHTS) for the identification of new potential N-P interaction inhibitors (left side); On the 
right side of the figure, the docking pose of one of the selected compounds and its 
interaction with the binding pocket. (FP clustering = Fingerprint clustering; V.I: = visual 
inspection) 
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3.1.2 Pharmacophore search
A hybrid structure-ligand-based approach was used as well to study the N protein. The 
information contained in the five available crystal structures was used for the generation of 
a pharmacophore model (PDB IDs: 4UC8, 4UC9, 4UCC, 4UCD, 4UCE). This model was 
generated using the PLIFs (Protein-Ligand interaction Fingerprints) tool in MOE.100 This is 
a method for summarising the interactions between ligands and proteins using a fingerprint 
scheme, which is representative of a given database of protein-ligand complexes. From the 
fingerprints it is possible to generate a pharmacophore model combining all the structural 
information in the dataset. 
 
 
Figure 15. Pharmacophoric filter generated with PLIFs. graphical representation of the 
pharmacophoric model built using the Protein Ligand interaction fingerprints (PLIFs) 
technique. The cyan spheres represent H-bond acceptor, heavy atom and anionic heavy 
atom features and in green a hydrophobic feature. 
 
A pharmacophoric model containing three features was generated (Fig. 15). F1 and F3 
(annotated as Anion, H-bond Acceptor and Metal Ligator), are H-bond acceptor (cyan), 
heavy atom and anionic heavy atom features. The last one, F2 (annotated as Hydrophobic 
Atom) is a hydrophobic group (green). 
This pharmacophore model was used for a pharmacophore search on 1893330 compounds 
from commercially available libraries (SPECS, ENAMINE and Life Chemicals).101-102 From 
this search, 65871 compounds were obtained that possess all of the three requested 
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features. The matching compounds were docked using Glide SP algorithm in a 12 Å radius 
grid generated, from the 4UCC crystal structure. 
The SP docking generated 429753 poses, which were then rescored using Glide XP, Plants 
and FlexX. 
The poses with the best results in the consensus scoring were selected and 8918 
compounds were obtained. The number of compounds was reduced to 6682 by the 
elimination of structures with a logD less than 2, and the remaining molecules were 
clustered using MACCS Fingerprints. From the Tanimoto similarity matrix the more different 
structures were selected. This process led to 2533 compounds, which were analysed 
through a visual inspection in the binding pocket. In the end, 20 compounds were selected 
based on their ability of compounds to bind deeply inside the hydrophobic pocket and based 
on the number of interactions (Fig. 16). The selected compounds (Table 2 in the appendix) 
were bought and tested in a cell-based assay.  
 
 
 
Figure 16. Pharmacophore search workflow and docked pose of a selected 
compound. schematic representation of the different molecular modelling techniques 
employed during the Pharmacophore search (Ph search) workflow for the identification of 
new potential N-P interaction inhibitors (left side); On the right side of the figure, the docking 
pose of one of the selected compounds and its interaction with the binding pocket. (PLIFs 
= Protein- Ligand Interaction fingerprints; FP clustering = Fingerprint clustering; V.I: = visual 
inspection) 
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3.1.3 Biological evaluation of selected compounds 
The compounds selected through the SBDD approaches for their ability to fit and bind inside 
the N-NTD pocket were tested in the Rega Institute for Medical Research, KU Leuven, 
Leuven, Belgium, under the supervision of Professor Johan Neyts. The compounds were 
evaluated in Vero cells co-infected with RSV A2-GFP-1 strain and were evaluated for their 
ability to inhibit the virus replication. In this assay, the Vero cells are infected with an 
engineered RSV-A2 virus, in which the green fluorescent protein (GFP) gene was inserted 
in front of the NS1 gene. This gene is encoding for the GFP, which is a protein used as a 
reporter of the viral expression. The GFP produced inside the infected cells can give a direct 
observation of the viral replication, and it is used to evaluate the antiviral activity of the 
tested molecules during the assay.103 
From the antiviral evaluation of the selected compounds, four hits were identified in the 
bioassay to be able to inhibit completely the RSV A2 strain replication (see table 1).  
 
Table 1. Hits identified. Chemical structures of the identified hits. These compounds were 
found to have antiviral activity on RSV A2-GFP-1 strain. The compounds were tested on 
cell based antiviral assay (AVA). Data are representative of two independent experiments. 
 
 
1 2 3 4 
EC50 
(μM) 
64 94 139 318 
 
The most potent compounds, compounds 1 and 2, were selected as a starting point for 
further investigations. 
 
3.1.4 M76 - 1-(2,4-dichlorobenzyl)-1H-pyrazole-3,5-dicarboxylic 
acid 
The most potent inhibitor of the 1-benzyl-1H- pyrazole-3,5-dicarboxylate (BPdC) series, 1-
(2,4-dichlorobenzyl)-1H-pyrazole-3,5-dicarboxylic acid, M76 (5, figure 17), was reported to 
be able to bind to the N-NTD pocket (Pdb. 4UCC) and to inhibit the RSV replication.94 M76 
was synthesised to be used as internal reference in the biological evaluation. 
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Figure 17. Chemical structure of M76. 
 
M76 was tested in the cell-based assay as acetoxymethyl (AM) esters prodrug to hinder the 
two carboxylic groups, because the free di-carboxylic acid was reported to be inactive, due 
to the double negative charge of the compound that could interfere with membrane 
permeability. For this reason, compound 5 was synthesised as di-AM and as free di-
carboxylic acid, along with the di-methyl ester. M76 (5) and its derivatives were synthesised 
through the synthetic pathway reported below (Scheme 1).104-105 
 
Scheme 1. Synthesis of M76. 
 
The synthesised compounds were biologically evaluated in a cytopathic effect (CPE) 
antiviral assay in Hep2 cells line, infected with RSV-A2 and RSV-B. The CPE refers to the 
structural modification of the infected cells by the virus. In the antiviral assay, the CPE is 
microscopically scored after five days of incubation. The score is used to calculate the EC50 
of the tested compounds. The cytotoxicity of the compound was evaluated by quantifying 
the metabolic activity of uninfected cells threated with the compound. The metabolic activity 
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was quantified after five days of incubation, using MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium). The reduction of the tetrazolium 
ring NAD(P)H-dependent cellular oxidoreductase enzymes by the cellular NAD(P)H-
dependent cellular oxidoreductase enzymes is giving the formation of a formazan product. 
The formazan product has an absorbance maximum at 490–500 nm in phosphate-buffered 
saline, which is used as readout for the cellular metabolic activity.106-107 
The results for these compounds were in line with the data previously reported by 
Ouizougun-Oubari and are showed in Table 2.  
 
Table 2. Biological evaluation of M76 (5), dimethyl ester derivatives of M76 and the 
diAM-M76 prodrug. The compounds were biologically evaluated in cell based antiviral 
assay (AVA) against RSV-A2 and RSV-B strains and for they cytotoxicity. Data are 
representative of two independent experiments.  
 
Compound 5 8 10 
EC50 (μM) 
RSV-A2 >400 >109 >116 
RSV-B ND ND ND 
CC50 (μM)  >400 118 14 
 
The prodrug of M76 showed a higher cytotoxicity in comparison with the reported value, 
due to the nature of the prodrug which is releasing of formaldehyde and to the different set 
up of the biological assay, which was two days longer.94 
All the compound synthesised in this project were biological evaluated in HEp2 cell line 
against RSV-A2, RSV-B in a 5 days long CPE antiviral assay and MTS cytotoxicity assay, 
as discussed previously.  
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Chapter 4: 2-(2-ethoxyphenyl)quinoline-4-
carboxylic acid and 2-(2-(N-(3-chloro-2-
methylphenyl) methylsulfonamido) 
acetamido)benzoic acid 
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4.1 Synthesis and biological evaluation of 2-(2-
ethoxyphenyl)quinoline-4-carboxylic acid (1) 
To confirm that the antiviral activity of hit 1 is related to the chemical structure provided from 
the vendor, this analogue was re-synthesised. Several attempts were performed to optimise 
its preparation and purification. In literature, the Pfitzinger reaction for the synthesis of this 
scaffold is reported to be performed in ethanol or in a mixture ethanol/water.108-109 Different 
attempts were performed and a system of ethanol/water with a 7:1 ratio was chosen as the 
best system of solvents. The chosen system is ensuring the solubility of the starting 
materials. 
1 was synthesised through an optimised microwave-assisted Pfitzinger reaction (Scheme 
2), between isatin 11 and 2-ethoxyacetophenone 12 in basic conditions that provide the 
compound with a purity >95% and a yield of 50%. 
 
 
Scheme 2. Synthesis of compound 1. 
 
The temperature for the reaction was chosen after performing several attempts. The yields 
for the different temperatures explored are shown in Table 3. 
 
Table 3. Different attempts for the selection of reaction conditions. (T = temperature; 
t = reaction time; Y = reaction yield; MW = microwave) 
T(°C) t(min) Y(%) 
reflux 36h 23 
100 (MW) 60 45 
125 (MW) 20 16 
150 (MW) 20 32 
150 (MW) 40 50 
 
In the Pfitzinger reaction (scheme 3), the basic hydrolysis of the isatin ring leads to the 
formation of 2-(2-aminophenyl)-2-oxoacetic acid intermediate I. At this stage of the reaction, 
the amine group of I is reacting with the carbonyl group of 2-ethoxyacetophenone which is 
forming the imine intermediate II, which is in equilibrium with the enamine intermediate III. 
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Intermediate III undergoes a cyclization step (IV) and then dehydration gives the final 
compound 1. 
 
 
Scheme 3. Pfitzinger reaction. 
 
Several attempts were performed to find better conditions for the synthesis of 1 and for its 
purification.  
The antiviral activity against RSV-A2 of compound 1 was confirmed in HEp2 cells. The 
compound was also active against RSV-B, showing an EC50 of 15 μM. Information on 
cytotoxicity (CC50=164 μM) confirms that the activity of the hit is not related to its toxicity. 
Another critical parameter used to express the efficacy of a drug is the Selectivity Index (SI), 
which represent the distance between the Antiviral activity (AVA) and the cytotoxicity effect 
(TOX) of the compound on the cell. The SI is calculated dividing the AVA (EC50) and the 
TOX (CC50). An ideal compound should have a high SI value, which means that the 
compound is showing an antiviral effect at a concentration that was much below the 
concentration in which the compound is showing cytotoxicity.110 
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Table 4. Biological evaluation of compound 1. Compound 1 was biologically evaluated 
in cell based antiviral assay (AVA) against RSV-A2 and RSV-B strains and for its 
cytotoxicity. In brackets the number of independent experiments. SI = selectivity index 
(CC50/EC50) 
  
 
  1 
EC50 (μM) 
RSV-A2 43 (8) 
RSV-B 15 (2) 
CC50 (μM)  164 (4) 
SI 
RSV-A2 3.8 
RSV-B 11 
 
The compound showed a Selectivity Index (SI) of 3.8 between the antiviral activity and the 
cytotoxicity against RSV-A2 and an SI of 11 against RSV-B. Starting from these results was 
decided to investigate further compound 1. 
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4.2 SAR of 2-(2-ethoxyphenyl)quinoline-4-carboxylic acid 
(1) 
From the docking pose of 1 (Figure 18.a), two major features of the compound are 
interacting with the N-NTD pocket: the carboxylic group and the 2-ethoxyphenyl moiety. The 
carboxylic group is interacting with the Arg150 and the 2-ethoxyphenyl moiety is fitting 
inside the hydrophobic pocket of the N-NTD. The quinolinic ring seems not to make major 
interactions with the protein but to provide the right orientation for the phenyl moiety. 
To understand better the chemical structure relevance for activity, three SAR analyses were 
designed to investigate the possibility of a further development of the selected hit as anti-
RSV agent (Figure 18.b). 
 
 
a.      b. 
Figure 18. a. Docking pose of compound 1; b. SAR analysis 
 
In SAR1 the interest is to understand the possibility to remove the carboxylic group or to 
convert it to another chemical group that can lead to an improved membrane permeability. 
SAR2 was designed to understand the importance of the 2-ethoxy group on the phenyl 
moiety by removing or replacing it with other similar groups or by changing its position on 
the phenyl ring. The last SAR analysis is focused on exploring the possibility of increasing 
the activity of the scaffold by modifying positions 6 and 7 on the quinolone ring. 
  
SAR 1 
SAR 2
SAR 3 
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4.2.1 SAR on the carboxylic group
In this first SAR analysis, several analogues were synthesised with the aim to understand 
the importance of the carboxylic group for the interaction with the N-NTD pocket (figure 19).  
 
 
       
13 14 15 16 17 18 19 
Figure 19. Synthesised analogues of the carboxylic group. 
 
Compound 13 was design based on the approach used for 10. The acetyloxy methyl ester 
is a pH-sensitive prodrug that should improve membrane permeability and once the 
compound enters the cell it should easily restore the free carboxylic group. This compound 
was synthesised by a nucleophilic displacement of the chloride on chloromethyl acetate in 
basic conditions (Scheme 4). 
 
 
Scheme 4. synthesis of compounds 13. 
 
The ester analogue 14, which was synthesised using an esterification reaction with thionyl 
chloride in methanol, was also made to see if the ester group could improve the activity of 
the compound by hindering the carboxylic group (scheme 5). 
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Scheme 5. Synthesis of compounds 14 and 15. 
 
Compound 15 was synthesised by converting the carboxyl ester in the primary alcohol 
analogue through a sodium borohydride reduction. With this analogue, the importance of 
the negative charge of the carboxylic group was explored. 
Starting from 1, three amide analogues (16-18) were synthesised by a coupling reaction 
using TBTU and DIPEA (scheme 6).  
 
 
Scheme 6. synthesis of compounds 16, 17, 18. The amines used are respectively 
ammonia, methylamine and morpholine 
 
The analogue of 1 without the carboxylic group (19) was synthesised using a Ruthenium-
Catalysed Friedlander protocol with a yield of 32%. The use of Ruthenium in catalytic 
amount is necessary to generate in situ the 2-aminobenzaldehyde 22 by oxidation of the 
aminobenzylalchol 20 (scheme 7).111 
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Scheme 7. a. synthesis of compound 17; b. chemical structure of the used Grubbs 
Catalyst 1st Generation 21 
 
For this reaction, a commercially available 1st generation Grubbs catalyst 21 was used as 
source of ruthenium (scheme 8). 
 
Scheme 8. Ruthenium-Catalysed Friedlander reaction mechanism. 
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The mechanism of this reaction, as shown in scheme 8, starts with the oxidation of the 2-
aminobenzyl alcohol (20) into 2-amine benzaldehyde (22). The ruthenium catalyst is 
regenerated through the reduction of the 2-(ethoxy)acetophenone (12). The acetophenone 
in basic conditions is then reacted with the amino benzaldehyde in a cross aldol reaction to 
form 24. 24 undergoes two subsequent H2O eliminations, thus providing the desired 
quinoline. Another proposed pathway for this reaction is that 24, by H2O elimination, is 
forming the trans enone intermediate (26), which is then hydrogenated by the [RuH2] to form 
intermediate 27. This could be an alternative way of regeneration of [Ru]. The desired 
compound is generated through a subsequent H2O elimination and dehydrogenation. 
  
Part II: RSV 
62 
4.2.2 Biological evaluation of the carboxylic acid analogues
Among the synthesised compounds, 13-19, as can be inferred from table 5, the pH-sensitive 
acetyloxy methyl ester prodrug (compound 13) was associated with cytotoxicity, without 
showing antiviral activity on RSV-A2 and RSV-B. Compound 15 and 16, with methyl alcohol 
and the carboxamide groups respectively instead of the carboxylic acid, were showing 
retention of antiviral activity against RSV-B. 
 
Table 5. Biological evaluation of the analogues 13-19. Compounds were biologically 
evaluated in cell based antiviral assay (AVA) against RSV-A2 and RSV-B strains and for its 
cytotoxicity. Data are representative of two independent experiments. NA = not active. SI = 
selectivity index (CC50/EC50) 
 
       
13 14 15 16 17 18 19 
 
Compound 
EC50 
RSV-A2 
(μM) 
EC50 
RSV-B 
(μM) 
CC50 
(μM) 
SI 
RSV-A2 
SI 
RSV-B 
1 43 15 164 3.8 11 
13 NA NA 32 - - 
14 NA 3 >300 - >100 
15 44 27 >300 >6.8 >11 
16 NA 27 196 - 7.2 
17 NA NA >300 - - 
18 NA NA 122 - - 
19 NA NA 37 - - 
 
On the other hand, compound 15 and not compound 16 was showing retention of antiviral 
activity against RSV-A2. Interestingly, the methyl ester derivative of compound 14 was 
showing the lowest EC50 against RSV-B (3 μM) but no antiviral effect on RSV-A2. The other 
three modifications attempted, the N-methyl carboxamide (compound 17), the N-
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morpholine carboxamide (compound 18) and removed carboxylic group (compound 19) are 
related to loss of activity.  
For the further exploration of the chemical structure of compound 1, was decided to 
synthesise all the analogues as free carboxylic acid and as methyl esters. 
 
4.2.3 SAR on the (2-ethoxy)phenyl moiety 
The second stage of the SAR analysis was to understand the importance of the substitution 
on the phenyl moiety for the activity of the scaffold. As predicted by the docking study, the 
phenyl moiety is the one which is interacting in the hydrophobic pocket of N-NTD. Starting 
from this observation, several analogues were synthesised, using the synthetic approach 
already optimised for 1, to investigate the importance of the phenyl moiety substituent. Each 
analogue was synthesised as free acid and ester derivatives, based on the preliminary 
results on the SAR on the carboxylic group.  
The first analogue synthesised was the unsubstituted compound, to understand the 
importance of the ethoxy group of 1 for the anti-RSV activity. 
The next stage was to investigate the importance of the length of the ethoxy group through 
the synthetisis of methoxy (42), isopropoxy (43), n-propoxy (44) and (cyclopropyl)methyloxy 
(45) analogues in position 2 of the phenyl moiety.  
 
Scheme 9. Synthesis of compounds 41-52. 
 
Table 6. Synthesis of compounds 41-52. 
Acetophenone R Product Yield % 
29 H 41 66 
30 2-OMe 42 58 
31 2-OiPr 43 39 
32 2-OPr 44 30 
33 2-Cyclopropylmethyloxy 45 12 
34 3-OEt 46 35 
35 4-OEt 47 47 
36 3-OMe 48 35 
37 4-OMe 49 99 
38 2,4-Cl 50 60 
39 2-OH 51 20 
40 3-OH 52 26 
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Analogues 41-52 shown in table 6 were synthesised using the same synthetic procedure 
used for 1, changing the acetophenone. The acetophenones required were not all 
commercially available. For this reason, 2-(isopropoxy)acetophenone 31, 2-
(propoxy)acetophenone 32 and 2-((cyclopropyl)methyloxy)acetophenone 33 were 
synthesised by alkylation of 2-hydroxyacetophenone 39, as shown in scheme 10.112 
 
 
Scheme 10. Synthesis of Acetophenones. 
 
With the same procedure, few attempts were performed to synthesise 2-
(cyclopropyl)acetophenone 66. The desired product was not obtained, probably duo to the 
different reactivity of the bromo-cyclopropane. During the reaction, the formation of several 
unknown by-products was observed (scheme 11). 
 
 
Scheme 11. Synthesis of 2-(cyclopropyl)acetophenone 66. 
 
The importance of the position of the ethoxy substituent on the phenyl ring was also 
investigated and the corresponding analogues with a 3-ethoxy and a 4-ethoxy group on the 
phenyl ring were synthesised. To have a wider overview on the importance of the 
substituent on the phenyl group, the corresponding analogues with a methoxy group in 
position 3 and 4 on the phenyl ring were also synthesised. 
The most active compound of the series 1-benzyl-1H- pyrazole-3,5-dicarboxylate (BPdC), 
able to bind into the N-NTD pocket, has 2,4-dichlorobenzyl moiety (Figure 20). Analogue 
50 was synthesised to see if it is possible to improve the affinity of the 2-(phenyl)quinolin-
4-carboxylic acid scaffold for the hydrophobic pocket.94 
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Figure 20. Comparison between 5 and 50. 
 
Hydroxy analogues on position 2 and 3 of the phenyl ring were synthesised to see if 
introducing a hydrogen donor group could affect the activity of this scaffold.  
 
 
Scheme 12. Synthesis of compounds 53-64. 
 
Table 7. Synthesis of compounds 53-64. 
Compound R Product Yield % 
41 H 53 72 
42 2-OMe 54 59 
43 2-OiPr 55 59 
44 2-OPr 56 84 
45 2-Cyclopropylmethyloxy 57 88 
46 3-OEt 58 68 
47 4-OEt 59 47 
48 3-OMe 60 45 
49 4-OMeH 61 25 
50 2,4-Cl 62 64 
51 2-OH 63 30 
52 3-OH 64 79 
 
 
The ester analogues (compounds 53-64) were synthesised starting from the free acid 
compounds 41-52 as shown in scheme 12 and table 7.  
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4.2.4 Biological evaluations of the (2-ethoxy)phenyl moiety 
analogues 
Among the free acid analogues synthesised (see table 8), a loss of activity was observed 
when removing the substituent on the phenyl ring (compound 41). Increasing or decreasing 
the length of the substituent on R1 was associated with a loss of activity, except for the n-
propoxy analogue (compound 44) which, retain the antiviral activity of compound 1. 
Changing the position of the ethoxy group on the phenyl ring (compound 46 and 47) is 
correlated with a loss of activity or increasing of cytotoxicity. 
 
Table 8. Biological evaluation of free acid analogues 41-52. Compounds were 
biologically evaluated in cell based antiviral assay (AVA) against RSV-A2 and RSV-B 
strains and for its cytotoxicity. Data are representative of two independent experiments. NA 
= not active. SI = selectivity index (CC50/EC50) 
 
 
Compound R1 R2 
EC50 
RSV-
A2 
(μM) 
EC50 
RSV-
B 
(μM) 
CC50 
(μM) 
SI 
RSV-
A2 
SI 
RSV-
B 
1 H 2-OEt 43 15 164 3.8 11 
14 Me 2-OEt NA 3 >300 - >100 
41 H H NA NA >400 - - 
42 H 2-OMe NA NA >300 - - 
43 H 2-OiPr 151 106 232 1.5 2.2 
44 H 2-OnPr 32 35 148 4.6 4.2 
45 H 2-Cyclopropyl-methyloxy NA 88 250 - 2.8 
46 H 3-OEt >150 63 206 <1.37 3.2 
47 H 4-OEt 70 66 111 1.6 1.7 
48 H 3-OMe NA NA >100 - - 
49 H 4-OMe NA NA >100 - - 
50 H 2,4-Cl >150 204 >300 <2 1.5 
51 H 2-OH >25 68 54 <2.1 0.8 
52 H 3-OH >25 46 41 <1.6 0.9 
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The same trend can be seen in compound 48 and 49. The substitution of the 2-ethoxy group 
with a hydroxy group is giving increased cytotoxicity. Compound 50 having the 2,4-
dichlorobenzyl moiety, like compound 5 is not showing retention of the antiviral activity in 
comparison with compound 1. 
Table 9. Biological evaluation of methyl ester analogues 53-64. Compounds were 
biologically evaluated in cell based antiviral assay (AVA) against RSV-A2 and RSV-B 
strains and for its cytotoxicity. Data are representative of two independent experiments. NA 
= not active. SI = selectivity index (CC50/EC50) 
 
Compound R1 R2 
EC50 
RSV-
A2 
(μM) 
EC50 
RSV-
B 
(μM) 
CC50 
(μM) 
SI 
RSV-
A2 
SI 
RSV-
B 
1 H 2-OEt 43 15 164 3.8 11 
14 Me 2-OEt      
53 Me H NA 66 92 - 1.4 
54 Me 2-OMe NA NA 15 - - 
55 Me 2-OiPr 9 NA 23 2.5 - 
56 Me 2-OnPr 11 16 17 1.5 1.1 
57 Me 2-Cyclopropyl-methyloxy 10 25 20 2 0.8 
58 Me 3-OEt 40 NA 69 1.7 - 
59 Me 4-OEt NA NA 4 - - 
60 Me 3-OMe NA 41 137 - 3.3 
61 Me 4-OMe NA 6 18 - 3 
62 Me 2,4-Cl >13 NA 92 <7.1 - 
63 Me 2-OH NA NA 13 - - 
64 Me 3-OH NA NA 26 - - 
 
For the methyl ester derivatives of 53-64 (see table 9), biological results indicate that all the 
analogues synthesised are showing an increase in cytotoxicity, with the exception for 
compound 60 and 62. Compound 60 seems to retain the antiviral activity against RSV-B 
only. Instead, compound 62 is retaining the antiviral activity RSV-A2 and is showing an 
increase of cytotoxicity.  
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4.2.5 SAR on the 6 and 7 positions of the quinolinic ring  
Aiming to reduce the cytotoxicity and enhance the anti-RSV activity of compound 1, the 
following five different groups, -Me, Cl, -OMe, -CF3 and -OCF3, were selected to be 
introduced on 6- and 7- positions of the quinolinic ring, keeping the phenyl moiety of the hit 
compound unchanged. The selected compounds 77-86 were synthesised using the 
synthetic procedure used for compound 1, starting from different commercially available 6- 
or 7-substituted isatines as shown in figure 21 and table 10. 
 
 
Figure 21. Synthesis of compounds 77-86. 
 
Table 10. Synthesis of compounds 77-86. 
Isatin R1 R2 Product Yield % 
67 Me H 77 61 
68 Cl H 78 63 
69 OMe H 79 20 
70 CF3 H 80 5 
71 OCF3 H 81 63 
72 H Me 82 34 
73 H Cl 83 20 
74 H OMe 84 17 
75 H CF3 85 60 
76 H OCF3 86 20 
 
The obtained quinolines 77-86 were, then used for the synthesis of the ester derivatives, 
compounds 87-96 as shown in figure 22 and in table 11. 
 
 
Figure 22. Synthesis of compounds 87-96. 
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Table 11. Synthesis of compounds 87-96. 
Compound R1 R2 Product Yield % 
77 Me H 87 99 
78 Cl H 88 70 
79 OMe H 89 54 
80 CF3 H 90 17 
81 OCF3 H 91 56 
82 H Me 92 62 
83 H Cl 93 21 
84 H OMe 94 46 
85 H CF3 95 37 
86 H OCF3 96 75 
 
4.2.6 Biological evaluations of 6 and 7 substituted quinolinic ring 
analogues 
Table 12. Biological evaluation of free acid analogues 77-86. Compounds were 
biologically evaluated in cell based antiviral assay (AVA) against RSV-A2 and RSV-B 
strains and for its cytotoxicity. Data are representative of two independent experiments. NA 
= not active. SI = selectivity index (CC50/EC50) 
 
Compounds R1 R2 
EC50 
RSV-A2 
(μM) 
EC50 
RSV-B 
(μM) 
CC50 
(μM) 
SI 
RSV-
A2 
SI 
RSV-B 
1 H H 43 15 164 3.8 11 
77 Me H NA 36 60 - 1.7 
78 Cl H 32 11 42 1.3 3.8 
79 OMe H NA NA >300 - - 
80 CF3 H 19 16 9 0.5 0.6 
81 OCF3 H 25 13 73 2.9 5.6 
82 H Me NA NA >300 - - 
83 H Cl 169 105 300 1.8 2.8 
84 H OMe NA NA >300 - - 
85 H CF3 36 36 174 4.8 4.8 
86 H OCF3 NA 35 229 - 6.5 
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From the biological data reported in table 12, compounds 77-86 did not show an 
improvement of antiviral activity on RSV-A2 and RSV-B. For the compounds showing 
retention of antiviral activity, the cytotoxic effect was enhanced since the SI was below the 
SI of compound 1. The only exceptions were compound 85 and 86, which were showing 
antiviral activity against RSV-B and cytotoxicity comparable to compound 1. Between those 
two compounds only 85 shown anti-RSV-A2 activity, like compound 1. 
Biological evaluation of 6-quinoline substituted methyl ester analogues are reported in table 
13. The 6-chloro and the 6-trifluoromethyl substituents, compounds 88 and 90, do not 
shown antiviral activity against the two RSV strains. Instead the 6-methyl and the 6-methoxy 
analogues (compound 87 and 89) showed an increased antiviral activity but also an 
enhanced cytotoxicity. 
 
Table 13. Biological evaluation of methyl ester analogues 87-96. Compounds were 
biologically evaluated in cell based antiviral assay (AVA) against RSV-A2 and RSV-B 
strains and for its cytotoxicity. Data are representative of two independent experiments. NA 
= not active. SI = selectivity index (CC50/EC50) 
 
Compounds R1 R2 
EC50 
RSV-A2 
(μM) 
EC50 
RSV-B 
(μM) 
CC50 
(μM) 
SI 
RSV-
A2 
SI 
RSV-
B 
1 H H 43 15 164 3.8 11 
87 Me H >19 8 25 <1.3 3.1 
88 Cl H NA NA >300 - - 
89 OMe H 4 4 24 6 6 
90 CF3 H NA NA >300 - - 
91 OCF3 H 65 33 >300 >4.6 9 
92 H Me 11 12 285 25.9 23.7 
93 H Cl NA NA >300 - - 
94 H OMe 11 23 >300 >27.3 >13 
95 H CF3 11 11 >300 >27.3 >27.3 
96 H OCF3 3 11 >300 >100 >27.3 
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The introduction of a trifluoromethoxy group in position 6 (compound 91) was associated 
with a retention of antiviral activity, comparable with compound 1, with no cytotoxicity 
observed at 300 μM. 
Finally, from the biological evaluation of the 7-quinoline substituted methyl ester analogues 
(compounds 92-96), except for compound 93, showed antiviral activity and no cytotoxicity 
at 300 μM. The most active compound was 96, with an EC50 of 3 μM and 11 μM, respectively 
against RSV-A2 and RSV-B. 
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4.3 Synthesis of 2-(2-(N-(3-chloro-2-methylphenyl) 
mesyl)acetamido)benzoic acid (2) 
The second most potent hit, identified through the SBDD approach, is the 2-(2-(N-(3-chloro-
2-methylphenyl)ethylsulfonamido)acetamido)benzoic acid (compound 2, figure 23 a). From 
the docking pose, the compound seems to interact with the N-NTD pocket, through an 
interaction between the carboxylic group and the Lys136. The 3-chloro-2-methylphenyl ring 
is interacting with the His151 through a π-π interaction, like for the 2-ethoxyphenyl moiety 
of compound 1. Also, the carbonyl oxygen of the amide bond and the mesyl group seem to 
interact, respectively with the Arg150 and the Arg132. (figure 23 b). 
 
   
a.       b. 
Figure 23. a) Chemical structure; b) Docking pose of compound 2. 
 
In order to confirm the antiviral activity of compound 2, was decided to synthesise the 
compound along with a small number of analogues, varying the carboxylic group and its 
position, and the 3-chloro-2-methylphenyl ring. 
From the retrosynthetic analysis, shown in scheme 13, the amide bond of compound 2 can 
be disconnected to give 2-aminobenzoic acid 98 and the N-(3-chloro-2-methylphenyl)-N-
(methylsulfonyl)glycine 97. For this last one, either the sulphonamide bond (path A in 
scheme 13) or the N-CH2 (path B in scheme 13) can be disconnected, giving two possible 
synthetic routes for the synthesis of compound 97. In the path A, the disconnection of 97 is 
giving origin to the (3-chloro-2-methylphenyl)glycine 99, which can be subsequently 
disconnected in 3-chloro-2-methylaniline 101 and 2-chloroacetic acid 102.  
Alternatively, the disconnection of compound 97 in path B of the N-CH2 bond is giving the 
2-chloroacetic acid 102 and N-(3-chloro-2-methylphenyl)methanesulfonamide 99, which 
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can be subsequently disconnected into 3-chloro-2-methylaniline 101 and mesyl chloride 
100. 
 
 
Scheme 13. Compound 2 retrosynthetic analysis. 
 
From the retrosynthetic analysis, two synthetic routes where planned to synthesise 
compound 97, see scheme 14. Those routes have in common the methyl ester precursor 
of compound 97. In synthetic route A, the first step is the nucleophilic substitution (SN2), 
followed by the mesylation step. Instead, in the synthetic route B, the mesylation of the 3-
chloro-2-methylaniline 101 is the first step, followed by the SN2, to give methyl ester 
precursor 105 of compound 97. 
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Scheme 14. Planned synthetic routes, Route A in pink and Route B in light blue. 
 
Synthetic route A 
Several attempts to synthesise compound 97 were performed starting from the 
commercially available 3-chloro-2-methylaniline 101 and the methyl 2-bromoacetate 103, 
instead of 2-chloroacetic acid 102, which is showed in scheme 15. The choice of using 
methyl 2-bromoacetate 103 was made to avoid any side reaction and because the bromo 
atom is a better leaving group then the chloro atom in nucleophilic substitution. The best 
result of the nucleophilic substitution for the formation of the methyl (3-chloro-2-
methylphenyl)glycinate 104, was obtained in acetone in presence of potassium carbonate 
as a base, the reaction was refluxed for 24 hours. After flash column chromatography the 
product was isolated in presence of the starting material 101, in a ratio of 3:2. The obtained 
mixture was then used for the next mesylation step. After flash column chromatography the 
desired product 105 was obtained, with an overall yield over two steps of 20%. 
 
Scheme 15. Synthetic route A. 
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Synthetic route B 
To increase the yield and to reduce the steps of flash chromatography purification, it was 
decided to try the mesylation of the 3-chloro-2-methylaniline 101 as first step and then the 
nucleophilic substitution on the methyl 2-bromoacetate 103 (scheme 16).  
The mesylation reaction of the aniline 101 was performed in dichloromethane in the 
presence of pyridine as a base, overnight at room temperature giving the intermediate 99, 
pure with a yield of 98%.113 The desired product was obtained by nucleophilic substitution 
on methyl 2-bromoacetate by the mesylated aniline in basic condition. This synthetic 
pathway lead to the synthesis of methyl N-(3-chloro-2-methylphenyl)-N-
(methylsulfonyl)glycinate 105 without requiring any step of flash chromatography 
purification.  
 
 
Scheme 16. Synthetic route B. 
 
Compound 97 was finally obtained by basic hydrolysis of the compound 105 as shown in 
scheme 17.  
 
 
Scheme 17. Hydrolysis of compound 105. 
 
To synthesise the compound 2, a first attempt of coupling between the free acid 97 and the 
commercial available methyl 2-aminobenzoate 106 was performed using the TBTU (O-
(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate) amide coupling 
reagent. The reaction was attempted several times, increasing the temperature of the 
reaction, with any success. This can be related to the low reactivity of the anilinic amine, 
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which is not able to replace the benzotriazole ester formed between the acid 97 and the 
TBTU. 
To overcome this problem, the acid was converted into the acyl chloride derivative using 
the chlorinating agents, thionyl chloride. The acyl chloride derivative of 97 was then added 
drop-wise to a DCM solution of methyl 2-aminobenzoate 106, using triethylamine as base 
(Scheme 18), giving the methyl ester derivative 107 with a yield of 86% over two steps. 
Finally compound 2 was obtained by basic hydrolysis of the methyl ester 107. 
 
 
Scheme 18. Synthesis of 2-(2-(N-(3-chloro-2-methylphenyl)ethylsulfonamido) 
acetamido)benzoic acid (2). i) TBTU, DIPEA, DMF, on; ii) SOCl2 neat, reflux, 2h; iii). 
Aniline, TEA, DCM, from 0°C to rt, on, Y=86% (over 2 steps); iv) NaOH, THF/MeOH (2:1), 
60°C, 2h, Y=99%; 
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4.3.1 2-(N-(3-chloro-2-methylphenyl)mesyl) acetamides analogues 
Four compounds were designed to investigate the importance of the carboxylic group of the 
hit compound 2, as shown in figure 24. In compound 108 and 109 the carboxylic group was 
respectively removed and substituted with the tetrazole ring, which is the bioisostere of the 
carboxylic acid group. Compounds 110-111 were designed to investigate if the position of 
the carboxylic group could affect the antiviral activity of compounds.  
 
Figure 24. Designed analogues 108-111. 
 
Compounds 108-111 were synthesised, starting from the common intermediate 97, using 
the optimised coupling procedure used for the synthesis of compound 2 in which, the acyl 
chloride derivative of 97 was added drop-wise to a solution of dichloromethane and 
triethylamine, containing the relative anilines: aniline, 2-(tetrazol-5-yl)aniline, methyl 3-
aminobenzoate and methyl 4-aminobenzoate, as shown in scheme 19 and table 14. 
 
 
Scheme 19. Synthesis of compounds 108-111. i) SOCl2 neat, reflux, 2h; ii). R-NH2, 
TEA, DCM, from 0°C to rt, on. 
 
Table. Synthesis of compounds 108-111. The yields are calculated over the two steps of 
synthesis. 
Product R Yield % 
108 phenyl 72 
109 2-(tetrazol-5-yl)phenyl 14 
110 methyl 3-benzoate 84 
111 methyl 4-benzoate 45 
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The methyl 3-benzoate 110 and the methyl 4-benzoate 111 were hydrolysed to obtain also 
the free acid derivatives 112-113, as shown in scheme 20 and the related yields are 
reported in table 15. 
 
 
Scheme 20. Hydrolysis of compounds 112-113. 
 
Table 14. Synthesis of compounds 112-113. 
Compound R1 R2 Product R1 R2 Yield 
% 
110 COOCH3 H 112 COOH H 40 
111 H COOCH3 113 H COOH 28 
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4.3.2 2-(2-(N-mesylphenyl)acetamido)benzoic acids analogues 
To investigate the importance of the 3-chloro-2-methylphenyl ring of compound 2 for the 
antiviral activity, two derivatives of compound 2 were designed (see figure 25). In the first 
one the 3-chloro-2-methylphenyl ring was replaced with a phenyl ring (compound 114). In 
the second derivatives of compound 2, the 3-chloro-2-methylphenyl moiety, which from the 
docking seems to bind in the hydrophobic pocket of the N protein, was replaced with the 2-
etoxyphenyl moiety (compound 115). This moiety is the same of compound 1, which from 
the docking pose seems to bind in the same pocket and to be able to make the same 
interaction in the pocket. 
 
 
Figure 25. Compounds 114 and 115. 
 
The designed compounds 114 and 115 were synthesised using the optimised five steps 
synthetic route which was used for the synthesis of compound 2. 
 
Scheme 21. Synthesis of compounds 114-115. i) mesyl chloride, pyridine, DCM, rt, on; 
ii) methyl 2-bromoacetate, NaH, DMF, rt, 5h; iii) NaOH, THF/MeOH(2:1), 60°C, 2h; iv) 
1)SOCl2 neat, reflux, 2h; 2). Aniline, TEA, DCM, from 0°C to rt, on; v) NaOH, 
THF/MeOH(2:1), rt, on. 
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Synthesis of N-mesylphenylamines (118-119) 
The two newly synthesised N-mesylphenylamines 116 and 117 were synthesised through 
the mesylating reaction used for the synthesis of 3-chloro-2-methylaniline 101, with a 
comparable yield (see table 16). 
 
Table 15. Synthesis of N-mesylphenylamines 118-119. 
 
Compound R1 Product Yield % 
116 H 118 99 
117 2-ethoxy 119 96 
 
Synthesis of methyl N-(mesyl)-N-phenylglycinates (120-121) 
The next step of synthesis, like for compound 2, was the SN2. The sulphonamide, which is 
deprotonatd by the strong base sodium hydride, is displacing the Br atom on the methyl 2-
bromoacetate 103 (see table 17). 
 
Table 16. Synthesis of methyl N-(mesyl)-N-phenylglycinates 120-121. 
 
Compound R Product Yield % 
118 H 120 96 
119 2-ethoxy 121 98 
 
Synthesis of N-(mesyl)-N-phenylglycines (122-123) 
The previously obtained N-(mesyl)-N-phenylglycinates 120-121, were then hydrolysed in 
basic conditions using an aqueous solution of sodium hydroxide (1M) and the reaction 
performed in solution of tetrahydrofuran and methanol, in a ratio of 2:1 (see table 18), to 
give the two desired free acids products 122-123 (see table 18). 
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Table 17. Synthesis of N-(mesyl)-N-phenylglycine (122-123). 
 
Compound R Product Yield % 
120 H 122 84 
121 2-ethoxy 123 99 
 
Synthesis of methyl 2-(2-(N-phenylmesyl)acetamido)benzoates (124-125) 
The glycines 122-123 where coupled with the methyl 2-aminobenzoate 106 using the 
coupling procedure optimised for the synthesis of compound 2. Both the glycines 122-123 
were converted to the respective acyl chloride and then added drop-wise to the solution of 
methyl 2-aminobenzoate 106 in dichloromethane and triethylamine (see table 19). Two 
methyl 2-(2-(N-phenylmesyl)acetamido)benzoates (124-125) were also biologically 
evaluated along with the free acids 114-115. 
Table 18. Synthesis of methyl 2-(2-(N-phenylmesyl)acetamido)benzoates 124-125 (* 
the yield is referred over two steps). 
 
 
Compound R Product *Yield % 
122 H 124 52 
123 2-ethoxy 125 96 
 
Synthesis of 2-(2-(N-phenylmesyl)acetamido)benzoic acids (114-115) 
Finally, the 2-(2-(N-phenylmesyl)acetamido)benzoic acids 114-115 were obtained by 
hydrolysis in basic condition of compounds 124-125 (see table 20). Two 2-(2-(N-
phenylmesyl)acetamido)benzoic acids (114-115) were also biological evaluated along with 
the methyl ester precursors 124-125. 
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Table 19. Synthesis of 2-(2-(N-phenylmesyl)acetamido)benzoic acid 114-115. 
 
Compound R Product Yield % 
124 H 114 71 
125 2-ethoxy 115 91 
 
4.3.3 Biological evaluation 
The newly synthetised 2-(2-(N-mesylphenyl)acetamido)benzoic acid compounds were 
tested for antiviral activity against RSV-A2 and RSV-B CPE antiviral assay and were 
evaluated for their cytotoxicity in HEp2 cells line. 
The re-synthetised compound 2 did not show any antiviral activity in HEp2 cell line against 
RSV-A2. Instead the compound shown a 58 μM EC50 against RSV-B and no cytotoxicity at 
300 μM. Besides, the methyl ester analogue compound 107, shown an EC50 against RSV-
A2 and RSV-B, respectively of 26 μM and 34 μM with no cytotoxicity at 300 μM (see table 
21). 
 
Table 20. Biological results for compounds 2 and 107. Compounds were biologically 
evaluated in cell based antiviral assay (AVA) against RSV-A2 and RSV-B strains and for its 
cytotoxicity. Data are representative of two independent experiments. NA = not active. SI = 
selectivity index (CC50/EC50) 
 
Compounds 
EC50 
RSV-A2 
(μM) 
EC50 
RSV-B 
(μM) 
CC50 
(μM) 
SI 
RSV-A2 
SI 
RSV-B 
 2 >300 58 >300 >1 >5.2 
107 26 34 >300 >11.5 >8.8 
 
 
The removal of the carboxylic group was associated with a CC50 and a lower SI in 
comparison with the compound 107. The replacement of the carboxylic group by the 
tetrazole ring was associated with a complete loss of antiviral activity (see table 22). 
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Table 21. Biological results for compounds 108-109. Compounds were biologically 
evaluated in cell based antiviral assay (AVA) against RSV-A2 and RSV-B strains and for its 
cytotoxicity. Data are representative of two independent experiments. NA = not active. SI = 
selectivity index (CC50/EC50) 
 
Compounds 
EC50 
RSV-A2 
(μM) 
EC50 
RSV-B 
(μM) 
CC50 
(μM) 
SI 
RSV-A2 
SI 
RSV-B 
108 76 35 155 2 4.4 
109 NA NA >300 - - 
 
The methyl 3-aminobenzoate 110 and methyl 4-aminobenzoate 111 derivatives of 
compound 107 lead to an antiviral activity retention but associated to a lower CC50 than 
compound 107. The free acid derivatives 112 and 113 did not show any antiviral activity 
(see table 23). 
 
Table 22. Biological results for compounds 110-113. Compounds were biologically 
evaluated in cell based antiviral assay (AVA) against RSV-A2 and RSV-B strains and for its 
cytotoxicity. Data are representative of two independent experiments. NA = not active. SI = 
selectivity index (CC50/EC50) 
 
 
Compounds 
EC50 
RSV-A2 
(μM) 
EC50 
RSV-B 
(μM) 
CC50 
(μM) 
SI 
RSV-A2 
SI 
RSV-B 
110 36 30 78 2.2 2.6 
112 NA NA >300 - - 
111 11 11 22 2 2 
113 NA NA >300 - - 
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The two designed modifications on the 3-chloro-2-methylphenyl moiety of compound 2, did 
not show any correlation with antiviral activity, neither the methyl ester derivatives 114 and 
115, nor the free acid derivatives 124 and 125 (see table 24). 
Table 23. Biological results for compounds 114-115, 124-125. Compounds were 
biologically evaluated in cell based antiviral assay (AVA) against RSV-A2 and RSV-B 
strains and for its cytotoxicity. Data are representative of two independent experiments. NA 
= not active. SI = selectivity index (CC50/EC50) 
 
 
Compounds 
EC50 
RSV-A2 
(μM) 
EC50 
RSV-B 
(μM) 
CC50 
(μM) 
SI 
RSV-
A2 
SI 
RSV-
B 
114 NA NA >300 - - 
124 NA 103 >300 - >2.91 
115 NA NA >300 - - 
125 NA NA >300 - - 
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4.4 Conclusions 
Different structure-based strategies were used to identify new potential compounds able to 
inhibit RSV viral replication. During the in-silico study, four of the selected compounds were 
able to inhibit the RSV replication in the cell-based assay fully. The two most active hits, 
compound 1 and 2, having a 2-phenylquinoline-4-carboxylic acid and 2-(2-(N-phenyl-N-
mesyl)acetamido)benzoic acid scaffolds respectively, were further investigated. 
 
 
 
 
1  2 
 
From the biological results, the antiviral activity of compound 1 against RSV was confirmed. 
Several derivatives were synthesised to explore the importance of the different features of 
the 2-phenylquinoline-4-carboxylic acid scaffold with some compound showing improved 
antiviral activity in comparison to compound 1.  
From the analogues synthesised to understand the importance of the carboxylic group, it 
was observed that the removal of the group was associated with a complete loss of antiviral 
activity. The replacement of the free acid group of the hit compound 1 with methyl alcohol 
was associated with retention of antiviral activity. The methyl ester analogue showed an 
improved activity against only RSV-B. Also, the carboxamide analogue showed retention of 
antiviral activity against only RSV-B. On the base of those results, was decided to 
synthesise the other analogue both as free acids and methyl esters. 
The analogues synthesised to understand the importance of the phenyl moiety were 
associated with low CC50 and SI values or loss of antiviral activity, either along the free acid 
series and in the methyl ester series. The only exception was compound 44 having the 2-
propoxy group on the phenyl group instead of the 2-ethoxy group. This compound was 
related to antiviral activity retention against both RSV-A2 and RSV-B. However, the results 
obtained for its methyl ester derivatives were inconsistent with the results obtained with the 
free acid compound, in which a low CC50 and SI were observed. 
The modification introduced on the quinolinic ring in position 6, were associated with low 
CC50 and SI values, both in the free acid and the methyl ester series. The only exception 
was compound 91, having the trifluoromethoxy group, showing retention of antiviral activity 
of compound 1.  
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Interestingly the methyl ester series of the 7-substituted quinoline analogues, few 
compounds showed antiviral activity against both RSV strains in the range of 3-11 μM for 
RSV-A2 and in a range of 11-23 μM for RSV-B with an SI major of 23.7. These findings, for 
the 2-phenylquinoline-4-carboxylic acid series, are summarised in table 25.  
 
Table 24. 2-phenylquinoline-4-carboxylic acid derivatives with an improved antiviral 
activity. Compounds were biologically evaluated in cell based antiviral assay (AVA) against 
RSV-A2 and RSV-B strains and for its cytotoxicity. Data are representative of two 
independent experiments. NA = not active. SI = selectivity index (CC50/EC50) 
 
 
Compound R1 R2 
EC50 
RSV-A2 
(μM) 
EC50 
RSV-B 
(μM) 
CC50 
(μM) 
SI 
RSV-
A2 
SI 
RSV-
B 
1 
 
H 43 15 164 3.8 11 
14 
 
H NA 3 >300 - >100 
15 
 
H 44 27 >300 >6.8 >11 
16 
 
H NA 27 196 - 7.2 
92 
 
Me 11 12 285 25.9 23.7 
94 
 
OMe 11 23 >300 >27.3 >13 
95 
 
CF3 11 11 >300 >27.3 >27.3 
96 
 
OCF3 3 11 >300 >100 >27.3 
 
Future modifications of 2-phenylquinoline-4-carboxylic acid series could be the replacement 
of quinoline ring with other heterocyclic aromatic rings, to improve the antiviral activity on 
RSV for this series of compounds.  
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The antiviral activity of the second hit, compound 2 was not confirmed. The methyl ester 
derivative of compound 2 showed a comparable antiviral activity on both RSV stains to 
compound 1. All the designed and synthesised 2-(2-(N-phenyl-N-mesyl)acetamido)benzoic 
acid analogues did not show any antiviral activity improvements.  
Further biological studies are ongoing, raising resistant virus for these compounds, to 
confirm or not that the N protein binding is the mechanism of action. 
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Chapter 5: F protein and α-Helix Mimics 
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5.1 F protein 
The F protein is responsible for the viral entry, through the fusion of the viral and cell 
membranes. The functional protein is a homotrimer of F proteins and has two functional 
conformations, one called pre-fusion and the second one called post-fusion (Figure 26 a,b). 
The transformation from the pre- to the post-fusion conformation is driven by a series of 
conformational rearrangements, as explained in the introduction. 
 
Figure 26. F protein. a) ribbon representation of the pre-fusion F protein conformation; b) 
ribbon representation of the post-fusion F protein conformation; c) schematic representation 
of the F protein domains. HRA = Heptad Repeat A domain; HRB = Heptad Repeat B 
domain, HRC = Heptad Repeat C domain, FP = fusion peptide. 
 
The protein has different domains (Figure 26 c.), but the most important are the HRB and 
HRA, which are fundamental for the fusion process.37 
Since 1980, different series of compounds were published and patented as RSV inhibitors 
of the F protein (Figure 27), and almost all of them are specifically targeting the 6-HB motif, 
which is generated during the late stage of the conformational rearrangements.114-122 The 
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rearrangements that lead to a stable 6-HB conformation are the most important for viral 
entry. All these inhibitors cause rapid development of viral strains resistance.123 The 
formation of the 6-HB seems to be driven by the hydrophobic interaction of the HRB 
hydrophobic residues.  
 
 
Figure 27. F protein inhibitors. 
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5.2 Rational design of a α-helix mimics 
In 1996, synthetic peptides with the helical structure of the HRB region of the F protein, 
were reported as potent inhibitors of RSV, in particular, they were able to inhibit the viral 
fusion in cell-based assays.124 The FDASISQVNEKINQSLAFIRKSDELL sequence was 
reported as the portion of the HRB responsible for the inhibition activity and can be observed 
in the crystal structure of the post-fusion F protein (Fig. 28; Pdb: 3RRR). 
The HIV gp41 protein has a fusion complex similar to the RSV 6-HB motif of the F fusion. 
A reported strategy for the inhibition of the formation of HIV gp41 6-HB is to inhibit the PPI 
between the trimeric inner coiled-coil and the external α-helix, using α-helix mimics.125 An 
α-helix mimic is a compound that mimics the topography of the crucial amino acids 
backbones that are important for the PPI.126 
 
 
Figure 28. Representation of the 6-HB motif. 
 
5.2.1 Virtual library generation 
Starting from this information and based on the model of the fusion process, the 
FDASISQVN fragment of the HRB helix (Fig. 29) was selected as a template for the rational 
design of α-helix mimics.  
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Figure 29. HRB Selected Fragment. 
 
This fragment shows hydrophobic Phe, Ile and Val residues in positions i, i+4, i+7 and can 
be speculated that in the hydrophobic driven rearrangement of the F protein, the order of 
importance of the hydrophobic amino acids is the Phe>Ile>Val. 
A series of scaffolds reported from conformational analysis to be able to mimic this kind of 
positions topologically were selected and explored.127-133 
 
 
Figure 30. i, i+4, i+7 mimic scaffold. 
 
Four diverse scaffolds were chosen; their structures are shown in Figure 30. Scaffold a is 
an N-alkylated aromatic oligoarylamide, b and c are 2-O-alkylated and 3-O-alkylated 
oligoarylamide, and d is a hybrid scaffold, composed of 2,3-O-alkylated arylamide and 
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aminoacids. To mimic the backbones of the hydrophobic residues, benzyl and phenyl 
moieties were selected for Phe residue. The sec-butyl moiety was chosen for Ile residue 
and an isopropyl moiety for Val residue. 
Based on the selected scaffolds, a virtual library of compounds was built considering all the 
possible combinations as shown in Figure 31.  
 
 
Figure 31. Generated virtual library. 
 
5.2.2 Conformational search and Molecular docking 
A conformational search using the QMD (Quenched molecular dynamic) technique was 
performed on the generated virtual library, using the open-source command-line tool 
Open3DAlign. The QMD uses short molecular dynamics simulations to find the most stable 
conformers for each given compound. The program uses the MMFF94 force field for atom 
assignment and minimisation of the generated structures. The conformers generated with 
this conformational analysis were manually superimposed to the target sequence and 
analysed through a visual inspection. Only the O-alkylated scaffolds a and b and the hybrid 
scaffold d have a topology for the hydrophobic moieties in the correct position to mimic the 
hydrophobic amino acidic residues of the target sequence (Figure 32).  
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Figure 32. Selected scaffolds. 
These compounds were then docked using Glide SP into a grid generated from the 6-HB 
of 3RRR crystal, after removing HRB peptides from the 6-HB. From the binding modes 
obtained only compound 126 (Figure 33) showed the correct orientation in the binding site 
to mimic the α-helix fragment of HRB. This compound was therefore selected for chemical 
synthesis and biological evaluation. 
 
 
Figure 33. Selected compound 126 and docked pose. 
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5.3 Synthesis of selected α-helix mimic compound 
The selected compound 126 structure, having a 3-O-alkylated oligoarylamide scaffold, can 
be split into the three 4-amino-3-O-functionalised benzoic acid building blocks (BB) 
represented in figure 34 by the letter A, B and C, which are the result of the amide bond 
disconnections showed with red lines in figure 34. Finally, the carboxylic group of the 3-O-
alkylated oligoarylamide scaffold is functionalised with a glycine. 
 
 
Figure 34. Structural composition of compound 126. 4-amino-3-O-functionalised 
benzoic acid building blocks A, B and C (in blue); in grey the oligoarylamide scaffold; in 
purple the glycine; the red lines represent the amide bond disconnections. 
 
 
Figure 35. Selected intermediate to be synthesised and evaluated. 
 
To validate the α-helix mimicry approach for the inhibition of the F protein rearrangement 
was decided to synthesise and biologically evaluate, along with the selected compound 
126, the synthetic intermediates (see figure 35). These intermediates could provide some 
evidence of the importance of the different hydrophobic backbones introduced in the α-helix 
mimic compound 126. 
During the planning of the synthesis for the coupling of the three building blocks, it was 
decided to protect the amino group of the 4-amino-3-O-functionalised benzoic acids B and 
C. 
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Scheme 22. Planned synthetic route for compound 126. 
 
The synthetic route chosen for compound 126, shown in Scheme 22, consists of three 
cycles of coupling and deprotection. This synthetic route was designed for the possible 
future generation of alpha-helix mimics libraries.  
Building blocks for the synthesis of the desired compound are not commercially available. 
Therefore, they were synthesised as shown in Scheme 23 and Scheme 24. 127 was 
synthesised through the synthesis shown in scheme 24, starting from methyl 3-fluoro-4-
nitrobenzoate 132. First, the fluoro group of 133 was replaced by a phenoxy group with an 
SNAr, and then the nitro group was reduced by hydrogenation to give the desired BB 127.131 
 
 
Scheme 23. Synthesis BB 127; i) Phenol, K2CO3, DMF, rt, o.n., Y=99%; ii) H2, Pd/C, 
MeOH/EtOAc (3:1), rt, o.n., Y=89%. 
 
The other two building blocks 128 and 130 were synthesised both from 4-amino-3-
hydroxybenzoic acid 134. After the protection of the carboxylic acid as methyl ester, the 
amine group was protected using the tert-butyloxycarbonyl protecting group. These two 
protections were necessary for the next step of O-alkylation, which after basic hydrolysis 
gives the desired building blocks 128 and 130.134-136 
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Scheme 24. Synthesis BBs 128, 130. i) SOCl2, MeOH, rt, o.n., Y=99%; ii) (Boc)2O, TEA, 
DCM, rt, 24h, Y=99%; iii) 2-bromoalkane, NaH, DMF, rt, on, Y=67-70%; iv) NaOH, 
THF/MeOH (2:1), rt, 3h, Y=88%; 
 
Different reaction conditions were used for the amide coupling of the building blocks 127 
and 128 (Scheme 25). 
 
 
Scheme 25. Coupling between building block 127 and 128. 
 
The first attempt was made using the T3P coupling reagent (Scheme 26). T3P 139 is a 
propyl phosphonic anhydride which is able to convert the oxygen of the carboxylic group 
(128) in a suitable leaving group, as shown in scheme 27.137 
 
 
Scheme 26. Coupling attempt with T3P. 
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Figure 36. T3P. 
 
The by-product of the leaving group is easily removable from the reaction mixture, making 
the T3P reagent a promising coupling reagent. Unfortunately, after several attempts, the 
formation of the desired product was not observed. This result can be related to the low 
reactivity of the aniline amine 127, and to the fact that the phenoxy group hinders the amine 
group.  
 
Scheme 27. T3P reaction mechanism. 
 
Other several attempts were performed using the TBTU (O-(Benzotriazol-1-yl)-N,N,N′,N′-
tetramethyluronium tetrafluoroborate 140 (Figure 37), amide coupling reagent (Scheme 28).  
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Scheme 28. Coupling attempt with TBTU. 
 
 
Figure 37. TBTU. 
 
Also, in this case, TBTU is necessary for the activation of the carboxylic acid to transform 
the oxygen in a leaving group that can be replaced by the amine (Scheme 29). Also, in this 
case, as for the T3P reactions, the formation of the desired product 129 was not observed. 
This result, as was supposed for the T3P, can be related to the low reactivity of the aniline 
amine and for the fact that the amine group is hindered by the phenoxy group.138  
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Scheme 29. TBTU reaction mechanism. 
 
After the results obtained with T3P and TBTU, an attempt using thionyl chloride to generate 
the acyl chloride in situ was made (Scheme 30).139 
 
 
Scheme 30. Thionyl chloride mediate coupling. 
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In this case, the desired product 129 was formed, but the reaction gave low yield and several 
by-products. The major by-product was 128, with the unprotected amine, due to the acid 
conditions given by the thionyl chloride in the reaction.  
Even if the yield was low, the coupling between the anilinic amine and the acyl chloride 
seems to work. For this reason, another protecting group or strategy needs to be introduced 
for the protection of the anilinic amine.  
 
  
Figure 38. New building blocks B and C. 
 
The previously performed conversion of the BB A 122, from the nitro precursor 133, 
suggested the use of the nitro group as an un-reactive group. This strategy will avoid the 
formation of any synthetic by-product during the coupling reaction between BBs A and B. 
For this reason, compounds 141 and 142 were decided to be used instead of the Boc 
protected BBs, and a new synthetic route was planned, see scheme 31. In this route the 
oligoarylamide scaffold 144, formed by the BBs A, B and C are synthesised by two cycles 
of coupling and reduction of the nitro group to amino group. The final functionalisation of 
the oligoarylamide scaffold 144 with the glycine is planned to be obtained by basic 
hydrolysis of the methyl ester, coupling with the methyl glycinate and finally, another step 
of basic hydrolysis to give compound 126. 
 
Scheme 31. New planned synthetic route for compound 126. 
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Like the other building blocks (127,128 and 130), the 3-alkyloxy-4-nitrobenzoic acids are 
not commercially available. As can be seen in scheme 32, compounds 141 and 142 were 
synthesised in a three steps synthetic pathway. 
 
 
Scheme 32. Synthesis BBs 141, 142. i)SOCl2, MeOH, rt, o.n., Y=98%; ii) bromoalkane, 
NaH, DMF, 70°C, 6h, Y=84-98%; iii) NaOH, THF/MeOH (2:1), rt, 3h, Y=86-93%. 
 
For the coupling between the building blocks A and B, was decided to try the coupling 
procedure developed for the synthesis of compound 2. The 3-(sec-butoxy)-4-nitrobenzoic 
acid 141 was converted into the acyl chloride and then added drop-wise to a DCM solution 
containing the BB A (127) and triethylamine, giving the methyl 4-(3-(sec-butoxy)-4-
nitrobenzamido)-3-phenoxybenzoate 149 with an overall yield over two steps of 86% 
(scheme 33).  
Then the obtained compound 149 was successfully reduced by hydrogenation the relative 
amine 150.  
 
 
Scheme 33. BB A and B coupling and reduction. i) SOCl2 neat, reflux, 4h; ii) TEA, DCM, 
rt, o.n., (over 2 steps Y=86%); iii) H2, Pd/C, EtOAc, rt, o.n., Y=90%. 
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The result obtained by the synthesis of the essential intermediate 150, gave a hint of the 
feasibility of the applied synthetic strategy for the coupling between the building blocks and 
the use of the nitro group to mask the anilinic amine. Compound 150 is the crucial synthetic 
intermediate for the synthesis of the other intermediates.  
The methyl 4-(4-amino-3-(sec-butoxy)benzamido)-3-phenoxybenzoate 150 was hydrolysed 
in basic condition to give the free acid derivative 151 which, was then functionalised with 
the glycine. For doing this, the TBTU coupling reagent to activate the carboxylic acid. In this 
case, the glycine amine is more reactive than the anilinic amine and for this reason, can 
replace the activated benzotriazole ester. The obtained methyl (4-(4-amino-3-(sec-
butoxy)benzamido)-3-phenoxybenzoyl)glycinate 152 was then hydrolysed in basic 
condition to give the free acid derivative 153 (scheme 34). 
 
 
Scheme 34. Synthesis of compound 153. i) NaOH, THF/MeOH (2:1), rt, 3h, Y=93%; ii) 
methyl glycinate hydrochloride, TBTU, DIPEA, DMF, rt, o.n., Y=94%; iii) LiOH, THF/MeOH 
(2:1), rt, on, Y=73%. 
 
The following stage was to synthesise the oligoarylamide 154 with the three hydrophobic 
features. As shown in scheme 35, this was obtained through the three steps (coupling, 
reduction of the nitro group and methyl ester hydrolysis) synthesis starting from the 
intermediate 150. The reduction step was optimised adding the THF as a co-solvent to 
increase the solubility of the starting material 155, which was partially soluble in EtOAc. 
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Figure 39. Oligoarylamide 154. 
 
Scheme 35. Synthesis of compound 154. i) SOCl2 neat, reflux, 4h; ii) TEA, DCM, rt, o.n., 
(over 2 steps Y=87%); iii) H2, Pd/C, EtOAc/THF, rt, o.n., Y=88%; iv) NaOH, THF/MeOH 
(2:1), rt, 3h, Y=44%. 
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The α-helix mimic, (4-(4-(4-amino-3-isopropoxybenzamido)-3-(sec-butoxy) benzamido)-3-
phenoxybenzoyl)glycine 126, was obtained by coupling reaction between the intermediate 
154, followed by basic hydrolysis of the methyl ester derivative 157 (Scheme 36). 
 
 
 
Scheme 36. Synthesis of compound 126. i) methyl glycinate hydrochloride, TBTU, 
DIPEA, DMF, rt, o.n., Y=99%; ii) LiOH, THF/MeOH (2:1), rt, on, Y=59% 
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5.3.1 Biological evaluation of selected α-helix mimic 
The synthesised α-helix mimic 126 and the selected intermediate were biologically 
evaluated in CPE antiviral assay in Hep2 cells line, infected with RSV-A2 and RSV-B and 
the cytotoxicity evaluated by MTS readout (table 26). 
Table 25. Antiviral and cytotoxicity data for compound 126 and the selected 
intermediates. Compounds were biologically evaluated in cell based antiviral assay (AVA) 
against RSV-A2 and RSV-B strains and for its cytotoxicity. Data are representative of two 
independent experiments. NA = not active. SI = selectivity index (CC50/EC50) 
 
 
Compounds 
EC50 
RSV-A2 
(μM) 
EC50 
RSV-B 
(μM) CC50 
SI 
RSV-A2 
SI 
RSV-B 
150 NA NA >300 - - 
151 NA NA >300 - - 
152 NA NA >300 - - 
153 NA NA >300 - - 
156 NA NA >300 - - 
154 NA NA 13 - - 
157 NA NA >300 - - 
126 12 12 39 3.2 3.2 
 
 
From the biological evaluation, only the designed α-helix mimic 126 among the synthesised 
intermediates shown an antiviral activity of 12 μM against both RSV strains, with a CC50 of 
39 μM and an SI of 3.2.   
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5.4 Synthesis of 126 α-helix mimic analogues 
Since the results obtained from the antiviral evaluation of compound 126 and its 
intermediates in which the addiction 4-amino-3-isopropoxybenzamido moiety is associated 
with the antiviral activity, it was decided to substitute the isopropoxy group in position 3 on 
the last benzamido moiety (building block C) to position 2 (compound 158 in figure 40). This 
change will give information on the antiviral activity associated with the orientation of the 3-
isopropoxy group. 
 
 
Figure 40. Compound 158 and building block 159. 
 
For the introduction of the planned modification, it was necessary to synthesise the new 
building block, the 2-isopropoxy-4-nitrobenzoic acid 159 (see figure 40). The building block 
was synthesised using the three steps synthetic pathway used for the synthesis of building 
blocks 141 and 142, as shown in scheme 37. 
 
 
Scheme 37. Synthesis BB 159. i)SOCl2, MeOH, rt, o.n., Y=89%; ii) 2-bromopropane, NaH, 
DMF, 70°C, 6h, Y=90%; iii) NaOH, THF/MeOH (2:1), rt, 3h, Y=92%; 
 
The obtained building block 159, was then coupled to the intermediate 152, using the 
optimised three steps of synthesis as shown in scheme 38 to give the desired product 158. 
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Scheme 38. Synthesis of compound 158. i) SOCl2 neat, reflux, 4h; ii) TEA, DCM, rt, o.n., 
(over 2 steps Y=95%); iii) H2, Pd/C, EtOAc/THF, rt, o.n., Y=95%; iv) LiOH, THF/MeOH (2:1), 
rt, 3h, Y=80%. 
 
To further investigate the influence of the 4-amino-3-isopropoxybenzamido moiety on the 
antiviral activity of compound 126, it was decided to functionalised intermediate 152 with 
three acyl chlorides, respectively acetyl chloride, isobutyryl chloride and 3-methylbutanoyl 
chloride. 
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The acyl chlorides were selected to introduce a methyl, an isopropyl and an isobutyl groups 
on the compound 152. The aim was to confirm the importance of the 4-amino-3-
isopropoxybenzamido moiety of compound 126, for the right orientation of the hydrophobic 
isopropyl group. As can be seen in scheme 39, the derivatives of compound 152 were 
obtained through the coupling between the selected acyl chloride and the intermediate 152, 
followed by methyl ester hydrolysis in basic condition. 
 
 
Scheme 39. Synthesis of the derivatives of compound 152. i) Acyl chloride, TEA, DCM, 
rt, o.n., Y=60-86%; ii) LiOH, THF/MeOH (2:1), rt, 3h, Y=82-93%. 
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5.4.1 Biological evaluation of 126 α-helix mimic analogues 
From the biological evaluation of the analogues of compound 126, any of the modification 
introduced to the original structure give retention or improvement of the antiviral activity (see 
table 27 and 28). The substitution of the isopropoxy group in position 3 on the last 
benzamido moiety to position 2 in compound 158 is suggesting that the position of the 
isopropoxy group is essential for the antiviral activity. 
 
Table 26. Antiviral evaluation of compounds 158 and 164. Compounds were biologically 
evaluated in cell based antiviral assay (AVA) against RSV-A2 and RSV-B strains and for its 
cytotoxicity. Data are representative of two independent experiments. NA = not active. SI = 
selectivity index (CC50/EC50) 
 
 
Compounds 
EC50 
RSV-A2 
EC50 
RSV-B CC50 
164 NA NA >300 
158 NA NA 65 
 
 
Also, the three alkylamide derivatives of compound 152 were not associated with any 
antiviral activity against RSV, suggesting that 4-amino-3-isopropoxybenzamido moiety in 
compound 126 is important to eventually orientate the isopropoxy group in the right position 
to bind with the protein. 
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Table 27. Antiviral evaluation of compounds 165 and 170. Compounds were biologically 
evaluated in cell based antiviral assay (AVA) against RSV-A2 and RSV-B strains and for its 
cytotoxicity. Data are representative of two independent experiments. NA = not active. SI = 
selectivity index (CC50/EC50) 
 
 
Compounds 
EC50 
RSV-A2 
EC50 
RSV-B CC50 
165 NA NA >300 
166 NA NA >300 
167 NA NA >300 
168 NA NA >300 
169 NA NA 198 
170 NA NA >300 
 
5.5 Conclusion 
Several chemoinformatic techniques were used to generate and evaluate a focussed 
virtual library of compounds designed to mimic the hydrophobic backbones in 
positions i, i+4, i+7 of the 488FDASISQVN496 fragment. The generated library was used 
for a structure-based virtual screening on the X-ray structure of the post-fusion F 
protein. Only compound 126 seemed to be able to have the hydrophobic groups in 
the proper orientation to mimic the hydrophobic backbones of the Phe488, Ile492 and 
Val495. 
 
 
A highly versatile synthetic route was developed for the synthesis of the selected α-helix 
mimic 126. The compound and the different intermediates were tested. Only the selected 
compound showed an antiviral activity, but with a low CC50 and SI.  
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The modifications on the selected compound suggested that the 4-amino-3-
isopropoxybenzamido moiety and the topological orientation of the isopropoxy seem to be 
crucial for the antiviral activity. 
Future modifications on the selected compound could be to improve the chemical-physical 
properties of the scaffold introducing alkyloxypicolonamido or alkyloxynicotinamido building 
blocks in the scaffold, to increase solubility. Another modification could be adding another 
4-amino-alkyloxybenzamido moiety to the scaffold and eventually optimise the hydrophobic 
mimicry groups in order to improve the antiviral activity.  
Further biological studies are ongoing to validate the hypothesis of the mode of action of 
the α-helix mimic approach for the inhibition of the F protein as an antiviral strategy.  
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Chapter 6: Experimental 
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6.1 General information 
All chemicals, reagents and solvents were purchased from Sigma-Aldrich, FluoroChem, 
Apollo Scientific, TCI UK or purified by standard techniques. 
 
Thin Layer Chromatography 
Silica gel plates (Merck Kieselgel 60F254) were used and were developed by the ascending 
method. After solvent evaporation, compounds were visualised by irradiation with UV light 
at 254 nm and 366 nm. 
 
Column Chromatography 
Column Chhromatography was performed using an automated Isolera One System 
(Biotage), using Biotage pre-packed silica cartridges (SNAP and KP types). Samples were 
applied as a concentrated solution in the same eluent. Fractions containing the product 
were identified by TLC, combined and the solvent removed in vacuo. 
 
UPLC-MS analysis 
UPLC-MS analysis was conducted on a Waters UPLC system with both Diode Array 
detection and Electrospray (+’ve and –‘ve ion) MS detection. The stationary phase was a 
Waters Acquity UPLC BEH C18 1.7um 2.1x50mm column. The mobile phase was H2O 
containing 0.1% Formic acid (A) and MeCN containing 0.1% Formic acid (B). Column 
temperature: 40°C. Sample diluent: acetonitrile. Sample concentration 10 ug/mL. Injection 
volume 2 uL. Two methods were used: 
Linear gradient standard method A: 90% A (0.1 min), 90%-0% A (2.6 min), 0% A (0.3 
min), 90% A (0.1 min); flow rate 0.5 mL/min.  
Linear gradient standard method B: 90% A (0.1 min), 90%-0% A (2.1 min), 0% A (0.8 
min), 90% A (0.1 min); flow rate 0.5 mL/min.  
Linear gradient standard method C: 90% A (0.1 min), 90%-0% A (1.5 min), 0% A (1.4 
min), 90% A (0.1 min); flow rate 0.5 mL/min. 
 
NMR Spectroscopy 
1H, 13C, NMR spectra were recorded on a Bruker AVANCE 500 spectrometer (500 MHz and 
75 MHz respectively) and auto calibrated to the deuterated solvent reference peak. 
Chemical shifts are given in δ relative to tetramethylsilane (TMS); the coupling constants 
(J) are given in Hertz. TMS was used as an internal standard (δ = 0 ppm) for 1H NMR and 
CDCl3 served as an internal standard (δ = 77.0 ppm) for 13C NMR. 
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6.1.1 Molecular modelling 
A PC 1.80 GHz Intel Xeon (8 cores), running Ubuntu 14.04 LTS was used for molecular 
modelling studies. 
Two molecular modelling softwares were used: Molecular Operating Environment (MOE) 
2015.10 and Maestro (Schrӧdinger version 10).140 
Pharmacophoric filters were created with PLIFs in MOE 2015.10. 
Docking experiments were performed using GlideSP module in Maestro, running the default 
option. 
Docking results were rescored using Plants ChemPLP, FlexX and Glide XP scoring 
function. 
The best docked poses were selected using a consensus scoring function: for each scoring 
function, the function fquart was calculated to determine the threshold limit under which 
relies the best 25% of the scoring results (negative energy value).  
Then for each scoring value of each docked pose, the function Sign was calculated. If the 
docked pose belongs to the best 25% the sign = +1 otherwise sign= -1. 
In the end, the three sign values, generated for each scoring values obtained from each 
docked pose were summed and only the ones with a sign sum equal to +3 were chosen. 
The consensus scoring function equation for a given docked pose X was calculated as 
follows: 
sign sum(X) = sign(fquartA - XA) + sign(fquartB - XB) + sign(fquartC - XC) 
A=GlideXP; B=Plants ChemPLP; C=FlexX 
Conformational search was performed with Open3DAlign version 2.3., using the default 
option.141  
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6.2 Synthesis of M76 
dimethyl 1-(2,4-dichlorobenzyl)-1H-pyrazole-3,5-dicarboxylate (8)  
(C14H12Cl2N2O4, M.W.: 343.1) 
 
A mixture of dimethyl 1H-pyrazole-3,5-dicarboxylate 6 (0.7 mmol), 1-(bromomethyl)-2,4-
dichlorobenzene 7 (0.7 mmol) and K2CO3 (1.05 mmol) in anhydrous DMF (1.0 mL) under 
nitrogen atmosphere was stirred at room temperature for 4 h. The reaction mixture was 
quenched with 10 ml of water. The aqueous layer was extracted with EtOAc (3 x 10 mL). 
The organic layers were combined, washed with brine (3 x 30 mL), dried over MgSO4 and 
was evaporated at reduced pressure. The crude residue was purified by flash column 
chromatography (Biotage Isolera One system, Cartridge: SNAP KP Sil 10g, n-hexane -
EtOAc 100:0 v/v increasing to 60:40 v/v in 15 CV) to give pure dimethyl 1-(2,4-
dichlorobenzyl)-1H-pyrazole-3,5-dicarboxylate 8 as a white solid. 
T.L.C. System: n-hexane – EtOAc 8:2 v/v, Rf: 0.35. 
Yield: 211 mg (87%) 
Purity: 99% 
UPLC-MS method C: Rt: 2.00, MS (ESI)+: 343.1 (56%), 345.1(37%), 347.1 (7%) [M+H]+, 
365.1[M+Na]+ 
1H NMR (DMSO-d6), δ: 7.70 (d, 4J=2.1 Hz, 1H), 7.42 – 7.36 (m, 2H), 6.76 (d, 3J=8.4 Hz, 
1H), 5.88 (s, 2H), 3.83 (s, 3H), 3.82 (s, 3H). 
13C NMR (DMSO-d6), δ: 161.56, 159.20 (C=O), 142.55, 134.47, 133.79, 133.65 (C, C-
aromatic), 133.14, 130.18, 129.40, 128.28, 113.97(CH, C-aromatic), 53.08(CH3), 52.96 
(CH2), 52.49 (CH3). 
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1-(2,4-dichlorobenzyl)-1H-pyrazole-3,5-dicarboxylic acid (5)  
(C12H8Cl2N2O4, M.W.: 315.1) 
 
To a solution of dimethyl 1-(2,4-dichlorobenzyl)-1H-pyrazole-3,5-dicarboxylate 8 (0.38 
mmol), in THF (2.0 mL), a solution of NaOH (15% m/v, 1.52 mmol) was added and the 
obtained mixture was stirred at room temperature for 2 days. The reaction mixture diluted 
with 5 ml of water. The aqueous layer was acidified with a 2N solution of HCl and extracted 
with EtOAc (3 x 10 mL). The organic layers were combined, washed with brine (3 x 30 mL), 
dried over MgSO4. The organic layer was evaporated at reduced pressure to afford the pure 
1-(2,4-dichlorobenzyl)-1H-pyrazole-3,5-dicarboxylic acid 5 as a: white solid. 
T.L.C. System: EtOAc-MeOH-TEA 8.2:1.6:0.2 v/v, Rf: 0.20. 
Yield: 113 mg (95%) 
Purity: >95% 
1H NMR (DMSO-d6), δ: 13.16 (s, 2H), 7.70 (d, 4J = 2.1 Hz, 1H), 7.39 (dd, 3J = 8.4 Hz, 4J = 
2.1 Hz, 1H), 7.26 (s, 1H), 6.71 (d, 3J = 8.4 Hz, 1H), 5.87 (s, 2H). 
13C NMR (DMSO-d6), δ: 162.71 (C=O), 160.34 (C=O), 143.55, 135.63, 134.21, 133.50, 
133.05(C, C-aromatic), 130.05, 129.34, 128.26, 113.93 (CH, C-aromatic), 52.70 (CH2). 
 
bis(acetoxymethyl) 1-(2,4-dichlorobenzyl)-1H-pyrazole-3,5-dicarboxylate (8)  
(C18H16Cl2N2O8, M.W.: 459.2) 
 
A mixture of 1-(2,4-dichlorobenzyl)-1H-pyrazole-3,5-dicarboxylic acid 5 (0.127 mmol), 
chloromethyl acetate 9 (0.254 mmol) and triethylamine (0.305 mmol) in Acetone (0.5 mL) 
was stirred at reflux overnight. The reaction mixture was concentrated under reduced 
pressure and the residue was diluted with 5 ml of water. The aqueous layer was extracted 
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with EtOAc (3 x 10 mL). The organic layers were combined, washed with brine (3 x 30 mL), 
dried over MgSO4. The organic layer was concentrated under reduced pressure and the 
obtained crude residue was purified by flash column chromatography (Biotage Isolera One 
system, Cartridge: SNAP KP Sil 10g, n-hexane -EtOAc 100:0 v/v increasing to 60:40 v/v in 
15 CV) to give pure bis(acetoxymethyl) 1-(2,4-dichlorobenzyl)-1H-pyrazole-3,5-
dicarboxylate (10) as a colourless oil. 
T.L.C. System: n-hexane – EtOAc 8:2 v/v, Rf: 0.18. 
Yield: 48 mg (82%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.983, MS (ESI)+: 481,0[M+Na]+ 
1H NMR (DMSO-d6), δ: 7.71 (d, 4J = 2.1 Hz, 1H), 7.46 (s, 1H), 7.39 (dd, 3J = 8.4 Hz, 4J = 
2.1 Hz, 1H), 6.80 (d, 3J = 8.4 Hz, 1H), 5.90 (s, 2H), 5.89(s, 2H), 5.87 (s, 2H), 2.11 (s, 3H), 
2.08 (s, 3H). 
13C NMR (DMSO-d6), δ: 169.81, 169.68, 159.61, 157.24 (C=O), 141.67, 133.94, 133.77, 
133.46, 133.20 (C, C-aromatic), 130.25, 129.45, 128.28, 115.25 (CH, C-aromatic), 80.24, 
79.98, 53.29 (CH2), 20.97, 20.91 (CH3). 
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6.3 Synthesis of Quinoline structures 
6.3.1 General procedures 1-3 
 
General procedure 1: synthesis of (alkyloxy)acetophenones 
 
 
 
A mixture of hydroxyacetophenone (1.47 mmol), bromoalkane (1.62 mmol) and K2CO3 (2.20 
mmol) in anhydrous DMF (1.4 mL) under nitrogen atmosphere was stirred under reflux for 
16 h. The reaction mixture was quenched with 10 ml of NaOH solution (15% p/v).  The 
aqueous layer was extracted with EtOAc (3 x 15 mL). The organic layers were combined, 
washed with brine (3 x 30 mL) and dried over MgSO4. The organic solvent was evaporated 
at reduced pressure and the crude residue was purified by flash column chromatography to 
afford pure (alkyloxy)acetophenones. 
 
General procedure 2: synthesis of 2-(phenyl)quinoline-4-carboxylic acid analogues 
 
 
 
Isatin (2.04 mmol) and KOH (6.12 mmol) were suspended in a solution of EtOH and water 
(7:1 ratio, 2mL). The reaction mixture was stirring at RT for 10 min and then acetophenone 
(2.448 mmol) was added. The reaction mixture was irradiated at the MW for 40 min at 
150°C.  
The reaction mixture was diluted with water (4 mL) and then concentrated under reduced 
pressure. The residue was diluted with water (10 ml) and washed remove the excess of 
acetophenone. The aqueous layer was then acidified to pH 5-6 with a solution of HCl (2N). 
The resulting precipitate was collected by filtration and then purified by re-crystallization 
from EtOH. 
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General procedure 3: synthesis of methyl 2-(phenyl)quinoline-4-carboxylate 
analogues 
 
 
2-(phenyl)quinoline-4-carboxylic acid (0.17 mmol) was suspended in anhydrous MeOH (2 
mL) and SOCl2 (0.51 mmol) was added dropwise at RT. The reaction was stirred at RT 
overnight. The reaction was quenched with water (2 mL) and then concentrated under 
reduced pressure. The residue where then dissolved in a sat. NaHCO3 solution (8 mL) and 
extracted with DCM (3 x 10 mL). The organic layers were combined, washed with brine (2 
x 20 mL) and dried over MgSO4. The organic solvent was evaporated under reduced 
pressure and the crude residue was purified by flash column chromatography to afford pure 
methyl 2-(phenyl)quinoline-4-carboxylate. 
 
6.3.2 (Alkyloxy)acetophenones (31-34) 
 
2’-isopropoxyacetophenone (31) 
(C11H14O2; M.W.: 178.2) 
 
General procedure 1; 
Pale yellow solid; 
T.L.C. System: n-hexane -EtOAc 7:3 v/v, Rf: 0.67. 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: ZIP 
KP Sil 30g (n-hexane -EtOAc 100:0 v/v increasing to 40:60 v/v in 11 CV). 
Yield: 470 mg (60%)  
1H-NMR (DMSO-d6), δ: 7.55 (dd, 3J = 7.7 Hz, 4J = 1.8 Hz, 1H), 7.50 (td, 3J = 8.4, 7.7 Hz, 
4J = 1.8 Hz, 1H), 7.17 (d, J = 8.4 Hz, 1H), 6.98 (td, 3J = 7.7 Hz, 4J = 0.9 Hz, 1H), 4.79 (hept, 
J = 6.0 Hz, 1H), 2.54 (s, 3H), 1.35 (s, 3H), 1.33 (s, 3H). 
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2’-propoxyacetophenone (32) 
(C11H14O2; M.W.: 178.2) 
 
General procedure 1; 
Pale yellow oil; 
T.L.C. System: n-hexane -EtOAc 7:3 v/v, Rf: 0.67. 
Purification: Purification: Flash column chromatography Isolera One system (Biotage), 
Cartridge: ZIP KP Sil 10g (n-hexane -EtOAc 100:0 v/v increasing to 40:60 v/v in 11 CV). 
Yield: 159 mg (60%)  
1H-NMR (DMSO-d6), δ: 7.59 (dd, 3J = 7.7, 4J = 1.9 Hz, 1H), 7.52 (td, 3J = 8.4, 4J = 1.9 Hz, 
1H), 7.15 (d, J = 8.4 Hz, 1H), 7.01 (td, 3J = 7.7, 4J = 0.9 Hz, 1H), 4.11 – 4.03 (m, 2H), 2.56 
(s, 3H), 1.87 – 1.76 (m, 2H), 1.03 (t, J = 7.4 Hz, 3H). 
 
2’-(cyclopropylmethoxy)acetophenone (33) 
(C12H14O2; M.W.: 190.2) 
 
General procedure 1; 
Pale yellow oil; 
T.L.C. System: n-hexane -EtOAc 7:3 v/v, Rf: 0.67. 
Purification: Purification: Flash column chromatography Isolera One system (Biotage), 
Cartridge: ZIP KP Sil 10g (n-hexane -EtOAc 100:0 v/v increasing to 40:60 v/v in 11 CV). 
Yield: 329 mg (78%)  
1H-NMR (DMSO-d6), δ: 7.58 (d, J = 7.7 Hz, 1H), 7.51 (t, J = 7.7 Hz, 1H), 7.13 (d, J = 8.3 
Hz, 1H), 7.01 (t, J = 7.4 Hz, 1H), 3.97 (d, J = 7.0 Hz, 2H), 2.60 (s, 3H), 1.36 – 1.23 (m, 1H), 
0.62 – 0.59 (m, 2H), 0.38 (d, J = 4.7 Hz, 2H). 
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3’-ethoxyacetophenone (34) 
(C10H12O2; M.W.: 164.2) 
 
General procedure 1; 
Pale yellow oil; 
T.L.C. System: n-hexane -EtOAc 7:3 v/v, Rf: 0.63. 
Purification: Purification: Flash column chromatography Isolera One system (Biotage), 
Cartridge: ZIP KP Sil 10g (n-hexane -EtOAc 100:0 v/v increasing to 40:60 v/v in 11 CV). 
Yield: 134 mg (55%)  
1H NMR (DMSO-d6), δ: 7.57 – 7.52 (m, 1H), 7.47 – 7.41 (m, 2H), 7.20 (ddd, 3J = 8.2 Hz, 4J 
= 2.7, 0.8 Hz, 1H), 4.09 (q, J = 7.0 Hz, 2H), 2.58 (s, 3H), 1.35 (t, J = 7.0 Hz, 3H). 
 
6.3.3 2-(phenyl)quinoline-4-carboxylic acid analogues (1, 13-19, 
41-52, 77-86) 
 
2-(2-ethoxyphenyl)quinoline-4-carboxylic acid (1) 
(C18H15NO3; M.W.: 293.3) 
 
 
General procedure 2; 
Yellow solid; 
T.L.C. System: EtOAc-MeOH-TEA 8.2:1.6:0.2 v/v, Rf: 0.48. 
Purification: re-crystallisation from EtOH 
Yield: 300 mg (50%) 
Purity: 99% 
UPLC-MS method B: Rt: 1.532, MS (ESI)+: 294.1[M+H]+ 
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1H NMR (DMSO-d6), δ: 13.84 (bs, 1H), 8.75 (dd, 3J = 8.4 Hz, 4J = 0.6 Hz, 1H), 8.54 (s, 1H), 
8.15 (dd, 3J = 8.4 Hz, 4J = 0.6 Hz, 1H), 7.92 (dd, 3J = 7.6 Hz, 4J = 1.8 Hz, 1H), 7.84 (td, 3J = 
7.7 Hz, 4J = 1.4 Hz, 1H), 7.72 (td, 3J = 7.7 Hz, 4J = 1.4 Hz, 1H), 7.49 (td, 3J = 7.8 Hz, 4J = 
1.8 Hz, 1H), 7.21 (d, J = 7.9 Hz, 1H), 7.14 (td, 3J = 7.5 Hz, 4J = 0.9 Hz, 1H), 4.18 (q, J = 6.9 
Hz, 2H), 1.35 (t, J = 6.9 Hz, 3H). 
13C NMR (DMSO-d6), δ: 168.18 (C=O), 156.96, 156.40, 149.00, 135.55 (C, C-aromatic), 
131.61, 131.39, 130.21, 130.19, 128.17(CH, C-aromatic), 128.15 (C, C-aromatic), 125.82, 
124.70 (CH, C-aromatic), 123.75 (C, C-aromatic), 121.35, 113.61 (CH, C-aromatic), 64.39 
(CH2), 15.00(CH3). 
 
Acetoxymethyl 2-(2-ethoxyphenyl)quinoline-4-carboxylate (13) 
(C21H19NO5; M.W.: 365.4) 
 
 
 
A mixture of 2-(2-ethoxyphenyl)quinoline-4-carboxylic acid 1 (0.2 mmol), chloromethyl 
acetate 105 (0.2 mmol) and triethylamine (0.48 mmol) in acetone (4 mL) was stirred at reflux 
for 48 hours. The reaction was concentrated under reduced pressure, diluted with water (8 
mL). The aqueous solution was extracted with DCM (3 x 10 mL). The combined organic 
layers were washed with brine (2 x 20 mL), dried over MgSO4 and evaporated under 
reduced pressure. The crude residue was purified by flash column chromatography 
(Biotage Isolera One system, Cartridge: ZIP KP Sil 5g, n-hexane -EtOAc 100:0 v/v 
increasing to 70:30 v/v in 12 CV) to give pure acetoxymethyl 2-(2-ethoxyphenyl)quinoline-
4-carboxylate (13) as colourless oil. 
T.L.C. System: n-hexane -EtOAc 8:2 v/v, Rf: 0.41. 
Yield: 22 mg (24%) 
Purity: 99% 
UPLC-MS method C: Rt: 2.143, MS (ESI)+: 366.3 [M+H]+ 
1H NMR (DMSO-d6), δ: 8.68 (dd, 3J = 8.5 Hz, 4J = 0.7 Hz, 1H), 8.61 (s, 1H), 8.18 (dd, 3J = 
8.5 Hz, 4J = 0.7 Hz, 1H), 7.96 (dd, 3J = 7.6 Hz, 4J = 1.7 Hz, 1H), 7.88 (td, 3J = 8.3 Hz, 4J = 
1.3 Hz, 1H), 7.77 (td, 3J = 8.3 Hz, 4J = 1.3 Hz, 1H), 7.50 (td, 3J = 8.4 Hz, 4J = 1.8 Hz, 1H), 
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7.22 (d, J = 8.1 Hz, 1H), 7.15 (td, 3J = 7.4 Hz, 4J = 0.8 Hz, 1H), 6.06 (s, 2H), 4.18 (q, J = 
6.9 Hz, 2H), 2.15 (s, 3H), 1.38 (t, J = 6.9 Hz, 3H). 
13C NMR (DMSO-d6), δ: 169.94, 164.88 (C=O), 156.99, 156.21, 148.96, 132.87 (C, C-
aromatic), 131.89, 131.36, 130.60, 130.38, 128.78 (CH, C-aromatic), 127.53 87 (C, C-
aromatic), 125.24, 125.17 (CH, C-aromatic), 123.29 (C, C-aromatic), 121.38, 113.49 (CH, 
C-aromatic), 80.55, 64.40 (CH2), 20.97, 14.85 (CH3). 
 
Methyl 2-(2-ethoxyphenyl)quinoline-4-carboxylate (14) 
(C19H17NO3; M.W.: 307.3) 
 
 
General procedure 3; 
Yellow solid; 
T.L.C. System: n-hexane -EtOAc 8:2 v/v, Rf: 0.53. 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: ZIP 
KP Sil 5g (n-hexane -EtOAc 100:0 v/v increasing to 40:60 v/v in 11 CV).  
Yield: 30 mg (29%) 
Purity: 99% 
UPLC-MS method C: Rt: 2.138, MS (ESI)+: 308.1[M+H]+ 
1H NMR (DMSO-d6), δ: 8.66 (dd, 3J = 8.5 Hz, 4J = 0.8 Hz, 1H), 8.57 (s, 1H), 8.17 (dd, 3J = 
8.4 Hz, 4J = 0.6 Hz, 1H), 7.94 (dd, 3J = 7.6 Hz, 4J = 1.8 Hz, 1H), 7.86 (td, 3J = 8.4 Hz, 4J = 
1.4 Hz, 1H), 7.74 (td, 3J = 8.3 Hz, 4J = 1.3 Hz, 1H), 7.50 (td, 3J = 8.4 Hz, 3J = 1.8 Hz, 1H), 
7.22 (d, J = 8.3 Hz, 1H), 7.14 (td, 3J = 7.5 Hz, 4J = 0.9 Hz, 1H), 4.19 (q, J = 6.9 Hz, 2H), 
4.01 (s, 3H), 1.37 (t, J = 6.9 Hz, 3H). 
13C NMR (DMSO-d6), δ: 166.81 (C=O), 156.99, 156.29, 148.94, 134.28 (C, C-aromatic), 
131.75, 131.34, 130.44, 130.28, 128.47 (CH, C-aromatic), 127.84 (C, C-aromatic), 125.52, 
124.81(CH, C-aromatic), 123.38 (C, C-aromatic), 121.37, 113.58 (CH, C-aromatic), 64.42 
(CH2), 53.37, 14.97 (CH3). 
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(2-(2-ethoxyphenyl)quinolin-4-yl)methanol (15) 
(C18H17NO2; M.W.: 279.3) 
 
 
 
Methyl 2-(2-ethoxyphenyl)quinoline-4-carboxylate 14 (0.21 mmol) was dissolved in 
anhydrous MeOH (3 mL). The reaction mixture was cooled to 0°C in an ice-bath. NaBH4 
(0.86 mmol) was added and the reaction was stirred at room temperature for 72 hours. The 
reaction mixture was concentrated under reduced pressure and the residue was then 
diluted with water (6 mL). The aqueous layer was extracted with EtOAc (3 x 10 mL). The 
organic layers were combined, washed with brine (2 x 20 mL) dried over MgSO4 and 
concentrated under reduced pressure. The crude residue was purified by flash column 
chromatography (Biotage Isolera One system, Cartridge: ZIP KP Sil 5g, n-hexane -EtOAc 
100:0 v/v increasing to 40:60 v/v in 11 CV) to give pure acetoxymethyl (2-(2-
ethoxyphenyl)quinolin-4-yl)methanol 15 as yellow solid. 
T.L.C. System: n-hexane -EtOAc 8:2 v/v, Rf: 0.15. 
Yield: 15 mg (25%) 
Purity: 97% 
UPLC-MS method C: Rt: 1.299, MS (ESI)+: 280.0 [M+H]+ 
1H NMR (DMSO-d6), δ: 8.13 (s, 1H), 8.10 – 8.01 (m, 2H), 7.82 (d, J = 7.4 Hz, 1H), 7.76 (t, 
J = 7.6 Hz, 1H), 7.60 (t, J = 7.6 Hz, 1H), 7.45 (t, J = 7.6 Hz, 1H), 7.19 (d, J = 8.2 Hz, 1H), 
7.11 (t, J = 7.4 Hz, 1H), 5.57 (t, J = 5.4 Hz, 1H), 5.07 (d, J = 5.4 Hz, 2H), 4.16 (q, J = 6.9 
Hz, 2H), 1.35 (t, J = 6.9 Hz, 3H). 
13C NMR (DMSO-d6), δ: 156.83, 156.78, 147.90, 147.07 (C, C-aromatic), 131.53, 130.97, 
130.04, 129.51, 126.59 (CH, C-aromatic), 124.82 (C, C-aromatic), 123.72, 121.16, 120.42, 
113.55 (CH, C-aromatic), 64.32, 60.31 (CH2), 15.07 (CH3). 
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2-(2-ethoxyphenyl)quinoline-4-carboxamide (16) 
(C18H16N2O2; M.W.: 292.3) 
 
 
 
A mixture of 2-(2-ethoxyphenyl)quinoline-4-carboxylic acid 1 (0.17 mmol), NH3 0.5M in 
Dioxane (0.34 mmol), TBTU (0.2 mmol), and DIPEA (0.39 mmol) in anhydrous DMF (2 ml) 
was stirred at room temperature for 3 hours. The reaction mixture was diluted in DCM (10 
mL) and washed with a sat. NaHCO3 solution (8 mL). The aqueous layer was then extracted 
with DCM (2 x 10 mL). The organic layers were then combined, washed with brine (2 x 20 
mL), dried over MgSO4 and concentrated under reduced pressure. The crude residue was 
purified by flash column chromatography (Biotage Isolera One system, Cartridge: ZIP KP 
Sil 5g, n-hexane -EtOAc 100:0 v/v increasing to 40:60 v/v in 11 CV) to give pure 2-(2-
ethoxyphenyl)quinoline-4-carboxamide 16 as white solid. 
T.L.C. System: n-hexane -EtOAc 6:4 v/v, Rf: 0.14. 
Yield: 96 mg (96%) 
Purity: 95% 
UPLC-MS method C: Rt: 1.521, MS (ESI)+: 293.1[M+H]+ 
1H NMR (DMSO-d6), δ: 8.69-8.61 (m, 1H), 8.19 (s, 1H), 8.11 (d, J = 8.4 Hz, 1H), 8.08 (s, 
1H), 7.88 (d, J = 7.7 Hz, 1H), 7.85 (s, 1H), 7.81 (t, J = 7.6 Hz, 1H), 7.66 (t, J = 7.6 Hz, 1H), 
7.48 (t, J = 7.7 Hz, 1H), 7.22 (d, J = 8.4 Hz, 1H), 7.14 (t, J = 7.6 Hz, 1H), 4.18 (q, J = 6.9 
Hz, 2H), 1.34 (t, J = 6.9 Hz, 3H). 
13C NMR (DMSO-d6), δ: 169.41 (C=O), 156.89, 156.40, 148.50, 141.98 (C, C-aromatic), 
131.52, 131.42, 130.18, 129.89 (CH, C-aromatic), 128.57 (C, C-aromatic), 127.44, 125.79 
(CH, C-aromatic), 123.40 (C, C-aromatic), 121.28, 121.25, 113.61 (CH, C-aromatic), 64.37 
(CH2), 15.04 (CH3). 
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2-(2-ethoxyphenyl)-N-methylquinoline-4-carboxamide (17) 
(C19H18N2O2; M.W.: 306.4) 
 
 
 
A mixture of 2-(2-ethoxyphenyl)quinoline-4-carboxylic acid 1 (0.17 mmol), methylamine 2M 
in THF (0.34 mmol), TBTU (0.2 mmol), and DIPEA (0.39 mmol) in anhydrous DMF (1 ml) 
was stirred at room temperature overnight. The reaction mixture was diluted in EtOAc(10 
mL) and was washed with sat. NH4Cl solution (3 x 8 mL), sat. NaHCO3 solution (3 x 8 mL) 
and brine (3 x 8 mL). The organic layers were then dried over MgSO4 and concentrated 
under reduced pressure. The crude residue was purified by flash column chromatography 
(Biotage Isolera One system, Cartridge: ZIP KP Sil 5g, n-hexane -EtOAc 100:0 v/v 
increasing to 40:60 v/v in 15 CV) to give pure 2-(2-ethoxyphenyl)-N-methylquinoline-4-
carboxamide 17 as white solid. 
T.L.C. System: n-hexane -EtOAc 6:4 v/v, Rf: 0.18. 
Yield: 12 mg (29%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.573, MS (ESI)+: 307.2[M+H]+ 
1H NMR (DMSO-d6), δ: 8.65 (d, 4J = 4.0 Hz, 1H), 8.15 (d, J = 8.3 Hz, 1H), 8.10 (d, J = 8.4 
Hz, 1H), 8.02 (s, 1H), 7.86 (d, J = 7.5 Hz, 1H), 7.80 (t, J = 7.6 Hz, 1H), 7.64 (t, J = 7.6 Hz, 
1H), 7.47 (t, J = 7.7 Hz, 1H), 7.20 (d, J = 8.3 Hz, 1H), 7.12 (t, J = 7.5 Hz, 1H), 4.17 (q, J = 
6.9 Hz, 3H), 2.88 (d, J = 4.5 Hz, 2H), 1.32 (t, J = 6.9 Hz, 3H). 
13C NMR (DMSO-d6), δ: 167.80 (C=O), 156.87, 156.47, 148.46, 142.09 (C, C-aromatic), 
131.50, 131.40, 130.24, 129.90 (CH, C-aromatic), 128.65 (C, C-aromatic), 127.46, 125.73 
(CH, C-aromatic), 123.52(C, C-aromatic), 121.31, 121.29, 113.67(CH, C-aromatic), 64.42 
(CH2), 26.59, 15.01 (CH3). 
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(2-(2-ethoxyphenyl)quinolin-4-yl)(morpholino)methanone (18) 
(C22H22N2O3; M.W.: 362.4) 
 
 
 
A mixture of 2-(2-ethoxyphenyl)quinoline-4-carboxylic acid 1 (0.17 mmol), morpholine (0.34 
mmol), TBTU (0.2 mmol), and DIPEA (0.39 mmol) in anhydrous DMF (1 ml) was stirred at 
room temperature overnight. The reaction mixture was diluted in EtOAc(10 mL) and was 
washed with sat. NH4Cl solution (3 x 8 mL), sat. NaHCO3 solution (3 x 8 mL) and brine (3 x 
8 mL). The organic layers were then dried over MgSO4 and concentrated under reduced 
pressure. The crude residue was purified by flash column chromatography (Biotage Isolera 
One system, Cartridge: ZIP KP Sil 5g, n-hexane -EtOAc 100:0 v/v increasing to 40:60 v/v 
in 15 CV) to give pure (2-(2-ethoxyphenyl)quinolin-4-yl)(morpholino)methanone (18) as 
white solid. 
T.L.C. System: n-hexane -EtOAc 6:4 v/v, Rf: 0.14. 
Yield: 44 mg (72%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.693, MS (ESI)+: 363.3[M+H]+ 
1H NMR (DMSO-d6), δ: 8.13 (d, J = 8.3 Hz, 1H), 7.90 (s, 1H), 7.88 – 7.80 (m, 3H), 7.68 (t, 
J = 7.3 Hz, 1H), 7.48 (t, J = 7.1 Hz, 1H), 7.20 (d, J = 8.3 Hz, 1H), 7.13 (t, J = 7.3 Hz, 1H), 
4.24 – 4.04 (m, 2H), 3.95 – 3.82 (m, 1H), 3.82 – 3.70 (m, 3H), 3.59 – 3.42 (m, 2H), 3.28 – 
3.10 (m, 2H), 1.32 (t, J = 6.9 Hz, 3H). 
13C NMR (DMSO-d6), δ: 166.48 (C=O), 156.83, 156.60, 148.26, 141.50 (C, C-aromatic), 
131.54, 131.43, 130.59, 130.09 (CH, C-aromatic), 128.69 (C, C-aromatic), 127.90, 125.08 
(CH, C-aromatic), 123.00 (C, C-aromatic), 121.24, 120.49, 113.47(CH, C-aromatic), 66.78, 
66.55, 64.38, 47.52, 42.10 (CH2), 15.08 (CH3). 
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2-(2-ethoxyphenyl)quinoline (19) 
(C17H15NO; M.W.: 249.3) 
 
          
 
A mixture of (2-aminophenyl)methanol 20 (1.46 mmol), 2-ethoxyacetophenone 12 (2.92 
mmol), KOH (0.4 mL of a solution 4M in Methanol) and 1st generation Grubbs catalyst 21 
(0.0146 mmol, Bis(tricyclohexylphosphine)benzylidine ruthenium(IV) dichloride) in 
anhydrous dioxane (4.3 mL) was placed in a 7 mL screw-capped vial. The reaction mixture 
was stirred at 80°C for 2 hours. The reaction mixture was filtered through a short silica gel 
column (EtOAc) to remove the catalyst and the inorganic salts. The solution obtained from 
the filtration was concentrated under reduced pressure and the crude was purified by flash 
column chromatography (Biotage Isolera One system, Cartridge: ZIP KP Sil 30g, n-hexane 
-EtOAc 100:0 v/v increasing to 40:60 v/v in 15 CV). The solvent was evaporated under 
reduced pressure. The residue was dissolved in EtOAc (10 mL), washed with water (2 x 8 
mL), dried over MgSO4 and concentrated under reduced pressure. The residue was purified 
by flash column chromatography (Biotage Isolera One system, Cartridge: ZIP KP Sil 10g, 
n-hexane -EtOAc 100:0 v/v increasing to 40:60 v/v in 11 CV) to give 2-(2-
ethoxyphenyl)quinoline 19 as yellow oil. 
T.L.C. System: n-hexane -EtOAc 8:2 v/v, Rf: 0.57. 
Yield: 118 mg (32%) 
Purity: 99% 
UPLC-MS method B: Rt: 1.779, MS (ESI)+: 250.2 [M+H]+ 
1H NMR (DMSO-d6), δ: 8.33 (d, J = 8.6 Hz, 1H), 8.05 (d, J = 8.4 Hz, 1H), 8.02 – 7.95 (m, 
2H), 7.82 (d, J = 6.8 Hz, 1H), 7.76 (t, J = 7.4 Hz, 1H), 7.60 (t, J = 7.3 Hz, 1H), 7.44 (t, J = 
7.3 Hz, 1H), 7.17 (d, J = 8.4 Hz, 1H), 7.10 (t, J = 7.4 Hz, 1H), 4.13 (q, J = 6.9 Hz, 2H), 1.31 
(t, J = 6.9 Hz, 3H). 
13C NMR (DMSO-d6), δ: 156.90, 156.79, 148.18 (C, C-aromatic), 135.58, 131.63, 131.03, 
129.91, 129.47 (CH, C-aromatic), 129.30 (C, C-aromatic), 128.12 (CH, C-aromatic), 127.11 
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(C, C-aromatic), 126.79, 123.72, 121.16, 113.44 (CH, C-aromatic), 64.27 (CH2), 15.04 
(CH3). 
 
2-phenylquinoline-4-carboxylic acid (41) 
(C16H11NO2; M.W.: 249.3) 
 
 
General procedure 2; 
Yellow solid; 
T.L.C. System: EtOAc-MeOH-TEA 8.2:1.6:0.2 v/v, Rf: 0.39. 
Purification: re-crystallisation from EtOH 
Yield: 335 mg (66%) 
Purity: 99% 
UPLC-MS method B: Rt: 1.683, MS (ESI)+: 250.1[M+H]+ 
1H NMR (DMSO-d6), δ: 14.01 (bs, 1H), 8.67 (d, J = 8.5 Hz, 1H), 8.47 (s, 1H), 8.31 (d, J = 
7.4 Hz, 2H), 8.18 (d, J = 8.4 Hz, 1H), 7.87 (t, J = 7.6 Hz, 1H), 7.72 (t, J = 7.6 Hz, 1H), 7.63-
7.51 (m, 3H). 
13C NMR (DMSO-d6), δ: 168.14 (C=O), 156.28, 148.87, 138.38, 138.23 (C, C-aromatic), 
130.70, 130.47, 130.26, 129.48, 128.25, 127.70, 125.90 (CH, C-aromatic), 123.94 (C, C-
aromatic), 119.59 (CH, C-aromatic). 
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2-(2-methoxyphenyl)quinoline-4-carboxylic acid (42) 
(C17H13NO3; M.W.: 279.3) 
 
 
General procedure 2; 
Yellow solid; 
T.L.C. System: EtOAc-MeOH-TEA 8.2:1.6:0.2 v/v, Rf: 0.39. 
Purification: re-crystallisation from EtOH 
Yield: 332 mg (58%) 
Purity: 99% 
UPLC-MS method B: Rt: 1.382, MS (ESI)+: 280.0 [M+H]+ 
1H NMR (DMSO-d6), δ: 13.91 (bs, 1H), 8.72 (d, J = 8.4 Hz, 1H), 8.37 (s, 1H), 8.15 (d, J = 
8.4 Hz, 1H), 7.87 – 7.82 (m, 2H), 7.72 (td, 3J = 8.2 Hz, 4J = 1.2 Hz, 1H), 7.51 (td, 3J = 7.7 
Hz, 4J = 1.8Hz, 1H), 7.24 (d, J = 8.3 Hz, 1H), 7.15 (t, J = 7.4 Hz, 1H), 3.89 (s, 3H). 
13C NMR (DMSO-d6), δ: 168.20 (C=O), 157.52, 156.50, 148.99, 135.97 (C, C-aromatic), 
131.57, 131.47, 130.29, 130.18 (CH, C-aromatic), 128.29 (C, C-aromatic), 128.20, 125.84, 
124.34 (CH, C-aromatic), 123.69 (C, C-aromatic), 121.34, 112.55 (CH, C-aromatic), 56.26 
(CH3). 
 
2-(2-isopropoxyphenyl)quinoline-4-carboxylic acid (43) 
(C19H17NO3; M.W.: 307.3) 
 
 
General procedure 2; 
White solid; 
T.L.C. System: EtOAc-MeOH-TEA 8.2:1.6:0.2 v/v, Rf: 0.5. 
Purification: re-crystallisation from EtOH 
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Yield: 247 mg (39%) 
Purity: 99% 
UPLC-MS method B: Rt: 1.667, MS (ESI)+: 308.1[M+H]+ 
1H NMR (DMSO-d6), δ: 13.78 (bs, 1H), 8.75 (d, J = 8.5 Hz, 1H), 8.54 (s, 1H), 8.14 (d, J = 
8.5 Hz, 1H), 7.91 (dd, 3J = 7.6 Hz, 4J = 1.8 Hz, 1H), 7.84 (td, 3J = 7.6 Hz, 4J = 1.3 Hz, 1H), 
7.71 (td, 3J = 7.6 Hz, 4J = 1.3 Hz, 1H), 7.48 (td, 3J = 7.6 Hz, 4J = 1.8 Hz, 1H), 7.24 (d, J = 
8.2 Hz, 1H), 7.13 (t, J = 7.5 Hz, 1H), 4.83-4.66 (m, 1H), 1.30 (s, 3H), 1.29 (s, 3H). 
13C NMR (DMSO-d6), δ: 168.18  (C=O), 156.55, 155.79, 149.01 (C, C-aromatic), 
131.63, 131.50, 130.16, 128.10, 125.88, 125.02 (CH, C-aromatic), 123.97 (C, C-
aromatic), 121.33, 115.18, (CH, C-aromatic) 70.79, 22.26 (CH3). 
 
2-(2-propoxyphenyl)quinoline-4-carboxylic acid (44) 
(C19H17NO3; M.W.: 307.3) 
 
 
General procedure 2; 
Yellow solid; 
T.L.C. System: EtOAc-MeOH-TEA 8.2:1.6:0.2 v/v, Rf: 0.57. 
Purification: re-crystallisation from EtOH 
Yield: 52 mg (30%) 
Purity: 99% 
UPLC-MS method B: Rt: 1.727, MS (ESI)+: 308.1[M+H]+ 
1H NMR (DMSO-d6), δ: 13.78 (s, 1H), 8.74 (d, J = 8.4 Hz, 1H), 8.52 (s, 1H), 8.15 (d, J = 
8.4 Hz, 1H), 7.91 (dd, 3J = 7.6 Hz, 4J = 1.7 Hz, 1H), 7.84 (td, 3J = 8.3 Hz, 4J = 1.3 Hz, 1H), 
7.72 (td, 3J = 8.3 Hz, 4J = 1.2 Hz, 1H), 7.52 – 7.46 (m, 3H), 7.21 (d, J = 8.3 Hz, 1H), 7.14 (t, 
J = 7.5 Hz, 1H), 4.08 (t, J = 6.2 Hz, 2H), 1.80 – 1.67 (m, 2H), 0.99 (t, J = 7.4 Hz, 3H). 
13C NMR (DMSO-d6), δ: 168.15 (C=O), 157.08, 156.43, 149.02, 135.67 (C, C-aromatic), 
131.60, 131.43, 130.21, 130.19, 128.19 (CH, C-aromatic), 128.14 (C, C-aromatic), 125.84, 
124.65 (CH, C-aromatic), 123.75 (C, C-aromatic), 121.26, 113.37 (CH, C-aromatic), 70.15, 
22.57 (CH2), 11.06 (CH3). 
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2-(2-(cyclopropylmethoxy)phenyl)quinoline-4-carboxylic acid (45) 
(C20H17NO3; M.W.: 319.4) 
 
 
General procedure 2; 
Yellow solid; 
T.L.C. System: EtOAc-MeOH-TEA 8.2:1.6:0.2 v/v, Rf:0.55. 
Purification: re-crystallisation from EtOH 
Yield: 55 mg (12%) 
Purity: 98% 
UPLC-MS method B: Rt: 1.929, MS (ESI)+: 320.19[M+H]+ 
1H NMR (DMSO-d6), δ: 13.82 (bs, 1H), 8.74 (d, J = 8.4 Hz, 1H), 8.61 (s, 1H), 8.16 (d, J = 
8.4 Hz, 1H) , 7.92 (d, J = 7.5 Hz, 1H), 7.84 (t, J = 7.5 Hz, 1H), 7.72 (t, J = 7.6 Hz, 1H), 7.47 
(t, J = 7.6 Hz, 1H), 7.20 (d, J = 8.3 Hz, 1H), 7.14 (t, J = 7.4 Hz, 1H), 4.01 (d, J = 6.8 Hz, 2H), 
1.31 – 1.12 (m, 1H), 0.58-0.53 (m, 2H), 0.41-0.32 (m, 2H). 
13C NMR (DMSO-d6), δ: 168.20 (C=O), 157.01, 156.47, 149.00, 135.71 (C, C-aromatic), 
131.55, 131.43, 130.18, 128.33 (CH, C-aromatic), 128.12 (C, C-aromatic), 125.82, 124.77 
(CH, C-aromatic), 123.78 (C, C-aromatic), 121.35, 113.85 (CH, C-aromatic), 73.02 (CH3), 
10.50(CH2), 3.40 (CH3). 
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2-(3-ethoxyphenyl)quinoline-4-carboxylic acid (46) 
(C18H15NO3; M.W.: 293.3) 
 
 
General procedure 2; 
White solid; 
T.L.C. System: EtOAc-MeOH-TEA 8.2:1.6:0.2 v/v, Rf: 0.53. 
Purification: re-crystallisation from EtOH 
Yield: 58 mg (35%) 
Purity: 99% 
UPLC-MS method B: Rt: 1.845, MS (ESI)+: 294.1[M+H]+ 
1H NMR (DMSO-d6), δ: 8.65 (dd, 3J = 8.4 Hz, 4J = 0.7 Hz, 1H), 8.44 (s, 1H), 8.18 (dd, 3J = 
8.4 Hz, 4J = 0.7 Hz, 1H), 7.91 – 7.80 (m, 3H), 7.71 (td, 3J = 8.3 Hz, 4J = 1.2 Hz, 1H), 7.49 (t, 
J = 7.9 Hz, 1H), 7.14 – 7.07 (m, 1H), 4.17 (q, J = 7.0 Hz, 2H), 1.40 (t, J = 7.0 Hz, 3H). 
13C NMR (DMSO-d6), δ: 168.14 (C=O), 159.61, 156.09, 148.78, 139.89, 138.42 (C, C-
aromatic), 130.68, 130.59, 130.28, 128.25, 125.88 (CH, C-aromatic), 123.99 (C, C-
aromatic), 119.99, 119.62, 116.68, 113.35 (CH, C-aromatic), 63.73 (CH2), 15.17 (CH3). 
 
2-(4-ethoxyphenyl)quinoline-4-carboxylic acid (47) 
(C18H15NO3; M.W.: 293.3) 
 
 
General procedure 2; 
Yellow solid; 
T.L.C. System: EtOAc-MeOH-TEA 8.2:1.6:0.2 v/v, Rf: 0.43. 
Purification: re-crystallisation from EtOH 
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Yield: 175 mg (29%) 
Purity: 99% 
UPLC-MS method B: Rt: 1.715, MS (ESI)+: 294.0 [M+H]+ 
1H NMR (DMSO-d6), δ: 13.95 (bs, 1H), 8.63 (d, J = 8.5 Hz, 1H), 8.42 (s, 1H), 8.27 (d, J = 
8.6 Hz, 2H), 8.13 (d, J = 8.4 Hz, 1H), 7.83 (t, J = 7.6 Hz, 1H), 7.67 (t, J = 7.6 Hz, 1H), 7.11 
(d, J = 8.6 Hz, 2H), 4.14 (q, J = 6.9 Hz, 2H), 1.39 (t, J = 6.9 Hz, 3H). 
13C NMR (DMSO-d6), δ: 168.47 (C=O), 160.64, 155.91, 148.85, 130.73 (C, C-aromatic), 
130.47, 129.95, 129.14, 127.55, 126.04 (CH, C-aromatic), 123.68 (C, C-aromatic), 
118.86, 115.22 (CH, C-aromatic), 63.73 (CH2), 15.10 (CH3). 
 
2-(3-methoxyphenyl)quinoline-4-carboxylic acid (48) 
(C17H13NO3; M.W.: 279.3) 
 
 
General procedure 2; 
Yellow solid; 
T.L.C. System: EtOAc-MeOH-TEA 8.2:1.6:0.2 v/v, Rf:0.44. 
Purification: re-crystallisation from EtOH 
Yield: 203 mg (35%) 
Purity: 99% 
UPLC-MS method B: Rt: 1.939, MS (ESI)+: 280.04[M+H]+ 
1H NMR (DMSO-d6), δ: 8.65 (d, J = 8.4 Hz, 1H), 8.45 (s, 1H), 8.18 (d, J = 8.4 Hz, 1H), 7.91 
– 7.81 (m, 3H), 7.72 (t, J = 7.5 Hz, 1H), 7.50 (t, J = 8.0 Hz, 1H), 7.12 (d, J = 8.0 Hz, 1H), 
3.90 (s, 3H). 
13C NMR (DMSO-d6), δ: 168.13 (C=O), 160.33, 156.08, 148.77, 139.90, 138.33 (C, C-
aromatic), 130.71, 130.60, 130.29, 128.29, 125.86 (CH, C-aromatic), 123.98 (C, C-
aromatic), 120.11, 119.66, 116.32, 112.76 (CH, C-aromatic), 55.79 (CH3). 
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2-(4-methoxyphenyl)quinoline-4-carboxylic acid (49) 
(C17H13NO3; M.W.: 279.3) 
 
 
General procedure 2; 
Yellow solid; 
T.L.C. System: EtOAc-MeOH-TEA 8.2:1.6:0.2 v/v, Rf:0.43. 
Purification: re-crystallisation from EtOH 
Yield: 564 mg (99%) 
Purity: 99% 
UPLC-MS method B: Rt: 1.685, MS (ESI)+: 280.0[M+H]+ 
1H NMR (DMSO-d6), δ: 8.62 (d, J = 8.4 Hz, 1H), 8.41 (s, 1H), 8.28 (d, J = 8.4 Hz, 2H), 
8.13 (d, J = 8.3 Hz, 1H), 7.83 (t, J = 7.6 Hz, 1H), 7.67 (t, J = 7.6 Hz, 1H), 7.13 (d, J = 8.4 
Hz, 2H), 3.86 (s, 3H). 
13C NMR (DMSO-d6), δ: 168.20 (C=O), 161.40, 155.95, 148.87, 138.11, 130.82 (C, C-
aromatic), 130.59, 130.02, 129.18, 127.76, 125.84 (CH, C-aromatic), 123.57 (C, C-
aromatic), 119.09, 114.86 (CH, C-aromatic), 55.82 (CH3). 
 
2-(2,4-dichlorophenyl)quinoline-4-carboxylic acid (50) 
(C16H9Cl2NO2; M.W.: 318.1) 
 
 
General procedure 2; 
Yellow solid; 
T.L.C. System: EtOAc-MeOH-TEA 8.2:1.6:0.2 v/v, Rf: 0.75. 
Purification: re-crystallisation from EtOH 
Yield: 194 mg (60%) 
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Purity: 99% 
UPLC-MS method B: Rt: 1.96, MS (ESI)+: 318.1 (56%), 320.1(37%), 322.1 (7%) [M+H]+ 
1H NMR (DMSO-d6), δ: 8.75 (d, J = 8.4 Hz, 1H), 8.17 (d, J = 8.4 Hz, 2H), 7.90 (dd, 3J = 6.9 
Hz, 4J = 1.2 Hz, 1H), 7.84 (d, 4J = 2.0 Hz, 1H), 7.79 (td, 3J = 8.4 Hz, 4J = 1.2 Hz, 2H), 7.63 
(dd, 3J = 8.4 Hz, 4J = 2.0 Hz, 1H). 
13C NMR (DMSO-d6), δ: 167.76 (C=O), 155.90, 148.77, 137.75, 137.12, 135.03 (C, C-
aromatic), 133.58 (CH, C-aromatic), 132.85 (C, C-aromatic), 130.82, 130.24, 129.93, 
129.00, 128.32, 125.99 (CH, C-aromatic), 123.94 (C, C-aromatic), 123.34 (CH, C-aromatic). 
 
2-(2-hydroxyphenyl)quinoline-4-carboxylic acid (51) 
(C16H11NO3; M.W.: 265.3) 
 
 
General procedure 2; 
Yellow solid; 
T.L.C. System: EtOAc-MeOH-TEA 8.2:1.6:0.2 v/v, Rf:0.36. 
Purification: re-crystallisation from EtOH 
Yield: 110 mg (20%) 
Purity: 99% 
UPLC-MS method A: Rt: 2.297, MS (ESI)+: 266.0[M+H]+ 
1H NMR (DMSO-d6), δ: 14.65 (bs, 2H), 8.59 (d, J = 8.0 Hz, 3H), 8.40 (s, 3H), 8.16 (dd, 3J 
= 8.0 Hz, 4J = 1.2 Hz, 3H), 8.06 (d, J = 8.3 Hz, 3H), 7.82 (td, 3J = 8.3 Hz, 4J = 1.2 Hz, 3H), 
7.64 (td, 3J = 8.2 Hz, 4J = 1.0 Hz, 3H), 7.39 (td, 3J = 8.4 Hz, 4J = 1.5 Hz, 3H), 7.03 – 6.97 
(m, 2H). 
13C NMR (DMSO-d6), δ: 168.45 (C=O), 160.41, 157.69, 145.41 (C, C-aromatic), 132.55, 
130.97, 128.32, 127.79, 127.42, 127.14 (CH, C-aromatic), 123.98 (C, C-aromatic), 
119.50(CH, C-aromatic), 119.47 (C, C-aromatic), 118.39, 116.97 (CH, C-aromatic). 
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2-(3-hydroxyphenyl)quinoline-4-carboxylic acid (52) 
(C16H11NO3; M.W.: 265.3) 
 
 
General procedure 2; 
Yellow solid; 
T.L.C. System: EtOAc-MeOH-TEA 8.2:1.6:0.2 v/v, Rf:0.32. 
Purification: re-crystallisation from EtOH 
Yield: mg (%) 
Purity: 99% 
UPLC-MS method A: Rt: 2.297, MS (ESI)+: 266.0[M+H]+ 
1H NMR (DMSO-d6), δ: 9.70 (bs, 1H), 8.67 (d, J = 8.4 Hz, 1H), 8.38 (s, 1H), 8.15 (d, J = 
8.4 Hz, 1H), 7.88 – 7.82 (m, 1H), 7.77 – 7.67 (m, 4H), 7.38 (t, J = 7.9 Hz, 1H), 6.94 (dd, 3J 
= 7.8 Hz, 4J = 2.1 Hz, 1H). 
13C NMR (DMSO-d6), δ: 168.10 (C=O), 158.44, 156.27, 148.86, 139.75, 138.11 (C, C-
aromatic), 130.65, 130.55, 130.20, 128.16, 125.93 (CH, C-aromatic), 124.01 (C, C-
aromatic), 119.63, 118.47, 117.60, 114.21 (CH, C-aromatic). 
 
2-(2-ethoxyphenyl)-6-methylquinoline-4-carboxylic acid (77) 
(C19H17NO3; M.W.: 307.3) 
 
 
General procedure 2; 
Yellow solid; 
T.L.C. System: EtOAc-MeOH-TEA 8.2:1.6:0.2 v/v, Rf:0.58. 
Purification: re-crystallisation from EtOH 
Yield: 348 mg (61%) 
Purity: 99% 
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UPLC-MS method B: Rt: 1.773, MS (ESI)+: 308.18[M+H]+ 
1H NMR (DMSO-d6), δ: 13.73 (bs, 1H), 8.50 (s, 1H), 8.49 (s, 1H), 8.03 (d, J = 8.6 Hz, 
1H), 7.89 (d, J = 7.5 Hz, 1H), 7.66 (d, J = 8.6 Hz, 1H), 7.45 (t, J = 7.7 Hz, 1H), 7.18 (d, J = 
8.3 Hz, 1H), 7.11 (t, J = 7.5 Hz, 1H), 4.15 (q, J = 6.9 Hz, 2H), 2.53 (s, 3H), 1.34 (t, J = 6.9 
Hz, 3H). 
13C NMR (DMSO-d6), δ: 168.31 (C=O), 156.92, 155.36, 147.68, 137.74, 135.03 (C, C-
aromatic), 132.23, 131.38, 131.31, 129.95 (CH, C-aromatic), 128.28 (C, C-aromatic), 
124.60, 124.57 (CH, C-aromatic), 123.78(C, C-aromatic), 121.32, 113.61(CH, C-aromatic), 
64.39 (CH2), 22.14, 15.00 (CH3). 
 
6-chloro-2-(2-ethoxyphenyl)quinoline-4-carboxylic acid (78) 
(C18H14ClNO3; M.W.: 327.8) 
 
 
General procedure 2; 
White solid; 
T.L.C. System: EtOAc-MeOH-TEA 8.2:1.6:0.2 v/v, Rf:0.59. 
Purification: re-crystallisation from EtOH 
Yield: 344mg (63%) 
Purity: 95% 
UPLC-MS method B: Rt: 2.33, MS (ESI)+: 328.15 (75%), 330.15 (25%)[M+H]+ 
1H NMR (DMSO-d6), δ: 13.68 (bs, 1H), 8.85 (s, 1H), 8.62 (s, 1H), 8.14 (d, J = 8.9 Hz, 1H), 
7.90 (d, J = 7.6 Hz, 1H), 7.83 (d, J = 9.0 Hz, 1H), 7.48 (t, J = 7.8 Hz, 1H), 7.20 (d, J = 8.3 
Hz, 1H), 7.12 (t, J = 7.5 Hz, 1H), 4.17 (q, J = 6.8 Hz, 2H), 1.34 (t, J = 6.9 Hz, 3H). 
13C NMR (DMSO-d6), δ: 167.71 (C=O), 157.02, 156.93, 147.53, 134.66, 132.76 (C, C-
aromatic), 132.24, 131.84, 131.36, 130.64 (CH, C-aromatic), 127.74 (C, C-aromatic), 
125.90, 124.84 (CH, C-aromatic), 124.62(C, C-aromatic), 121.36, 113.63 (CH, C-aromatic), 
64.43 (CH2), 14.98 (CH3). 
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2-(2-ethoxyphenyl)-6-methoxyquinoline-4-carboxylic acid (79) 
(C19H17NO4; M.W.: 323.3) 
 
 
General procedure 2; 
Yellow solid; 
T.L.C. System: EtOAc-MeOH-TEA 8.2:1.6:0.2 v/v, Rf:0.56. 
Purification: re-crystallisation from EtOH 
Yield: 108 mg (20%) 
Purity: 97% 
UPLC-MS method B: Rt: 1.798, MS (ESI)+: 324.2[M+H]+ 
1H NMR (DMSO-d6), δ: 13.66 (bs, 1H), 8.56 (s, 1H), 8.21 (d, 4J = 2.3 Hz, 1H), 8.06 (d, J = 
9.2 Hz, 1H), 7.89 (d, J = 7.6 Hz, 1H), 7.49 (dd, 3J = 9.2 Hz, 4J = 2.3 Hz, 1H), 7.45 (t, J = 7.6 
Hz, 1H), 7.19 (d, J = 8.2 Hz, 1H), 7.11 (t, J = 7.4 Hz, 1H), 4.16 (q, J = 6.9 Hz, 2H), 3.92 (s, 
3H), 1.35 (t, J = 6.9 Hz, 3H). 
13C NMR (DMSO-d6), δ: 168.28 (C=O), 158.76, 156.86, 153.55, 145.32, 133.61 (C, C-
aromatic), 131.78, 131.20 (CH, C-aromatic), 128.23 (C, C-aromatic), 125.26 (CH, C-
aromatic), 125.22 (C, C-aromatic), 122.36, 121.32, 113.62, 104.20(CH, C-aromatic), 
64.38(CH2), 55.92, 15.02 (CH3). 
 
2-(2-ethoxyphenyl)-6-(trifluoromethyl)quinoline-4-carboxylic acid (80) 
(C19H14F3NO3; M.W.: 361.3) 
 
 
General procedure 2; 
Orange solid; 
T.L.C. System: EtOAc-MeOH-TEA 8.2:1.6:0.2 v/v, Rf: 0.58. 
Purification: re-crystallisation from EtOH 
Part II: RSV 
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Yield: 26 mg (5%) 
Purity: 97% 
UPLC-MS method B: Rt: 2.07, MS (ESI)+: 362.2[M+H]+ 
1H NMR (DMSO-d6), δ: 14.14 (bs, 1H), 9.25 (s, 1H), 8.73 (s, 1H), 8.35 (d, J = 8.7 Hz, 1H), 
8.09 (d, J = 8.6 Hz, 1H), 7.97 (d, J = 7.5 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 7.25 (d, J = 8.3 
Hz, 1H), 7.17 (t, J = 7.5 Hz, 1H), 4.21 (q, J = 6.9 Hz, 2H), 1.37 (t, J = 6.9 Hz, 3H). 
13C NMR (DMSO-d6), δ: 167.56 (C=O), 159.10, 158.94, 157.18, 150.03 (C, C-aromatic), 
132.26, 131.82, 131.50 (CH, C-aromatic), 127.54 (C, C-aromatic), 126.30, 125.48, 124.18 
(CH, C-aromatic), 123.10 (C, C-aromatic), 121.45, 113.73 (CH, C-aromatic), 64.50 (CH2), 
14.97 (CH3). 
19F NMR (DMSO-d6), δ: -61.36. 
 
2-(2-ethoxyphenyl)-6-(trifluoromethoxy)quinoline-4-carboxylic acid (81) 
(C19H14F3NO4; M.W.:377.3) 
 
General procedure 2; 
white/pale yellow solid; 
T.L.C. System: EtOAc-MeOH-TEA 8.2:1.6:0.2 v/v, Rf:0.54. 
Purification: re-crystallisation from EtOH 
Yield: 307 mg (63%) 
Purity: 99% 
UPLC-MS method B: Rt: 2,063, MS (ESI)+: 378,3[M+H]+ 
1H NMR (DMSO-d6), δ: 14.03 (s, 1H), 8.81 (d, 4J = 1.4 Hz, 1H), 8.70 (s, 1H), 8.29 (d, J = 
9.2 Hz, 1H), 7.93 (dd, 3J = 7.6 Hz, 4J = 1.7 Hz, 1H), 7.84 (dd, 3J = 9.1 Hz, 4J = 2.4 Hz, 1H), 
7.55 – 7.48 (m, 1H), 7.23 (d, J = 8.2 Hz, 1H), 7.15 (t, J = 7.5 Hz, 1H), 4.19 (q, J = 6.9 Hz, 
2H), 1.36 (t, J = 6.9 Hz, 3H). 
13C NMR (DMSO-d6), δ: 167.59 (C=O), 157.34, 157.05, 147.48, 134.89 (C, C-aromatic), 
132.91, 131.97, 131.38 (CH, C-aromatic), 127.66 (C, C-aromatic), 126.24 (CH, C-aromatic), 
124.23 (C, C-aromatic), 124.01, 121.41, 116.57, 113.68 (CH, C-aromatic), 64.46 (CH2), 
14.97 (CH3). 
19F NMR (DMSO-d6), δ: -56.67 
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2-(2-ethoxyphenyl)-7-methylquinoline-4-carboxylic acid (82) 
(C19H17NO3; M.W.: 307.3) 
 
 
General procedure 2; 
Yellow solid; 
T.L.C. System: EtOAc-MeOH-TEA 8.2:1.6:0.2 v/v, Rf: 0.57. 
Purification: re-crystallisation from EtOH 
Yield: 194mg (34%) 
Purity: 99% 
UPLC-MS method B: Rt: 1.506, MS (ESI)+: 308.1[M+H]+ 
1H NMR (DMSO-d6), δ: 13.75 (bs, 1H), 8.63 (d, J = 8.7 Hz, 1H), 8.45 (s, 1H), 7.93 (s, 1H), 
7.89 (d, J = 7.6 Hz, 1H), 7.54 (d, J = 8.7 Hz, 1H), 7.47 (t, J = 7.8 Hz, 1H), 7.20 (d, J = 8.3 
Hz, 1H), 7.12 (t, J = 7.4 Hz, 1H), 4.16 (q, J = 6.9 Hz, 2H), 2.55 (s, 3H), 1.34 (t, J = 6.9 Hz, 
3H). 
13C NMR (DMSO-d6), δ: 168.27 (C=O), 156.95, 156.29, 149.30, 140.02, 135.40 (C, C-
aromatic), 131.47, 131.35, 130.26, 129.09 (CH, C-aromatic), 128.34 (C, C-aromatic), 
125.52, 123.87 (CH, C-aromatic), 121.82 (C, C-aromatic), 121.33, 113.64 (CH, C-aromatic), 
64.40 (CH2), 21.66, 15.01 (CH3). 
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7-chloro-2-(2-ethoxyphenyl)quinoline-4-carboxylic acid (83) 
(C18H14ClNO3; M.W.: 327.8) 
 
 
General procedure 2; 
White solid; 
T.L.C. System: EtOAc-MeOH-TEA 8.2:1.6:0.2 v/v, Rf:0.60. 
Purification: re-crystallisation from EtOH 
Yield: 110 mg (20%) 
Purity: 99% 
UPLC-MS method B: Rt: 2.374, MS (ESI)+: 328.1 (75%), 330.1 (25%)[M+H]+ 
1H NMR (DMSO-d6), δ: 13.91 (bs, 1H), 8.78 (d, J = 9.1 Hz, 1H), 8.56 (s, 1H), 8.17 (s, 1H), 
7.89 (d, J = 7.7 Hz, 1H), 7.73 (d, J = 9.1 Hz, 1H), 7.48 (t, J = 7.7 Hz, 1H), 7.20 (d, J = 8.3 
Hz, 1H), 7.13 (t, J = 7.4 Hz, 1H), 4.17 (q, J = 6.9 Hz, 2H), 1.34 (t, J = 6.9 Hz, 3H). 
13C NMR (DMSO-d6), δ: 167.81 (C=O), 157.78, 157.05, 149.49, 135.86, 134.77 (C, C-
aromatic), 131.93, 131.43, 128.66, 128.58, 128.02 (CH, C-aromatic), 127.72 (C, C-
aromatic), 125.12 (CH, C-aromatic), 122.50 (C, C-aromatic), 121.36, 113.65 (CH, C-
aromatic), 64.44 (CH2), 14.98 (CH3). 
 
2-(2-ethoxyphenyl)-7-methoxyquinoline-4-carboxylic acid (84) 
(C19H17NO4; M.W.: 323.3) 
 
 
General procedure 2; 
Yellow solid; 
T.L.C. System: EtOAc-MeOH-TEA 8.2:1.6:0.2 v/v, Rf:0.57. 
Purification: re-crystallisation from EtOH 
Yield: 92mg (17%) 
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Purity: 98% 
UPLC-MS method B: Rt: 1.512, MS (ESI)+: 324.2[M+H]+ 
1H NMR (DMSO-d6), δ: 13.71 (bs, 1H), 8.65 (d, J = 9.3 Hz, 1H), 8.40 (s, 1H), 7.92 (d, J = 
7.6 Hz, 1H), 7.53 (d, J = 2.2 Hz, 1H), 7.48 (t, J = 7.7 Hz, 1H), 7.36 (dd, 3J = 9.3 Hz, 4J = 2.5 
Hz, 1H), 7.21 (d, J = 8.2 Hz, 1H), 7.13 (t, J = 7.4 Hz, 1H), 4.17 (q, J = 6.9 Hz, 2H), 3.96 (s, 
3H), 1.35 (t, J = 6.9 Hz, 3H). 
13C NMR (DMSO-d6), δ: 168.31 (C=O), 160.57, 156.97, 156.58, 150.98, 135.49 (C, C-
aromatic), 131.45, 131.36 (CH, C-aromatic), 128.30 (C, C-aromatic), 126.99, 122.36, 
121.27, 120.73 (CH, C-aromatic), 118.83 (C, C-aromatic), 113.66, 108.49 (CH, C-aromatic), 
64.40 (CH2), 56.00, 15.01 (CH3). 
 
2-(2-ethoxyphenyl)-7-(trifluoromethyl)quinoline-4-carboxylic acid (85) 
(C19H14F3NO3; M.W.: 361.3) 
 
 
General procedure 2; 
Yellow solid; 
T.L.C. System: EtOAc-MeOH-TEA 8.2:1.6:0.2 v/v, Rf: 0.53. 
Purification: re-crystallisation from EtOH 
Yield: 302 mg (60%) 
Purity: 97% 
UPLC-MS method B: Rt: 2,101, MS (ESI)+: 362,2[M+H]+ 
1H NMR (DMSO-d6), δ: 14.10 (bs, 1H), 9.00 (d, J = 8.9 Hz, 1H), 8.72 (s, 1H), 8.48 (s, 
1H), 7.99 (d, J = 9.1 Hz, 1H), 7.96 (d, J = 7.6 Hz, 1H), 7.52 (t, J = 7.6 Hz, 1H), 7.24 (d, J = 
8.3 Hz, 1H), 7.16 (t, J = 7.4 Hz, 1H), 4.20 (q, J = 6.9 Hz, 2), 1.37 (t, J = 6.9 Hz, 3H). 
13C NMR (DMSO-d6), δ: 167.59 (C=O), 158.27, 157.11, 147.94, 135.71 (C, C-aromatic), 
132.17, 131.46 (CH, C-aromatic), 130.21 (C, C-aromatic), 128.08, 127.50 (CH, C-aromatic), 
127.46 (C, C-aromatic), 126.88 (CH, C-aromatic), 125.79, 125.48 (C, C-aromatic), 123.24, 
121.43, 113.70 (CH, C-aromatic), 64.49 (CH2), 14.97 (CH3). 
19F NMR (DMSO-d6), δ: -61.36. 
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2-(2-ethoxyphenyl)-7-(trifluoromethoxy)quinoline-4-carboxylic acid (86) 
(C19H14F3NO4; M.W.: 377.3) 
 
General procedure 2; 
white/pale yellow solid; 
T.L.C. System: EtOAc-MeOH-TEA 8.2:1.6:0.2 v/v, Rf:0.56. 
Purification: re-crystallisation from EtOH 
Yield: 100 mg (20%) 
Purity: 98% 
UPLC-MS method B: Rt: 2,098, MS (ESI)+: 378,2 [M+H]+ 
1H NMR (DMSO-d6), δ: 14.01 (s, 1H), 8.92 (d, J = 9.3 Hz, 1H), 8.63 (s, 1H), 8.06 (s, 1H), 
7.94 (dd, 3J = 7.6 Hz, 4J = 1.7 Hz, 1H), 7.74 (dd, 3J = 9.1 Hz, 4J = 2.2 Hz, 1H), 7.56 – 7.47 
(m, 1H), 7.23 (d, J = 8.2 Hz, 1H), 7.15 (t, J = 7.5 Hz, 1H), 4.19 (q, J = 6.9 Hz, 2H), 1.36 (t, 
J = 6.9 Hz, 3H). 
13C NMR (DMSO-d6), δ: 13C NMR (126 MHz, DMSO) δ 167.71 (C=O), 158.16, 157.08, 
149.42, 149.21, 135.61 (C, C-aromatic), 132.06, 131.45, 128.79 (CH, C-aromatic), 127.60 
(C, C-aromatic), 125.38 (CH, C-aromatic), 122.55 (C, C-aromatic), 121.74, 121.39, 119.97, 
113.69 (CH, C-aromatic), 64.48 (CH2), 14.97 (CH3). 
19F NMR (DMSO-d6), δ: 19F NMR (471 MHz, DMSO) δ -56.60. 
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6.3.4 Methyl 2-(phenyl)quinoline-4-carboxylate analogues (53-64, 
87-96) 
 
Methyl 2-phenylquinoline-4-carboxylate (53) 
(C17H13NO2; M.W.: 263.3) 
 
 
General procedure 3; 
White solid; 
T.L.C. System: n-hexane -EtOAc 8:2 v/v, Rf: 0.57. 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: ZIP 
KP Sil 5g (n-hexane -EtOAc 100:0 v/v increasing to 70:30 v/v in 12 CV).  
Yield: 38 mg (72%) 
Purity: 99% 
UPLC-MS method B: Rt: 2.498, MS (ESI)+: 264.09[M+H]+ 
1H NMR (DMSO-d6), δ: 8.56 (d, J = 8.4 Hz, 1H), 8.48 (s, 1H), 8.29 (d, J = 7.6 Hz, 2H), 8.18 
(d, J = 8.4 Hz, 1H), 7.87 (t, J = 7.6 Hz, 1H), 7.72 (t, J = 7.6 Hz, 1H), 7.62 – 7.51 (m, 3H), 
4.03 (s, 3H). 
13C NMR (DMSO-d6), δ: 166.78 (C=O), 156.26, 148.83, 138.22, 136.80 (C, C-aromatic), 
130.90, 130.56, 130.33, 129.49, 128.52, 127.70, 125.59 (CH, C-aromatic), 123.61 (C, C-
aromatic), 119.82 (CH, C-aromatic), 53.43 (CH3). 
 
Methyl 2-(2-methoxyphenyl)quinoline-4-carboxylate (54) 
(C18H15NO3; M.W.: 293.3) 
 
 
General procedure 3; 
Yellow solid; 
T.L.C. System: n-hexane -EtOAc 8:2 v/v, Rf: 0.47. 
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Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: ZIP 
KP Sil 5g (n-hexane -EtOAc 100:0 v/v increasing to 40:60 v/v in 11 CV).  
Yield: 31 mg (59%) 
Purity: 99% 
UPLC-MS method C: Rt: 2.022, MS (ESI)+: 294.1[M+H]+  
1H NMR (DMSO-d6), δ: 8.62 (d, J = 8.4 Hz, 1H), 8.37 (s, 1H), 8.17 (d, J = 8.4 Hz, 1H), 7.91 
– 7.81 (m, 2H), 7.74 (t, J = 7.7 Hz, 1H), 7.52 (t, J = 7.8 Hz, 1H), 7.25 (d, J = 8.3 Hz, 1H), 
7.15 (t, J = 7.4 Hz, 1H), 4.02 (s, 3H), 3.89 (s, 3H). 
13C NMR (DMSO-d6), δ: 166.86 (C=O), 157.55, 156.47, 148.94, 134.80 (C, C-aromatic), 
131.66, 131.44, 130.51, 130.27, 128.47 (CH, C-aromatic), 128.17 (C, C-aromatic), 125.56, 
124.36 (CH, C-aromatic), 123.33 (C, C-aromatic), 121.38, 112.63 (CH, C-aromatic), 56.31, 
53.42(CH3). 
 
Methyl 2-(2-isopropoxyphenyl)quinoline-4-carboxylate (55) 
(C20H19NO3; M.W.: 321.4) 
 
 
General procedure 3; 
Yellow oil; 
T.L.C. System: n-hexane -EtOAc 8:2 v/v, Rf: 0.51. 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: ZIP 
KP Sil 5g (n-hexane -EtOAc 100:0 v/v increasing to 40:60 v/v in 11 CV).  
Yield: 31 mg (59%)  
Purity: 99% 
UPLC-MS method C: Rt: 2.212, MS (ESI)+: 322.3[M+H]+ 
1H NMR (CDCl3-d), δ: 8.81 (d, J = 8.5 Hz, 1H), 8.64 (s, 1H), 8.24 (d, J = 8.5 Hz, 1H), 7.99 
(d, J = 7.6 Hz, 1H), 7.76 (t, J = 7.6 Hz, 1H), 7.64 (t, J = 7.8 Hz, 1H), 7.42 (t, J = 7.8 Hz, 1H), 
7.14 (t, J = 7.5 Hz, 1H), 7.06 (d, J = 8.3 Hz, 1H), 4.61 (hept, J = 5.9 Hz, 1H), 4.06 (s, 3H), 
1.35 (s, 3H), 1.34 (s, 3H). 
13C NMR CDCl3-d), δ: 167.10 (C=O), 156.78, 155.75, 149.22, 133.49 (C, C-aromatic), 
131.52, 130.67, 130.26 (CH , C-aromatic), 129.79 (C, C-aromatic), 129.36, 127.62, 125.44, 
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125.35 (CH, C-aromatic), 123.85 (C, C-aromatic), 121.41, 114.74 (CH, C-aromatic), 71.17, 
52.54, 22.06 (CH3). 
 
Methyl 2-(2-propoxyphenyl)quinoline-4-carboxylate (56) 
(C20H19NO3; M.W.: 321.4) 
 
 
General procedure 3; 
Yellow solid; 
T.L.C. System: n-hexane -EtOAc 8:2 v/v, Rf: 0.54. 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: ZIP 
KP Sil 5g (n-hexane -EtOAc 100:0 v/v increasing to 40:60 v/v in 11 CV).  
Yield: 23 mg (84%) 
Purity: 99% 
UPLC-MS method A: Rt: 2.653, MS (ESI)+: 322.23[M+H]+ 
1H NMR (CDCl3-d), δ: 8.71 (d, J = 8.5 Hz, 1H), 8.52 (s, 1H), 8.14 (d, J = 8.4 Hz, 1H), 7.88 
(d, J = 7.6 Hz, 1H), 7.67 (t, J = 7.6 Hz, 1H), 7.55 (t, J = 7.8 Hz, 1H), 7.33 (t, J = 7.8 Hz, 1H), 
7.05 (t, J = 7.6 Hz, 1H), 6.95 (d, J = 8.4 Hz, 1H), 4.00 – 3.90 (m, 5H), 1.78 – 1.66 (m, 2H), 
0.95 (t, J = 7.4 Hz, 3H). 
13C NMR (CDCl3-d), δ: 167.06 (C=O), 156.98, 156.63, 149.24, 133.58 (C, C-aromatic), 
131.36, 130.81, 130.25, 129.40 (CH, C-aromatic), 128.70 (C, C-aromatic), 127.64, 125.36, 
125.31 (CH, C-aromatic), 123.87 (C, C-aromatic), 121.19, 112.38 (CH, C-aromatic), 70.10, 
52.48 (CH3), 22.62 (CH2), 10.70 (CH3). 
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Methyl 2-(2-(cyclopropylmethoxy)phenyl)quinoline-4-carboxylate (57) 
(C21H19NO3; M.W.: 333.4) 
 
 
General procedure 3; 
Yellow oil; 
T.L.C. System: n-hexane -EtOAc 8:2 v/v, Rf: 0.51. 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: ZIP 
KP Sil 5g (n-hexane -EtOAc 100:0 v/v increasing to 70:30 v/v in 12 CV).  
Yield: 26 mg (88%) 
Purity: 98% 
UPLC-MS method C: Rt: 2.207, MS (ESI)+: 334.2 [M+H]+ 
1H NMR (DMSO-d6), δ: 8.65 (d, J = 8.5 Hz, 1H), 8.63 (s, 1H), 8.16 (d, J = 8.4 Hz, 1H), 7.93 
(d, J = 7.6 Hz, 1H), 7.85 (t, J = 7.6 Hz, 1H), 7.73 (t, J = 7.7 Hz, 1H), 7.47 (t, J = 7.8 Hz, 1H), 
7.19 (d, J = 8.3 Hz, 1H), 7.13 (t, J = 7.4 Hz, 1H), 4.00 (s, 5H), 1.28 – 1.17 (m, 1H), 0.61 – 
0.50 (m, 2H), 0.41 – 0.31 (m, 2H). 
13C NMR (DMSO-d6), δ: 166.81 (C=O), 157.03, 156.36, 148.96, 134.30 (C, C-aromatic), 
131.70, 131.40, 130.41, 130.28, 128.44 (CH, C-aromatic), 127.99 (C, C-aromatic), 125.51, 
124.88 (CH, C-aromatic), 123.42 (C, C-aromatic), 121.36, 113.76 (CH, C-aromatic), 72.98 
(CH2), 53.27, 10.48 (CH3), 3.35 (CH2). 
 
Methyl 2-(3-ethoxyphenyl)quinoline-4-carboxylate (58) 
(C19H17NO3; M.W.: 307.3) 
 
 
General procedure 3; 
Yellow solid; 
T.L.C. System: n-hexane -EtOAc 8:2 v/v, Rf: 0.59 
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Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: ZIP 
KP Sil 5g (n-hexane -EtOAc 100:0 v/v increasing to 40:60 v/v in 11 CV).  
Yield: 20 mg (68%) 
Purity: 99% 
UPLC-MS method A: Rt: 2.603, MS (ESI)+: 308.12[M+H]+ 
1H NMR (CDCl3-d), δ: 8.67 (d, J = 8.5 Hz, 1H), 8.31 (s, 1H), 8.14 (d, J = 8.4 Hz, 1H), 7.76 
– 7.62 (m, 3H), 7.54 (t, J = 7.7 Hz, 1H), 7.36 (t, J = 7.9 Hz, 1H), 6.94 (dd, 3J = 8.1 Hz, 4J = 
1.7 Hz, 1H), 4.10 (q, J = 6.9 Hz, 2H), 3.99 (s, 3H), 1.40 (t, J = 6.9 Hz, 3H). 
13C NMR (CDCl3-d), δ: 166.85 (C=O), 159.60, 156.53, 149.23, 140.22, 135.54 (C, C-
aromatic), 130.37, 129.93, 129.90, 127.83, 125.43 (CH, C-aromatic), 124.09 (C, C-
aromatic), 120.46, 119.80, 116.07, 113.46 (CH, C-aromatic), 63.66 (CH2), 52.73, 14.91 
(CH3). 
 
Methyl 2-(4-ethoxyphenyl)quinoline-4-carboxylate (59) 
(C19H17NO3; M.W.: 307.3) 
 
 
General procedure 3; 
Yellow solid; 
T.L.C. System: n-hexane -EtOAc 8:2 v/v, Rf: 0.53. 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: ZIP 
KP Sil 5g (n-hexane -EtOAc 100:0 v/v increasing to 40:60 v/v in 11 CV).  
Yield: 24 mg (47%) 
Purity: 99% 
UPLC-MS method C: Rt: 2.18, MS (ESI)+: 308.2[M+H]+ 
1H NMR (DMSO-d6), δ: 8.53 (d, J = 8.5 Hz, 1H), 8.44 (s, 1H), 8.26 (d, J = 8.9 Hz, 2H), 8.14 
(d, J = 8.4 Hz, 1H), 7.85 (t, J = 8.1 Hz, 1H), 7.69 (t, J = 8.1 Hz, 1H), 7.12 (d, J = 8.9 Hz, 2H), 
4.14 (q, J = 7.0 Hz, 2H), 4.04 (s, 3H), 1.38 (t, J = 7.0 Hz, 3H). 
13C NMR (DMSO-d6), δ: 166.88 (C=O), 160.78, 155.93, 148.83, 136.66 (C, C-aromatic), 
130.79 (CH, C-aromatic), 130.48 (C, C-aromatic), 130.09, 129.20, 128.01, 125.54 (CH, C-
aromatic), 123.23 (C, C-aromatic), 119.35, 115.29 (CH, C-aromatic), 63.78 (CH2), 53.39, 
15.08 (CH3). 
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Methyl 2-(3-methoxyphenyl)quinoline-4-carboxylate (60) 
(C18H15NO3; M.W.: 293.3) 
 
 
General procedure 3; 
Yellow solid; 
T.L.C. System: n-hexane -EtOAc 8:2 v/v, Rf: 0.48. 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: ZIP 
KP Sil 5g (n-hexane -EtOAc 100:0 v/v increasing to 40:60 v/v in 11 CV).  
Yield: 48 mg (45%) 
Purity: 98% 
UPLC-MS: Rt: 2.488, MS (ESI)+: 294.1[M+H]+ 
1H NMR (DMSO-d6), δ: 8.56 (d, J = 8.5 Hz, 1H), 8.49 (s, 1H), 8.20 (d, J = 8.5 Hz, 1H), 7.93 
– 7.83 (m, 3H), 7.74 (t, J = 7.6 Hz, 1H), 7.51 (t, J = 7.9 Hz, 1H), 7.13 (d, J = 8.1 Hz, 1H), 
4.04 (s, 3H), 3.90 (s, 3H). 
13C NMR (DMSO-d6), δ: 166.83 (C=O), 160.35, 156.04, 148.72, 139.71, 136.92 (C, C-
aromatic), 130.92, 130.62, 130.37, 128.57, 125.57 (CH, C-aromatic), 123.67 (C, C-
aromatic), 120.11, 119.92, 116.36, 112.83 (CH, C-aromatic), 55.81, 53.44 (CH3). 
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Methyl 2-(4-methoxyphenyl)quinoline-4-carboxylate (61) 
(C18H15NO3; M.W.: 293.3) 
 
 
General procedure 3; 
White solid; 
T.L.C. System: n-hexane -EtOAc 8:2 v/v, Rf: 0.43. 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: ZIP 
KP Sil 5g (n-hexane -EtOAc 100:0 v/v increasing to 70:30 v/v in 12 CV).  
Yield: 24 mg (25%) 
Purity: 99% 
UPLC-MS method C: Rt: 2.454, MS (ESI)+: 294.12[M+H]+ 
1H NMR (CDCl3-d), δ: 8.71 (d, J = 8.5 Hz, 1H), 8.37 (s, 1H), 8.19 (d, J = 8.5 Hz, 3H), 7.75 
(t, J = 7.7 Hz, 1H), 7.60 (t, J = 7.7 Hz, 1H), 7.06 (d, J = 8.4 Hz, 2H), 4.08 (s, 3H), 3.90 (s, 
3H). 
13C NMR (CDCl3-d), δ: 166.97 (C=O), 161.16, 156.28, 149.30, 135.51, 131.40 (C, C-
aromatic), 130.13, 129.84, 128.86, 127.40, 125.40 (CH, C-aromatic), 123.68 (C, C-
aromatic), 119.93, 114.34 (CH, C-aromatic), 55.44, 52.71 (CH3). 
 
Methyl 2-(2,4-dichlorophenyl)quinoline-4-carboxylate (62) 
(C17H11Cl2NO2; M.W.: 332.2) 
 
 
General procedure 3; 
White solid; 
T.L.C. System: n-hexane -EtOAc 8:2 v/v, Rf: 0.57. 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: ZIP 
KP Sil 5g (n-hexane -EtOAc 100:0 v/v increasing to 40:60 v/v in 11 CV).  
Yield: 17 mg (64%) 
Part II: RSV 
153 
Purity: 99% 
UPLC-MS method A: Rt: 2.683, MS (ESI)+: 332.1 (56%), 335.1(37%), 336.1 (7%) [M+H]+  
1H NMR (DMSO-d6), δ: 8.81 (d, J = 8.5 Hz, 1H), 8.27 (s, 1H), 8.21 (d, J = 8.5 Hz, 1H), 7.80 
(t, J = 7.6 Hz, 1H), 7.69 (t, J = 9.4 Hz, 2H), 7.55 (s, 1H), 7.42 (d, J = 8.2 Hz, 1H), 4.06 (s, 
3H). 
13C NMR (DMSO-d6), δ: 166.52 (C=O), 155.78, 149.10, 137.37, 135.63, 134.74, 133.22 
(C, C-aromatic), 132.60, 130.26, 130.11, 129.98, 128.55, 127.67, 125.55 (CH, C-aromatic), 
124.08 (C, C-aromatic), 123.83 (CH, C-aromatic), 52.83 (CH3). 
 
Methyl 2-(2-hydroxyphenyl)quinoline-4-carboxylate (63) 
(C17H13NO3; M.W.: 279.3) 
 
 
General procedure 3; 
Yellow solid; 
T.L.C. System: n-hexane -EtOAc 8:2 v/v, Rf: 0.48. 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: ZIP 
KP Sil 5g (n-hexane -EtOAc 100:0 v/v increasing to 70:30 v/v in 11 CV).  
Yield: 11 mg (30%) 
Purity: 99% 
UPLC-MS method A: Rt: 2.106, MS (ESI)+: 280.0[M+H]+ 
1H NMR (DMSO-d6), δ: 14.74 (s, 1H), 8.75 (d, J = 8.5 Hz, 1H), 8.58 (s, 1H), 8.11 (d, J = 
8.4 Hz, 1H), 8.02 (d, J = 8.2 Hz, 1H), 7.81 (t, J = 7.0 Hz, 1H), 7.67 (t, J = 7.0 Hz, 1H), 7.42 
(t, J = 7.0 Hz, 1H), 7.13 (d, J = 8.2 Hz, 1H), 7.02 (t, J = 7.0 Hz, 1H), 4.13 (s, 3H). 
13C NMR (DMSO-d6), δ: 166.35 (C=O), 160.87, 157.46, 145.80, 136.48 (C, C-aromatic), 
132.52, 130.77, 128.17, 128.06, 127.07, 125.65 (CH, C-aromatic), 123.46 (C, C-aromatic), 
119.16, 119.04, 118.74 (CH, C-aromatic), 118.57 (C, C-aromatic), 53.02 (CH3). 
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Methyl 2-(3-hydroxyphenyl)quinoline-4-carboxylate (64) 
(C17H13NO3; M.W.: 279.3) 
 
 
General procedure 3; 
Orange solid; 
T.L.C. System: n-hexane -EtOAc 8:2 v/v, Rf: 0.20. 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: ZIP 
KP Sil 5g (n-hexane -EtOAc 100:0 v/v increasing to 40:60 v/v in 11 CV).  
Yield: 40 mg (79%) 
Purity: >95% 
UPLC-MS method A: Rt: 2.084, MS (ESI)+: 280.03[M+H]+ 
1H NMR (CDCl3-d), δ: 8.74 (d, J = 8.5 Hz, 1H), 8.34 (s, 1H), 8.22 (d, J = 8.4 Hz, 1H), 7.75 
(d, J = 9.2 Hz, 2H), 7.67 – 7.59 (m, 2H), 7.36 (t, J = 7.8 Hz, 1H), 6.93 (d, J = 7.7 Hz, 1H), 
6.61 (s, 1H), 4.07 (s, 3H). 
13C NMR (CDCl3-d), δ: 166.81 (C=O), 156.76, 156.63, 148.96, 140.17, 135.88 (C, C-
aromatic), 130.24, 130.19, 129.87, 128.00, 125.48 (CH, C-aromatic), 124.14(C, C-
aromatic), 120.82, 119.80, 117.21, 114.65 (CH, C-aromatic), 52.85 (CH3). 
 
Methyl 2-(2-ethoxyphenyl)-6-methylquinoline-4-carboxylate (87) 
(C20H19NO3; M.W.: 321.4) 
 
 
General procedure 3; 
White solid; 
T.L.C. System: n-hexane -EtOAc 8:2 v/v, Rf: 0.51. 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: ZIP 
KP Sil 5g (n-hexane -EtOAc 100:0 v/v increasing to 70:30 v/v in 12 CV).  
Yield: 58 mg (99%) 
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Purity: 99% 
UPLC-MS method B: Rt: 2.606, MS (ESI)+: 322.24[M+H]+ 
1H NMR (DMSO-d6), δ: 8.51 (s, 1H), 8.41 (s, 1H), 8.05 (d, J = 8.5 Hz, 1H), 7.92 (d, J = 7.1 
Hz, 1H), 7.68 (d, J = 8.5 Hz, 1H), 7.47 (t, J = 7.4 Hz, 1H), 7.19 (d, J = 8.3 Hz, 1H), 7.12 (t, 
J = 7.4 Hz, 1H), 4.16 (q, J = 6.9 Hz, 2H), 4.00 (s, 3H), 2.55 (s, 3H), 1.36 (t, J = 6.9 Hz, 3H). 
13C NMR (DMSO-d6), δ: 166.91 (C=O), 156.96, 155.24, 147.63, 138.16, 133.64 (C, C-
aromatic), 132.48, 131.53, 131.25, 130.03 (CH, C-aromatic), 127.95 (C, C-aromatic), 
124.66, 124.22 (CH, C-aromatic), 123.39 (C, C-aromatic), 121.34, 113.60 (C,H C-aromatic), 
64.43, 53.27, 22.12, 14.96 (CH3). 
 
Methyl 6-chloro-2-(2-ethoxyphenyl)quinoline-4-carboxylate (88) 
(C19H16ClNO3; M.W.: 341.8) 
 
 
General procedure 3; 
Yellow solid; 
T.L.C. System: n-hexane -EtOAc 8:2 v/v, Rf: 0.51. 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: ZIP 
KP Sil 5g (n-hexane -EtOAc 100:0 v/v increasing to 70:30 v/v in 12 CV).  
Yield: 39 mg (70%) 
Purity: 99% 
UPLC-MS method C: Rt: 2.333, MS (ESI)+: 342.2 (75%), 344.2 (25%)[M+H]+  
1H NMR (DMSO-d6), δ: 8.73 (s, 1H), 8.65 (s, 1H), 8.16 (d, J = 9.0 Hz, 1H), 7.93 (d, J = 7.2 
Hz, 1H), 7.87 (d, J = 9.0 Hz, 1H), 7.50 (t, J = 7.6 Hz, 1H), 7.21 (d, J = 8.3 Hz, 1H), 7.13 (t, 
J = 7.4 Hz, 1H), 4.18 (q, J = 6.9 Hz, 2H), 4.00 (s, 3H), 1.37 (t, J = 6.9 Hz, 3H). 
13C NMR (DMSO-d6), δ: 166.30 (C=O), 157.07, 156.78, 147.46, 133.19, 133.12 (C, C-
aromatic), 132.33, 132.02, 131.31, 130.94 (CH, C-aromatic), 127.39 (C, C-aromatic), 
125.89, 124.52 (CH, C-aromatic), 124.13 (C, C-aromatic), 121.41, 113.64 (CH, C-aromatic), 
64.49 (CH2), 53.49, 14.94 (CH3). 
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Methyl 2-(2-ethoxyphenyl)-6-methoxyquinoline-4-carboxylate (89) 
(C20H19NO4; M.W.: 337.38) 
 
 
General procedure 3; 
pale yellow solid; 
T.L.C. System: n-Hex/EtOAc 9:1 v/v, Rf: 0,37. 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: ZIP 
KP Sil 5g (n-hexane -EtOAc 100:0 v/v increasing to 70:30 v/v in 12 CV).  
Yield: 28 mg (54%) 
Purity: 99% 
UPLC-MS method C: Rt:2.14, MS (ESI)+: 338.2 [M+H]+ 
1H NMR (DMSO-d6), δ: 8.61 (s, 1H), 8.13 (d, 4J = 2.6 Hz, 1H), 8.08 (d, J = 9.2 Hz, 1H), 
7.93 (dd, 3J = 7.7 Hz, 4J = 1.5 Hz, 1H), 7.52 (dd, 3J = 9.2 Hz, 4J = 2.6 Hz, 1H), 7.46 (t, J = 
7.7 Hz, 1H), 7.20 (d, J = 8.3 Hz, 1H), 7.13 (t, J = 7.5 Hz, 1H), 4.18 (q, J = 6.9 Hz, 2H), 4.01 
(s, 3H), 3.94 (s, 3H), 1.38 (t, J = 6.9 Hz, 3H). 
13C NMR (DMSO-d6), δ: 166.91 (C=O), 158.99, 156.89, 153.40, 145.28, 132.29 (C, C-
aromatic), 131.88, 131.31, 131.13 (CH, C-aromatic), 127.91 (C, C-aromatic), 125.23 (CH, 
C-aromatic), 124.89 (C, C-aromatic), 122.60, 121.33, 113.59, 103.85 (CH, C-aromatic), 
64.41 (CH2), 55.96, 53.21, 14.97 (CH3). 
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Methyl 2-(2-ethoxyphenyl)-6-(trifluoromethyl)quinoline-4-carboxylate (90) 
(C20H16F3NO3; M.W.: 375.35) 
 
 
General procedure 3; 
pale yellow solid; 
T.L.C. System: n-Hex/EtOAc 9:1 v/v, Rf:0. 0.42. 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: 
ZIP KP Sil 5g (n-hexane -EtOAc 100:0 v/v increasing to 70:30 v/v in 12 CV).  
Yield: 307 mg (63%) 
Purity: 99% 
UPLC-MS method C: Rt: 2.326, MS (ESI)+: 376.3 [M+H]+ 
1H NMR (CDCl3-d), δ: 9.13 (s, 1H), 8.67 (s, 1H), 8.25 (d, J = 8.8 Hz, 1H), 7.92 (dd, 3J = 7.6 
Hz, 4J = 1.7 Hz, 1H), 7.85 (dd, 3J = 8.8 Hz, 4J = 1.9 Hz, 1H), 7.40 – 7.34 (m, 1H), 7.07 (t, J 
= 7.5 Hz, 1H), 6.98 (d, J = 8.2 Hz, 1H), 4.09 (q, J = 6.9 Hz, 2H), 4.00 (s, 3H), 1.36 (t, J = 
7.0 Hz, 3H). 
13C NMR (CDCl3-d), δ: 166.22(C=O), 158.12, 157.16, 147.89, 134.32 (C, C-aromatic), 
132.32, 131.41, 130.54 (CH, C-aromatic), 127.78, 127.62, 127.59 (C, C-aromatic), 127.14, 
126.97, 125.38 (CH, C-aromatic), 123.50 (C, C-aromatic), 121.45, 113.68 (CH, C-aromatic), 
64.53 (CH2), 53.56, 14.93 (CH3). 
19F NMR (CDCl3-d), δ: -61.36. 
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Methyl 2-(2-ethoxyphenyl)-6-(trifluoromethoxy)quinoline-4-carboxylate (91) 
(C20H16F3NO4; M.W.: 391.35) 
 
 
General procedure 3; 
white solid; 
T.L.C. System: n-Hex/EtOAc 9:1 v/v, Rf:0. 0.47. 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: 
ZIP KP Sil 5g (n-hexane -EtOAc 100:0 v/v increasing to 70:30 v/v in 12 CV).  
Yield: 58 mg (56%) 
Purity: 99% 
UPLC-MS method B: Rt: 2.347, MS (ESI)+: 392.2 [M+H]+ 
1H NMR (DMSO-d6), δ: 8.72 (s, 1H), 8.71 (s, 1H), 8.30 (d, J = 9.2 Hz, 1H), 7.95 (dd, 3J = 
7.6 Hz, 4J = 1.7 Hz, 1H), 7.86 (dd, 3J = 9.1 Hz, 4J = 2.4 Hz, 1H), 7.55 – 7.48 (m, 1H), 7.23 
(d, J = 8.3 Hz, 1H), 7.15 (t, J = 7.5 Hz, 1H), 4.20 (q, J = 6.9 Hz, 2H), 4.02 (s, 3H), 1.38 (t, J 
= 6.9 Hz, 4H). 
13C NMR (DMSO-d6), δ: 166.23 (C=O), 157.18, 157.10, 147.43, 133.67 (C, C-aromatic), 
132.99, 132.10, 131.32 (CH, C-aromatic), 127.35 (C, C-aromatic), 126.18 , 124.21 (CH, C-
aromatic), 123.83 (C, C-aromatic), 121.42, 116.29, 113.66 (CH, C-aromatic), 64.51 (CH2), 
53.51, 14.93 (CH3). 
19F NMR (DMSO-d6), δ: -56.60. 
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Methyl 2-(2-ethoxyphenyl)-7-methylquinoline-4-carboxylate (92) 
(C20H19NO3; M.W.: 321.38) 
 
 
 
General procedure 3; 
pale yellow solid; 
T.L.C. System: n-Hex/EtOAc 9:1 v/v, Rf:0. 0.34. 
Purification: Flash column chromatography Isolera One system (Biotage), 
Cartridge: 
ZIP KP Sil 5g (n-hexane -EtOAc 100:0 v/v increasing to 70:30 v/v in 12 CV).  
Yield: 58 mg (62%) 
Purity: 99% 
UPLC-MS method C: Rt: 2.185, MS (ESI)+: 322.3 [M+H]+ 
1H NMR (DMSO-d6), δ: 8.55 (d, J = 8.7 Hz, 1H), 8.50 (s, 1H), 7.96 (s, 1H), 7.92 (dd, 
3J = 7.6 Hz, 4J = 1.8 Hz, 1H), 7.58 (dd, 3J = 8.7 Hz, 4J = 1.7 Hz, 1H), 7.49 (ddd, 3J = 
8.4, 7.4 Hz, 4J = 1.8 Hz, 1H), 7.21 (d, J = 8.3 Hz, 1H), 7.14 (td, 3J = 7.5 Hz, 4J = 0.9 
Hz, 1H), 4.18 (q, J = 6.9 Hz, 2H), 4.00 (s, 3H), 2.56 (s, 3H), 1.37 (t, J = 6.9 Hz, 3H). 
13C NMR (DMSO-d6), δ: 166.90 (C=O), 156.99, 156.18, 149.25, 140.32, 134.04 (C, 
C-aromatic), 131.61, 131.29, 130.57, 129.17 (CH, C-aromatic), 128.03 (C, C-
aromatic), 125.19, 123.96 (CH, C-aromatic), 121.44 (C, C-aromatic), 121.35, 113.63 
(CH, C-aromatic), 64.44 (CH2), 53.28, 21.65, 14.97 (CH3). 
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Methyl 7-chloro-2-(2-ethoxyphenyl)quinoline-4-carboxylate (93) 
(C19H16ClNO3; M.W.: 341.8) 
 
 
General procedure 3; 
White solid; 
T.L.C. System: n-hexane -EtOAc 8:2 v/v, Rf: 0.51. 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: ZIP 
KP Sil 5g (n-hexane -EtOAc 100:0 v/v increasing to 70:30 v/v in 12 CV).  
Yield: 11 mg (21%) 
Purity: 99% 
UPLC-MS method C: Rt: 2.353, MS (ESI)+: 342.2 (75%), 344.2 (25%)[M+H]+ 
1H NMR (DMSO-d6), δ: 8.68 (d, J = 9.1 Hz, 1H), 8.60 (s, 1H), 8.19 (d, 4J = 1.4 Hz, 1H), 
7.92 (d, J = 7.5 Hz, 1H), 7.76 (dd, 3J = 9.1 Hz, 4J = 1.8 Hz, 1H), 7.50 (t, J = 7.6 Hz, 1H), 
7.21 (d, J = 8.3 Hz, 1H), 7.13 (t, J = 7.4 Hz, 1H), 4.18 (q, J = 6.9 Hz, 2H), 4.00 (s, 3H), 1.36 
(t, J = 6.9 Hz, 3H). 
13C NMR (DMSO-d6), δ: 166.41 (C=O), 157.64, 157.10, 149.42, 135.03, 134.32 (C, C-
aromatic), 132.10, 131.37, 128.89, 128.77, 127.67 (CH, C-aromatic), 127.38 (C, C-
aromatic), 125.23 (CH, C-aromatic), 122.08 (C, C-aromatic), 121.39, 113.64(CH, C-
aromatic), 64.49 (CH2), 53.47, 14.94 (CH3). 
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Methyl 2-(2-ethoxyphenyl)-7-methoxyquinoline-4-carboxylate (94) 
(C20H19NO4; M.W.: 337.38) 
 
 
 
General procedure 3; 
pale yellow solid; 
T.L.C. System: n-Hex/EtOAc 9:1 v/v, Rf:0. 0.37. 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: 
ZIP KP Sil 5g (n-hexane -EtOAc 100:0 v/v increasing to 70:30 v/v in 12 CV).  
Yield: 24 mg (46%) 
Purity: 99% 
UPLC-MS method C: Rt: 2.08, MS (ESI)+: 338.3 [M+H]+ 
1H NMR (DMSO-d6), δ: 8.56 (d, J = 9.3 Hz, 1H), 8.43 (s, 1H), 7.95 (dd, 3J = 7.6 Hz, 4J = 
1.7 Hz, 1H), 7.55 (d, J = 2.6 Hz, 1H), 7.48 (ddd, 3J = 9.0, 7.4 Hz, 4J = 1.8 Hz, 1H), 7.38 (dd, 
3J = 9.3 Hz, 4J = 2.7 Hz, 1H), 7.21 (d, J = 8.0 Hz, 1H), 7.14 (td, 3J = 7.6 Hz, 4J = 0.8 Hz, 1H), 
4.18 (q, J = 6.9 Hz, 2H), 4.00 (s, 3H), 3.97 (s, 3H), 1.37 (t, J = 6.9 Hz, 3H). 
13C NMR (DMSO-d6), δ: 166.95 (C=O), 160.72, 157.01, 156.49, 150.96, 134.13 (C, C-
aromatic), 131.60, 131.31 (CH, C-aromatic), 127.99 (C, C-aromatic), 126.68, 122.40, 
121.30, 121.05 (CH, C-aromatic), 118.45 (C, C-aromatic), 113.64, 108.58 (CH, C-aromatic), 
64.44 (CH2), 56.04, 53.29, 14.97 (CH3). 
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Methyl 2-(2-ethoxyphenyl)-7-(trifluoromethyl)quinoline-4-carboxylate (95) 
(C20H16F3NO3; M.W.: 375.35) 
 
 
General procedure 3; 
yellow solid; 
T.L.C. System: n-Hex/EtOAc 9:1 v/v, Rf:0. 0.42. 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: 
ZIP KP Sil 5g (n-hexane -EtOAc 100:0 v/v increasing to 70:30 v/v in 12 CV).  
Yield: 39 mg (37%) 
Purity: 99% 
UPLC-MS method C: Rt: 2.355, MS (ESI)+: 376.3 [M+H]+ 
1H NMR (DMSO-d6), δ: 8.90 (d, J = 8.9 Hz, 1H), 8.75 (s, 1H), 8.49 (s, 1H), 8.04 – 7.96 (m, 
2H), 7.56 – 7.50 (m, 1H), 7.24 (d, J = 8.3 Hz, 1H), 7.16 (t, J = 7.5 Hz, 1H), 4.21 (q, J = 6.9 
Hz, 2H), 4.03 (s, 3H), 1.39 (t, J = 6.9 Hz, 3H). 
13C NMR (DMSO-d6), δ: 166.22 (C=O), 158.12, 157.16, 147.89, 134.32 (C, C-aromatic), 
132.32, 131.41 (CH, C-aromatic), 130.54 (C, C-aromatic), 127.78, 127.60 (CH, C-aromatic), 
127.14 (C, C-aromatic), 126.97 (CH, C-aromatic), 125.38 (C, C-aromatic), 123.50, 121.45, 
113.68 (CH, C-aromatic), 64.53 (CH2), 53.56, 14.93 (CH3). 
19F NMR (DMSO-d6), δ -61.36. 
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Methyl 2-(2-ethoxyphenyl)-7-(trifluoromethoxy)quinoline-4-carboxylate (96) 
(C20H16F3NO4; M.W.: 391.35) 
 
 
General procedure 3; 
off-white solid; 
T.L.C. System: n-Hex/EtOAc 9:1 v/v, Rf:0. 0.47. 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: 
ZIP KP Sil 5g (n-hexane -EtOAc 100:0 v/v increasing to 70:30 v/v in 12 CV).  
Yield: 39 mg (75%) 
Purity: 99% 
UPLC-MS method C: Rt: 2.362, MS (ESI)+: 392.3 [M+H]+ 
1H NMR (DMSO-d6), δ: 8.82 (d, J = 9.3 Hz, 1H), 8.65 (s, 1H), 8.07 (d, 4J = 1.1 Hz, 1H), 
7.96 (dd, 3J = 7.7 Hz, 4J = 1.7 Hz, 1H), 7.75 (dd, 3J = 9.3 v, 4J = 1.9 Hz, 1H), 7.52 (ddd, 3J 
= 8.4, 7.4 Hz, 4J = 1.8 Hz, 1H), 7.23 (d, J = 8.0 Hz, 1H), 7.15 (td, 3J = 7.6 Hz, 4J = 0.9 Hz, 
1H), 4.20 (q, J = 6.9 Hz, 2H), 4.02 (s, 3H), 1.38 (t, J = 6.9 Hz, 3H). 
13C NMR (DMSO-d6), δ: 166.36 (C=O), 158.02, 157.12, 149.36, 134.35 (C, C-aromatic), 
132.19, 131.40, 128.51 (CH, C-aromatic), 127.30 (C, C-aromatic), 125.44 (CH, C-aromatic), 
122.15 (C, C-aromatic), 121.98, 121.40, 120.02, 113.67 (CH, C-aromatic), 64.51 (CH2), 
53.51, 14.93 (CH3). 
19F NMR (DMSO-d6), δ: -56.60. 
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6.4 Synthesis of 2-(2-(N-(3-chloro-2-
methylphenyl)methylsulfonamido) acetamido)benzoic 
acid and derivatives 
6.4.1 General procedures 4-8 
General procedure 4: synthesis of N-mesylphenylamines 
 
 
 
Aniline (4.254 mmol) and pyridine (4.680 mmol) were dissolved in anhydrous DCM (10 ml) 
under a nitrogen atmosphere. Methane sulfonyl chloride (4.254 mmol) was added dropwise 
at 0°C. The reaction mixture was stirred at rt overnight. After the complete conversion of 
the starting material aniline, the reaction mixture was quenched with a aqueous solution of 
NaOH (3M). The aqueous layer was extracted with DCM (3x20 ml) to remove the pyridine. 
Then the aqueous layer was acidified with HCl conc. and the resulting precipitate was 
collected by filtration. The recovered precipitate was dried under vacuum and used without 
further purification. 
 
General procedure 5: synthesis of methyl N-mesyl-N-phenylglycinates 
 
 
 
To a solution of N-phenylmethanesulfonamide (0.789 mmol) in anhydrous DMF (2 ml), NaH 
(0.789 mmol) was added under nitrogen atmosphere. The reaction mixture was stirred for 
10 min before adding drop-wise a solution of methyl 2-bromoacetate (0.658 mmol) in 
anhydrous DMF (1 ml). The resulting reaction mixture was stirred at rt for 5 hours. The 
reaction was quenched with water (8 ml) and then the aqueous layer was extracted with 
EtOAc (3x10 ml). The organic layers were combined, washed with brine (3 x 30 mL) and 
dried over MgSO4. The organic solvent was evaporated at reduced pressure and the crude 
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residue was purified by flash column chromatography to afford pure methyl N-
(methylsulfonyl)-N-phenylglycinate. 
 
General procedure 6: synthesis of N-mesyl-N-phenylglycines 
 
 
 
To a solution of N-(methylsulfonyl)-N-phenylglycinate (3.78 mmol) in tetrahydrofuran and 
methanol (0.1 M, ratio 2:1) was added a solution 1N of NaOH (6 mL). The reaction mixture 
was stirred at 60°C for 2 hours. The reaction mixture was concentrated under reduced 
pressure and the residue was dissolved in water (20 mL). The aqueous layer was acidified 
with HCl 2N and then extracted with EtOAc (3x20mL). The organic layers were combined, 
washed with Brine and then dried over MgSO4 and concentrated under reduced pressure 
to give N-(methylsulfonyl)-N-phenylglycine that were used for the following step without 
further purification. 
 
General procedure 7: synthesis of methyl 2-(2-(N-phenylmesyl)acetamido) 
benzoates 
 
 
N-(methylsulfonyl)-N-phenylglycine (0.5 mmol) in SOCl2 (0.5 ml) was refluxed for 6 hours. 
SOCl2 was eliminated from the reaction mixture under reduced pressure. The resulting 
residue was dissolved in anhydrous DCM (0.5 ml) and added drop-wise to a solution, at 
0°C, of methyl 2-aminobenzoate (0.6 mmol), triethylamine (1.0 mmol) in anhydrous DCM 
(3 ml) under nitrogen atmosphere. The reaction was allowed to warm-up to rt and was 
stirred overnight. The reaction mixture was quenched with water and the organic layer was 
extracted with DCM (3x10ml). The organic layers were combined, washed with brine (3 x 
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30 mL) and dried over MgSO4. The organic solvent was evaporated at reduced pressure 
and the crude residue was purified by flash column chromatography to afford pure methyl 
2-(2-(N-phenylmethylsulfonamido)acetamido)benzoate.  
 
General procedure 8: synthesis of 2-(2-(N-phenylmesyl)acetamido)benzoic acids 
 
 
 
To a solution of methyl 2-(2-(N-phenylmethylsulfonamido)acetamido)benzoate (0.244 
mmol) in tetrahydrofuran and methanol (0.05 M, ratio 2:1) was added a solution 1N of NaOH 
(0.39 mL). The reaction mixture was stirred overnight at room temperature. The reaction 
mixture was concentrated under reduced pressure and the residue was dissolved in water 
(20 mL). The aqueous layer was acidified with HCl 2N and then extracted with DCM 
(3x10mL). The organic layers were combined, washed with Brine, then dried over MgSO4 
and concentrated under reduced pressure. The crude residue was purified by flash column 
chromatography to afford pure 2-(2-(N-phenylmethylsulfonamido)acetamido)benzoic acid. 
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6.4.2 Synthesis of 2-(2-(N-(3-chloro-2-
methylphenyl)methylsulfonamido) acetamido)benzoic acid (2) 
 
N-(3-chloro-2-methylphenyl)methanesulfonamide (99) 
(C8H10ClNO2S; M.W.: 219.68) 
 
 
 
General procedure 4; 
White powder; 
T.L.C. System: n-Hex/EtOAc 7:3 v/v, Rf:0. 0.37. 
Yield: 941 mg (98%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.657, MS (ESI)-: 218.1 [M-H]- 
1H NMR (CDCl3-d), δ: 7.41 (d, J = 8.0 Hz, 1H), 7.31 (d, J = 8.0 Hz, 1H), 7.19 (t, J = 8.1 Hz, 
1H), 6.43 (s, 1H), 3.06 (s, 3H), 2.42 (s, 3H). 
13C NMR (CDCl3-d), δ: 135.84, 135.66, 129.78 (C, C-aromatic), 127.43, 122.14 (CH, C-
aromatic), 40.09, 15.03 (CH3). 
 
Methyl N-(3-chloro-2-methylphenyl)-N-(methylsulfonyl)glycinate (105) 
(C11H14ClNO4S; M.W.: 291.75) 
 
 
General procedure 5; 
pale yellow solid; 
T.L.C. System: n-Hex/EtOAc 7:3 v/v, Rf: 0.38. 
Yield: 1.68g (99%) 
Purity: 99% 
Part II: RSV 
168 
UPLC-MS method C: Rt: 1.825, MS (ESI)+: 292.0 (75%), 294.0 (25%)[M+H]+, 311.2 [M+Na]+ 
1H NMR (DMSO-d6), δ: 7.54 (d, J = 8.0 Hz, 1H), 7.50 (d, 1H), 7.31 (t, J = 8.0 Hz, 1H), 4.47 
(dd, J = 88.8, 18.1 Hz, 2H), 3.65 (s, 3H), 3.15 (s, 3H), 2.40 (s, 3H). 
13C NMR (DMSO-d6), δ: 169.94 (C=O), 140.81, 137.89, 134.93 (C, C-aromatic), 129.86, 
128.70, 128.02 (CH, C-aromatic), 52.69 (CH2), 52.53, 39.30, 16.46 (CH3). 
 
N-(3-chloro-2-methylphenyl)-N-(methylsulfonyl)glycine (97) 
(C10H12ClNO4S; M.W.: 277.72) 
 
 
 
General procedure 6; 
White powder; 
T.L.C. System: DCM/MeOH 95:5 v/v, Rf: 0.23. 
Yield: 846 mg (81%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.617, MS (ESI)-: 276.1 [M-H]- 
1H NMR (DMSO-d6), δ: 12.83 (bs, 1H), 7.56 (d, J = 8.0 Hz, 1H), 7.49 (d, J = 8.0 Hz, 1H), 
7.30 (t, J = 8.0 Hz, 1H), 4.34 (dd, J = 123.8, 18.0 Hz, 2H), 3.15 (s, 3H), 2.39 (s, 3H). 
13C NMR (DMSO-d6), δ: 170.84, 140.98 (C=O), 137.92, 134.88 (C, C-aromatic), 129.78, 
128.73, 127.95 (CH, C-aromatic), 52.82 (CH2), 39.52, 16.46 (CH3).  
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Methyl 2-(2-(N-(3-chloro-2-methylphenyl)methylsulfonamido)acetamido)benzoate 
(107) 
(C18H19ClN2O5S; M.W.: 410.87) 
 
 
General procedure 7; 
White powder; 
T.L.C. System: n-Hex/EtOAc 7:3 v/v, Rf: 0.25. 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: 
SNAP KP-Sil 25g (n-hexane -EtOAc 100:0 v/v increasing to 60:40 v/v in 20 CV).  
Yield: 346 mg (84%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.988, MS (ESI)+: 411.2 (75%), 413.2 (25%)[M+H]+, 433.2 [M+Na]+ 
1H NMR (DMSO-d6), δ: 10.62 (s, 1H), 8.14 (d, J = 7.7 Hz, 1H), 7.90 (dd, 3J = 7.9 Hz, 4J = 
1.5 Hz, 1H), 7.66 – 7.56 (m, 2H), 7.50 (d, J = 7.4 Hz, 1H), 7.31 (t, J = 8.0 Hz, 1H), 7.28 – 
7.20 (m, 1H), 4.55 (dd, J = 115.5, 17.1 Hz, 2H), 3.83 (s, 3H), 3.23 (s, 3H), 2.41 (s, 3H). 
13C NMR (DMSO-d6), δ: 167.73 (C=O), 167.44 (C=O), 140.96, 139.03, 137.70, 134.95 (C, 
C-aromatic), 134.32, 130.98, 129.86, 128.91, 128.04, 124.30, 122.13 (C, C-aromatic), 
119.15 (CH, C-aromatic), 55.26 (CH2), 52.88, 39.71, 16.47 (CH3). 
 
2-(2-(N-(3-chloro-2-methylphenyl)methylsulfonamido)acetamido)benzoic acid (2) 
(C17H17ClN2O5S; M.W.: 396.84) 
 
 
 
General procedure 8; 
White powder; 
T.L.C. System: DCM/MeOH 97:3 v/v, Rf: 0.35. 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: 
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SNAP KP-Sil 25g (DCM-MeOH 100:0 v/v increasing to 90:10 v/v in 16 CV). 
Yield: 39 mg (40%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.8, MS (ESI)+: 397.2 (75%), 399.2 (25%) [M+H]+, 419.2 [M+Na]+ 
1H NMR (DMSO-d6), δ: 11.86 (bs, 1H), 8.42 (d, J = 7.9 Hz, 1H), 7.99 (dd, 3J = 7.9 Hz, 4J = 
1.5 Hz, 1H), 7.68 (d, J = 7.7 Hz, 1H), 7.57 – 7.51 (m, 1H), 7.49 (d, J = 7.7 Hz, 1H), 7.30 (t, 
J = 8.0 Hz, 1H), 7.15 (t, J = 7.2 Hz, 1H), 4.53 (dd, J = 106.0, 17.0 Hz, 2H), 3.23 (s, 3H), 
2.42 (s, 3H). 
13C NMR (DMSO-d6), δ: 169.82 (C=O), 167.21 (C=O), 141.05, 141.01, 140.51, 137.62, 
134.99 (C, C-aromatic), 133.85, 133.82, 131.59, 129.84, 128.98, 128.01, 123.40, 120.41 
(CH, C-aromatic), 55.74 (CH2), 39.51, 16.56 (CH3). 
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6.4.3 2-(N-(3-chloro-2-methylphenyl)mesyl) acetamides analogues 
(108-113) 
 
2-(N-(3-chloro-2-methylphenyl)methylsulfonamido)-N-phenylacetamide (108) 
(C16H17ClN2O3S; M.W.: 352.83) 
 
 
General procedure 7; 
off-white solid; 
T.L.C. System: n-Hex/EtOAc 7:3 v/v, Rf: 0.21. 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: 
SNAP KP-Sil 25g (n-hexane -EtOAc 100:0 v/v increasing to 50:50 v/v in 21 CV). 
Yield: 126 mg (71%)) 
Purity: 99% 
UPLC-MS method C: Rt: 1.836, MS (ESI)+: 353.2 (75%), 355.2 (25%) [M+H]+, 375.2 
[M+Na]+ 
1H NMR (DMSO-d6), δ: 10.03 (s, 1H), 7.59 (d, J = 8.0 Hz, 1H), 7.54 (d, J = 7.7 Hz, 2H), 
7.50 (d, J = 7.4 Hz, 1H), 7.33 – 7.28 (m, 3H), 7.06 (t, J = 7.4 Hz, 1H), 4.44 (dd, J = 208.1, 
16.9 Hz, 2H), 3.26 (s, 3H), 2.40 (s, 3H). 
13C NMR (DMSO-d6), δ: 167.07 (C=O), 140.95, 138.90, 137.69, 134.89 (C, C-aromatic), 
129.88, 129.29, 129.07, 128.05, 124.10, 119.70 (CH, C-aromatic), 54.53 (CH2), 40.57, 
16.29 (CH3). 
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N-(2-(1H-tetrazol-5-yl)phenyl)-2-(N-(3-chloro-2-methylphenyl)methylsulfonamido) 
acetamide (109) 
(C17H17ClN6O3S; M.W.: 420.87) 
 
 
General procedure 7; 
pale yellow solid; 
T.L.C. System: DCM/MeOH 95:5 v/v, Rf: 0.25. 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: 
SNAP KP-Sil 25g (DCM-MeOH 100:0 v/v increasing to 99:1 v/v in 24 CV). 
Yield: 29 mg (14%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.735, MS (ESI)+: 421.2 (75%), 423.2 (25%) [M+H]+, 443.2 
[M+Na]+ 
1H NMR (DMSO-d6), δ: 12.48 (s, 1H), 8.47 (d, J = 7.8 Hz, 1H), 8.18 (dd, 3J = 7.8 Hz, 4J = 
1.3 Hz, 1H), 7.73 (d, J = 7.5 Hz, 1H), 7.47 (d, J = 7.5 Hz, 1H), 7.32 – 7.25 (m, 2H), 7.17 – 
7.12 (m, 1H), 4.59 (dd, J = 144.8, 16.9 Hz, 2H), 3.29 (s, 3H), 2.45 (s, 3H). 
13C NMR (DMSO-d6), δ: 166.86 (C=O), 141.05, 137.88, 136.17, 134.92 (C, C-aromatic), 
129.80, 129.09, 128.60, 127.98, 127.90, 123.76, 120.13 (CH, C-aromatic), 118.95 (C, C-
aromatic), 55.62 (CH2), 40.02, 16.58 (CH3). 
 
Methyl 3-(2-(N-(3-chloro-2-methylphenyl)methylsulfonamido)acetamido)benzoate 
(110) 
(C18H19ClN2O5S; M.W.: 410.87) 
 
 
General procedure 7; 
White powder; 
T.L.C. System: n-Hex/EtOAc 7:3 v/v, Rf: 0.28. 
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Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: 
SNAP KP-Sil 25g (n-hexane -EtOAc 100:0 v/v increasing to 60:40 v/v in 28 CV). 
Yield: 110 mg (37%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.842, MS (ESI)+: 411.3 (75%), 413.3 (25%) [M+H]+, 433.2 
[M+Na]+ 
1H NMR (DMSO-d6), δ: 10.29 (s, 1H), 8.26 (s, 1H), 7.75 (d, 3J = 8.1 Hz, 4J = 2.1 Hz, 1H), 
7.66 (d, J = 8.0 Hz, 1H), 7.60 (d, J = 7.9 Hz, 1H), 7.51 – 7.44 (m, 2H), 7.31 (t, J = 8.0 Hz, 
1H), 4.46 (dd, J = 203.3, 17.0 Hz, 2H), 3.86 (s, 3H), 3.26 (s, 3H), 2.41 (s, 3H). 
13C NMR (DMSO-d6), δ: 167.46 (C=O), 166.46 (C=O), 140.92, 139.31, 137.64, 134.89, 
130.67 (C, C-aromatic), 129.90, 129.85, 129.15, 128.07, 124.70, 124.13, 120.04 (CH, C-
aromatic), 54.51 (CH2), 52.71, 40.55, 16.29 (CH3). 
 
Methyl 4-(2-(N-(3-chloro-2-methylphenyl)methylsulfonamido)acetamido)benzoate 
(111) 
(C18H19ClN2O5S; M.W.: 410.87) 
 
 
General procedure 7; 
off-white solid; 
T.L.C. System: n-Hex/EtOAc 7:3 v/v, Rf: 0.27. 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: 
SNAP KP-Sil 25g (n-hexane -EtOAc 100:0 v/v increasing to 50:50 v/v in 25 CV). 
Yield: 186 mg (45%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.853, MS (ESI)+: 411.3 (75%), 413.3 (25%) [M+H]+, 433.3 
[M+Na]+ 
1H NMR (DMSO-d6), δ: 10.39 (s, 1H), 7.92 (d, J = 8.8 Hz, 2H), 7.69 (d, J = 8.8 Hz, 2H), 
7.60 (d, J = 7.9 Hz, 1H), 7.50 (d, J = 7.4 Hz, 1H), 7.30 (t, J = 8.0 Hz, 1H), 4.49 (dd, J = 
194.8, 17.2 Hz, 2H), 3.83 (s, 3H), 3.25 (s, 3H), 2.41 (s, 3H). 
13C NMR (DMSO-d6), δ: 167.77 (C=O), 166.21 (C=O), 143.28, 140.93, 137.67, 134.90 (C, 
C-aromatic), 130.84, 129.90, 129.13, 128.06 (CH, C-aromatic), 124.79 (C, C-aromatic), 
119.11 (CH, C-aromatic), 54.57 (CH2), 52.38, 40.50, 16.30 (CH3).   
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3-(2-(N-(3-chloro-2-methylphenyl)methylsulfonamido)acetamido)benzoic acid (112) 
(C17H17ClN2O5S; M.W.: 396.84) 
 
 
General procedure 8; 
White powder; 
T.L.C. System: DCM/MeOH 97:3 v/v, Rf: 0.27. 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: 
SNAP KP-Sil 25g (DCM-MeOH 100:0 v/v increasing to 90:10 v/v in 16 CV). 
Yield: 23 mg (28%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.709, MS (ESI)+: 397.2 (75%), 399.2 (25%) [M+H]+, 419.2 
[M+Na]+ 
1H NMR (DMSO-d6), δ: 13.00 (bs, 1H), 10.24 (s, 1H), 8.22 (s, 1H), 7.72 (d, J = 8.1 Hz, 1H), 
7.64 (d, J = 7.7 Hz, 1H), 7.60 (d, J = 8.0 Hz, 1H), 7.49 (d, J = 8.1 Hz, 1H), 7.43 (t, J = 7.9 
Hz, 1H), 7.30 (t, J = 8.1 Hz, 1H), 4.45 (dd, J = 206.3, 17.1 Hz, 2H), 3.25 (s, 3H), 2.40 (s, 
3H). 
13C NMR (DMSO-d6), δ: 167.52 (C=O), 167.39 (C=O), 140.93, 139.15, 137.65, 134.88, 
131.86 (C, C-aromatic), 129.89, 129.60, 129.14, 128.07, 124.88, 123.74, 120.33 (CH, C-
aromatic), 54.50 (CH2), 40.57, 16.29 (CH3). 
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4-(2-(N-(3-chloro-2-methylphenyl)methylsulfonamido)acetamido)benzoic acid (113) 
(C17H17ClN2O5S; M.W.: 396.84) 
 
 
General procedure 8; 
White powder; 
T.L.C. System: DCM/MeOH 97:3 v/v, Rf: 0.25. 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: 
SNAP KP-Sil 25g (DCM-MeOH 100:0 v/v increasing to 90:10 v/v in 16 CV). 
Yield: 68 mg (70%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.717, MS (ESI)+: 397.3 (75%), 399.3 (25%) [M+H]+ 
1H NMR (DMSO-d6), δ: 12.75 (bs, 1H), 10.35 (s, 1H), 7.90 (d, J = 8.8 Hz, 2H), 7.66 (d, J 
= 8.8 Hz, 2H), 7.59 (d, J = 8.0 Hz, 1H), 7.49 (d, J = 8.1 Hz, 1H), 7.30 (t, J = 8.2 Hz, 1H), 
4.48 (dd, J = 197.1, 17.2 Hz, 2H), 3.25 (s, 3H), 2.40 (s, J = 8.2 Hz, 3H). 
13C NMR (DMSO-d6), δ: 167.68 (C=O), 167.30 (C=O), 142.91, 140.93, 137.67, 134.89 (C, 
C-aromatic), 130.94, 129.90, 129.12, 128.06 (CH, C-aromatic), 125.98 (C, C-aromatic), 
118.98 (CH, C-aromatic), 54.56 (CH2), 40.51, 16.30 (CH3). 
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6.4.4 Methyl 2-(2-(N-mesylphenyl)acetamido)benzoic acids 
analogues (114-115, 124-125) 
 
N-phenylmethanesulfonamide (118) 
(C7H9NO2S; M.W.:171.21) 
 
 
 
General procedure 4; 
White powder; 
T.L.C. System: n-Hex/EtOAc 7:3 v/v, Rf:0. 0.33. 
Yield: 1.45g (99%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.338, MS (ESI)+: 171.9 [M+H]+ 
1H NMR (DMSO-d6), δ: 9.72 (s, 1H), 7.36 – 7.31 (m, 2H), 7.25 – 7.18 (m, 2H), 7.11 (t, J = 
7.4 Hz, 1H), 2.98 (s, 3H). 
13C NMR (DMSO-d6), δ: 138.86 (C, C-aromatic), 129.76, 124.30, 120.24 (CH, C-aromatic), 
39.65 (CH3). 
 
N-(2-ethoxyphenyl)methanesulfonamide (119) 
(C9H13NO3S; M.W.: 215.27) 
 
 
. 
General procedure 4; 
White powder; 
T.L.C. System: n-Hex/EtOAc 7:3 v/v, Rf:0. 0.35. 
Yield: 1.75g (96%) 
Purity: 99% 
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UPLC-MS method C: Rt: 1.608, MS (ESI)+: 216.1 [M+H]+, 235.1 [M+Na]+ 
1H NMR (DMSO-d6), δ: 8.81 (s, 1H), 7.25 (dd, 3J = 7.8 Hz, 4J = 1.6 Hz, 1H), 7.18 (ddd, 3J 
= 8.2, 7.5 Hz, 4J = 1.7 Hz, 1H), 7.05 (dd, 3J = 8.3 Hz, 4J = 1.2 Hz, 1H), 6.91 (td, 3J = 7.7 Hz, 
4J = 1.3 Hz, 1H), 4.08 (q, J = 7.0 Hz, 2H), 2.95 (s, 3H), 1.37 (t, J = 7.0 Hz, 3H). 
13C NMR (DMSO-d6), δ: 152.28 (C, C-aromatic), 127.20, 126.51(CH, C-aromatic), 126.28 
(C, C-aromatic), 120.84, 113.01 (CH, C-aromatic), 64.25 (CH2), 40.63, 14.99 (CH3). 
 
Methyl N-(methylsulfonyl)-N-phenylglycinate (120) 
(C10H13NO4S; M.W.: 243.28) 
 
 
 
General procedure 5; 
pale yellow powder; 
T.L.C. System: n-Hex/EtOAc 7:3 v/v, Rf: 0.38. 
Yield: 1.55g (96%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.564, MS (ESI)+: 244.1 [M+H]+, 266.0 [M+Na]+ 
1H NMR (DMSO-d6), δ: 7.48 – 7.40 (m, 4H), 7.34 (m, 1H), 4.53 (s, 2H), 3.65 (s, 3H), 3.10 
(s, 3H). 
13C NMR (DMSO-d6), δ: 170.18 (C=O), 140.67(C, C-aromatic), 129.73, 128.02, 127.95 
(CH, C-aromatic), 52.53 (CH3), 52.52 (CH2), 39.28 (CH3). 
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Methyl N-(2-ethoxyphenyl)-N-(methylsulfonyl)glycinate (121) 
(C12H17NO5S; M.W.: 287.33) 
 
 
 
General procedure 5; 
purple solid; 
T.L.C. System: n-Hex/EtOAc 7:3 v/v, Rf: 0.35. 
Yield: 1.55 g (98%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.717, MS (ESI)+: 288.0 [M+H]+, 310.1 [M+Na]+ 
1H NMR (DMSO-d6), δ: 7.41 (dd, 3J = 7.8 Hz, 4J = 1.7 Hz, 1H), 7.33 (ddd, 3J = 8.3, 7.5 Hz, 
4J = 1.8 Hz, 1H), 7.10 (dd, 3J = 8.3 Hz, 4J = 1.2 Hz, 1H), 6.95 (td, 3J = 7.6 Hz, 4J = 1.3 Hz, 
1H), 4.35 (s, 2H), 4.11 (q, J = 7.0 Hz, 2H), 3.62 (s, 3H), 3.04 (s, 3H), 1.37 (t, J = 7.0 Hz, 
3H). 
13C NMR (DMSO-d6), δ: 170.15 (C=O), 155.35 (C, C-aromatic), 133.56, 130.38 (CH, C-
aromatic), 127.63 (C, C-aromatic), 120.64, 113.48 (CH, C-aromatic), 64.13 (CH3), 
52.32(CH3), 51.19 (CH2), 40.07, 14.99 (CH3). 
 
N-(methylsulfonyl)-N-phenylglycine (122) 
(C9H11NO4S; M.W.: 229.25) 
 
 
 
General procedure 6; 
off-White solid; 
T.L.C. System: DCM/MeOH 95:5 v/v, Rf: 0.21 
Yield: 1.23g (84%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.287, MS (ESI)-: 228.2 [M-H]- 
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1H NMR (DMSO-d6), δ: 12.92 (bs, 1H), 7.49 – 7.39 (m, 4H), 7.35 – 7.30 (m, 1H), 4.41 (s, 
2H), 3.09 (s, 3H). 
13C NMR (DMSO-d6), δ: 171.11 (C=O), 140.84 (C, C-aromatic), 129.68, 127.83, 127.80 
(CH, C-aromatic), 52.64 (CH2), 39.41 (CH3). 
 
N-(2-ethoxyphenyl)-N-(methylsulfonyl)glycine (123) 
(C11H15NO5S; M.W.: 273.30) 
 
 
General procedure 6; 
off-White solid; 
T.L.C. System: DCM/MeOH 95:5 v/v, Rf: 0.21. 
Yield: 1.46 g (99%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.484, MS (ESI)+: 274.0 [M+H]+, 296.0 [M+Na]+ 
MS (ESI)-: 272.1 [M-H]- 
1H NMR (DMSO-d6), δ: 12.71 (s, 1H), 7.42 (dd, 3J = 7.7 Hz, 4J = 1.7 Hz, 1H), 7.33 (ddd, 3J 
= 8.3, 7.6 Hz, 4J = 1.7 Hz, 1H), 7.09 (dd, 3J = 8.3 Hz, 4J = 1.1 Hz, 1H), 6.94 (td, 3J = 7.6 Hz, 
4J = 1.3 Hz, 1H), 4.24 (s, 2H), 4.11 (q, J = 7.0 Hz, 2H), 3.03 (s, 3H), 1.37 (t, J = 7.0 Hz, 3H). 
13C NMR (DMSO-d6), δ: 171.05 (C=O), 155.37 (C, C-aromatic), 133.70, 130.25 (CH, C-
aromatic), 127.76 (C, C-aromatic), 120.59, 113.45 (CH, C-aromatic), 64.11, 51.22 (CH2), 
40.22, 15.00 (CH3). 
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Methyl 2-(2-(N-phenylmethylsulfonamido)acetamido)benzoate (124) 
(C17H18N2O5S; M.W.: 362.4) 
 
 
General procedure 7; 
pale yellow powder; 
T.L.C. System: n-Hex/EtOAc 7:3 v/v, Rf: 0.24. 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: 
SNAP KP-Sil 25g (n-hexane -EtOAc 100:0 v/v increasing to 60:40 v/v in 28 CV). 
Yield: 249 mg (52%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.815, MS (ESI)+: 363.3 [M+H]+, 385.2 [M+Na]+ 
1H NMR (DMSO-d6), δ: 11.31 (s, 1H), 8.42 (d, J = 8.4 Hz, 1H), 7.98 (dd, 3J = 8.0 Hz, 4J = 
1.5 Hz, 1H), 7.65 – 7.58 (m, 3H), 7.46 (t, J = 7.8 Hz, 2H), 7.36 (t, J = 7.4 Hz, 1H), 7.21 (t, J 
= 7.6 Hz, 1H), 4.59 (s, 2H), 3.93 (s, 3H), 3.13 (s, 3H). 
13C NMR (DMSO-d6), δ: 167.94 (C=O), 167.71 (C=O), 140.79, 139.79 (C, C-aromatic), 
134.75, 131.20, 129.81, 128.37, 128.19, 123.94, 120.88 (CH, C-aromatic), 117.25 (C, C-
aromatic), 55.47 (CH2), 53.09, 37.48 (CH3). 
 
Methyl 2-(2-(N-(2-ethoxyphenyl)methylsulfonamido)acetamido)benzoate (125) 
(C19H22N2O6S; M.W.: 406.45) 
 
 
General procedure 7; 
yellow powder; 
T.L.C. System: n-Hex/EtOAc 7:3 v/v, Rf: 0.25. 
Yield: 1.75 g (96%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.886, MS (ESI)+: 407.3 [M+H]+, 429.3 [M+Na]+ 
Part II: RSV 
181 
1H NMR (DMSO-d6), δ: 11.28 (s, 1H), 8.45 (d, J = 8.4 Hz, 1H), 7.99 (d, J = 8.0 Hz, 1H), 
7.67 (d, J = 7.8 Hz, 1H), 7.62 (t, J = 7.9 Hz, 1H), 7.35 (t, J = 7.9 Hz, 1H), 7.22 (t, J = 7.6 Hz, 
1H), 7.14 (d, J = 8.3 Hz, 1H), 6.97 (t, J = 7.6 Hz, 1H), 4.43 (s, 2H), 4.16 (q, J = 6.9 Hz, 2H), 
3.93 (s, 3H), 3.11 (s, 3H), 1.41 (t, J = 7.0 Hz, 3H). 
13C NMR (DMSO-d6), δ: 168.22 (C=O), 167.88 (C=O), 155.14 (C, C-aromatic), 139.86 (C, 
C-aromatic), 134.75, 133.39, 131.25, 130.57 (CH, C-aromatic), 127.89 (C, C-aromatic), 
123.88, 120.91, 120.85 (CH, C-aromatic), 117.19 (C, C-aromatic), 113.73 (CH, C-aromatic), 
64.23, 54.70 (CH2), 53.13, 39.01, 14.98 (CH3). 
 
2-(2-(N-phenylmethylsulfonamido)acetamido)benzoic acid (114) 
(C16H16N2O5S; M.W.: 348.37) 
 
 
General procedure 8; 
pale yellow powder; 
T.L.C. System: DCM/MeOH 97:3 v/v, Rf: 0.25. 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: 
SNAP KP-Sil 25g (DCM-MeOH 100:0 v/v increasing to 90:10 v/v in 16 CV). 
Yield: 71 mg (71%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.663, MS (ESI)+: 349.2 [M+H]+, 371.2 [M+Na]+ 
1H NMR (DMSO-d6), δ: 12.05 (s, 1H), 8.59 (d, J = 8.5 Hz, 1H), 8.02 (dd, 3J = 8.0 Hz, 4J = 
1.6 Hz, 1H), 7.69 – 7.64 (m, 2H), 7.59 (ddd, 3J = 8.7, 7.4 Hz, 4J = 1.7 Hz, 1H), 7.45 (t, J = 
7.8 Hz, 2H), 7.38 – 7.33 (m, 1H), 7.17 (td, 3J = 8.0, 4J = 1.2 Hz, 1H), 4.56 (s, 2H), 3.10 (s, J 
= 4.2 Hz, 3H). 
13C NMR (DMSO-d6), δ: 170.07 (C=O), 167.78 (C=O), 140.88, 140.86 (C, C-aromatic), 
134.75, 131.68, 129.78, 128.44, 128.34, 123.47, 119.86 (CH, C-aromatic), 116.54 (C, C-
aromatic), 55.77 (CH2), 36.90 (CH3). 
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2-(2-(N-(2-ethoxyphenyl)methylsulfonamido)acetamido)benzoic acid (115 from 125) 
(C18H20N2O6S; M.W.: 392.43) 
 
 
General procedure 8; 
White powder; 
T.L.C. System: DCM/MeOH 97:3 v/v, Rf: 0.28. 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: 
SNAP KP-Sil 25g (DCM-MeOH 100:0 v/v increasing to 90:10 v/v in 16 CV). 
Yield: 76 mg (91%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.758, MS (ESI)+: 393.3 [M+H]+, 415.3 [M+Na]+ 
1H NMR (DMSO-d6), δ: 13.90 (bs, 1H), 12.08 (s, 1H), 8.63 (d, J = 8.4 Hz, 1H), 8.04 (dd, 3J 
= 7.9 Hz, 4J = 1.6 Hz, 1H), 7.78 (dd, 3J = 7.9 Hz, 4J = 1.6 Hz, 1H), 7.60 (t, J = 7.9 Hz, 1H), 
7.35 (t, J = 7.9 Hz, 1H), 7.18 (t, J = 7.6 Hz, 1H), 7.14 (d, J = 8.3 Hz, 1H), 6.94 (t, J = 7.6 Hz, 
1H), 4.41 (s, 2H), 4.15 (q, J = 7.0 Hz, 2H), 3.08 (s, 3H), 1.41 (t, J = 7.0 Hz, 3H). 
13C NMR (DMSO-d6), δ: 170.08 (C=O), 168.42 (C=O), 155.04, 140.96 (C, C-aromatic), 
134.74, 133.50, 131.67, 130.59 (CH, C-aromatic), 127.91 (C, C-aromatic), 123.43, 120.73, 
119.92 (CH, C-aromatic), 116.52 (C, C-aromatic), 113.72 (CH, C-aromatic), 64.21, 54.97 
(CH2), 38.68, 14.98 (CH3). 
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6.5 Synthesis of the α-helix mimic 126 
6.5.1 Synthesis of α-helix mimic building blocks  
 
Methyl 4-amino-3-phenoxybenzoate (127) 
Methyl 4-nitro-3-phenoxybenzoate (133) 
(C14H11NO5; M.W.: 273.24) 
 
A mixture of methyl 3-fluoro-4-nitrobenzoate 132 (1.25 mmol), phenol (2.5 mmol), 
Potassium Carbonate (2.5 mmol) in anhydrous DMF (3 ml) was stirred at room temperature 
for three days. The reaction mixture was diluted with water (7 mL) and was extracted with 
EtOAc (3 x 10 mL). The organic layers were combined and then dried over MgSO4 and 
concentrated under reduced pressure. The crude residue was purified by flash column 
chromatography (Biotage Isolera One system, Cartridge: ZIP KP Sil 25g, isocratic method 
with DCM in 11 CV) to give pure methyl 4-nitro-3-phenoxybenzoate 133 as a yellow oil. 
T.L.C. System: DCM, Rf: 0.35. 
Yield: 1.23g (87%) 
Purity: 99% 
UPLC-MS method C: Rt: 2.003, MS (ESI)+: 274.2[M+1]+ 
1H NMR (DMSO-d6), δ: 8.20 (d, J = 8.5 Hz, 1H), 7.86 (dd, 3J = 8.4 Hz, 4J = 1.7 Hz, 1H), 
7.53 – 7.46 (m, 3H), 7.30 (t, J = 7.4 Hz, 1H), 7.19 (dd, 3J = 8.6 Hz, 4J = 0.9 Hz, 2H), 3.84 
(s, 3H). 
13C NMR (DMSO-d6), δ 164.66 (C=O), 155.34, 149.97, 144.00, 135.17 (C, C-aromatic), 
131.03, 126.63, 125.76, 124.69, 120.49, 119.80 (CH, C-aromatic), 53.40 (CH3). 
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Methyl 4-amino-3-phenoxybenzoate (127) 
(C14H13NO3; M.W.: 243.26) 
 
 
A solution of methyl 4-nitro-3-phenoxybenzoate 133 (0.9 mmol) in MeOH/EtOAc (ratio 3:1, 
12 ml) was stirred under H2 atmosphere in presence of Pd/C (15%) at RT for 48 hours. The 
reaction mixture was filtered on Celite. The filtered solution was concentrated under 
reduced pressure and the obtained residue was purified by flash column chromatography 
(Biotage Isolera One system, Cartridge: ZIP KP Sil 25g, n-hexane -EtOAc 100:0 v/v 
increasing to 40:60 v/v in 11 CV) to give pure Methyl 4-amino-3-phenoxybenzoate 127 as 
a colourless oil. 
T.L.C. System: n-hexane -EtOAc 7:3 v/v, Rf: 0.35. 
Yield: 290 mg (99%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.845, MS (ESI)+: 244.1[M+1]+ 
71H NMR (DMSO-d6), δ: 7.55 (dd, 3J = 8.4 Hz, 4J = 1.9 Hz, 1H), 7.40 – 7.35 (m, 2H), 7.26 
(d, 4J = 1.9 Hz, 1H), 7.13 – 7.09 (m, 1H), 6.99 – 6.95 (m, 2H), 6.83 (d, J = 8.4 Hz, 1H), 5.91 
(s, 2H), 3.71 (s, 3H). 
13C NMR (DMSO-d6), δ 166.32 (C=O), 157.43, 145.98, 141.65 (C, C-aromatic), 130.37, 
127.30, 123.44, 120.70, 118.00 (CH, C-aromatic), 116.75 (C, C-aromatic), 114.74 (CH, C-
aromatic), 51.86 (CH3). 
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Boc protected 3-(alkyloxy)-4-(amino)benzoic acid (128,130) 
 
Methyl 4-amino-3-hydroxybenzoate (135) 
(C8H9NO3; M.W.: 167.16) 
 
To a solution of 4-amino-3-hydroxybenzoic acid 134 (6.5 mmol) in anhydrous methanol (20 
mL), thionyl chloride (19.5 mmol) was added drop-wise at 0°C. The reaction mixture was 
stirred at room temperature for 24 hours. The mixture was concentrated under reduced 
pressure and the obtained residue was then diluted with a sat. NaHCO3 solution (60 mL) 
and extracted with EtOAc (3x80 mL). The organic layers were combined, washed with Brine 
and then dried over MgSO4 and concentrated under reduced pressure to give methyl 4-
amino-3-hydroxybenzoate 135, that were used for the following step without further 
purification. 
T.L.C. System: n-hexane -EtOAc 7:3 v/v, Rf: 0.7. 
Yield: 1.13 g (99%) 
1H NMR (DMSO-d6), δ: 9.41 (s, 1H), 7.34 – 7.17 (m, 2H), 6.68 – 6.50 (m, 1H), 5.40 (s, 
2H), 3.73 (s, 3H). 
 
Boc protected methyl 4-(amino)-3-hydroxybenzoate (136) 
(C13H17NO5; M.W.: 267.28) 
 
To a solution of methyl 4-amino-3-hydroxybenzoate 135 (1.79 mmol) and triethylamine 
(1.97 mmol) in anhydrous DCM (6 mL), a solution of di-tert-butyl decarbonate (1.97 mmol) 
in anhydrous DCM (1.2 mL) was added drop-wise. The reaction mixture was stirred at room 
temperature for 24 hours. To the reaction mixture water (7 mL) was added and extracted 
with DCM (3x8 mL). The organic layers were combined, washed with Brine and then dried 
over MgSO4 and concentrated under reduced pressure. The obtained residue was purified 
by flash column chromatography (Biotage Isolera One system, Cartridge: ZIP KP Sil 25g, 
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n-hexane -EtOAc 95:5 v/v increasing to 40:60 v/v in 11 CV) to give pure Boc protected 
methyl 4-(amino)-3-hydroxybenzoate 136 as a white solid. 
T.L.C. System: n-hexane -EtOAc 7:3 v/v, Rf: 0.45. 
Yield: 486 mg (99%) 
Purity: >95% 
1H NMR (CDCl3-d), δ: 7.81 (d, 4J = 1.8 Hz, 1H), 7.77 (dd, 3J = 8.4 Hz, 4J = 1.8 Hz, 1H), 
6.80 – 6.75 (m, 1H), 4.19 (s, 2H), 3.88 (s, 3H), 1.59 (s, 9H). 
 
Boc protected methyl 3-(sec-butoxy)-4-(amino)benzoate (137) 
(C17H25NO5; M.W.: 323.39) 
 
A solution of Boc protected methyl 4-(amino)-3-hydroxybenzoate 136 (0.75 mmol) and 
sodium hydride (0.82 mmol) in anhydrous DMF (10 mL) was stirred at room temperature 
for 15 minutes, then 2-bromobutane (1.8 mmol) was added drop-wise and the reaction 
mixture was stirred at room temperature for 19 hours. The reaction mixture was diluted with 
water (15 mL) and then extracted with EtOAc (3x20 mL). The organic layers were combined, 
washed with Brine and then dried over MgSO4 and concentrated under reduced pressure. 
The obtained residue was purified by flash column chromatography (Biotage Isolera One 
system, Cartridge: ZIP KP Sil 25g, n-hexane -EtOAc 95:5 v/v increasing to 60:40 v/v in 11 
CV) to give pure Boc protected methyl 3-(sec-butoxy)-4-(amino)benzoate 137 as a white 
solid. 
T.L.C. System: n-hexane -EtOAc 7:3 v/v, Rf: 0.56. 
Yield: 163 mg (67%) 
1H NMR (DMSO-d6), δ: 8.00 (d, J = 8.5 Hz, 1H), 7.95 (s, 1H), 7.54 (dd, 3J = 8.5 Hz, 4J = 
1.7 Hz, 1H), 7.48 (d, 4J = 1.6 Hz, 1H), 4.50 (h, J = 6.0 Hz, 1H), 3.84 (d, J = 16.2 Hz, 3H), 
1.83 – 1.69 (m, 1H), 1.69 – 1.57 (m, 1H), 1.49 (s, 9H), 1.26 (d, J = 6.0 Hz, 3H), 0.93 (t, J = 
7.4 Hz, 3H). 
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Boc protected methyl 3-(iso-propoxy)-4-(amino)benzoate (138) 
(C16H23NO5; M.W.: 309.36) 
 
A solution of Boc protected methyl 4-(amino)-3-hydroxybenzoate 136 (0.75 mmol) and 
sodium hydride (0.82 mmol) in anhydrous DMF (10 mL) was stirred at room temperature 
for 15 minutes, then 2-bromopropane (1.8 mmol) was added drop-wise and the reaction 
mixture was stirred at room temperature for 19 hours. The reaction mixture was diluted with 
water (15 mL) and then extracted with EtOAc (3x20 mL). The organic layers were combined, 
washed with Brine and then dried over MgSO4 and concentrated under reduced pressure. 
The obtained residue was purified by flash column chromatography (Biotage Isolera One 
system, Cartridge: ZIP KP Sil 25g, n-hexane -EtOAc 95:5 v/v increasing to 60:40 v/v in 11 
CV) to give pure Boc protected methyl 3-(iso-propoxy)-4-(amino)benzoate 138 as a white 
solid. 
T.L.C. System: n-hexane -EtOAc 7:3 v/v, Rf: 0.56. 
Yield: 162 mg (70%) 
1H NMR (CDCl3-d), δ: 8.20 (d, J = 8.4 Hz, 1H), 7.66 (dd, 3J = 8.5 Hz, 4J = 1.6 Hz, 1H), 7.54 
(d, 4J = 1.6 Hz, 1H), 4.72 (hept, J = 6.0 Hz, 1H), 3.91 (s, 3H), 1.57 (s, 10H), 1.42 (s, 3H), 
1.41 (s, 3H). 
 
Boc protected 3-(sec-butoxy)-4-(amino)benzoic acid (128) 
(C16H23NO5; M.W.: 309.36) 
 
To a solution of Boc protected methyl 3-(sec-butoxy)-4-(amino)benzoate 137 (0.18 mmol) 
in tetrahydrofuran and methanol (ratio 2:1) was added a solution 1N of NaOH (0.3 mL). The 
reaction mixture was stirred at 60°C for 4 hours. The reaction mixture was concentrated 
under reduced pressure and the residue was dissolved in water (5 mL). The aqueous layer 
was acidified with HCl 2N and then extracted with EtOAc (3x8mL). The organic layers were 
combined, washed with Brine and then dried over MgSO4 and concentrated under reduced 
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pressure to give Boc protected 3-( sec-butoxy)-4-(amino)benzoic acid 128, that were used 
for the following step without further purification. 
T.L.C. System:  n-hexane -EtOAc 7:3 v/v, Rf: 0.23. 
Yield: 39 mg (88%) 
1H NMR (DMSO-d6), δ: 12.81 (bs, 1H), 7.95 (d, J = 8.4 Hz, 1H), 7.92 (s, 1H), 7.52 (dd, 3J 
= 8.4 Hz, 4J = 1.7 Hz, 1H), 7.47 (d, 4J = 1.6 Hz, 1H), 4.48 (h, J = 6.1 Hz, 1H), 1.82 – 1.69 
(m, 1H), 1.69 – 1.58 (m, 1H), 1.49 (s, 9H), 1.27 (d, J = 6.0 Hz, 3H), 0.94 (t, J = 7.4 Hz, 3H). 
 
3-(alkyloxy)-4-nitrobenzoic acids (141,142) 
methyl 3-hydroxy-4-nitrobenzoate (146) 
(C8H7NO5; M.W.: 197.15) 
 
 
To a solution of methyl 3-hydroxy-4-nitrobenzoate 145 (3.46 mmol) in anhydrous methanol 
(10 mL), thionyl chloride (16.39 mmol) was added drop-wise at 0°C. The reaction mixture 
was stirred at room temperature for 24 hours. The mixture was concentrated under reduced 
pressure and the obtained residue was then diluted with a sat. NaHCO3 solution (60 mL) 
and extracted with EtOAc (3x80 mL). The organic layers were combined, washed with 
Brine, dried over MgSO4 and concentrated under reduced pressure to give methyl 3-
hydroxy-4-nitrobenzoate 146 as a yellow solid, which was used without further purification. 
T.L.C. System: n-Hex/EtOAc 8:2 0,44 
Yield:1.07 g (97%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.691, MS (ESI)+: - 
1H NMR (DMSO-d6), δ: 11.46 (s, 1H), 7.94 (d, J = 8.5 Hz, 1H), 7.67 (d, J = 1.7 Hz, 1H), 
7.47 (dd, 3J  = 8.5 Hz, 4J = 1.7 Hz, 1H), 3.87 (s, 3H). 
13C NMR (DMSO-d6), δ: 165.20 (C=O), 151.78, 140.59, 134.97 (C, C-aromatic), 125.96, 
119.87 (CH, C-aromatic), 53.19 (CH3). 
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methyl 3-(sec-butoxy)-4-nitrobenzoate (147) 
(C12H15NO5; M.W.: 253.25) 
 
 
A solution of methyl 3-hydroxy-4-nitrobenzoate 146 (5.07 mmol) and potassium carbonate 
(8.12 mmol) in anhydrous DMF (0.7 M) was stirred at room temperature for 15 minutes, 
then 2-bromobutane (107) (6.09 mmol) was added drop-wise and the reaction mixture was 
stirred overnight at 70°C. The reaction mixture was diluted with EtOAc (20 mL) and then 
extracted with HCl 1N solution (4x20 mL). The organic layer was then washed with Brine, 
dried over MgSO4 and concentrated under reduced pressure to give methyl 3-(sec-butoxy)-
4-nitrobenzoate 147 as a yellow/orange solid, which was used without further purification. 
T.L.C. System: n-hexane -EtOAc 8:2 v/v, Rf: 0.46. 
Yield:1.25 g (97%) 
Purity: 99% 
UPLC-MS method C: Rt: 2.024, MS (ESI)+: 195[C10H12NO3 +1]+, 224[C10H10NO5 +1]+ 
1H NMR (DMSO-d6), δ: 7.95 (d, J = 8.3 Hz, 1H), 7.77 (d, J = 1.6 Hz, 1H), 7.63 (dd, 3J = 8.3 
Hz,  4J 1.6 Hz, 1H), 4.73 (h, J = 6.0 Hz, 1H), 3.91 (s, 3H), 1.71 – 1.60 (m, 2H), 1.27 (d, J = 
6.1 Hz, 3H), 0.92 (t, J = 7.4 Hz, 3H). 
13C NMR (DMSO-d6), δ: 165.28 (C=O), 150.33, 143.90, 134.53 (C, C-aromatic), 125.47, 
121.54, 116.69 (CH, C-aromatic), 77.52 (CH), 53.31 (CH3), 28.81 (CH2), 19.09, 9.56 (CH3). 
 
methyl 3-isopropoxy-4-nitrobenzoate (148) 
(C11H13NO5; M.W.: 239.23) 
 
 
A solution of methyl 3-hydroxy-4-nitrobenzoate 146 (5.07 mmol) and potassium carbonate 
(8.12 mmol) in anhydrous DMF (0.7 M) was stirred at room temperature for 15 minutes, 
then 2-bromopropane (101) (6.09 mmol) was added drop-wise and the reaction mixture was 
stirred overnight at 70°C. The reaction mixture was diluted with EtOAc (20 mL) and then 
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washed with HCl 1N solution (4x20 mL). The organic layer was then washed with Brine, 
dried over MgSO4 and concentrated under reduced pressure to give methyl 3-isopropoxy-
4-nitrobenzoate 148 as a yellow solid, which was used without further purification. 
T.L.C. System: n-hexane -EtOAc 8:2 v/v, Rf: 0.46. 
Yield: 1,02 g (84%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.946, MS (ESI)+: 181.1[C9H10NO3 +1]+ 
1H NMR (DMSO-d6), δ: 7.94 (d, J = 8.3 Hz, 1H), 7.78 (d, 4J = 1.6 Hz, 1H), 7.63 (dd, 3J  = 
8.3 Hz, 4J = 1.6 Hz, 1H), 4.91 (hept, J = 6.0 Hz, 1H), 3.90 (s, 3H), 1.30 (d, J = 6.0 Hz, 6H). 
13C NMR (DMSO-d6), δ: 165.26 (C=O), 150.08, 143.98, 134.52 (C, C-aromatic), 125.44, 
121.64, 116.96 (CH, C-aromatic), 73.06 (CH), 53.28, 21.92 (CH3). 
 
3-(sec-butoxy)-4-nitrobenzoic acid (141) 
(C11H13NO5; M.W.: 239.23) 
 
 
To a solution of methyl 3-(sec-butoxy)-4-nitrobenzoate 147 (4.41 mmol) in tetrahydrofuran 
and methanol (0.12 M, ratio 2:1) was added a solution 1N of NaOH (8.82 mL). The reaction 
mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated 
under reduced pressure and the residue was dissolved in water (10 mL). The aqueous layer 
was acidified with HCl 2N and then extracted with DCM (3x15mL). The organic layers were 
combined, washed with Brine, dried over MgSO4 and concentrated under reduced pressure 
to give 3-(sec-butoxy)-4-nitrobenzoic acid 141, as a yellow powder which was used without 
further purification. 
T.L.C. System: DCM/MeOH 95:5 v/v, Rf: 0.3. 
Yield: 1.12 g (97%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.807, MS (ESI)+: 262.8[M+Na]+ 
1H NMR (DMSO-d6), δ: 13.60 (bs, 1H), 7.92 (d, J = 8.3 Hz, 1H), 7.75 (d, 4J = 1.5 Hz, 1H), 
7.61 (dd, 3J = 8.3 Hz, 4J = 1.5 Hz, 1H), 4.77 – 4.65 (m, 1H), 1.73 – 1.58 (m, 2H), 1.27 (d, J 
= 6.1 Hz, 3H), 0.92 (t, J = 7.4 Hz, 3H). 
13C NMR (DMSO-d6), δ: 166.29 (C=O), 150.31, 143.65, 135.87 (C, C-aromatic), 125.33, 
121.59, 116.74 (CH, C-aromatic), 77.42 (CH), 28.83 (CH2), 19.11, 9.58 (CH3). 
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3-isopropoxy-4-nitrobenzoic acid (142) 
(C10H11NO5; M.W.: 225.2) 
 
To a solution of methyl 3-isopropoxy-4-nitrobenzoate 148 (4.3 mmol) in tetrahydrofuran and 
methanol (0.12 M, ratio 2:1) was added a solution 1N of NaOH (8.6 mL). The reaction 
mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated 
under reduced pressure and the residue was dissolved in water (10 mL). The aqueous layer 
was acidified with HCl 2N and then extracted with DCM (3x15mL). The organic layers were 
combined, washed with Brine, dried over MgSO4 and concentrated under reduced pressure 
to give 3-isopropoxy-4-nitrobenzoic acid 142, as a yellow solid which was used without 
further purification. 
T.L.C. System: DCM/MeOH 95:5 v/v, Rf: 0.3. 
Yield: 840 mg (86%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.723, MS (ESI)+: 224.1[M-1]- 
1H NMR (DMSO-d6), δ: 13.60 (bs, 1H), 7.91 (d, J = 8.3 Hz, 1H), 7.76 (d, 4J = 1.6 Hz, 1H), 
7.62 (dd, 3J = 8.3 Hz, 4J = 1.6 Hz, 1H), 4.90 (hept, J = 6.0 Hz, 1H), 1.30 (d, J = 6.0 Hz, 6H). 
13C NMR (DMSO-d6), δ: 166.29 (C=O), 150.07, 143.73, 135.88 (C, C-aromatic), 125.31, 
121.70, 117.01 (CH, C-aromatic), 72.92 (CH), 21.95 (CH3). 
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6.5.2 Synthesis of (4-(4-amino-3-(sec-butoxy)benzamido)-3-
phenoxybenzoyl)glycine (150) 
methyl 4-(3-(sec-butoxy)-4-nitrobenzamido)-3-phenoxybenzoate (149) 
(C25H24N2O7; M.W.: 464.47) 
 
 
3-(sec-butoxy)-4-nitrobenzoic acid 141 (1.78 mmol) in SOCl2 (1.5 ml) was refluxed for 2 
hours. SOCl2 was eliminated from the reaction mixture under reduced pressure. The 
resulting residue was dissolved in anhydrous DCM (3 ml) and added drop-wise to a solution, 
at 0°C, of methyl 4-amino-3-phenoxybenzoate 127 (2.14 mmol), triethylamine (3.57 mmol) 
in anhydrous DCM (10 ml) under nitrogen atmosphere. The reaction was allowed to warm-
up to room temperature and was stirred for 3h. The reaction mixture was diluted with DCM 
and extracted with 1N HCl solution (3x15ml). The organic layer was washed with brine (3 x 
30 mL) and dried over MgSO4. The organic solvent was evaporated at reduced pressure 
and the crude residue was purified by flash column chromatography (Biotage Isolera One 
system, Cartridge: ZIP KP Sil 5g, n-hexane -EtOAc 100:0 v/v increasing to 80:20 v/v in 16 
CV) to give methyl 4-(3-(sec-butoxy)-4-nitrobenzamido)-3-phenoxybenzoate 149 as white 
powder. 
T.L.C. System:  n-Hex/EtOAc 8:2 v/v, Rf: 0.4 
Yield: 828 mg 
Purity: 80% 
UPLC-MS method C: Rt: 2.22, MS (ESI)+: 465.3[M+1]+/244.1[M+1]+, 463.2[M-1]- 
1H NMR (DMSO-d6), δ:  
Major species: 10.33 (s, 1H), 8.04 (d, J = 8.4 Hz, 1H), 7.92 (d, J = 8.3 Hz, 1H), 7.83 (dd, 3J 
= 8.4 Hz, 4J = 1.9 Hz, 1H), 7.62 (d, 4J = 1.3 Hz, 1H), 7.48 (td, 3J = 4.0 Hz, 4J = 1.6 Hz, 2H), 
7.44 – 7.38 (m, 2H), 7.20 – 7.15 (m, 1H), 7.06 (dd, 3J = 8.6 Hz, 4J = 0.9 Hz, 2H), 4.65 (h, J 
= 6.0 Hz, 1H), 3.82 (s, 3H), 1.72 – 1.59 (m, 2H), 1.26 (d, J = 6.1 Hz, 3H), 0.91 (t, J = 7.4 Hz, 
3H). 
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Minor species (methyl 4-amino-3-phenoxybenzoate): 7.55 (dd, 3J = 8.4 Hz, 4J = 1.9 Hz, 1H), 
7.42 – 7.33 (m, 2H), 7.26 (d, 4J = 1.9 Hz, 1H), 7.16 – 7.05 (m, 1H), 7.01 – 6.92 (m, 2H), 
6.83 (d, J = 8.4 Hz, 1H), 5.91 (s, 2H), 3.71 (s, 3H). 
 
Methyl 4-(4-amino-3-(sec-butoxy)benzamido)-3-phenoxybenzoate (150) 
(C25H26N2O5; M.W.: 434.49) 
 
 
 
A solution of methyl methyl 4-(3-(sec-butoxy)-4-nitrobenzamido)-3-phenoxybenzoate 149 
(1.44 mmol) in anhydrous EtOAc (0.5 M) was stirred under H2 atmosphere in presence of 
Pd/C (15%) at room temperature for overnight. The reaction mixture was filtered on Celite. 
The filtered solution was concentrated under reduced pressure and the obtained residue 
was purified by flash column chromatography (Biotage Isolera One system, Cartridge: ZIP 
KP Sil 80g, n-hexane-EtOAc 100:0 v/v increasing to 80:20 v/v in 16 CV) to give pure methyl 
4-(4-amino-3-(sec-butoxy)benzamido)-3-phenoxybenzoate 150 as a white solid. 
T.L.C. System:  n-Hex/EtOAc 8:2 v/v, Rf: 0,25 
Yield: 538 mg (86% over two steps) 
Purity: 99% 
UPLC-MS method C: Rt: 2.086, MS (ESI)+: 435.3[M+1]+ 
1H NMR (DMSO-d6), δ: 9.44 (s, 1H), 8.18 (d, J = 8.5 Hz, 1H), 7.79 (dd, 3J = 8.5 Hz, 4J = 
1.9 Hz, 1H), 7.45 – 7.38 (m, 3H), 7.32 – 7.26 (m, 2H), 7.20 – 7.15 (m, 1H), 7.11 – 7.07 (m, 
2H), 6.65 (d, J = 8.2 Hz, 1H), 5.39 (s, 2H), 4.31 (h, J = 6.0 Hz, 1H), 3.80 (s, 3H), 1.74 – 1.64 
(m, 1H), 1.64 – 1.54 (m, 1H), 1.22 (d, J = 6.1 Hz, 3H), 0.93 (t, J = 7.4 Hz, 3H). 
13C NMR (DMSO-d6), δ: 165.84 (C=O), 165.57 (C=O), 156.47, 148.12, 143.79, 143.75, 
135.31 (C, C-aromatic), 130.60 (CH, C-aromatic), 125.96 (C, C-aromatic), 125.35, 124.46, 
124.14, 122.26 (CH, C-aromatic), 121.02 (C, C-aromatic), 119.18, 119.02, 113.24, 112.88 
(CH, C-aromatic), 75.67 (CH), 52.62 (CH3), 29.03 (CH2), 19.56, 10.06 (CH3). 
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4-(4-amino-3-(sec-butoxy)benzamido)-3-phenoxybenzoic acid (151) 
(C24H24N2O5; M.W.: 420.46) 
 
 
To a solution of methyl 4-(4-amino-3-(sec-butoxy)benzamido)-3-phenoxybenzoate 150 (1.0 
mmol) in tetrahydrofuran and methanol (0.03 M, ratio 2:1) was added a solution 1N of NaOH 
(1.1 mL). The reaction mixture was stirred overnight at room temperature. The reaction 
mixture was concentrated under reduced pressure and the residue was dissolved in water 
(10 mL). The aqueous layer was acidified with HCl 2N and then extracted with DCM 
(3x15mL). The organic layers were combined, washed with Brine, dried over MgSO4 and 
concentrated under reduced pressure to give 4-(4-amino-3-(sec-butoxy)benzamido)-3-
phenoxybenzoic acid 151, as a pale-yellow solid which was used without further purification. 
T.L.C. System: DCM/MeOH 97:3 v/v, Rf:0.3 
Yield: 459 mg (99%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.848, MS (ESI)+: 421.3[M+1]+ 
1H NMR (DMSO-d6), δ: 12.92 (bs, 1H), 9.41 (s, 1H), 8.13 (d, J = 8.4 Hz, 1H), 7.76 (dd, 3J 
= 8.4 Hz, 4J = 1.9 Hz, 1H), 7.45 – 7.38 (m, 3H), 7.32 – 7.26 (m, 2H), 7.20 – 7.15 (m, 1H), 
7.12 – 7.05 (m, 2H), 6.64 (d, J = 8.1 Hz, 1H), 5.37 (s, 2H), 4.32 (h, J = 6.0 Hz, 1H), 1.73 – 
1.64 (m, 1H), 1.64 – 1.54 (m, 1H), 1.22 (d, J = 6.1 Hz, 3H), 0.93 (t, J = 7.4 Hz, 3H). 
13C NMR (DMSO-d6), δ: 166.93 (C=O), 165.54 (C=O), 156.51, 148.20, 143.79, 143.69, 
134.81 (C, C-aromatic), 130.57 (CH, C-aromatic), 127.32 (C, C-aromatic), 125.38, 124.41, 
124.12, 122.22 (CH, C-aromatic), 121.10 (C, C-aromatic), 119.31, 119.08, 113.24, 112.89 
(CH, C-aromatic), 75.67 (CH), 29.04 (CH2), 19.57, 10.07 (CH3). 
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Methyl (4-(4-amino-3-(sec-butoxy)benzamido)-3-phenoxybenzoyl)glycinate (152) 
(C27H29N3O6; M.W.: 491.54) 
 
 
 
A mixture of 4-(4-amino-3-(sec-butoxy)benzamido)-3-phenoxybenzoic acid 151 (0.92 
mmol), methyl glycinate (1.1 mmol), TBTU (1.1 mmol), and DIPEA (3.67 mmol) in 
anhydrous DMF (0.2 M) was stirred at room temperature for 6 hours. The reaction mixture 
was diluted in EtOAc (20 mL) and was washed with HCl 1N solution (3 x 20 mL), sat. 
NaHCO3 solution (3 x 20 mL) and brine (3 x 20 mL). The organic layers were then dried 
over MgSO4 and concentrated under reduced pressure. The crude residue was purified by 
flash column chromatography (Biotage Isolera One system, Cartridge: SNAP KP Sil 25g, n-
hexane - DCM 100:0 v/v increasing to 0:100 v/v in 5 CV and DCM – MeOH 100:0 v/v 
increasing to 97:3 v/v in 13 CV) to give pure (methyl (4-(4-amino-3-(sec-butoxy)benzamido)-
3-phenoxybenzoyl)glycinate 152 as yellow/orange solid. 
T.L.C. System: DCM/MeOH 97:3 v/v, Rf: 0.37 
Yield: 256 mg (57%) 
Purity: 96% 
UPLC-MS method C: Rt: 1.816, MS (ESI)+: 492.2[M+1]+ 
1H NMR (DMSO-d6), δ: 9.39 (s, 1H), 8.95 (t, J = 5.8 Hz, 1H), 8.07 (d, J = 8.4 Hz, 1H), 7.73 
(dd, 3J = 8.5 Hz, 4J = 2.0 Hz, 1H), 7.50 (d, 4J = 2.0 Hz, 1H), 7.42 – 7.35 (m, 2H), 7.30 – 7.24 
(m, 2H), 7.16 – 7.11 (m, 1H), 7.07 – 7.01 (m, 2H), 6.63 (d, J = 8.1 Hz, 1H), 5.35 (s, 2H), 
4.35 – 4.26 (m, 1H), 3.98 (d, J = 5.8 Hz, 2H), 3.65 (s, 3H), 1.75 – 1.64 (m, 1H), 1.64 – 1.53 
(m, 1H), 1.22 (d, J = 6.1 Hz, 3H), 0.93 (t, J = 7.4 Hz, 3H). 
13C NMR (DMSO-d6), δ: 170.83 (C=O), 165.93 (C=O), 165.54 (C=O), 156.90, 148.09, 
143.76, 143.57, 133.92 (C, C-aromatic), 130.48 (CH, C-aromatic), 130.43 (C, C-aromatic), 
124.54, 124.02, 123.37, 122.19 (CH, C-aromatic), 121.16 (C, C-aromatic), 118.62, 118.48, 
113.19, 112.89 (CH, C-aromatic), 75.64 (CH), 52.21 (CH3), 41.69, 29.04 (CH2), 19.57, 10.07 
(CH3). 
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(4-(4-amino-3-(sec-butoxy)benzamido)-3-phenoxybenzoyl)glycine (153) 
(C26H27N3O6; M.W.: 477.52) 
 
 
 
(methyl (4-(4-amino-3-(sec-butoxy)benzamido)-3-phenoxybenzoyl)glycinate 152 (0.039 
mmol)  was solubilised in tetrahydrofuran and methanol (0.025 M, ratio 2:1) and a solution 
1N of LiOH (0.04 mL) was added. The reaction mixture was stirred overnight at room 
temperature. The reaction mixture was concentrated under reduced pressure and the 
residue was dissolved in water (10 mL). The aqueous layer was acidified with HCl 2N and 
then extracted with DCM (3x15mL). The organic layers were combined, washed with Brine, 
dried over MgSO4 and concentrated under reduced pressure. The crude residue was 
purified by flash column chromatography (Biotage Isolera One system, Cartridge: SNAP KP 
Sil 5g, n-hexane - DCM 100:0 v/v increasing to 0:100 v/v in 5 CV and DCM – MeOH 100:0 
v/v increasing to 9:1 v/v in 11 CV) to give pure (4-(4-amino-3-(sec-butoxy)benzamido)-3-
phenoxybenzoyl)glycine 153 as yellow powder. 
T.L.C. System: DCM/MeOH 9:1 v/v. Rf 0.23 
Yield: 13.6 mg (73%) 
Purity: 97% 
UPLC-MS method C: Rt: 1.723, MS (ESI)+: 478.3[M+1]+ 
1H NMR (DMSO-d6), δ: 12.58 (bs, 1H), 9.38 (s, 1H), 8.83 (t, J = 5.6 Hz, 1H), 8.06 (d, J = 
8.4 Hz, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.50 (s, J = 1.1 Hz, 1H), 7.38 (t, J = 7.8 Hz, 2H), 7.31 
– 7.22 (m, 2H), 7.13 (t, J = 7.3 Hz, 1H), 7.04 (d, J = 7.9 Hz, 2H), 6.63 (d, J = 8.0 Hz, 1H), 
5.34 (s, 2H), 4.30 (m, 1H), 3.88 (d, J = 5.6 Hz, 2H), 1.75 – 1.64 (m, 1H), 1.64 – 1.53 (m, 
1H), 1.22 (d, J = 6.0 Hz, 3H), 0.93 (t, J = 7.4 Hz, 3H). 
13C NMR (DMSO-d6), δ: 171.76 (C=O), 165.78 (C=O), 165.54 (C=O), 156.94, 148.06, 
143.76, 143.55, 133.82, 130.72 (C, C-aromatic), 130.47, 124.54, 123.98, 123.36, 122.18 
(CH, C-aromatic), 121.18 (C, C-aromatic), 118.66, 118.43, 113.18, 112.89 (CH, C-
aromatic), 75.64 (CH), 41.69, 29.04 (CH2), 19.57, 10.07 (CH3). 
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6.5.3 Synthesis of (4-(4-(4-amino-3-isopropoxybenzamido)-3-(sec-
butoxy)benzamido)-3-phenoxybenzoyl)glycine (126) 
 
Methyl 4-(3-(sec-butoxy)-4-(3-isopropoxy-4-nitrobenzamido)benzamido)-3-
phenoxybenzoate (155) 
(C35H35N3O9; M.W.: 641.67) 
 
 
 
3-isopropoxy-4-nitrobenzoic acid 142 (0.228 mmol) in SOCl2 (0.5 ml) was refluxed for 2 
hours. SOCl2 was eliminated from the reaction mixture under reduced pressure. The 
resulting residue was dissolved in anhydrous DCM (3 ml) and added drop-wise to a solution, 
at 0°C, of methyl 4-(4-amino-3-(sec-butoxy)benzamido)-3-phenoxybenzoate 152 (0.346 
mmol), triethylamine (0.576 mmol) in anhydrous DCM (3 ml) under nitrogen atmosphere. 
The reaction was allowed to warm-up to room temperature and was stirred overnight. The 
reaction mixture was diluted with DCM and extracted with 1N HCl solution (3x10ml). The 
organic layer was washed with brine (3 x 10 mL), dried over MgSO4 and evaporated at 
reduced pressure. The obtained crude residue was purified by flash column 
chromatography (Biotage Isolera One system, Cartridge: ZIP KP Sil 5g, DCM -MeOH 100:0 
v/v increasing to 95:5 v/v in 6 CV) to methyl 4-(3-(sec-butoxy)-4-(3-isopropoxy-4-
nitrobenzamido)benzamido)-3-phenoxybenzoate 155 as yellow powder. 
T.L.C. System: DCM/MeOH 95:5 v/v, Rf: 0.32 
Yield: 195 mg (87%) 
1H NMR (DMSO-d6), δ: 10.02 (s, 1H), 9.69 (s, 1H), 8.07 (d, J = 8.4 Hz, 1H), 7.98 (d, J = 
8.4 Hz, 2H), 7.82 (dd, 3J = 8.4 Hz, 4J = 1.9 Hz, 1H), 7.79 (d, J = 1.3 Hz, 1H), 7.58 (dd, 3J = 
8.3 Hz, 4J = 1.6 Hz, 1H), 7.53 – 7.46 (m, 3H), 7.44 – 7.39 (m, 2H), 7.18 (t, J = 7.4 Hz, 1H), 
7.08 (dd, 3J = 8.7 Hz, 4J = 1.0 Hz, 2H), 4.99 – 4.90 (m, 1H), 4.52 – 4.44 (m, 1H), 3.82 (s, 
3H), 1.77 – 1.67 (m, 1H), 1.67 – 1.59 (m, 1H), 1.34 (d, J = 5.3 Hz, 6H), 1.26 (d, J = 6.0 Hz, 
3H), 0.93 (t, J = 7.4 Hz, 3H). 
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13C NMR (DMSO-d6), δ: 176.62 (C=O), 165.81 (C=O), 164.21 (C=O), 150.22, 149.68, 
149.20, 142.80, 139.66, 134.54, 131.64, 131.40 (C, C-aromatic), 130.60 (CH, C-aromatic), 
127.56, 127.23 (C, C-aromatic), 125.75, 125.46, 125.24, 124.46, 123.71, 120.61, 120.00, 
119.48, 118.99, 115.59, 113.52 (CH, C-aromatic), 76.53, 72.99 (CH), 52.74 (CH3), 28.97 
(CH2), 22.03, 19.27, 9.86 (CH3). 
 
Methyl 4-(4-(4-amino-3-iso-propoxybenzamido)-3-(sec-butoxy)benzamido)-3-
phenoxybenzoate (156) 
(C35H37N3O7; M.W.: 611.69) 
 
 
 
A solution of methyl 4-(3-(sec-butoxy)-4-(3-isopropoxy-4-nitrobenzamido)benzamido)-3-
phenoxybenzoate 155 (0.268 mmol) in anhydrous EtOAc (0.025 M) was stirred under H2 
atmosphere in presence of Pd/C (15%) at room temperature overnight. The reaction mixture 
was filtered on Celite. The filtered solution was concentrated under reduced pressure and 
the obtained residue was purified by flash column chromatography (Biotage Isolera One 
system, Cartridge: ZIP KP Sil 10g, DCM - MeOH 100:0 v/v increasing to 97:3 v/v in 8 CV) 
to give pure methyl 4-(4-(4-amino-3-isopropoxybenzamido)-3-(sec-butoxy)benzamido)-3-
phenoxybenzoate 156 as a white solid. 
T.L.C. System: DCM/MeOH 97:3 v/v, Rf: 0.22 
Yield: 145 mg (88%) 
Purity: 99% 
UPLC-MS method C: Rt: 2.228, MS (ESI)+: 612.3[M+1]+ 
1H NMR (DMSO-d6), δ: 9.93 (s, 1H), 8.92 (s, 1H), 8.24 (d, J = 8.5 Hz, 1H), 8.09 (d, J = 8.4 
Hz, 1H), 7.81 (dd, 3J = 8.4 Hz, 4J = 1.9 Hz, 1H), 7.53 – 7.45 (m, 3H), 7.45 – 7.38 (m, 2H), 
7.36 – 7.29 (m, 2H), 7.22 – 7.14 (m, 1H), 7.11 – 7.06 (m, 2H), 6.72 (d, J = 8.2 Hz, 1H), 5.45 
(s, 2H), 4.65 – 4.56 (m, 1H), 4.56 – 4.47 (m, 1H), 3.82 (s, 3H), 1.80 – 1.73 (m, 1H), 1.73 – 
1.64 (m, 1H), 1.32 (dd, 3J = 6.0 Hz, 4J = 2.0 Hz, 6H), 1.29 (d, J = 6.1 Hz, 3H), 0.96 (t, J = 
7.4 Hz, 3H). 
13C NMR (DMSO-d6), δ 176.62 (C=O), 165.79 (C=O), 165.41 (C=O), 164.89, 156.48, 
149.01, 147.40, 143.86, 143.69, 134.70, 132.76 (C, C-aromatic), 130.58 (CH, C-aromatic), 
129.38, 127.01 (C, C-aromatic), 125.48, 125.25, 124.43, 121.78 (CH, C-aromatic), 121.23 
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(C, C-aromatic), 121.01, 120.33, 119.45, 119.00, 113.25, 113.02 (CH, C-aromatic), 76.55, 
70.84 (CH), 52.71 (CH3), 28.99 (CH), 22.42, 22.38, 19.32, 9.84 (CH3). 
 
4-(4-(4-amino-3-isopropoxybenzamido)-3-(sec-butoxy)benzamido)-3-
phenoxybenzoic acid (154) 
(C34H35N3O7; M.W.: 597.67) 
 
 
 
methyl 4-(4-(4-amino-3-isopropoxybenzamido)-3-(sec-butoxy)benzamido)-3-phenoxy 
benzoate 156 (0.196 mmol) was solubilised in tetrahydrofuran and methanol (0.07 M, ratio 
2:1) and a solution 1N of NaOH (0.11 mL) was added. The reaction mixture was stirred 
overnight at room temperature. The reaction mixture was concentrated under reduced 
pressure and the residue was dissolved in water (10 mL). The aqueous layer was acidified 
with HCl 2N and then extracted with DCM (3x15mL). The organic layers were combined, 
washed with Brine, dried over MgSO4 and concentrated under reduced pressure. The crude 
residue was purified by flash column chromatography (Biotage Isolera One system, 
Cartridge: SNAP KP Sil 10g, DCM – MeOH 100:0 v/v increasing to 9:1 v/v in 11 CV) to give 
pure 4-(4-(4-amino-3-isopropoxybenzamido)-3-(sec-butoxy)benzamido)-3-phenoxy 
benzoic acid 154 as white powder. 
T.L.C. System: DCM/MeOH 95:5 v/v, Rf: 0.27 
Yield: 52 mg (44%) 
Purity: 97% 
UPLC-MS method C: Rt: 2.003, MS (ESI)+: 598.3 [M+1]+ 
1H NMR (DMSO-d6), δ: 13.01 (bs, 1H), 9.90 (s, 1H), 8.92 (s, J = 6.6 Hz, 1H), 8.24 (d, J = 
8.8 Hz, 1H), 8.04 (d, J = 8.4 Hz, 1H), 7.78 (dd, 3J = 8.4 Hz, 4J = 1.9 Hz, 1H), 7.51 – 7.47 (m, 
2H), 7.45 (d, J = 1.9 Hz, 1H), 7.44 – 7.38 (m, 2H), 7.34 – 7.29 (m, 2H), 7.19 – 7.14 (m, 1H), 
7.10 – 7.06 (m, 2H), 6.72 (d, J = 8.1 Hz, 1H), 5.45 (s, 2H), 4.64 – 4.55 (m, 1H), 4.55 – 4.47 
(m, 1H), 1.82 – 1.72 (m, 1H), 1.72 – 1.62 (m, 1H), 1.32 (dd, 3J = 6.0 Hz, 4J = 2.0 Hz, 6H), 
1.30 (d, J = 6.1 Hz, 3H), 0.96 (t, J = 7.4 Hz, 3H). 
13C NMR (DMSO-d6), δ 176.62 (C=O), 166.87 (C=O), 165.37 (C=O), 164.89, 156.51, 
149.08, 147.41, 143.85, 143.69, 134.20, 132.71 (C, C-aromatic), 130.55 (CH, C-aromatic), 
129.44 (C, C-aromatic), 125.45, 125.29, 124.38, 121.77 (CH, C-aromatic), 121.24 (C, C-
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aromatic), 120.98, 120.34, 119.57, 119.06, 113.25, 113.02, 112.99 (CH, C-aromatic), 
76.54, 70.84 (CH), 29.00 (CH2), 22.42, 22.39, 19.33, 9.84 (CH3). 
 
Methyl (4-(4-(4-amino-3-isopropoxybenzamido)-3-(sec-butoxy)benzamido)-3-
phenoxybenzoyl)glycinate (157) 
(C37H40N4O8; M.W.: 668.75) 
 
 
 
A mixture of 4-(4-(4-amino-3-isopropoxybenzamido)-3-(sec-butoxy)benzamido)-3-
phenoxybenzoic acid 154 (0.067 mmol), methyl glycinate (0.08 mmol), TBTU (0.08 mmol), 
and DIPEA (2.68 mmol) in anhydrous DMF (0.05 M) was stirred at room temperature for 6 
hours. The reaction mixture was diluted in EtOAc (8 mL) and was washed with HCl 1N 
solution (3 x 10 mL), sat. NaHCO3 solution (3 x 10 mL) and brine (3 x 10 mL). The organic 
layers were then dried over MgSO4 and concentrated under reduced pressure. The crude 
residue was purified by flash column chromatography (Biotage Isolera One system, 
Cartridge: ZIP KP Sil 5g, n-hexane - DCM 100:0 v/v increasing to 0:100 v/v in 5 CV and 
DCM – MeOH 100:0 v/v increasing to 97:3 v/v in 14 CV) to give pure methyl (4-(4-(4-amino-
3-isopropoxybenzamido)-3-(sec-butoxy)benzamido)-3-phenoxybenzoyl)glycinate 157 as 
white powder. 
T.L.C. System: DCM/MeOH 97:3 v/v, Rf: 0.38 
Yield: 49.5 mg (99%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.992, MS (ESI)+: 669.3[M+1]+  
1H NMR (CDCl3-d), δ: 8.74 – 8.71 (m, 2H), 8.67 (s, 1H), 8.61 (d, J = 8.4 Hz, 1H), 7.58 (dd, 
3J = 8.6 Hz, 4J = 1.9 Hz, 1H), 7.53 (d, 4J = 1.7 Hz, 1H), 7.45 (dd, 3J = 13.2 Hz, 4J = 1.8 Hz, 
1H), 7.42 – 7.37 (m, 1H), 7.30 – 7.23 (m, 1H), 7.19 (t, J = 7.4 Hz, 1H), 7.10 – 7.06 (m, 2H), 
6.73 (d, J = 8.1 Hz, 1H), 6.57 (t, J = 5.0 Hz, 1H), 4.72 – 4.63 (m, 1H), 4.58 – 4.49 (m, 1H), 
4.21 (s, 2H), 4.20 (s, 2H), 3.79 (s, 3H), 1.83 (s, 1H), 1.74 (s, 1H), 1.39 (d, J = 6.0 Hz, 6H), 
1.37 (d, J = 6.1 Hz, 3H), 1.02 (t, J = 7.5 Hz, 3H). 
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13C NMR (CDCl3-d), δ: 176.62 (C=O), 170.47 (C=O), 166.27 (C=O), 165.12 (C=O), 165.03, 
155.79, 146.49, 145.76, 144.86, 141.44, 133.28, 132.99 (C, C-aromatic), 130.32 (CH, C-
aromatic), 128.99, 128.68 (C, C-aromatic), 124.59 (CH, C-aromatic), 124.04 (C, C-
aromatic), 122.56, 119.89, 119.14, 118.71, 118.57, 117.02, 113.62, 112.33, 111.80 (CH, C-
aromatic), 76.62, 70.87 (CH), 52.51 (CH3), 41.76, 29.22 (CH2), 22.22, 22.21, 19.32, 9.70 
(CH3). 
 
(4-(4-(4-amino-3-isopropoxybenzamido)-3-(sec-butoxy)benzamido)-3-phenoxy 
benzoyl)glycine (126) 
(C36H38N4O8; M.W.: 654.72) 
 
 
methyl (4-(4-(4-amino-3-isopropoxybenzamido)-3-(sec-butoxy)benzamido)-3-phenoxy 
benzoyl)glycinate 157 (0.06 mmol) was solubilised in tetrahydrofuran and methanol (0.04 
M, ratio 2:1) and a solution 1N of LiOH (0.06 mL) was added. The reaction mixture was 
stirred overnight at room temperature. The reaction mixture was concentrated under 
reduced pressure and the residue was dissolved in water (10 mL). The aqueous layer was 
acidified with HCl 2N and then extracted with DCM (3x15mL). The organic layers were 
combined, washed with Brine, dried over MgSO4 and concentrated under reduced pressure. 
The crude residue was purified by flash column chromatography (Biotage Isolera One 
system, Cartridge: ZIP KP Sil 5g, DCM – MeOH 100:0 v/v increasing to 9:1 v/v in 15 CV) to 
give pure (4-(4-(4-amino-3-isopropoxybenzamido)-3-(sec-butoxy)benzamido)-3-
phenoxybenzoyl) glycine 126 as yellow powder. 
T.L.C. System: DCM/MeOH 9:1 v/v, Rf: 0.23 
Yield: 23 mg (59%) 
Purity: 96% 
UPLC-MS method C: Rt: 1.881, MS (ESI)+: 665.3[M+1]+ 
1H NMR (DMSO-d6), δ: 12.59 (bs, 1H), 9.87 (s, 1H), 8.91 (s, 1H), 8.87 (t, J = 5.9 Hz, 1H), 
8.23 (d, J = 8.9 Hz, 1H), 7.98 (d, J = 8.4 Hz, 1H), 7.76 (dd, 3J = 8.4 Hz, 4J = 1.9 Hz, 1H), 
7.54 (d, 4J = 1.9 Hz, 1H), 7.49 – 7.45 (m, 2H), 7.41 – 7.36 (m, 2H), 7.34 – 7.29 (m, 2H), 
7.13 (t, J = 7.4 Hz, 1H), 7.04 (dd, 3J = 8.6 Hz, 4J = 0.9 Hz, 2H), 6.72 (d, J = 8.1 Hz, 1H), 
5.44 (s, 2H), 4.59 (hept, J = 6.0 Hz, 1H), 4.51 (h, J = 6.0 Hz, 1H), 3.90 (d, J = 5.8 Hz, 2H), 
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1.80 – 1.72 (m, 1H), 1.72 – 1.64 (m, 1H), 1.32 (dd, 3J = 6.0 Hz, 4J = 1.9 Hz, 6H), 1.29 (d, J 
= 6.1 Hz, 3H), 0.96 (t, J = 7.4 Hz, 3H). 
13C NMR (DMSO-d6), δ: 171.73 (C=O), 165.74 (C=O), 165.33 (C=O), 164.88 (C=O), 
156.94, 148.92, 147.38, 143.84, 143.69, 133.20, 132.62, 131.71 (C, C-aromatic), 130.45 
(CH, C-aromatic), 129.48 (C, C-aromatic), 125.80, 123.95, 123.33 (CH, C-aromatic), 121.76 
(C, C-aromatic), 121.26, 120.94, 120.33, 118.90, 118.41, 113.25, 113.01, 112.93 (CH, C-
aromatic), 76.52, 70.84 (CH), 41.70, 29.00 (CH2), 22.42, 22.38, 19.33, 9.85 (CH3). 
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6.5.4 Synthesis of (4-(4-(4-amino-2-isopropoxybenzamido)-3-(sec-
butoxy)benzamido)-3-phenoxybenzoyl)glycine (158) 
 
Methyl 2-hydroxy-4-nitrobenzoate (161) 
(C8H7NO5; M.W.: 197.15) 
 
 
 
To a solution of 2-hydroxy-4-nitrobenzoic acid 160 (5.46 mmol) in anhydrous methanol (0.5 
M), thionyl chloride (16.39 mmol) was added drop-wise at 0°C. The reaction mixture was 
stirred at room temperature overnight. The mixture was concentrated under reduced 
pressure and the obtained residue was then diluted with a sat. NaHCO3 solution (60 mL) 
and extracted with EtOAc (3x60 mL). The organic layers were combined, washed with Brine 
and then dried over MgSO4 and concentrated under reduced pressure to give methyl 2-
hydroxy-4-nitrobenzoate 161 as a yellow powder, that was used without further purification. 
T.L.C. System: n-hexane - n-Hex/EtOAc 8:2 v/v, Rf: 0.5. 
Yield: 961 mg (89%) 
Purity: 97% 
UPLC-MS method C: Rt: 1.803, MS (ESI)+: 196.3[M-1]- 
1H NMR (DMSO-d6), δ: 10.97 (s, 1H), 7.92 (d, J = 8.6 Hz, 1H), 7.74 (d, 4J = 2.2 Hz, 1H), 
7.71 (dd, 3J = 8.6 Hz, 4J = 2.2 Hz, 1H), 3.89 (s, 3H). 
13C NMR (DMSO-d6), δ: 167.03 (C=O), 159.21, 151.14 (C, C-aromatic), 132.34 (CH, C-
aromatic), 121.71 (C, C-aromatic), 113.94, 112.38 (CH, C-aromatic), 53.18 (CH3). 
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Methyl 2-hydroxy-4-nitrobenzoate (162) 
(C11H13NO5; M.W.: 239.23) 
 
 
 
A solution of methyl 2-hydroxy-4-nitrobenzoate 161 (2.33 mmol) and potassium carbonate 
(2.79 mmol) in anhydrous DMF (0.7 M) was stirred at room temperature for 15 minutes, 
then 2-bromopropane (3.73 mmol) was added drop-wise and the reaction mixture was 
stirred overnight at 70°C. The reaction mixture was diluted with EtOAc (20 mL) and then 
extracted with HCl 1N solution (4x20 mL). The organic layer was then washed with Brine, 
dried over MgSO4 and concentrated under reduced pressure. The crude residue was 
purified by flash column chromatography (Biotage Isolera One system, Cartridge: SNAP KP 
Sil 50g, n-Hexane – EtOAc 100:0 v/v increasing to 80:20 v/v in 10 CV) to give pure methyl 
2-hydroxy-4-nitrobenzoate 162 as a yellow solid. 
T.L.C. System: n-hexane -EtOAc 8:2 v/v, Rf: 0.46. 
Yield: 504 mg (90%) 
Purity: 96% 
UPLC-MS method C: Rt: 1.946, MS (ESI)+: 181.1[C9H10NO3 +1]+ 
1H NMR (DMSO-d6), δ: 7.88 (d, 4J = 1.7 Hz, 1H), 7.85 – 7.80 (m, 2H), 4.86 (hept, J = 6.0 
Hz, 1H), 3.84 (s, 3H), 1.31 (d, J = 6.0 Hz, 6H). 
13C NMR (DMSO-d6), δ: 165.79 (C=O), 156.85, 150.62 (C, C-aromatic), 131.67 (CH, C-
aromatic), 128.32 (C, C-aromatic), 115.48, 110.09 (CH, C-aromatic), 72.54 (CH), 52.88, 
21.97 (CH3). 
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2-isopropoxy-4-nitrobenzoic acid (159) 
(C10H11NO5; M.W.: 225.2) 
 
 
To a solution of methyl 2-hydroxy-4-nitrobenzoate 162 (1.89 mmol) in tetrahydrofuran and 
methanol (0.12 M, ratio 2:1) was added a solution 1N of NaOH (3.8 mL). The reaction 
mixture was stirred at room temperature overnight. The reaction mixture was concentrated 
under reduced pressure and the residue was dissolved in water (10 mL). The aqueous layer 
was acidified with HCl 2N and then extracted with DCM (3x15mL). The organic layers were 
combined, washed with Brine, dried over MgSO4 and concentrated under reduced pressure 
to give 2-isopropoxy-4-nitrobenzoic acid 159, as an off-whtie powder which was used 
without further purification. 
T.L.C. System: DCM/MeOH 95:5 v/v, Rf: 0.3. 
Yield: 394 mg (92%) 
Purity: 97% 
UPLC-MS method C: Rt: 1.684, MS (ESI)-: 224.1[M-1]- 
1H NMR (DMSO-d6), δ: 13.31 (bs, 1H), 7.90 (d, J = 2.0 Hz, 1H), 7.86 (dd, 3J = 8.4 Hz, 4J = 
2.1 Hz, 1H), 7.81 (d, J = 8.4 Hz, 1H), 4.89 (hept, J = 6.0 Hz, 1H), 1.36 (d, J = 6.0 Hz, 6H).  
13C NMR (DMSO-d6), δ: 167.07 (C=O), 156.40, 150.14 (C, C-aromatic), 131.15 (CH, C-
aromatic), 130.19 (C, C-aromatic), 115.45, 109.84 (CH, C-aromatic), 72.29 (CH), 22.00 
(CH3). 
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Methyl (4-(3-(sec-butoxy)-4-(2-isopropoxy-4-nitrobenzamido)benzamido)-3-
phenoxybenzoyl)glycinate (163) 
(C37H38N4O10; M.W.: 698.73) 
 
 
 
2-isopropoxy-4-nitrobenzoic acid 159 (0.135 mmol) in SOCl2 (0.5 ml) was refluxed for 2 
hours. SOCl2 was eliminated from the reaction mixture under reduced pressure. The 
resulting residue was dissolved in anhydrous DCM (3 ml) and added drop-wise to a solution, 
at 0°C, of methyl (4-(4-amino-3-(sec-butoxy)benzamido)-3-phenoxybenzoyl)glycinate 152 
(0.203 mmol), triethylamine (0.406 mmol) in anhydrous DCM (3 ml) under nitrogen 
atmosphere. The reaction was allowed to warm-up to room temperature and was stirred 
overnight. The reaction mixture was diluted with DCM and extracted with 1N HCl solution 
(3x10ml). The organic layer was washed with brine (3 x 10 mL), dried over MgSO4 and 
evaporated at reduced pressure. The obtained crude residue was purified by flash column 
chromatography (Biotage Isolera One system, Cartridge: SNAP KP Sil 10g, DCM -MeOH 
100:0 v/v increasing to 99:1 v/v in 10 CV) to give pure methyl (4-(3-(sec-butoxy)-4-(2-
isopropoxy-4-nitrobenzamido)benzamido)-3-phenoxybenzoyl)glycinate 163 as yellow 
powder. 
T.L.C. System: DCM/MeOH 99:1 v/v, Rf: 0.22 
Yield: 134.8 mg (95%) 
Purity: 99% 
UPLC-MS method C: Rt: 2.213, MS (ESI)+: 699.3[M+1]+, 721.3[M+Na]+ 
1H NMR (DMSO-d6), δ: 9.98 (s, 1H), 9.94 (s, 1H), 9.00 (t, J = 5.8 Hz, 1H), 8.46 (d, J = 8.7 
Hz, 1H), 8.18 (d, J = 8.6 Hz, 1H), 8.01 (d, 4J = 1.8 Hz, 1H), 7.98 (d, J = 8.4 Hz, 1H), 7.95 
(dd, 3J = 8.6 Hz, 4J = 2.1 Hz, 1H), 7.77 (dd, 3J = 8.4 Hz, 4J = 1.9 Hz, 1H), 7.54 (d, 4J = 1.9 
Hz, 1H), 7.53 – 7.48 (m, 2H), 7.41 – 7.36 (m, 2H), 7.13 (t, J = 7.4 Hz, 1H), 7.04 (d, J = 7.7 
Hz, 2H), 5.10 – 5.01 (m, 1H), 4.56 – 4.48 (m, 1H), 3.99 (d, J = 5.8 Hz, 2H), 3.65 (s, 3H), 
1.84 – 1.72 (m, 1H), 1.72 – 1.59 (m, 1H), 1.45 (d, J = 6.0 Hz, 3H), 1.43 (d, J = 6.0 Hz, 3H), 
1.31 (d, J = 6.1 Hz, 3H), 0.92 (t, J = 7.4 Hz, 3H). 
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13C NMR (DMSO-d6), δ: 170.81 (C=O), 165.88 (C=O), 165.23 (C=O), 162.25 (C=O), 
156.91, 156.04, 150.79, 149.00, 147.36 (C, C-aromatic), 133.26 (CH, C-aromatic), 133.24, 
131.55, 131.53 (C, C-aromatic), 130.45 (CH, C-aromatic), 129.16 (C, C-aromatic), 125.91, 
123.98, 123.37, 121.02, 120.61, 118.91, 118.42, 116.28, 113.23, 110.59 (CH, C-aromatic), 
77.62, 74.42 (CH), 52.22(CH3), 41.71, 29.22 (CH2), 22.10, 22.09, 19.84, 10.26 (CH3). 
 
Methyl (4-(4-(4-amino-2-isopropoxybenzamido)-3-(sec-butoxy)benzamido)-3-
phenoxybenzoyl)glycinate (164) 
(C37H40N4O8; M.W.: 668.75) 
 
 
 
A solution of methyl (4-(3-(sec-butoxy)-4-(2-isopropoxy-4-nitrobenzamido)benzamido)-3-
phenoxybenzoyl)glycinate 163 (0.16 mmol) in anhydrous ethyl acetate and tetrahydrofuran 
(0.004 M, ratio 3:1) was stirred under H2 atmosphere in presence of Pd/C (15%) at room 
temperature overnight. The reaction mixture was filtered on Celite. The filtered solution was 
concentrated under reduced pressure and the obtained residue was purified by flash 
column chromatography (Biotage Isolera One system, Cartridge: SNAP KP Sil 10g, DCM - 
MeOH 100:0 v/v increasing to 97:3 v/v in 8 CV) to give pure methyl (4-(4-(4-amino-2-
isopropoxybenzamido)-3-(sec-butoxy)benzamido)-3-phenoxybenzoyl)glycinate 164 as a 
yellow solid. 
T.L.C. System: DCM/MeOH 97:3 v/v, Rf: 0.36 
Yield: 102 mg (95%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.958, MS (ESI)+: 669.4[M+1]+ 
1H NMR (DMSO-d6), δ: 10.00 (s, 1H), 9.85 (s, J = 6.2 Hz, 1H), 8.99 (t, J = 5.8 Hz, 1H), 8.46 
(d, J = 8.4 Hz, 1H), 8.00 (d, J = 8.4 Hz, 1H), 7.78 – 7.72 (m, 2H), 7.53 (d, 4J = 1.9 Hz, 1H), 
7.49 – 7.42 (m, 2H), 7.42 – 7.35 (m, 2H), 7.13 (t, J = 7.4 Hz, 1H), 7.04 (d, J = 8.5 Hz, 2H), 
6.34 (d, J = 1.8 Hz, 1H), 6.28 (dd, 3J = 8.6 Hz, 4J = 1.9 Hz, 1H), 5.91 (s, 2H), 4.67 (hept, J 
= 6.1 Hz, 1H), 4.46 (h, J = 6.2 Hz, 1H), 3.99 (d, J = 5.8 Hz, 2H), 3.65 (s, 3H), 1.85 – 1.71 
(m, 1H), 1.71 – 1.60 (m, 1H), 1.42 (d, J = 6.1 Hz, 3H), 1.40 (d, J = 6.1 Hz, 3H), 1.31 (d, J = 
6.1 Hz, 3H), 0.93 (t, J = 7.4 Hz, 3H). 
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13C NMR (DMSO-d6), δ 170.82 (C=O), 165.90 (C=O), 165.36 (C=O), 163.88 (C=O), 158.08, 
156.91, 154.71, 148.86, 146.95 (C, C-aromatic), 133.65 (CH, C-aromatic), 133.38, 133.13, 
131.36 (C, C-aromatic), 130.45 (CH, C-aromatic), 128.78 (C, C-aromatic), 125.71, 123.98, 
123.37, 121.07, 120.14, 118.87, 118.42, 113.33 (CH, C-aromatic), 109.82 (C, C-aromatic), 
107.62, 98.94 (CH, C-aromatic), 77.86, 72.79 (CH), 52.22 (CH3), 41.71, 29.36 (CH2), 22.49, 
22.47, 20.01, 10.29 (CH3). 
 
(4-(4-(4-amino-2-isopropoxybenzamido)-3-(sec-butoxy)benzamido)-3-
phenoxybenzoyl)glycine (158) 
(C36H38N4O8; M.W.: 654.72) 
 
 
 
methyl (4-(4-(4-amino-2-isopropoxybenzamido)-3-(sec-butoxy)benzamido)-3-phenoxy 
benzoyl)glycinate 164 (0.06 mmol) was solubilised in tetrahydrofuran and methanol (0.04 
M, ratio 2:1) and a solution 1N of LiOH (0.06 mL) was added. The reaction mixture was 
stirred overnight at room temperature. The reaction mixture was concentrated under 
reduced pressure and the residue was dissolved in water (10 mL). The aqueous layer was 
acidified with HCl 2N and then extracted with DCM (3x15mL). The organic layers were 
combined, washed with Brine, dried over Na2SO4 and concentrated under reduced 
pressure. The crude residue was purified by flash column chromatography (Biotage Isolera 
One system, Cartridge: SNAP KP Sil 10g, DCM – MeOH 100:0 v/v increasing to 97:3 v/v in 
14 CV) to give pure (4-(4-(4-amino-2-isopropoxybenzamido)-3-(sec-butoxy)benzamido)-3-
phenoxybenzoyl)glycine 158 as pale yellow powder. 
T.L.C. System: DCM/MeOH 9:1 v/v, Rf: 0.2 
Yield: 32 mg (80%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.851, MS (ESI)+: 655.3[M+1]+ 
1H NMR (DMSO-d6), δ: 12.56 (s, 1H), 10.00 (s, 1H), 9.84 (s, 1H), 8.91 – 8.82 (m, 1H), 8.46 
(d, J = 8.4 Hz, 1H), 7.99 (d, J = 8.4 Hz, 1H), 7.78 – 7.69 (m, 2H), 7.54 (d, 4J = 1.5 Hz, 1H), 
7.50 – 7.42 (m, 2H), 7.38 (t, J = 8.0 Hz, 2H), 7.13 (t, J = 7.4 Hz, 1H), 7.03 (d, J = 7.8 Hz, 
2H), 6.33 (d, 4J = 1.7 Hz, 1H), 6.28 (dd, 3J = 8.6 Hz, 4J = 1.8 Hz, 1H), 5.90 (s, 2H), 4.67 
(hept, J = 6.0 Hz, 1H), 4.46 (h, J = 6.1 Hz, 1H), 3.89 (d, J = 4.0 Hz, 2H), 1.83 – 1.71 (m, 
Part II: RSV 
209 
1H), 1.71 – 1.59 (m, 1H), 1.42 (d, J = 6.1 Hz, 3H), 1.40 (d, J = 6.1 Hz, 3H), 1.31 (d, J = 6.1 
Hz, 3H), 0.93 (t, J = 7.4 Hz, 3H). 
13C NMR (DMSO-d6), δ: 171.73 (C=O), 165.74 (C=O), 165.35 (C=O), 163.88 (C=O), 
158.08, 156.96, 154.71, 148.83, 146.95 (C, C-aromatic), 133.65 (CH, C-aromatic), 133.28, 
133.12, 131.65 (C, C-aromatic), 130.44 (CH, C-aromatic), 128.79 (C, C-aromatic), 125.71, 
123.94, 123.35, 121.06, 120.14, 118.91, 118.38, 113.32 (CH, C-aromatic), 109.82 (C, C-
aromatic), 107.62, 98.94 (CH, C-aromatic), 77.85, 72.79 (CH), 41.74, 29.36 (CH2), 22.49, 
22.47, 20.01, 10.29 (CH3). 
 
6.5.5 Synthesis of methyl (4-(4-amino-3-(sec-butoxy)benzamido)-
3-phenoxybenzoyl)glycine derivatives(168-170) 
General procedure 9: synthesis of methyl (4-(4-amino-3-(sec-butoxy)benzamido)-3-
phenoxybenzoyl)glycinate derivatives 
 
 
The Acyl chloride was added drop-wise to a solution, at 0°C, of 4-(4-amino-3-(sec-
butoxy)benzamido)-3-phenoxybenzoic acid (0.108 mmol), triethylamine (0.216 mmol) in 
anhydrous DCM (0.1 M) under nitrogen atmosphere. The reaction was allowed to warm-up 
to rt and was stirred overnight. The reaction mixture was concentrated at reduced pressure 
and the residue was purified by flash column chromatography to afford pure methyl (4-(4-
amino-3-(sec-butoxy)benzamido)-3-phenoxybenzoyl)glycinate derivative. 
 
General procedure 10: synthesis of (4-(4-amino-3-(sec-butoxy)benzamido)-3-
phenoxybenzoyl)glycine derivatives 
 
 
To a solution of methyl (4-(4-amino-3-(sec-butoxy)benzamido)-3-phenoxybenzoyl)glycinate 
derivative (0.037 mmol) in tetrahydrofuran and methanol (0.05 M, ratio 2:1) was added a 
solution 1N of LiOH (0.04 mL). The reaction mixture was stirred overnight at room 
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temperature. The reaction mixture was concentrated under reduced pressure and the 
residue was dissolved in water (10 mL). The aqueous layer was acidified with HCl 2N and 
then extracted with DCM (3x10mL). The organic layers were combined, washed with Brine, 
then dried over MgSO4 and concentrated under reduced pressure. The crude residue was 
purified by flash column chromatography to afford pure (4-(4-amino-3-(sec-
butoxy)benzamido)-3-phenoxybenzoyl)glycine derivative. 
Methyl (4-(4-acetamido-3-(sec-butoxy)benzamido)-3-phenoxybenzoyl)glycinate (165) 
(C29H31N3O7; M.W.: 533.58) 
 
 
Procedure: 9 
white powder; 
T.L.C. System: DCM/MeOH 98:2 v/v, Rf: 0.28 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: ZIP 
KP Sil 5g (DCM -MeOH 100:0 v/v increasing to 96:4 v/v in 11 CV).  
Yield: 34 mg (60%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.871, MS (ESI)+: 534.2[M+1]+, 556.2[M+Na]+ 
1H NMR (DMSO-d6), δ: 9.85 (s, 1H), 9.03 – 8.95 (m, 2H), 8.11 (d, J = 8.1 Hz, 1H), 7.97 (d, 
J = 8.4 Hz, 1H), 7.75 (dd, 3J = 8.4 Hz, 4J = 1.9 Hz, 1H), 7.52 (d, 4J = 1.9 Hz, 1H), 7.43 – 
7.34 (m, 4H), 7.13 (t, J = 7.4 Hz, 1H), 7.03 (d, J = 8.5 Hz, 2H), 4.47 – 4.38 (m, 1H), 3.98 (d, 
J = 5.8 Hz, 2H), 3.65 (s, 3H), 2.14 (s, 3H), 1.82 – 1.70 (m, 1H), 1.70 – 1.56 (m, 1H), 1.26 
(d, J = 6.1 Hz, 3H), 0.94 (t, J = 7.4 Hz, 3H). 
13C NMR (DMSO-d6), δ: 176.62 (C=O), 170.81 (C=O), 169.29 (C=O), 165.88 (C=O), 
165.34, 156.88, 148.94, 133.29, 132.40, 131.42, 130.65 (C, C-aromatic), 130.44, 125.78, 
123.98, 123.34, 120.90, 120.64, 118.84, 118.44, 113.17 (CH, C-aromatic), 76.74 (CH), 
52.22(CH3), 41.70 (CH2), 40.59 (CH3), 28.88 (CH2), 19.43, 10.18 (CH3).  
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Methyl (4-(3-(sec-butoxy)-4-isobutyramidobenzamido)-3-phenoxybenzoyl)glycinate 
(166) 
(C31H35N3O7; M.W.: 561.63) 
 
 
Procedure: 9 
yellow solid; 
T.L.C. System: DCM/MeOH 98:2 v/v, Rf: 0.28 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: ZIP 
KP Sil 5g (DCM -MeOH 100:0 v/v increasing to 96:4 v/v in 11 CV).  
Yield: 68 mg (86%) 
Purity: 99% 
UPLC-MS method C: Rt: 2.026, MS (ESI)+: 562.3[M+1]+, 584.3[M+Na]+ 
1H NMR (DMSO-d6), δ: 9.86 (s, 1H), 8.99 (t, J = 5.8 Hz, 1H), 8.85 (s, 1H), 8.07 (d, J = 8.3 
Hz, 1H), 7.97 (d, J = 8.4 Hz, 1H), 7.75 (dd, 3J = 8.4 Hz, 4J = 1.9 Hz, 1H), 7.53 (d, 4J = 1.9 
Hz, 1H), 7.44 – 7.33 (m, 4H), 7.16 – 7.10 (m, 1H), 7.03 (dd, 3J = 8.6 Hz, 4J = 0.9 Hz, 2H), 
4.42 (h, J = 6.0 Hz, 1H), 3.99 (d, J = 5.8 Hz, 2H), 3.65 (s, 3H), 2.80 (hept, J = 6.8 Hz, 1H), 
1.80 – 1.69 (m, 1H), 1.69 – 1.59 (m, 1H), 1.26 (d, J = 6.1 Hz, 3H), 1.11 (d, J = 6.8 Hz, 6H), 
0.94 (t, J = 7.4 Hz, 3H). 
13C NMR (DMSO-d6), δ: 175.85 (C=O), 170.81 (C=O), 165.89 (C=O), 165.32 (C=O), 
156.88, 148.96, 147.78, 133.27, 132.32, 131.45 (C, C-aromatic), 130.45 (CH, C-aromatic), 
129.82 (C, C-aromatic), 125.84, 123.98, 123.34, 121.27, 120.69, 118.87, 118.43, 113.24 
(CH, C-aromatic), 76.77 (CH), 52.22 (CH), 41.71(CH2), 35.18 (CH3), 28.95 (CH2), 20.01, 
19.86, 19.44, 10.03 (CH3). 
  
Part II: RSV 
212 
Methyl (4-(3-(sec-butoxy)-4-(3-methylbutanamido)benzamido)-3-
phenoxybenzoyl)glycinate (167) 
(C32H37N3O7; M.W.: 575.66) 
 
 
Procedure: 9 
white powder; 
T.L.C. System: DCM/MeOH 98:2 v/v, Rf: 0.28 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: ZIP 
KP Sil 5g (DCM -MeOH 100:0 v/v increasing to 96:4 v/v in 11 CV).  
Yield: 65 mg (81%) 
Purity: 99% 
UPLC-MS method C: Rt: 2.077, MS (ESI)+: 576.4[M+1]+, 598.3[M+Na]+ 
1H NMR (DMSO-d6), δ: 9.90 (s, 1H), 9.04 (t, J = 5.8 Hz, 1H), 8.94 (s, 1H), 8.11 (d, J = 8.3 
Hz, 1H), 8.03 (d, J = 8.4 Hz, 1H), 7.81 (dd, 3J = 8.4 Hz, 4J = 1.5 Hz, 1H), 7.58 (d, J = 1.5 
Hz, 1H), 7.50 – 7.39 (m, 4H), 7.18 (t, J = 7.3 Hz, 1H), 7.08 (d, J = 7.9 Hz, 2H), 4.47 (h, J = 
5.9 Hz, 1H), 4.04 (d, J = 5.7 Hz, 2H), 3.70 (s, 3H), 2.37 (d, J = 6.4 Hz, 2H), 2.17 – 2.04 (m, 
1H), 1.85 – 1.74 (m, 1H), 1.74 – 1.63 (m, 1H), 1.31 (d, J = 6.0 Hz, 3H), 0.99 (s, 9H). 
13C NMR (DMSO-d6), δ: 171.46 (C=O), 170.81 (C=O), 165.89 (C=O), 165.35 (C=O), 
156.89, 148.91, 147.76, 133.30, 132.22, 131.43 (C, C-aromatic), 130.44 (CH, C-aromatic), 
129.87 (C, C-aromatic), 125.78, 123.97, 123.36, 121.46, 120.61, 118.89, 118.41, 113.21 
(CH, C-aromatic), 76.68 (CH), 52.22 (CH), 45.83, 41.71, 28.93 (CH2), 26.16, 22.68, 22.67, 
19.44, 10.09 (CH3). 
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(4-(4-acetamido-3-(sec-butoxy)benzamido)-3-phenoxybenzoyl)glycine (168) 
(C28H29N3O7; M.W.: 519.55) 
 
 
Procedure 10 
pale yellow powder; 
T.L.C. System: DCM/MeOH 95:5 v/v, Rf: 0.33 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: ZIP 
KP Sil 5g (DCM -MeOH 100:0 v/v increasing to 95:5 v/v in 16 CV). 
Yield: 17 mg (93%) 
Purity: 98% 
UPLC-MS method C: Rt: 1.748, MS (ESI)+: 520.3[M+1]+ 
1H NMR (DMSO-d6), δ: 12.55 (bs, 1H), 9.84 (s, 1H), 8.98 (s, 1H), 8.87 – 8.80 (m, 1H), 8.11 
(d, J = 8.1 Hz, 1H), 7.96 (d, J = 8.4 Hz, 1H), 7.75 (dd, 3J = 8.4 Hz, 4J = 1.9 Hz, 1H), 7.53 (d, 
4J = 1.9 Hz, 1H), 7.43 – 7.34 (m, 4H), 7.15 – 7.09 (m, 1H), 7.05 – 7.00 (m, 2H), 4.42 (dq, J 
= 12.1, 6.1 Hz, 1H), 3.88 (d, J = 5.7 Hz, 2H), 2.14 (s, 3H), 1.83 – 1.70 (m, 1H), 1.70 – 1.58 
(m, 1H), 1.26 (d, J = 6.1 Hz, 3H), 0.94 (t, J = 7.4 Hz, 3H). 
13C NMR (DMSO-d6), δ: 171.70 (C=O), 169.30 (C=O), 165.70 (C=O), 165.33 (C=O), 
156.93, 148.92, 133.18, 132.38, 131.74 (C, C-aromatic), 130.44, 125.79, 123.94, 123.31, 
120.96, 120.64, 118.88, 118.40, 113.16 (CH, C-aromatic), 76.74 (CH), 41.76 (CH2), 40.58 
(CH3), 28.88 (CH2), 19.43, 10.18 (CH3). 
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(4-(3-(sec-butoxy)-4-isobutyramidobenzamido)-3-phenoxybenzoyl)glycine (169) 
(C30H33N3O7; M.W.: 547.61) 
 
 
Procedure 10 
white powder; 
T.L.C. System:  DCM/MeOH 95:5 v/v, Rf: 0.33 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: ZIP 
KP Sil 5g (DCM -MeOH 100:0 v/v increasing to 95:5 v/v in 16 CV). 
Yield: 39 mg (82%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.94, MS (ESI)+: 548.3[M+1]+ 
1H NMR (DMSO-d6), δ: 12.59 (bs, 1H), 9.85 (s, 1H), 8.92 – 8.74 (m, 2H), 8.06 (d, J = 8.2 
Hz, 1H), 7.96 (d, J = 8.4 Hz, 1H), 7.75 (dd, 3J = 8.4 Hz, 4J = 1.8 Hz, 1H), 7.53 (d, 4J = 1.8 
Hz, 1H), 7.44 – 7.34 (m, 4H), 7.12 (t, J = 7.4 Hz, 1H), 7.02 (d, J = 7.8 Hz, 2H), 4.46 – 4.37 
(m, 1H), 3.89 (d, J = 5.8 Hz, 2H), 2.80 (hept, J = 6.7 Hz, 1H), 1.80 – 1.70 (m, 1H), 1.69 – 
1.57 (m, 1H), 1.26 (d, J = 6.1 Hz, 3H), 1.11 (d, J = 6.8 Hz, 6H), 0.94 (t, J = 7.4 Hz, 3H). 
13C NMR (DMSO-d6), δ: 175.85 (C=O), 171.73 (C=O), 165.72 (C=O), 165.31 (C=O), 
156.93, 148.92, 147.78, 133.17, 132.31, 131.74 (C, C-aromatic), 130.43 (CH, C-aromatic), 
129.83 (C, C-aromatic), 125.82, 123.94, 123.33, 121.26, 120.68, 118.91, 118.39, 113.23 
(CH, C-aromatic), 76.77 (CH), 41.73(CH2), 35.18 (CH), 28.95 (CH2), 20.01, 19.86, 19.44, 
10.03 (CH3). 
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(4-(3-(sec-butoxy)-4-(3-methylbutanamido)benzamido)-3-phenoxybenzoyl)glycine 
(170) 
(C31H35N3O7; M.W.: 561.63) 
 
 
Procedure 10 
white powder; 
T.L.C. System: DCM/MeOH 95:5 v/v, Rf: 0.33 
Purification: Flash column chromatography Isolera One system (Biotage), Cartridge: ZIP 
KP Sil 5g (DCM -MeOH 100:0 v/v increasing to 95:5 v/v in 16 CV). 
Yield: 39 mg (87%) 
Purity: 99% 
UPLC-MS method C: Rt: 1.979, MS (ESI)+: 562.3[M+1]+ 
1H NMR (DMSO-d6), δ: 12.59 (bs, 1H), 9.84 (s, 1H), 8.88 (s, 1H), 8.84 (t, J = 5.8 Hz, 1H), 
8.06 (d, J = 8.2 Hz, 1H), 7.96 (d, J = 8.4 Hz, 1H), 7.75 (dd, 3J = 8.4 Hz, 4J = 1.9 Hz, 1H), 
7.53 (d, 4J = 1.9 Hz, 1H), 7.44 – 7.32 (m, 4H), 7.12 (t, J = 7.4 Hz, 1H), 7.02 (d, J = 8.6 Hz, 
2H), 4.42 (h, J = 6.0 Hz, 1H), 3.88 (d, J = 5.8 Hz, 2H), 2.32 (d, J = 5.8 Hz, 2H), 2.12 – 1.99 
(m, 1H), 1.80 – 1.69 (m, 1H), 1.69 – 1.56 (m, 1H), 1.25 (d, J = 6.1 Hz, 3H), 0.95 (s, 9H). 
13C NMR (DMSO-d6), δ: 171.71 (C=O), 171.46 (C=O), 165.69 (C=O), 165.34 (C=O), 
156.94, 148.88, 133.18, 132.20, 131.75 (C, C-aromatic), 130.43 (CH, C-aromatic), 129.88 
(C, C-aromatic), 125.79, 123.93, 123.33, 120.60, 118.92, 118.36, 113.20 (CH, C-aromatic), 
76.68 (CH), 45.83, 41.79, 28.93 (CH2), 26.16 (CH), 22.69, 22.67, 19.44, 10.09 (CH3). 
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Appendix 
All compounds were purchased from SPECS, Enamine Ltd and Life Chemicals Inc. 
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7.1 Enterovirus 
Enteroviruses are part of the Picornaviridae family. They are positive single-stranded RNA, 
non-enveloped virus member of the Group IV in the Baltimore classification, in which the 
viral genome in inside an icosahedral capsid. Poliovirus, discovered in 1908, is the most 
studied enterovirus, and it is the etiological cause of Poliomyelitis, also known as Polio, an 
infectious disease of the central nervous system. The Poliovirus is affecting mainly children, 
and during the infection it spread and damage the motor neurons, leading in the worst cases 
in total paralysis. Since the 1960s, in which the Sabin's vaccine against the three Poliovirus 
serotype was licensed, an extensive vaccine campaign to eradicate Polio was performed. 
Today, poliovirus is declared eradicated in the developed countries but remains a battle in 
Nigeria, Syria, Afghanistan and Pakistan. Furthermore, at the beginning of 2018, an 
outbreak of Polio was reported in Papua New Guinea, a county defined Polio-free since 
2000.1 
The three serotypes Poliovirus, with the other Non-Polio Enteroviruses (NPEVs), are part 
of the 260 serotypes among the seven human pathogens species in the enterovirus genus. 
One hundred of those serotypes can be divided into Enterovirus A-D and the other 160 into 
Rhinovirus A-C. Those NPEVs have emerged in the last decades as severe treats for public 
health.  
 
 
Figure 1. Enterovirus genus and human pathogen species. graphic representation of 
the Non-Polio Enteroviruses (NPEVs) species, in which the seven human pathogens 
species (Enterovirus A-D and Rhinovirus A-C) include 260 different viral serotypes. 
 
Few examples are EVA-71, the primary cause of Hand-foot-and-mouth disease (HFMD). 
EVD-68, causes severe respiratory disease and Acute Flaccid Paralysis (AFP) and cranial 
nerve dysfunction in children. Coxsackieviruses are associated with aseptic meningitis but 
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also related to the aetiology of type 1 diabetes. Rhinoviruses are the cause of the common 
cold, but they can also be related to asthma and development of chronic obstructive 
pulmonary disease (COPD).2 
Enteroviruses transmission occurs through the faecal-oral or respiratory routes and during 
the infection they can spread and infect other different tissues and organs and, as said 
before, they can infect the central nervous system. Except for the Anti-polio vaccines and 
two recently approved vaccine against EVA-71 in China, there is no antiviral therapy 
available on the market.3-4 
 
7.2 Viral Genome organisation and life-cycle 
The viral genome of enterovirus is ∼7.5 kb long positive single-stranded RNA. The genome 
can be divided into three parts: 5′-untranslated region (5′UTR), the coding region and a 3′-
untranslated region (3′UTR) (figure 2). 
 
 
Figure 2. Enterovirus genome organisation. Schematic representation of the enterovirus 
genome which encodes 11 viral proteins. At the 5′UTR contains six stem-loop 
intramolecular base pairing structures, the internal ribosome entry site (IRES) and it is 
covalently bounded to the VPg protein, a protein essential for the 3Dpol. At the 3′UTR the 
viral genome has three stem-loop structures which are involved in the viral replication 
(Designed by Denise Seitner). 
 
The 5′UTR contains six stem-loop intramolecular base pairing structures which are involved 
in the viral RNA synthesis and include internal ribosome entry site (IRES) which is essential 
for the viral protein translation.5 The 5′UTR is covalently bound to the VPg protein, which is 
the primer for the viral RNA- dependent RNA polymerase 3Dpol. The coding region has 
only one open reading frame (ORF) and is encoding for a ∼2,100 amino acids polyprotein. 
The viral polyprotein is successively cleaved by the viral proteinase 2Apro, 3Cpro and 
3CDpro into four capsid proteins and six non-structural proteins (NSPs) and several 
functional cleavage intermediates. The last part of the viral genome is 3′UTR. This region 
is highly conserved and has three stem-loop structures which are essential for the viral 
replication. 
As said before the polyprotein is cleaved in ten proteins that can be four structural and six 
non-structural proteins. The four structural proteins, VP1-4, are the structural subunit of the 
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icosahedral capsid of the virion. VP1-3 are on the surface of the capsid, VP4 instead is 
internalised in the virion. Those proteins are the functional unit for the assembly of the viral 
capsid of the new virions. The enterovirus life-cycle, like for the other viruses, can be divided 
into three main stages: 1) Entry process; 2) Translation and genome replication; 3) Virion 
assembly and release (figure 3).4  
 
 
 
Figure 3. Viral cycle representation. The viral life-cycle of enterovirus can be divided into 
three steps: 1) entry process; 2) translation and genome replication; 3) virion assembly and 
release. The viruses enter the cell thought two different mechanism, both mediated by the 
viral capsid proteins: by binding to the cell membrane or by endocytosis. Once the virus 
enters or is bonded to the cell, the viral genome is released by the viral capsid protein 
rearrangement. The viral proteins, produced by the auto-proteolytic process of the 
polyprotein, which is obtained by the translation of the viral genome, are involved in the 
formation of the replication organelles (ROs). The ROs are essential for the viral genome 
replication. Once the viral genome is replicated and the structural proteins are produced, 
the new virions are auto-assembled and released by lytic or non-lytic mechanisms. 
(Designed by Denise Seitner) 
 
Entry process 
The virus to begin the infectious life-cycle must release the viral genome inside the host 
cell. For doing this, the virus binds to specific receptors expressed on the cell surface. 
Several different NPEV receptors have been recognised, explaining the various spectrum 
of diseases caused by enteroviruses. Those receptors can be classified as uncoating or 
attachment receptors, in which the first type is triggering the rearrangement of the capsid's 
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proteins to release the viral genome. The second type is promoting the endocytosis of the 
viral particle. Then in the endosome, the low pH is stimulating the capsid's proteins 
uncoating process. Both pathways end with the release of the viral genome into the cytosol 
of the host cell.  
Translation and genome replication 
Now that the viral genome is in the cytosol, it is translated by the host cell ribosomes into 
the polyprotein. As soon as the viral proteins are produced by the auto-proteolytic process 
of the polyprotein, the production of new virion can start. The newly produced non-structural 
proteins 3A and 2BC intermediate, together with several host-cell proteins, are driving the 
formation of the replication organelles (ROs), in which the viral genome is replicated by 
RNA-dependent RNA polymerase 3Dpol. The viral polymerase is working with 2C, 3CDpro 
and 3AB for the synthesis of a negative RNA strand as a double-strand RNA genome and 
act as a template for the viral genome replication.  
Virion assembly and release 
Now that the viral genome and the structural protein have been produced, the virion 
assembly stage can begin. The VP0 (precursor of VP2 and VP4), VP1 and VP3 structural 
proteins, formed through the proteolytical activity of the non-structural protein 3CDpro, are 
self-oligomerising around the newly replicated viral-RNA. Then the viral-RNA is cleaving 
the VP0 into VP2 and VP4 to give the mature virion. The lysis of the cell releases the new 
virions which are now able to infect other cells and organs. 
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7.3 Therapeutic strategies 
There is an unmet need for antiviral drugs for NPEV and Polio infections, due to the lack of 
antiviral therapy on the market. Several compounds were evaluated in clinical trials to treat 
rhinovirus infections. 
 
 
 
Figure 4. Enteroviruses Drug candidates. In the figure are reported the chemical 
structures of the drug candidates in clinical trials for the treatment of rhinovirus infections. 
On the left side of the figure are shown four capsid inhibitors: Pleconaril, Vapendavir, 
Pirodavir and Pocapavir. In the middle two inhibitors of the viral protease 3Cpro: Rupintrivir 
and AG-7404. On the right side, the chemical structure of Enviroxime a PI4KB inhibitor. 
 
Mainly these compounds were capsid inhibitors, able to inhibit the release process of the 
viral genome by blocking the uncoating process of the virus. Other compounds were 
protease inhibitors targeting the viral protease 3Cpro. Another compound which was clinically 
evaluated was Enviroxime. This compound inhibits the phosphatidylinositol 4-kinase-β 
(PI4KB), a host factor which is crucial in the formation of the ROs for the viral genome 
replication. Those compounds never reached the market, because they did not show 
efficacy or low toxicity.4,6  
During the last decades, several compounds were reported to be able to inhibit the 
enteroviruses replication by targeting the previously described target but also other targets, 
either viral or host factors. Among the viral targets, several compounds were identified 
through drug repurposing screenings, to inhibit the 3Dpol RNA-dependent-RNA polymerase 
and others the non-structural protein 2C, which is taking part in several steps of the viral 
replication life-cycle. The inhibitions of another host factor target, the oxysterol-binding 
protein (OSBP) which is involved together with PI4KB in the formation of the Ros, was 
reported to block the viral replication. The inhibition of three host factors was reported to be 
useful as antiviral strategies, interfering with the viral uncoating or the capsid assembly. The 
inhibition of the N-myristoyltransferase 1 and the depletion of Glutathione was 
demonstrated to interfere with the uncoating process. Heat shock protein 90 (HSP90), 
Part III: Enterovirus 
242 
involved with the assembly process of the virions, was demonstrated to interfere with the 
capsid assembly.7 
 
7.4 Non-structural protein 2C 
Among the human enterovirus species, the non-structural 2C protein, encoded in the P2 
region, is highly conserved, and it is composed of 329 amino acids. This protein was 
extensively studied during the years, different interacting and functional regions on the 2C 
protein have been identified (figure 5). 
 
 
 
Figure 5. Representation of the interacting and functional motifs on the 2C protein. 
The non-structural 2C protein has RNA binding domains between the residues 21-54 and 
312-319 and a zinc binding domain between 269-286 residues. The viral 2C protein has 
also highly conserved motifs, Walker A, Walker B and the motif C, which are part of the 
ATPase domain. Between the resides 1-54 of the N-TD, the protein has two regions which 
are essential for the interaction with the membranes and for the oligomerisation. 
 
A region crucial for the interaction with the membranes and the oligomerisation was 
identified between 21-54 residues of the N-terminal domain.8-10 This region, together with 
another region, close to the C-terminal domain (312-319 residues), were identified as RNA 
binding domains.11-12 The zinc binding motif, another region identified in the CTD and 
located between 269-286 residues, seem to be involved either in interaction with other 
protein or with RNA.13 The 2C protein also has two highly conserved motifs which are part 
of the ATPase domain. The first motif, also called Walker A, located between 129 and 136, 
is involved in the binding with the ATP and hydrolysis of the ATP into ADP, related with 
energy release. The second motif, called Walker B, is involved in the coordination of the 
Mg2+.14-16 The ATPase domain of 2C was demonstrated to be crucial for the RNA replication 
process and proliferation of enteroviruses.14,16-17 
The protein has a highly conserved helicase motif, called motif C, located between the 217-
223 residues.18 For these three conserved motifs, Walker A, Walker B and motif C, the 2C 
protein can be classified as a member of the superfamily3 helicases.19 The 2C protein, for 
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which was observed hexameric oligomerisation, was associated with RNA helicases and 
ATP-independent RNA chaperones function.20-23 The 2C protein, by directly interacting with 
other viral and host proteins, is also essential for the rearrangement of intracellular 
membranes, the formation of ROs and the viral genome encapsidation.24-28  
 
Crystal structure of the non-structural 2C protein 
In 2017, Guan et al. released a truncated X-ray crystal structure of the EV71 2C protein, 
consisting of an ATPase domain, a zinc finger, and a long C-terminal α-helix.  
 
 
 
Figure 6. Representation EV-A71 2C protein. Ribbon representation of the crystal 
structure of the truncated non-structural 2C protein (116-329 residues, PDB ID:5GRB-chain 
A). Walker A, Walker B and the motif C are respectively represented in cyan, blue and 
purple. Zinc finger motif is represented in grey and the C-terminal α-helix in orange. 
 
The ATPase domain is composed of five parallel β strands, forming a β-sheet, surrounded 
by three α-helixes, forming the α/β Rossman fold, typical of enzymes binding to nucleotide 
cofactors. The Walker A, Walker B motifs and motif-C are located in the ATPase domain, 
as shown in figure 6. The Zinc finger domain is formed by the 267 to 298 residues, and the 
zinc atom Is coordinated by three cysteine residues, C270, C281 and C286 respectively, 
and the carbonyl of S282 backbone. The last domain is the long C-terminal α-helix, formed 
by the residues 299-329. This α-helix seems to be involved in the stabilisation of the 
hexameric configuration of the 2C proteins and the residues 312-319 is known to interact 
with the RNA. 
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Even if the crystal of EV-A71 2C protein were obtained by removing the N-terminal domain 
(1-116 residues), which is responsible for the membrane binding and oligomerisation, the 
polymerisation of the 2C proteins was observed when co-crystallised with adenosine 5´-O-
(3-thiotriphosphate (ATP-γ-S). The ATP-γ-S occupies the pocket formed by the neighboring 
chain A and chain F. The triphosphate group of the ATP-γ-S is interacting with the G132, 
G134, K135, S136 (Walker A motif) and with D176, D177 (Walker B motif) of chain A. 
 
Figure 7. ATP-γ-S binding to the ATPase pocket formed. In the top part of the figure, 
the structure of two neighbouring 2C proteins ant the ATP-γ are shown. In the bottom part 
of the figure, the ATPase binding pocket and the amino acids involved in the interaction 
with the ATP-γ are shown. Walker A, Walker B and the motif C are respectively represented 
in cyan, blue and purple 
 
The N223 of motif C is located behind the Walker B motif. The chain F is interacting with 
the ATP-γ-S through a hydrogen bond between the T196 of the ATP-γ-S base. The chain 
F is also providing two arginines, close to the phosphate group, the R240 and the R241. 
These two arginines, through mutation studies, were demonstrated to be essential for the 
ATPase activity, suggesting that they might function as arginine finger during the 
hydrolysis.29 
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The released structure of the EV-A71 2C protein represents the starting point for the 
understanding of the mode of action of the known 2C inhibitors and the development of new 
inhibitors using structure-based drug design approaches. 
 
7.5 Non-structural protein 2C inhibitors 
Over the past decades, several compounds have been identified to inhibit the viral 
replication of different enterovirus species. From the isolation and sequencing analysis of 
resistant-enterovirus mutant to these compounds, mutations on the 2C protein were 
observed, suggesting the 2C protein as a target for these inhibitors. 
 
 
 
Figure 8. Chemical structure of guanidine and 2-(α-Hydroxybenzyl)-Benzimidazole 
(HBB). 
 
The first two inhibitors which were identified to target the 2C protein, were guanidine and 
the 2-(α-Hydroxybenzyl)-Benzimidazole (HBB). Both of the compounds were found to be 
active against poliovirus-1 (PV-1), echovirus-9 (E-9), coxsackievirus A9 (CVA9) and 
CVB3.30-35 Guanidine was able to block the initiation step of the negative-sense RNA but 
not the replication of the positive one and at higher concentration, guanidine was inhibiting 
the ATP hydrolysis.36-38 The compound was also reported to inhibit the association of the 
protein precursor, 2BC, with the membrane structures.39 
Also, for those two compounds, dependent-mutant were identified. These mutants required 
the presence of guanidine or HBB, to be able to replicate correctly.40  
Other benzimidazole were found to target the 2C protein, the {1-(2,6-difluorophenyl)-6-
trifluoromethyl-1H,3H-thiazolo[3,4-a]benzimidazole (TBZE-029) and the 1-(4-fluorophenyl)-
2-(4-imino-1,4-dihydropyridin-1-yl)methylbenzimidazole (MRL-1237) (figure 9).18,41 These 
two compounds were able to inhibit the viral replication of CVB3 and showed cross-
resistance to the human enterovirus-B species (HEV-B) resistant to guanidine and HBB. 
Most of the mutations were found to be located within the three ATPase domain and 
especially on a loop, 224-229 residues.15,30,32,42-43 
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Figure 9. Chemical structure of TBZE-029 and MRL-1237. 
 
In 2012, during a screening of a library of FDA-approved drugs, fluoxetine ((RS)-N-methyl-
3-phenyl-3-(4-(trifluoromethyl)phenoxy)propan-1-amine), was identified as a potent 
inhibitor of CVB3.44  
 
 
Figure 10 Chemical structure of fluoxetine 
 
In the same study, norfluoxetine, the active metabolite of fluoxetine, was achieving a 
comparable antiviral activity. Fluoxetine was then confirmed to inhibit HEV-B and D species 
replication but not the HEV-A and HEV-C, and during the study, the same mutation that 
conferred resistance to TBZE-029 were conferring cross-resistance to fluoxetine. 
Interestingly, one of the CVB3 mutant, the A224V-I227V-A229V, was cross-resistance to 
guanidine, HBB and MRL-1237 and the mutations are summarised in table 1.45 
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Table 1. Mutation and cross-resistant mutant for Guanidine. TBZE-029, MRL-1237 and 
fluoxetine against EV-A71 and CVB3. +++: high resistance; ++: moderate resistance; +: 
low resistance; /:no resistance; Dep: dependent for viral replication; No Dep: not dependent 
for viral replication; -: not evaluated; NA: not active. 
  Mutation 
Fluoxe
tine 
MRL-
1237 
Gua 
HCl 
HBB 
TBZE
-029 
Ref 
Gua 
HCl 
EV-A71 
I127V 
NA 
- ++ - - 
ref 46 
T173M - - - - 
M187I - - - - 
M193L - +++ - - 
S224C - - - - 
M193L + 
I127V 
- +++ - - 
TBZE
-029 
CVB3 
Nancy 
A224V / / ++ / / 
ref 18 
I227V +++ ++ / / / 
A229V No Dep Dep Dep Dep Dep 
A224V + 
I227V 
+++ +++ ++ ++ +++ 
A224V + 
A229V 
No Dep Dep Dep Dep Dep 
I227V + 
A229V 
/ +++ ++ ++ ++ 
A224V + 
I227V + 
A229V 
+++ +++ +++ +++ +++ 
MRL-
1237 
CVB3 
Nancy 
A224V - ++ / - - 
ref 18 
I227V - +++ +++ - - 
 
Pirlindole, dibucaine, mefloquine and zuclopenthixol were also found, during another 
screening of FDA-approved compounds, to be able to inhibit the viral replication of CVB3 
and EV-D68. Pirlindole and dibucaine also showed a weak antiviral activity against EV-A71. 
Cross-resistance of the A224V-I227V-A229V 2C CVB3 mutant to Pirlindole, dibucaine and 
zuclopenthixol was observed, suggesting that also these compounds are targeting the 2C 
protein. 47-48  
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Figure 11. Chemical structure of pirlindole, dibucaine, mefloquine and zuclopenthixol 
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7.6 Project aims 
The 2C protein is highly conserved 2C protein among the enterovirus species and is 
essential during the viral replication. Several compounds have been identified to inhibit viral 
replication by targeting 2C protein. Among them, fluoxetine, a selective serotonin reuptake 
inhibitor, was showing a strong antiviral effect against HEV-B and D species whereas HEV-
A and C species are not inhibited. The information available on the mutation-sensible to 
fluoxetine, together with the new resolved EVA 71 2C crystal structure were used to 
investigate the region of the protein close to the fluoxetine resistant-mutations.  
Below, the activities performed during the project on the non-structural 2C protein: 
· Different molecular modelling techniques were used to investigate and to elucidate 
the binding mechanism of fluoxetine; 
· Different fragments and analogues of fluoxetine were synthesised and biologically 
evaluated; 
· Mutation studies were performed to further explore the potential binding mechanism 
of fluoxetine; 
· The gained information on fluoxetine were used to design pan-enterovirus inhibitors; 
· The designed compounds were synthesised and biologically evaluated. 
 
Furthermore, different molecular modelling techniques will be used to perform a virtual 
screening in order to identify new potential inhibitors of the ATPase pocket. This project, on 
the 2C protein, was carried out in close collaboration with Lisa Bauer, PhD student in the 
group of Professor Frank J.M. van Kuppeveld at Utrecht University, and Birgit Zonsics, PhD 
student in the group pf Professor Andrea Brancale. 
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Chapter 8: Fluoxetine 
 
  
Part III: Enterovirus 
251 
8.1 Fluoxetine  
Fluoxetine was the blockbuster drug of Eli Lilly. Introduced on the market in 1987 under the 
market name Prozac, it was the first selective serotonin reuptake inhibitor (SSRI) approved 
by the FDA. It is used for the treatment of major depression and anxiety disorders, but it is 
also indicated for different disorders: bulimia, obsessive-compulsive disorder, bipolar and 
panic disorders.49  
In 2012, during a drug-repurposing screening, fluoxetine was identified as an inhibitor of the 
viral replication of Coxsackievirus B-3 (CVB-3), member of the Human enterovirus B (HEV-
B) genus, with an EC50 of 2.3 μM and a CC50 of 25 μM, showing a selectivity index of 
approximately 10 in HeLa-RW cells.44 Fluoxetine, in further studies, showed an antiviral 
activity also against HEV-D, but not against HEV-A, HEV-C and rhinovirus species.50 
Afterwards, mutations on the CVB-3 non-structural protein 2C were reported to confer 
resistance to fluoxetine. These mutations were close to the Walker C motif and were on the 
224AGSINA229 loop (A224V, I227V and A229V) which, is highly conserved among the HEV-
B and HEV-D species but not the HEV-A and HEV-C.51 Thus, the antiviral activity shown by 
fluoxetine may be a result of direct interaction with the non-structural 2C protein. The fact 
also confirmed the specific interaction of fluoxetine with 2C protein, that other SSRIs like 
citalopram, paroxetine, and sertraline, did not show any antiviral effect on CVB-3.45  
In 2106, fluoxetine was successfully used to treat a child with X-linked agammaglobulinemia 
(XLA), affected by life-threatening chronic enterovirus encephalitis, caused by CVB-2.52 
However, the association between the use of SSRIs and an enhanced risk of bleeding, 
together with other non-neurological and pharmacological off-target effects of fluoxetine are 
limiting the use as an anti-enterovirus agent, especially in newborns.53-55 
That evidence is making fluoxetine the perfect candidate for the elucidation of the molecular 
mechanism of the 2C inhibitors, sensible to the mutation on 224AGSINA229 loop and able to 
inhibit viral replication. The elucidation of the molecular mechanism of inhibition of 2C 
protein by fluoxetine will provide essential information for the development of potential 
enterovirus pan-inhibitors. 
The FDA-approved SSRI Fluoxetine is a racemic mixture of (RS)-N-methyl-3-phenyl-3-(4-
(trifluoromethyl) phenoxy)propan-1-amine, in which both enantiomers were demonstrated 
to have the same SSRI activity, in several in vitro and in vivo preclinical models.56 The two 
fluoxetine enantiomers were purchased and biologically evaluated to understand if the 
antiviral activity of fluoxetine is independent of the stereochemical configuration. 
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Figure 12. Fluoxetine enantiomers. 
 
8.2 Antiviral evaluation of fluoxetine enantiomers 
The antiviral evaluation of the compounds was performed in Virology Division, Department 
of Infectious Diseases and Immunology at Utrecht University, under the supervision of 
Professor Frank J.M. van Kuppeveld. The fluoxetine racemate and both the enantiomers 
were tested in multicycle CPE-reduction assay in Hela R19 cell-line infected with CVB-3 
virus. In this assay, the cytopathic effect induced by the virus after three days and the related 
cell viability is used to calculate the EC50 of the tested compound. The cell viability is 
evaluated using MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium), as a readout for the cellular metabolic activity. The un-
infected cell, treated with the compounds, are used for the evaluation of the CC50, using the 
MTS as a readout of the assay. The racemic mixture inhibited CVB3 with an EC50 of 3.2 ± 
0.95 µM and a CC50 of 29.32 ± 0.35 µM, with a selectivity index of 9. Those results were in 
line with the previously reported EC50 and CC50 on CVB-3 (figure 13).50  
 
Figure 13. Antiviral evaluation of fluoxetine enantiomers. Both fluoxetine enantiomers 
and the racemate were tested in a multicycle CPE-reduction assay in Hela R19 cell-line 
infected with CVB-3 virus. MTS assay was used for the readout. The same assay was used 
on un-infected cells for the evaluation of CC50. Data are shown from one experiment 
representative of at least two independent experiments.  
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Interestingly the S-enantiomer inhibited the viral replication with an EC50 of 0.4 ± 0.15 µM 
and a CC50 of 28.63 ± 1.40 µM. On the other hand, the R-enantiomer of fluoxetine did not 
show any antiviral activity.  
To confirm the results obtained for the compounds by the multicycle CPE-reduction assay, 
the compounds were evaluated in a single-cycle assay. In this assay, the HeLa R19 cells 
are infected with RLuc-CVB3. The RLuc-CVB3 is a genetically engineered Coxsackievirus 
B-3, in which a gene encoding for Renilla luciferase is inserted upstream of the capsid 
coding region. Seven hours post-infection, the intracellular activity of the luciferase proteins, 
produced during the viral replication, it is used as a sensitive readout for the calculation of 
the antiviral activity of the tested compounds. 
 
Figure 14. Antiviral evaluation of fluoxetine enantiomers by single-cycle assay. Both 
fluoxetine enantiomers and the racemate were tested in a multicycle CPE-reduction assay 
in Hela R19 cell-line infected with RLuc-CVB3. Data are shown from one experiment 
representative of at least two independent experiments. 
 
As shown in figure 14, the single-cycle assay confirmed that only the S-enantiomer inhibit 
the viral replication, showing a potency ∼5-fold higher (EC50=0.42 ± 0.17 µM) than the 
racemic mixture (EC50=2.02 ± 0.94 µM). 
 
8.2.1 In-vitro binding of fluoxetine enantiomers to 2C protein 
The in-vitro binding assays of the compounds were performed in the CNRS at Aix-Marseille 
Université, under the supervision of Professor Bruno Coutard. To test the potential 
selectivity of the (S)-fluoxetine as an antiviral agent, both enantiomers were evaluated in 
two different binding assays, thermal shift assay (TSA) and isothermal titration calorimetry 
(ITC). These assays were performed on a monomeric 2C protein, generated by removing 
the amphipathic helix at the N-terminal domain (CV-B3 2C Del36).47  
In the thermal shift assay (TSA), the binding of a ligand to the protein is affecting the melting 
temperature (Tm) of the protein which is directly related with a variation of the thermal 
stability of the protein. The racemic mixture showed a dose-dependent increase of the ΔTm 
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of 2C protein from 10 µM to 250 µM was observed; then at higher concentrations, the ΔTm 
decreased (figure 15). 
 
 
 
Figure 15. TSA evaluation of the fluoxetine enantiomers. The (S)-fluoxetine shown to 
thermally stabilize the 2C protein and the (R)-fluoxetine showed a dose-dependent 
destabilizing effect on the protein. Data are shown from one experiment representative of 
at least three independent experiments 
 
 
The (S)-fluoxetine shown to thermally stabilize the 2C protein with no destabilization at high 
concentrations of compound, suggesting a direct binding of the enantiomer to the 2C 
protein. On the other hand, the (R)-fluoxetine has a dose-dependent destabilizing effect on 
the protein which could explain the effect observed for the racemic mixture at a 
concentration >250 µM. 
Then, the binding of the fluoxetine enantiomers was assessed using the isothermal titration 
calorimetry (ITC) technique. This technique is extensively used to evaluate the protein-
ligand interactions, but also for other macromolecule interactions. The ITC is a quantitative 
technique that can be used to determine the thermodynamics of binding interactions 
(variation of enthalpy, ΔH) and the kinetics of enzyme-catalyzed reactions (dissociation 
equilibrium constant Kd).57  
A Kd of ~9.5 µM was obtained for the (S)-fluoxetine, confirming the binding of the S-
enantiomer to 2C protein. Instead, when the 2C protein was titrated with (R)-fluoxetine, the 
aggregation of the protein was observed, and it was not possible to obtain a precise Kd 
value. 
 
8.2.2 Antiviral evaluation of fluoxetine enantiomers against other 
enteroviruses 
Fluoxetine, as a racemic mixture, was previously reported to inhibit CVB3 (strain Nancy) 
and EV-D68 (strain Fermon), which represent the HEV-B and HEV-D species.44,50  
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After finding that the (S)-fluoxetine, among the fluoxetine enantiomers, is the only 
responsible for the antiviral activity of the racemic mixture, was decided to test the 
compounds on a panel of representative enteroviruses species (EV-A71, CVB3, EV-D68, 
PV-1) and rhinoviruses (HRV-A2, HRV-B14). 
 
Table 2. Antiviral evaluation of the fluoxetine enantiomers against other enterovirus 
species. Data represents mean values ± SD calculated from three independent 
experiments and are expressed in μM. NA = not active. SI = selectivity index (CC50/EC50). 
 
EC50 
EV-A71 
(BrCr) 
EC50 
CVB3 
(Nancy) 
EC50 
PV-1 
(Sabin1) 
EC50 
EV-D68 
(Fermon) 
EC50 
HRV-
A2 
EC50 
HRV-
B14 
CC50 
(RS)-
fluoxetine 
NA 
2.02 
±0.52 
NA 
1.85 
±0.10 
NA NA 
29.32 
±0.35 
(S)-
fluoxetine 
NA 
0.42 
±0.17 
NA 
0.67 
±0.22 
7.95 
±0.39 
6.34 
±1.02 
28.63 
±1.40 
(R)-
fluoxetine 
NA NA NA NA NA NA 
23.63 
±1.40 
        
SIRacemic - 14.51 - 21.72 - -  
SI(S)-fluoxetine - 71.56 - 42.73 3.60 4.52  
 
 
As expected, fluoxetine showed antiviral activity only against CVB3 and EV-D68 species, 
and neither the fluoxetine racemic mixture nor the enantiomers showed antiviral activity 
against EV-A71 and Poliovirus-1 (PV-1) at 30 µM (see table 2). The previously observed 
enhanced antiviral effect of (S)-fluoxetine against CVB3, was also observed against EV-
D68, with an EC50 of 0.67±0.22 µM. 
The compounds were also tested against rhinovirus A2 (HRV-A2) and rhinovirus B14 (HRV-
B14). Only the (S)-fluoxetine was able to inhibit the viral replication of the two rhinoviruses, 
with an EC50 7.95±0.39 on HRV-A2 and 6.34±1.02 on HRV-B14. Taking in consideration 
the results obtained testing the (S)-fluoxetine against the two species of rhinovirus, the 
antiviral activity of (S)-fluoxetine against the other enteroviruses tested, EV-A71 and PV-1, 
at a concentration higher than the CC50 cannot be excluded. 
 
8.3 Identification of fluoxetine binding site 
The mode of action and the interactions between the fluoxetine and the 2C protein are 
unknown. The stereospecific antiviral activity of the (S)-fluoxetine and the reported mutation 
on the 224AGSINA229 loop of 2C protein, which confers resistance to the compound are 
suggesting a specific interaction between the (S)-fluoxetine and the 2C protein. Several in-
silico modelling approaches were used to elucidate the fluoxetine binding site and 
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eventually the mode of action. Unfortunately, the crystal structure of CVB3-2C protein, 
which is sensitive to the (S)-fluoxetine, is not available. In 2017, a truncated (116-329 amino 
acids) crystal structures of the EV-A71 2C protein was released.29 The EV-A71 2C protein 
has a sequence identity and similarity with the CVB3 2C protein of 62% and 80%, 
respectively. The EV-A71 2C protein crystal structure, which is non-sensible to the (S)-
fluoxetine, was used as a starting point for molecular modelling studies, to understand the 
interaction between the protein and the compound.  
 
8.3.1 Molecular modelling studies 
The molecular modelling studies were done in collaboration with Birgit Zonsics, PhD student 
in Professor Brancale’s group, which provided the homology models and performed the 
docking of the compounds. Chain A of the published EV-A71 2C structure (PDB: 5GRB) 
was used as a template to generate the homology model of CVB3 2C protein. The 
generation of the homology model was necessary because the EV-A71 2C protein is not 
sensible to (S)-fluoxetine, and the crystal structure of EV-A71 2C protein is an ideal starting 
point for the generation of the homology model. 
 
 
 
Figure 16. Homology model of the 2C protein of CVB3. The model was built on the 
crystal structure of EV-A71. Ribbon of 224AGSINA229 loop are in blue, the 175-183 loop are 
in violet. In pink the ribbon of non-structure 2C protein of EV71 and in grey the homology 
model of CVB3. 
 
As can be seen in figure 17, around the 224AGSINA229 loop, two potential binding sites were 
identified (site A and site B in figure 17) on the homology model of CVB3 2C protein. Site A 
is formed by the 224AGSINA229 loop and hydrophilic residues (D245, R295 and R296). The 
site is also composed by a lipophilic pocket with the potentiality to bind the 
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trifluoromethylphenyl moiety of fluoxetine. Site B, on the other hand, is located between the 
224AGSINA229 loop and the flexible 175-183 loop part of Walker B motif, which is the motif 
responsible for binding to Mg2+ to assure proper function of the ATPase activity of the 2C 
protein. 
 
 
Figure 17. S- and R-enantiomers of fluoxetine docked into sites A and B of the 
homology model. Ribbon of 224AGSINA229 loop are in blue, the 175-183 loop are in 
violet. (S)-fluoxetine in purple and the (R)-fluoxetine in bottle green. 
 
Due to the flexible nature of the loops, the binding of the compound to these two sites 
located around the 224AGSINA229 loop could lead to variation in the shape and size of the 
binding pocket. Molecular Dynamics (MD) studies were decided to be used to assess the 
change of the loops during the interaction with the pockets. 
Both enantiomers of fluoxetine were docked in site A and site B, as can be seen in figure 
12, and then used to perform the molecular dynamic (MD) simulations. Both enantiomers 
docked in site A has the trifluoromethylphenyl moiety interacting in the hydrophobic pocket. 
The hydrophobic pocket was defined by the residues L178, C179, V187 and F190. In site 
B, instead, the enantiomers were interacting superficially and were exposed to the solvent. 
The best docking pose, showed in figure 17, were used as a starting point for the MD 
simulations. 
MD simulations are a useful tool to address various issues, such as loop flexibility and the 
potential shape changes that can occur during the interaction between the protein and a 
ligand. Three independent molecular dynamics simulations of 100 ns were performed, for 
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each enantiomer for each site (see figure 18), to investigate the behaviour of the fluoxetine 
enantiomers, binding to the two potential binding sites. 
 
Figure 18. Scheme of the MD simulations performed on site A and site B. For each 
site and both enantiomers a MD simulation was performed. MD simulation were performed 
in triplicates. 
 
To estimate the binding affinity, to potentially discriminate and identify the binding pocket of 
(S)-fluoxetine, molecular mechanics energies combined with generalised Born and surface 
area continuum solvation (MM/GBSA) method was applied to each MD simulation. 
 
G = Ebinding + Eel + EvdW +Gpol + Gnp – TS 
 
The free-energy (G) is obtained considering conformational energy terms (the MM part, 
represented by Ebinding, Eel and EvdW, considering the potential energy of a molecular 
structure), and a solvation free-energy term, whch is the sum of a polar component and a 
non-polar contribution (Gpol + Gnp). 
This method can be located between the docking method and the free-energy perturbation 
(FEP). The first one is extremely efficient, but not accurate. It is a perfect tool to discriminate 
between binding and non-binding ligands. The other method, the FEP, is very accurate but 
it is a very time-consuming method.  
The ΔGbinding, calculated through the MM/GBSA method, is obtained after splitting the 
trajectory file of the MD simulation into snapshots. for each snapshot is calculated the free 
energy of the binding of the ligand: 58  
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ΔGbinding = Ecomplex - (Eligand + Ereceptor) 
From the results obtained analysing the MD simulations of (S)-fluoxetine, a stronger binding 
on the site A was suggested, as can be seen in table 3, with a lower ΔGbinding in comparison 
with site B. During the MD simulation of the (S)-fluoxetine in site B, dissociation of the ligand 
from the protein was observed. 
 
Table 3. Binding energies of the protein ligand complexes during MD simulations. 
The indicated values are calculated ΔGbinding (kJ/mol) * indicate dissociation of the ligand 
from the protein. 
 SIte MD1 MD2 MD3 
(S)-fluoxetine 
A -41.63 -42.28 -41.54 
B -34.79 -29.88 -30.83* 
(R)-fluoxetine 
A -29.71* -42.70 -19.85* 
B -29.59* -42.95 -27.38 
 
The (R)-fluoxetine analysis of the ΔGbinding is suggesting that the binding to the protein is not 
stable, indeed in both site A and B, dissociation of the R-enantiomer was observed. This 
result is in line with the lack of antiviral activity of the R-enantiomer of fluoxetine against the 
2C protein of CVB3.  
In each MD simulations of the (S)-fluoxetine in site A, the compound is oriented with the 
trifluoromethylphenyl moiety inside a hydrophobic pocket, defined by the residues L126, 
L178, C179, V187, F190, I227, A229, L238, F242. A hydrogen bond repeatedly formed 
between the amino acid D245 and the positively charged amino group of (S)-fluoxetine was 
also observed, as can be seen in figure 19. 
 
 
Figure 19. View of (S)-fluoxetine in site A as identified in the MD simulation. Ribbon 
and carbon atoms of 224AGSINA229 loop are in blue, the 175-183 loop are in violet. 
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The MD simulations revealed a stereospecific binding selectivity for the (S)-fluoxetine to 2C 
protein and the identified pocket, composed by a hydrophobic part and a potential binding 
point for the positively charged amino group. The speculated binding pocket could also be 
supported by the fact that the triple mutation A224V-I227V-A229V (AVIVAV) on the 
224AGSINA229 loop, in which the residues A229 is interacting with the ligand, was previously 
shown to provide resistance to the racemic fluoxetine mixture.50 
 
8.3.2 Mutations studies on the identified pocket 
For the validation of the identified binding pocket, several CVB3 mutant viruses were made, 
and those viruses were used for antiviral evaluation of the (S)-fluoxetine. BF738735, known 
to be a broad-spectrum anti-enterovirus which is acting as an inhibitor of the cellular protein 
PI4KIIIβ, was used as a reference.59  
The first step was to understand the single contribution of the three reported mutations on 
the A224V-I227V-A229V (AVIVAV) on the 224AGSINA229 loop. For this reason, the mutant 
of CVB3 virus, containing the single mutations (A224V, I227V and A229V) were made. As 
can be deducted from figure 20, the only amino acid giving resistance to the (S)-fluoxetine 
is the CVB3 I227V mutant.  
 
 
Figure 20 Antiviral evaluation of (S)-fluoxetine against the CVB3 mutant viruses. Data 
are shown from one experiment representative of at least two independent experiments.  
 
Previously, the dependency of the CVB3 A229V mutant to several compounds to were 
reported. These compounds were, Guanidine, HBB, TBZE-029 and MRL-1237, did not 
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inhibit the mutant virus but instead, they were required for efficient viral replication.18 The 
test of the (S)-fluoxetine against the CVB3 A229V mutant, conferred neither dependency 
nor resistance. However, when the mutant virus was treated with both (S)-fluoxetine and 
Guanidine a reduction of the viral replication, in comparison to the Guanidine treated virus, 
was observed. 
Two other mutant viruses of CVB3 were made to investigate the critical residues inside the 
hydrophobic pocket. These mutants were C179F, V187M and F190L and they raise 
resistance to the (S)-fluoxetine, except for the V187M mutation. 
Finally, the importance of D245 amino acid was investigated. As was said before, this 
residue should be able to interact with the amino group on the (S)-fluoxetine. The 
substitution of the glutamic acid to an asparagine did not confer resistance. 
The result obtained is suggesting that (S)-fluoxetine binding might be different from the 
predicted one because the D245N and A229V are not raising resistance. On the other hand, 
the C179F and F190L mutations are confirming the interaction of the trifluoromethylphenyl 
moiety within the hydrophobic pocket. Another possibility is that the (S)-fluoxetine could 
reach the C179 and F190 through the 158-164 loop. However, in the homology model and 
the EV-A71 crystal structure, a potential pocket between the 175-183 loop (violet ribbon in 
figure 21) and the 158-164 loop (cyan ribbon in figure 21) was not present. A possible 
pocket, generating between these two loops, make the explanation of the mutation on the 
224AGSINA229 loop (blue ribbon in figure 21) more complicated. 
 
 
 
 
Figure 21 The three possible entrances of (S)-fluoxetine. C179 is represented in green 
line surface. Ribbon and carbon atoms of 224AGSINA229 loop are in blue, the 175-183 
loop are in violet and the 158-164 loop are in cyan.   
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8.4 Fluoxetine fragments 
Moira Lorenzo Lopez, an Erasmus student in Professor Brancale’s group, has contribute 
towards the synthesis of the compounds of this part of the project. The contribution of the 
different chemical features on the fluoxetine were explored by testing six fragments. Those 
fragments, which were not all commercially available like N-methyl-3-(4-
(trifluoromethyl)phenoxy)propan-1-amine 211 and 1-(benzyloxy)-4-(trifluoromethyl) 
benzene 214 or quite expensive like the N-methyl-3-phenylpropan-1-amine 212, were 
synthesised. 
 
 
Figure 22. Chemical structure of the fluoxetine selected fragments. 
 
8.4.1 Synthesis of fluoxetine fragments 
The N-methyl-3-(4-(trifluoromethyl)phenoxy)propan-1-amine 211 fragment was 
synthesised through a two-step synthesis (see scheme 1). In the first step, an SN2 between 
the 4-(trifluoromethyl)phenol 216 and the dibromopropane occur in basic conditions. 
Successively, the methylamine is used to replace the bromo on the 1-(3-bromopropoxy)-4-
(trifluoromethyl)benzene 217 intermediate. 
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Scheme 1 Synthesis N-methyl-3-(4-(trifluoromethyl)phenoxy)propan-1-amine 211. i) 
1,3-dibromopropane, K2CO3, DMF, 70°C, 2h, Y=47%; ii) Methylamine, EtOH absolute, rt, 
on, Y=69%. 
The 1-(benzyloxy)-4-(trifluoromethyl) benzene 214 fragment was obtained by SN1, between 
the 4-(trifluoromethyl)phenol 216 and the benzylbromide 218 (scheme 2). 
 
 
Scheme 2 Synthesis of 1-(benzyloxy)-4-(trifluoromethyl) benzene 214 fragment 
 
The last not commercially available fragment synthesised was N-methyl-3-phenylpropan-1-
amine 212. This compound was obtained by the methylamine nucleophilic replacement on 
the bromo atom of the (3-bromopropyl)benzene 219. 
 
Scheme 3 Synthesis of N-methyl-3-phenylpropan-1-amine 212 
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8.4.2 Antiviral evaluation of Fluoxetine fragments and 2C binding assay 
The six fragments were evaluated in a multicycle-CPE antiviral assay against CVB3. As can 
be seen in figure 23, the only fragment that showed a weak antiviral activity against CVB3 
was the N-methyl-3-(4-(trifluoromethyl)phenoxy)propan-1-amine 211. However, the 
antiviral activity was close to the cytotoxicity effect on the HeLa R19. 
 
Figure 23. Antiviral evaluation of 211-216 fragments. The fluoxetine fragments were 
tested in a multicycle CPE-reduction assay in Hela R19 cell-line infected with CVB-3 virus. 
MTS assay was used for the readout. The same assay was used on un-infected cells for 
the evaluation of CC50. Data are shown from one experiment representative of at least two 
independent experiments. 
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Fragment 211, which contain the methylamino group and the trifluoromethylphenyl moiety, 
was tested against EV-A71 to evaluate if the antiviral effect is related to the cytotoxicity and 
no-antiviral effect was observed. Like for fluoxetine, fragment 211 did not show antiviral 
effect against the EV-A71. The obtained result suggested that the antiviral activity is specific 
to the fragment. 
 
 
Figure 24. Antiviral evaluation of 211 fragment against CVB3 and EV-A71. Data are 
shown from one experiment representative of at least two independent experiments 
 
Finally, the fragments were evaluated in TSA assay. No fragment showed a binding to the 
2C protein. Also, the 211 did not stabilise the protein at 400 μM. This result could be 
implicated to the eventuality that the concentration of the fragment might be much higher 
than the concentration in which the fragment was tested. 
 
Figure 25. TSA evaluation of the fragments. Data are shown from one experiment 
representative of at least three independent experiments 
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8.5 Fluoxetine analogues 
As was said before, the repurpose of fluoxetine could be difficult duo neurological effect as 
SSRI and to the pharmacological off-target effect. Four analogues of fluoxetine were 
synthesised to try to separate the neurological effect from the antiviral activity. The 
analogues have different substituted phenyl moieties. Those compounds were chosen 
because they had reduced SSRI activity.49  
 
 
Figure 26. Selected fluoxetine analogues. 
 
8.5.1 Synthesis of fluoxetine analogues 
From the retrosynthetic analysis (scheme 4), the compounds 220-223 could be synthesised 
through the Mitsunobu reaction between the phenols 225-228 and the 3-(methylamino)-1-  
 
 
Scheme 4. Retrosynthetic analysis for compounds 220-223. 
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phenylpropan-1-ol 229. To avoid any potential by-products during the Mitsunobu reaction, 
the amino group of the starting material 229, was protected with a tert-butoxycarbonyl 
protecting group (scheme 5). 
 
Scheme 5. Synthesis of the amino protected compound 230. 
 
The obtained compound 230, was then used for the Mitsunobu reaction for the formation of 
the alkyl-aryl ether bond formation with the 2-(trifluoromethyl)phenol 225. The Mitsunobu 
reaction is a very versatile tool used for dehydration coupling between an alcohol and an 
acid or a nucleophile. In a first attempt, the reaction was performed, dissolving the phenol 
225, the alcohol 230 and triphenylphosphine (PPh3) in tetrahydrofuran (THF) (scheme 6). 
The resulting solution was then cooled to 0°C before the addition of Diisopropyl 
azodicarboxylate (DIAD), and the reaction left at room temperature. Formation of the 
desired product was not observed, and different attempts changing the molar ratio of the 
starting materials were unsuccessful. 
 
 
Scheme 6. Synthesis of the Boc protected N-methyl-3-phenyl-3-(2-(trifluoromethyl) 
phenoxy)propan-1-amine 231. 
 
Another attempt was performed using a Mitsunobu reaction under sonication condition and 
increasing the concentration to 3.0 M. This procedure is reported to be extremely useful for 
sterically hindered substrates and the sonication process together with the increased 
concentration is reported to speed-up the Mitsunobu reaction. Unfortunately, also this 
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attempt was unsuccessful.60 Finally, the formation of the desired procedure was obtained 
with a good yield using a reported procedure for similar compounds. In this procedure, 
toluene was used instead of THF and the reaction was heated at 80°C for 21h. After a work-
up and then purification of the crude, the desired product was obtained with a yield of 79%.61 
To try to avoid the use of toluene and the needs to do a work-up before the purification, 
another procedure reported in the literature for a similar compound was used. In this 
procedure, diethyl ether was used as a solvent, and the DIAD and the PPh3 were added 
before the phenol and the alcohol, aiming to perform the betaine salt. This reaction occurs 
at room temperature and with a comparable yield after purification.62  
 
Scheme 7. Reaction Mechanism of the Mitsunobu reaction. 
 
As shown in scheme 7, the reaction starts with the formation of quaternary phosphonium 
salt, also called betaine salt 234. The betaine salt is then deprotonating the 2-
(trifluoromethyl)phenol, to give the ion pair 235, which subsequently react with the alcohol 
230 to form the alkoxy-phosphonium salt 236 and the diethyl hydrazinedicarboxylate 237. 
In the end, the Boc protected N-methyl-3-phenyl-3-(2-(trifluoromethyl)phenoxy)propan-1-
amine 231 and triphenylposphine oxide 238 are obtained by an SN2 displacement of the 
alkoxy-phosphonium salt 236 by the phenol 225.63  
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The last step of synthesis was the deprotection of the Boc protected compound 231 (see 
scheme 8). This step was carried out using a 2 M solution of hydrogen chloride (HCl) in 
diethyl ether. By monitoring the reaction by TLC, a partial conversion of the starting material 
231 was observed. Increasing the equivalents of the HCl did not provide further conversion 
of the 231. Indeed, the formation of the phenol 225 was observed which could be due to 
the ether cleavage side-reaction when using strong acid like HCl. 
 
Scheme 8. Deprotection of Boc protected N-methyl-3-phenyl-3-(2-(trifluoromethyl) 
phenoxy)propan-1-amine 231. 
 
This side-reaction was avoided, changing the HCl to the trifluoroacetic acid, a weaker acid, 
which gives after liquid chromatography the desired N-methyl-3-phenyl-3-(2-
(trifluoromethyl)phenoxy) propan-1-amine 220 with a yield of 83%. 
 
Scheme 9. Synthesis of the fluoxetine analogues 221-223. i) DIAD, PPh3, Et2O, rt, 2h, 
Y=60-64%; ii) TFA, DCM, rt, on, Y=62-64%.  
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The other fluoxetine analogues 221-223 were synthesised using the two steps synthetic 
route optimised for the synthesis of compound 220, as showed in scheme 9. The desired 
analogues were obtained with comparable yields to the ones obtained during the synthesis 
of 220. 
For the synthesis of the 3-(2-methoxy-4-(trifluoromethyl)phenoxy)-N-methyl-3-
phenylpropan-1-amine 223, the synthesis of the 2-methoxy-4-(trifluoromethyl)phenol was 
required. Starting from 1-fluoro-2-methoxy-4-(trifluoromethyl)benzene 245, 1-(benzyloxy)-
2-methoxy-4-(trifluoromethyl)benzene 246 was obtained through a SNAr. The benzyloxy 
benzene 246 was then subjected to a hydrogenation step which leads to the desired product 
241 (scheme 10). 
 
Scheme 10. Synthesis of 2-methoxy-4-(trifluoromethyl)phenol 241. i) benzyl alcohol, 
NaH, DMF, rt, 5h, Y=85%; ii) H2, Pd/C, EtOAc, rt, on, Y=99% 
 
To investigate the importance and the contribution of the fluoxetine amino group for the 
antiviral activity was decided to synthesise the acetyl analogue 247.  
 
Figure 27. Acetyl analogue of fluoxetine. 
 
This compound was synthesised by acetylation of the 3-phenyl-3-(4-(trifluoromethyl) 
phenoxy)propan-1-amine 251 (norfluoxetine), as showed in scheme 11. The norfluoxetine 
was synthesised using the three-steps synthetic route used to synthesise the other 
fluoxetine analogues, starting from the 3-amino-1-phenylpropan-1-ol 248 instead of 3-
(methylamino)-1-phenylpropan-1-ol 229. 
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Scheme 11. Synthesis of the fluoxetine analogues 247. i) (Boc)2O, DCM, rt, on, Y=87%; 
ii) 4-(trifluoromethyl)phenol, DIAD, PPh3, Et2O, rt, on, Y=69%; iii) TFA, DCM, rt, on, Y=64% 
iv) acetyl chloride, TEA, DCM, rt, 2h, Y=98%. 
 
8.5.2 Antiviral evaluation of fluoxetine analogues 
The fluoxetine analogues 220-223 and 247, were evaluated in the multicycle-CPE antiviral 
assay on CBV3. As reported in table 4, no antiviral activity was observed for any of the 
fluoxetine analogues synthesised. Except for compounds 220 and 247, the other 
compounds were associated with increased cytotoxic effect. 
Table 4. Antiviral evaluation and cytotoxicity assessment of compounds 220-223 and 
247. Compounds were tested in a multicycle CPE-reduction assay in Hela R19 cell-line 
infected with CVB-3 virus. MTS assay was used for the readout. The same assay was used 
on un-infected cells for the evaluation of CC50. Data represents mean values ± SD 
calculated from three independent experiments and are expressed in μM. NA = not active.  
 
Compound 
EC50 
CVB3 
(μM) 
CC50 
(μM) 
220 NA 28.86±0.86 
221 NA 12.56±1.79 
222 NA 3.14±0.07 
223 NA 18.41±1.26 
247 NA >30 
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8.6 Conclusions 
In the first part of this project, the antiviral activity of the fluoxetine enantiomers was 
explored. The (S)-fluoxetine is the only enantiomer of the racemic mixture which is 
associated with an antiviral activity, which was found to be ∼5-fold higher (EC50 0.42 ± 0.17 
µM) than the racemic mixture (EC50 2.02 ± 0.94 µM). This result was also confirmed by TSA 
and ITC assays, confirming that only the (S)-fluoxetine is binding to the 2C non-structural 
protein of CVB3. Also, the S-enantiomer showed enhanced antiviral activity, compared to 
the racemate, against CVB3 and EV-D68. Interestingly, the active enantiomer was found to 
be also active against the rhinoviruses HRV-A2 and HRV-B14.  
 
 
Figure 28. Summary picture. 
 
Starting from the information acquired on the stereospecificity of the antiviral activity of the 
(S)-fluoxetine, molecular modelling techniques were used to elucidate the binding mode of 
fluoxetine on 2C protein. The available crystal structure of the EV-A71 2C protein was used 
to generate the homology model of the CVB3 2C protein. The model was then used to dock 
the enantiomers in two potential pockets, presents near the 224AGSINA229 loop, and was 
then subjected to MD simulations. The results obtained suggested that only site A was able 
to make a stable interaction with the S-enantiomer. Stable interactions were observed for 
the R-enantiomer neither in site A nor in site B.  
Unfortunately, from mutations study, the interaction of the (S)-fluoxetine with the 
hydrophobic pocket identified are crucial for the antiviral activity. On the other hand, the 
mutant viruses having the D245N and A229V mutation, respectively, did not show any 
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resistance. These results are suggesting that the binding of the (S)-fluoxetine could be 
slightly different or another entrance for the hydrophobic, potentially between 175-183 and 
158-164 loops cannot be excluded.  
Further, to investigate the importance of the different chemical features of the fluoxetine, 
six fragments were tested in the antiviral assay. The results suggested that the 4-
trifluoromethylphenyl moiety and the amino group are crucial for the antiviral activity.  
Trying to separate the SSRI from the antiviral activity, four analogues of fluoxetine were 
synthesised and biologically evaluated against the CVB3. No antiviral activity was detected, 
suggesting that the hydrophobic pocket in which part of the (S)-fluoxetine is interacting, is 
selective for the 4-trifluoromethylphenyl moiety, and any of the changes introduced with the 
analogues are allowed. 
Finally, the importance of the amino group for the interaction with the protein 2C was 
confirmed by the acetylated analogues of fluoxetine. The compound in which, the amino 
group of fluoxetine is involved in an amide bond, is losing the antiviral activity. 
Instead, the resolution of a crystal structure, co-crystallised with the (S)-fluoxetine could 
confirm or not the binding mode and the predicted pocket. The crystal structure could help 
to understand the difference among the 2C protein of the different enterovirus species, and 
the explanation of the selectivity of fluoxetine for HEV-B and HEV-D species will help for 
the rational design of new enterovirus pan-inhibitors. 
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Chapter 9: Guanidine derivatives of 
fluoxetine 
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9.1 Design and synthesis of Guanidine derivatives of 
fluoxetine 
The guanidine hydrochloride is one of the most studied inhibitor of enterovirus replication 
since 1964. The compound is interfering with an early stage of the viral replication. The 
mechanism of action proposed is that the guanidine is inhibiting only the initiation of the 
negative-strand RNA synthesis which prevents the positive-strand RNA synthesis.36  
 
 
Figure 29. Guanidine. 
 
Mutations on the 2C protein characterise nearly all Guanidine-raised mutants.30,33 Those 
mutations are providing resistance also on HBB, MRL-1237 and TBZE-029, known to be 
also 2C inhibitors. Some of these mutations are making the mutants dependent on the 
presence of guanidine for viral replication.15,32,43 The A224V-I227V-A229V mutations on the 
224AGSINA229 loop, the same which makes the CVB3 mutant resistant to fluoxetine were 
also giving resistance to guanidine, and in particular the A229V mutation alone or in 
combination with A224V, were making the mutant dependent on guanidine for the viral 
replication.18 
The previously gained information about the important of the amino group of the fluoxetine 
analogue for the antiviral activity, together with knowledge that the common mutations on 
the 224AGSINA229 loop are making CVB3 mutants to guanidine, led to the design of the 1-
(3-phenyl-3-(4-(trifluoromethyl)phenoxy)propyl)guanidine 252 compound. 
 
 
Figure 30. Guanidine analogue of fluoxetine. 
From a retrosynthetic analysis, compound 252 could be synthesised starting from the 
previously synthesised norfluoxetine 251 and a guanidinylating agent (schem12). The N,Nʹ-
bis(Boc)-S-methylisothiourea guanidinylating agent 254 was decided to be used. It was not 
commercially available, and its synthesis was required. 
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Scheme 12. Retrosybthessi for 1-(3-phenyl-3-(4-(trifluoromethyl)phenoxy) propyl) 
guanidine 252. 
 
The N,Nʹ-bis(Boc)-S-methylisothiourea 254 was synthesised by Boc protecting the S-
methyl isothiourea (253), following the reported procedure, shown in scheme 13.64 
 
 
Scheme 13. Synthesis of N,Nʹ-bis(Boc)-S-methylisothiourea 254. 
 
The guanidinylating agent 254 was then used for the synthesis N',N''-Bis(tert-
butoxycarbonyl)-(1-(3-phenyl-3-(4-(trifluoromethyl) phenoxy)propyl))guanidine 255. This 
step of synthesis consisted of a nucleophilic displacement of the thiomethyl group of 254 
by the amino group of the norfluoxetine (251) in the presence of DIPEA as a base (scheme 
14).65 The last step of the synthesis was the di-Boc deprotection of the intermediate 255. A 
first attempt was performed using the same procedure used for the Boc deprotection of 
norfluoxetine, increasing the amount of acid (scheme 15). Even by increasing the amount 
of TFA, only the mono Boc deprotected 255 was recovered.  
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Scheme 14. Synthesis of N',N''-Bis(tert-butoxycarbonyl)-(1-(3-phenyl-3-(4-
(trifluoromethyl)phenoxy)propyl))guanidine 255. 
 
As an alternative to TFA, stannic chloride (SnCl4) was used, a reagent which was reported 
to remove both the Boc protecting groups under mild and neutral conditions.66-67 The 
reaction was performed in ethyl acetate (EtOAc) at room temperature, and the desired 1-
(3-phenyl-3-(4-(trifluoromethyl)phenoxy)propyl)guanidine (252) was obtained as a free-
base (scheme 15). 
 
Scheme 15. Boc deprotection of intermediate 255. 
 
To modify the distance between the guanidinium group added to the fluoxetine was decided 
to synthesise the 1-(2-phenyl-2-(4-(trifluoromethyl)phenoxy)ethyl)guanidine 256, with a 
methylene bridge less than the previously synthesised guanidine compound 252. 
 
 
Figure 31. Guanidine analogue of fluoxetine with a methylene bridge less. 
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The planned compound was synthesised through the five-step synthetic route, showed in 
scheme 16, starting from the 2-amino-1-phenylethan-1-ol 257. The synthetic intermediate 
260 was obtained by Boc deprotection of the precursor 259, using the HCl. In this case, the 
desired product precipitate during the reaction, giving the desired product after filtration. 
 
 
Scheme 16. Synthesis of 1-(2-phenyl-2-(4-(trifluoromethyl)phenoxy)ethyl)guanidine 
256. i) (Boc)2O, TEA, DCM, rt, on, Y=93%; ii) 4-(trifluoromethyl)phenol, DIAD, PPh3, Et2O, 
rt, on; iii) HCl, DCM, rt, 24h, Y=37%(over 2 steps); iv) 205, DIPEA,DCM, rt, on, Y=46%; v) 
SnCl4, EtOAc, rt, on, Y=95%  
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9.2 Antiviral evaluation of Guanidine derivatives of 
fluoxetine 
As can be deducted from table 5, the introduction from the guanidine group is related to a 
∼7-fold increase of the antiviral activity in comparison with the fluoxetine racemic mixture. 
The compound 252 is equipotent to the (S)-fluoxetine, with an EC50 of 0.41 ± 0.27 μM and 
a CC50 >50 μM. The analogue of norfluoxetine with a methylene bridge less 260 showed to 
be active in the same range of activity of the fluoxetine, and the introduction of the guanidine 
group 256 is related with a ∼3-fold increased antiviral activity. 
 
Table 5. Antiviral evaluation of the guanidine analogues. Compounds were tested in a 
multicycle CPE-reduction assay in Hela R19 cell-line infected with CVB-3 virus. MTS assay 
was used for the readout. The same assay was used on un-infected cells for the evaluation 
of CC50. Data represents mean values ± SD calculated from three independent experiments 
and are expressed in μM. SI = selectivity index (CC50/EC50). 
 
Compound 
EC50 
CVB3 
(μM) 
CC50 
(μM) 
SI 
(RS)-fluoxetine 3.2 ± 0.95 29.32±0.35 9.1 
(S)-fluoxetine 0.4 ± 0.15 28.63±1.40 71.6 
252 0.41±0.27 >50 >121.9 
260 4.20±0.93 32.26±0.10 7.7 
256 1.22±0.15 >50 >40.9 
 
 
The guanidine analogues of fluoxetine 252 and 256 were then tested on a panel of 
enterovirus. The tested compounds had the same trend the other enterovirus as (S)-
fluoxetine. The compound was equipotent to (S)-fluoxetine against EV-D68, and they did 
not show any antiviral activity against the tested HEV-A and HEV-C species. Finally, 
compound 252 was the only one showing antiviral activity against HRV-B14. 
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Table 6. Antiviral evaluation of the guanidine analogues on other enteroviruses. 
Compounds were tested in a multicycle CPE-reduction assay in Hela R19 cell-line infected 
with different enteroviruses. MTS assay was used for the readout. The same assay was 
used on un-infected cells for the evaluation of CC50. Data represents mean values ± SD 
calculated from three independent experiments and are expressed in μM. NA = not active.  
 
Compound 
EC50 
EV-D68 
(Fermon) 
EC50 
EV-A71 
(BrCr) 
EC50 
PV-1 
(Sabin1) 
EC50 
HRV-A2 
EC50 
HRV-B14 
(S)-fluoxetine 0.67±0.22 NA NA 7.95±0.39 6.34±1.02 
252 0.34±0.05 NA NA NA 2.11±0.34 
256 0.55±0.04 NA NA NA NA 
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9.3 Conclusions 
Starting from the information available on the antiviral activity of guanidine, and the 
stereospecific antiviral activity of the (S)-fluoxetine, a novel guanidine analogue of fluoxetine 
was designed.  
 
The designed compound 252, synthesised as a racemic mixture, was found to be 
equipotent against CVB3 in comparison with the (S)-fluoxetine and the same trend of 
antiviral activity against other enteroviruses.  
The influence of the methylene bridge length between the amino group and the rest of the 
chemical feature of norfluoxetine and the guanidine analogue 252 was also explored. The 
synthesised analogues of norfluoxetine and compound 252 were associated with retention 
of antiviral activity equipotent to the racemic mixture of fluoxetine. Also, in compound 256, 
the guanidine analogue with a methylene bridge less than 252, showed the same trend of 
fluoxetine against the other enterovirus species. The analogue 256 was active against EV-
D68, but not against EV-A71 and PV-1. 
Further, the biological evaluation will be performed to confirm that these analogues of 
fluoxetine are affected by the same mutations that are conferring to CVB3 resistance to 
fluoxetine. 
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Chapter 10: N-benzyl-N-phenylfuran-2-
carboxamide 
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10.1 N-benzyl-N-phenylfuran-2-carboxamide 
In 2016, Zuo et al. reported and patented several chemical structures, which were identified 
by a screening campaign on 85585 compounds, to be able to inhibit the viral replication of 
CVB3.48,68 Selection of resistant-CVB3 mutants, followed by sequence analysis, for those 
compounds, revealed that the 2C protein was containing most of the mutations observed, 
especially mutations at the 179 and 227 positions on the protein sequence. Furthermore, 
the C179F CVB3 mutant showed resistance against all the identified compounds, 
confirming the 2C protein as the target for the identified compounds. Interestingly the I227V 
and the C179F mutations were the same ones found to confer resistance to CB3 against 
the (S)-fluoxetine. 
 
Figure 32. (S)-fluoxetine and compound 262. 
 
One of the compounds, the N-(4-fluorobenzyl)-N-(4-methoxyphenyl)furan-2-carboxamide 
262, reported inhibiting a panel of HEV-B, but not HEV-A and HEV-C. The compound was 
reported to have an EC50 of 2.9 μM and a CC50 of 45.5 μM. This compound was raising 
mutations for which the (S)-fluoxetine was also sensible, suggesting that, probably, the 4-
fluorobenzyl moiety might interact in the same pocket in which the 4-trifluoromethyl moiety 
of fluoxetine is interacting. Besides, compound 262 has a second aromatic ring and an H-
bond acceptor heteroatom in the same orientation as (S)-fluoxetine. 
 
Figure 33. Superimposition of (S)-fluoxetine (purple) and compound 262 (cyan). 
 
The similarity of the chemical features and their orientation between the (S)-fluoxetine and 
compound 262 (figure 32 and 33) and the lack of chiral center, made the N-(4-fluorobenzyl)-
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N-(4-methoxyphenyl)furan-2-carboxamide 262 the perfect candidate for the further 
development of an enterovirus pan-inhibitors.  
 
10.1.1 Synthesis of N-(4-fluorobenzyl)-N-(4-methoxyphenyl)furan-2-
carboxamide 
The synthesis of compound 262 was required because the compound is not commercially 
available. From the retrosynthetic analysis (scheme 17), compound 262 can be synthesised 
by a two steps synthesis, consisting from a reductive amination step between the 4-
fluorobenzaldehyde 265 and the 4-methoxyaniline 266, followed by a coupling reaction 
between amine, obtained by the reductive amination, and the furan-2-carboxylic acid 264.  
 
Scheme 17. Retrosynthetic analysis for compound 262. 
 
The reductive amination for the synthesis of the N-(4-fluorobenzyl)-4-methoxyaniline 263, 
was performed by solubilising the benzaldehyde 265 and the aniline 266 in a solution of 
methanol and tetrahydrofuran in a ratio of 4:1. The use of THF as a co-solvent was required 
to increase the solubility of the starting material, which is crucial for the formation of the 
imine intermediate. The imine formation was monitored by TLC, followed by the addition of 
sodium borohydride as reductive agent., to give the desired product with a yield of 99%. 
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Scheme 18. Synthesis of the N-(4-fluorobenzyl)-4-methoxyaniline 263. 
 
Then, the N-(4-fluorobenzyl)-4-methoxyaniline 263 was used for the coupling reaction, with 
the furan-2-carboxylic acid 264, using TBTU as coupling reagent. The reaction gives the 
desired N-(4-fluorobenzyl)-N-(4-methoxyphenyl)furan-2-carboxamide 262, with a yield of 
60%, as shown in scheme 19. 
 
 
Scheme 19. Synthesis of the N-(4-fluorobenzyl)-N-(4-methoxyphenyl) furan-2-
carboxamide 262. 
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10.1.2 Antiviral evaluation of N-(4-fluorobenzyl)-N-(4-methoxyphenyl)furan-2-
carboxamide 
The compound was evaluated in the multicycle-CPE antiviral assay, showing an antiviral 
activity on CVB3 comparable to the one reported in the paper.48 The EC50 of 1.12±0.28 μM 
found for compound 262, is ∼3-fold more potent compared to the fluoxetine and ∼3-fold 
less potent than the (S)-fluoxetine and guanidine analogue 252 (table 7). 
 
Table 7. Antiviral evaluation of compound 262. Compounds were tested in a multicycle 
CPE-reduction assay in Hela R19 cell-line infected with CVB-3 virus. MTS assay was used 
for the readout. The same assay was used on un-infected cells for the evaluation of CC50. 
Data represents mean values ± SD calculated from three independent experiments and are 
expressed in μM. SI = selectivity index (CC50/EC50). 
Compound 
EC50 
CVB3 
(μM) 
CC50 
(μM) 
SI 
(RS)-fluoxetine 
3.2 
±0.95 
29.32 
±0.35 
9.1 
(S)-fluoxetine 
0.4 
±0.15 
28.63 
±1.40 
71.6 
252 
0.41 
±0.27 
>50 >121.9 
262 
1.12 
±0.28 
>50 >44.6 
 
Compound 262 was also tested against other representative enterovirus species. The 
compound showed the same trend observed for the (S)-fluoxetine and the guanidine 
analogue 252, and with the data previously reported.48 Compound 262 was able to inhibit 
the viral replication of EV-D68, HRV-A2 and HRV-B14 with EC50 comparable to the (S)-
fluoxetine and antiviral activity against EV-A71 and PV-1 was not observed. 
 
Table 8. Antiviral evaluation of compound 262 against other enteroviruses. 
Compounds were tested in a multicycle CPE-reduction assay in Hela R19 cell-line infected 
with different enteroviruses. MTS assay was used for the readout. The same assay was 
used on un-infected cells for the evaluation of CC50. Data represents mean values ± SD 
calculated from three independent experiments and are expressed in μM. NA = not active. 
Compound 
EC50 
EV-D68 
(Fermon) 
EC50 
EV-A71 
(BrCr) 
EC50 
PV-1 
(Sabin1) 
EC50 
HRV-A2 
EC50 
HRV-
B14 
CC50 
(RS)-fluoxetine 
1.85 
±0.10 
NA NA NA NA 
29.32 
±0.35 
(S)-fluoxetine 
0.67 
±0.22 
NA NA 
7.95 
±0.39 
6.34 
±1.02 
28.63 
±1.40 
252 
0.34 
±0.05 
NA NA NA 
2.11 
±0.34 
>50 
262 
0.31 
±0.06 
NA NA 
15.15 
±1.13 
10.85  
±1.86 
>50 
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10.2 N-(4-fluorobenzyl)-N-(4-methoxyphenyl)furan-2-
carboxamide analogues 
To explore the shared chemical features between compound 262 and the (S)-fluoxetine 
(see figure 34), three analogues were designed. These N-benzyl-2-(methylamino)-N-
phenylacetamide compounds were designed to introduce the methylamino group instead 
of the furan ring of compound 262. The first of this series of the compound was 267, in 
which the methylamino group replaced the furan ring. In compound 268 and 269, in addition 
to the methylamine group introduced in 267, the trifluoromethyl substituent was introduced 
on the benzyl ring and on the phenyl ring respectively, instead of the fluoro and methoxy 
substituent, to understand how the trifluoromethyl group could affect the antiviral activity of 
the compound. 
 
Figure 34. Designed analogues of 262 having the methyl amine group instead of the 
furan ring. 
 
In order to investigate the possibility to introduce the trifluoromethyl feature of the (S)-
fluoxetine in compound 262, two other analogues, compound 268 and 269 were designed. 
In compound 270, the N-(4-fluorobenzyl)-4-methoxyaniline moiety was replaced by the N-
(4-(trifluoromethyl)benzyl)aniline moiety. In this compound, the trifluoromethyl group should 
be in the same position as the trifluoromethyl group of the (S)-fluoxetine. On the other 
compound 271, instead, the N-(4-fluorobenzyl)-4-methoxyaniline moiety was replaced by 
the N-benzyl-4-(trifluoromethyl)aniline moiety. In this case, the trifluoromethyl group should 
not affect the antiviral activity, because it is located on the aniline ring (see figure 35). 
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Figure 35. Designed analogues of 262 with the trifluoromethyl group. 
 
10.2.1 Synthesis of N-benzyl-2-(methylamino)-N-phenyl acetamides 
To obtain the N-benzyl-2-(methylamino)-N-phenyl acetamides 267-269, the N-(4-
(trifluoromethyl)benzyl)aniline 276 and N-benzyl-4-(trifluoromethyl)aniline 277 were 
synthesised by reductive amination, using the same procedure for the synthesis of N-(4-
fluorobenzyl)-4-methoxyaniline 263 (scheme 20). 
 
 
Scheme 20. Synthesis of N-(4-(trifluoromethyl)benzyl)aniline 276 and  
N-benzyl-4-(trifluoromethyl)aniline 277. 
 
The N-benzyl-2-(methylamino)-N-phenyl acetamides 267-269 were then synthesised by a 
two-step synthesis (scheme 21). In the first step, the N-benzylanilines 263 and 276-277 
were used to prepare the N-benzyl-2-chloro-N-phenylacetamides 278-280, by amide bond 
formation between the N-benzylanilines and 2-bromoacetyl chloride in basic conditions. 
Finally, the chloro atom of the N-benzyl-2-chloro-N-phenylacetamides 278-280, was 
displaced by the methylamine to give the desired N-benzyl-2-(methylamino)-N-phenyl 
acetamides 267-269. 
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Scheme 21. Synthesis of the N-benzyl-2-(methylamino)-N-phenylacetamides 267-269. 
i) 2-bromoacetyl chloride, TEA, DCM, rt, 1h, Y=64-87%; ii) methylamine, EtOH, rt, on, Y=64-
66%. 
 
10.2.2 Synthesis of N-(4-fluorobenzyl)-N-(4-methoxyphenyl) furan-2-
carboxamide analogues 
The two others analogue of compound 262, in which the N-(4-fluorobenzyl)-4-
methoxyaniline moiety was replaced by the N-(4-(trifluoromethyl)benzyl)aniline moiety 
(270) and N-benzyl-4-(trifluoromethyl)aniline moiety (271) (figure 36), were synthesised 
starting from the previously synthesised N-benzylanilines 276-277. 
 
 
Figure 36. Designed analogues of 262 with the trifluoromethyl group. 
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The N-benzylanilines 276-277 were coupled with the furan-2-carbonyl chloride 215, in basic 
condition to give the desired N-phenyl-N-(4-(trifluoromethyl)benzyl)furan-2-carboxamide 
270 and N-benzyl-N-(4-(trifluoromethyl)phenyl)furan-2-carboxamide 271 (scheme 22). The 
furan-2-carbonyl chloride was used as activated carboxylic acid to avoid the use of a 
coupling agent. 
 
Scheme 22. Synthesis of N-(4-fluorobenzyl)-N-(4-methoxyphenyl) furan-2-
carboxamide analogues 270-271. 
10.2.3 Antiviral evaluation of N-(4-fluorobenzyl)-N-(4-methoxy phenyl)furan-
2-carboxamide analogues 
The newly synthesised N-benzyl-2-(methylamino)-N-phenyl acetamides 267-269 and the 
N-(4-fluorobenzyl)-N-(4-methoxyphenyl) furan-2-carboxamide analogues 270-271 were 
biological evaluated on the multicycle-CPE antiviral assay. The substitution of the furanic 
ring with the methylamine group in compound 267, as can be seen from table 9, was not 
related to antiviral activity. Also, the other designed compound 268-269 were not active on 
CVB3. The results obtained on N-benzyl-2-(methylamino)-N-phenyl acetamides 267-269 
are suggesting that probably the furan ring of compound 262 is interacting with 2C in a 
different way than the (S)-fluoxetine. 
Table 9. Antiviral evaluation of compounds 267-271. Compounds were tested in a 
multicycle CPE-reduction assay in Hela R19 cell-line infected with CVB-3 virus. MTS assay 
was used for the readout. The same assay was used on un-infected cells for the evaluation 
of CC50. Data represents mean values ± SD calculated from three independent experiments 
and are expressed in μM. SI = selectivity index (CC50/EC50). 
 
EC50 
CVB3 
(μM) 
CC50 
(μM) 
SI 
262 
1.12 
±0.28 
>50 >44.6 
267 NA >50 - 
268 NA >50 - 
269 NA >50 - 
270 
0.84 
±0.03 
>50 >50 
271 
2.42 
±0.42 
>50 >20 
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Compound 270, in which the N-(4-fluorobenzyl)-4-methoxyaniline moiety of 262 was 
replaced by the N-(4-(trifluoromethyl)benzyl)aniline moiety, showed retention of antiviral 
activity compared to 262. The N-benzyl-4-(trifluoromethyl)aniline moiety of compound 271 
was also related with retention of antiviral activity but with a ஧2-fold lower potency 
compared with 262. 
Table 10. Antiviral evaluation of compounds 267-271 against different enterovirus 
species. Compounds were tested in a multicycle CPE-reduction assay in Hela R19 cell-
line infected with different enteroviruses. MTS assay was used for the readout. The same 
assay was used on un-infected cells for the evaluation of CC50. Data represents mean 
values ± SD calculated from three independent experiments and are expressed in μM. NA 
= not active. 
 
Compound 
EC50 
EV-D68 
(Fermon
) 
EC50 
EV-A71 
(BrCr) 
EC50 
PV-1 
(Sabin1) 
EC50 
HRV-A2 
EC50 
HRV-B14 
CC50 
262 
0.31 
±0.06 
NA NA 
15.15 
±1.13 
10.85 
±1.86 
>50 
270 
1.395 
±0.2 
0.39 
±0.005 
21± 
0.85 
NA 
4.76 
±2.8 
>50 
271 
3.16 
±0.12 
NA NA NA NA >50 
 
Compound 270 and 271, in which retention of antiviral activity was observed, were tested 
against the other representative enterovirus species. Surprisingly, the introduction of the 
trifluoromethyl group on the benzylic ring in compound 270, provide a pan-inhibitory antiviral 
activity to the compound. This pan-inhibitory activity observed for compound 270 was not 
observed in compound 271, in which the trifluoromethyl group is located on the aniline ring. 
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10.3 Furamide analogues 
After the discovery that the scaffold of the compound 262 is suitable for pan-inhibitory 
antiviral activity, the role of the furamide moiety was further investigated. Different 
analogues were designed in order to identify a potential candidate group for the 
replacement of the furamide moiety (figure 37). 
 
 
 
Figure 37. Furamide analogues. 
 
In order to understand the importance of the furan ring for the antiviral activity, it was 
replaced by a methyl group in compound 282. Furthermore, in compound 283 and 284, the 
role of the amide bond was investigated, by replacing the carbonyl group with a methylene 
bridge and a sulfonyl group respectively. Lastly, the furan ring was replaced by a pyrrole 
and pyridine in compound 285 and 286.  
 
10.3.1 Synthesis of furamide analogues 
The N-(4-fluorobenzyl)-N-(4-methoxyphenyl)acetamide (282) was synthesised by 
acetylation of the N-(4-fluorobenzyl)-4-methoxyaniline 263 in the presence of triethylamine 
as a base (scheme 23). 
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Scheme 23. Synthesis of N-(4-fluorobenzyl)-N-(4-methoxyphenyl)acetamide 282. 
 
The reductive amination between the N-(4-fluorobenzyl)-4-methoxyaniline 263 and the 
furan-2-carbaldehyde 287, using the sodium triacetoxyborohydride as a reductive agent, 
give the desired N-(4-fluorobenzyl)-N-(furan-2-ylmethyl)-4-methoxyaniline 283. 
 
 
Scheme 24. Synthesis of N-(4-fluorobenzyl)-N-(furan-2-ylmethyl)-4-methoxyaniline 
283. 
 
The furan-2-sulfonamide analogue 284 was synthesised by SN2 displacement between the 
N-benzylaniline 263 and the furan-2-sulfonyl chloride 288, in the presence of triethylamine 
as a base (scheme 25). 
 
 
Scheme 25. Synthesis of N-(4-fluorobenzyl)-N-(4-methoxyphenyl)furan-2-
sulfonamide 284. 
 
For the synthesis of the pyrometer-2-carboxamide analogue 285, the first attempt of 
coupling between the 1H-pyrrole-2-carboxylate acid 289 and the N-(4-fluorobenzyl)-4-
methoxyaniline 263 was performed using TBTU as a coupling reagent, but the formation of 
the desired product was not observed. The desired N-(4-fluorobenzyl)-N-(4-
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methoxyphenyl)-1H-pyrrole-2-carboxamide 285 was obtained by converting the carboxylic 
acid of 289 in the respective acrylic chloride, which was then coupled with the N-
benzylaniline 263 (scheme 26). 
 
 
Scheme 26. Synthesis of N-(4-fluorobenzyl)-N-(4-methoxyphenyl)-1H-pyrrole-2-
carboxamide 285. 
 
The last furamide analogue, the N-(4-fluorobenzyl)-N-(4-methoxyphenyl)picolinamide 286, 
was obtained by Aimee bond formation between the N-benzylaniline 263 and the picolinic 
acid, using TBTU as coupling reagent. 
 
 
Scheme 27. Synthesis of N-(4-fluorobenzyl)-N-(4-methoxyphenyl)picolinamide 286. 
 
10.3.2 Antiviral evaluation of furamide analogues 
From the antiviral evaluation of the furamide analogues, reported in table 11, the 
substitution of the furan ring with a methyl group in compound 282 and the substitution of 
the carbonyl group with a methylene bridge in compound 283 were related with loss of 
antiviral activity. Also, the replacement of the furanamide with the furansulfonamide in 
compound 284 loss of antiviral activity was observed. From this information, can be 
deducted that the furan ring is important for the interaction with the protein, like also the 
carbonyl group part of the amine bond. 
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The pyrrole analogue 285 was associated with antiviral activity retention with an EC50 
comparable to 262. A loss of 5-fold in antiviral activity was observed when a pyridine ring 
replaced the furan ring. 
 
Table 11. Antiviral evaluation of compounds 282-286. Compounds were tested in a 
multicycle CPE-reduction assay in Hela R19 cell-line infected with CVB-3 virus. MTS assay 
was used for the readout. The same assay was used on un-infected cells for the evaluation 
of CC50. Data represents mean values ± SD calculated from three independent experiments 
and are expressed in μM. SI = selectivity index (CC50/EC50). 
 
Compound 
EC50 
CVB3 
(μM) 
CC50 
(μM) 
SI 
262 
1.12 
±0.28 
>50 >44.6 
282 NA >50 - 
283 NA >50 - 
284 NA >50 - 
285 
1.04 
±0.16 
>50 >16 
286 
6.18 
±0.12 
>50 >7.8 
 
The two compounds, 285 and 286, active on CVB3, were also tested on the representative 
panel of enteroviruses. The compounds were only able to inhibit the viral replication of EV-
D68. They were also not showing antiviral activity on the HRV species. 
 
Table 12. Antiviral evaluation of compounds 285-286 against different enterovirus 
species. Compounds were tested in a multicycle CPE-reduction assay in Hela R19 cell-
line infected with different enteroviruses. MTS assay was used for the readout. The same 
assay was used on un-infected cells for the evaluation of CC50. Data represents mean 
values ± SD calculated from three independent experiments and are expressed in μM. NA 
= not active. 
 
Compound 
EC50 
EV-D68 
(Fermon) 
EC50 
EV-A71 
(BrCr) 
EC50 
PV-1 
(Sabin1) 
EC50 
HRV-A2 
EC50 
HRV-B14 
CC50 
262 
0.31 
±0.06 
NA NA 
15.15 
±1.13 
10.85 
±1.86 
>50 
285 
1.39 
±0.42 
NA NA NA NA >50 
286 
11.82 
±0.56 
NA NA NA NA >50 
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10.4 Conclusions 
The N-(4-fluorobenzyl)-N-(4-methoxyphenyl)furan-2-carboxamide 262 was reported to 
inhibit the viral replication of CVB3, by targeting the non-structural protein 2C. Like 
fluoxetine, compound 262 was able to inhibit HEV-B species but not HEV-A and HEV-C. 
Both compounds were affected by the same mutations, C179F and the mutations on the 
AGSINA loop, suggesting that both compounds might potentially share the same 
mechanism of action. Furthermore, the chemical structure similarity observed between 
compound 262 and (S)-fluoxetine, was suggesting the possibility to avoid the chiral centre 
on fluoxetine for further development, by using the scaffold of compound 262. Several 
analogues of compound 262 were designed to introduce the relevant features of fluoxetine 
for the antiviral activity into compound 262 and to explore the importance of the furamide 
group for the antiviral activity.  
Interestingly, the replacement of the fluoro group on the benzylic ring of compound 262 by 
the trifluoromethyl group, was associated with pan-inhibitor antiviral activity, suggesting that 
the scaffold of 262 is suitable for the development of a pan-enterovirus inhibitor of the viral 
replication. Besides, the antiviral evaluation of the tested analogues of 262 is suggesting 
that the amide bond is essential for retention of antiviral activity. The role of the heterocyclic 
furan ring was also explored, by replacing the furan by a pyrrole or a pyridine ring. In both 
cases, the antiviral activity was retained, but the pyrrole ring was associated with an EC50 
comparable to 262.  
These results obtained on the N-(4-fluorobenzyl)-N-(4-methoxyphenyl)furan-2-
carboxamide 262 analogues, represent a promising starting point for further development 
of a novel class of enterovirus pan-inhibitor.  
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Chapter 11: 2C ATPase pocket 
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11.1 2C protein ATPase activity 
The 2C protein is classified as AAA+ (ATPases Associated with various cellular Activities) 
SF3 helicase superfamily, in which six monomeric 2C proteins assemble into a hexameric 
structure to form a ring. It was observed by electron microscopy in different enteroviruses 
for the 2C protein.19,20,23,29 The 2C hexamer structure is responsible for the ATP-dependent 
RNA helicase activity, which it unwinds the viral RNA in 3’-to-5’ direction.21 The hexameric 
helicases are characterised to have six ATPase sites, forming between the hexamer units, 
and this is also true for the 2C protein hexamers. As for other helicases, the ATPase activity 
of the 2C protein is coupled with the translocase activity of the hexamer.69-70 
 
 
Figure 38. Representation of 2C protein hexameric ring. 2C unit represented as a grey 
triangle and the ATPase site as a purple circle. 
The ATPase pockets, as can be seen in figure 38, are located between two 2C units, and 
the hydrolysis of the ATP occur through a movement of the two units. This movement brings 
the arginine finger close to the triphosphate moiety of the ATP during the hydrolysis.  
For the identification of new inhibitors of the ATPase activity of the 2C protein, molecular 
dynamics simulations were used to generate several conformations of the ATPase pocket. 
These conformations were then used to perform an ensemble docking approach. 
 
11.2 Ensemble docking 
In general, during a molecular docking approach, several generated-conformations of a 
ligand are docked into a rigid receptor model and evaluated for their binding affinity. In a 
situation in which the pocket in the receptor could have different conformations, MD-
generated conformation ensemble of the protein can be used to identify new inhibitor 
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candidate, addressing the flexibility of the binding site.71 The MD simulations can generate 
a high number of protein conformations and performing an ensemble docking using all the 
generated conformations is related with a very high molecular docking cost in term of time 
and computing cost, especially when docking a large set of ligands. This issue can be 
addressed by selecting the more representative and significant conformations using the 
RMSD clustering approach, in which each representative structure conformation of a cluster 
is representative for each of the cluster member.72-73 
11.2.1 MD simulation and clustering analysis 
Chain A and chain F of the published EV-A71 2C structure (PDB: 5GRB), in which the ATP-
γ-S is interacting with the Walker A and B motifs, and the arginine finger is close to the 
triphosphate moiety, were used to prepare the model system for the MD simulations. The 
system was used to perform three independent 500ns MD simulations, recording the frames 
every 20 ps during the simulations, obtaining three trajectories of 25000 frames each. To 
reduce the computational cost only the last 200 ns of each MD simulation were used for the 
clustering analysis The density-based spatial clustering of applications with noise 
(DBSCAN) algorithm was used to cluster the atom-positional RMSD of all atoms in the 
binding site close to the ATP-γ-S as the similarity criterion in each of the obtained frame.74-
75 This algorithm is grouping the frames in the high-density region into clusters, and the 
frames in the low-density region are considered as noise. Eight clusters were obtained 
considering all the frames with a neighboring distance of 1Å (ε=1Å) with 30 as a minimum 
number of neighboring frames (figure 39). 
 
 
Figure 39. Centroid frames obtained from the clusterisation analysis of the three MD 
trajectories. The three graphs represent the atom-positional RMSD of all atoms in the 
binding site close to the ATP-γ-S. In pink the centroid frames of the most representative 
clusters. 
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For each of the obtained cluster, the centroid frames were used as ensemble conformations 
of the ATPase pocket for the ensemble docking. 
 
11.2.2 Ensemble Docking 
The centroid frames, which they were obtained from the cluster analysis, they were used 
for the ensemble docking. The Glide Virtual Screening Workflow was used to virtual 
screening the SPECS library of 342047 commercially available compounds on the eight 
centroid frames. The best 25% docked compounds with the VS algorithm were then docked 
using Glide SP and rescored using Glide XP. The obtained docking results from each of the 
centroid frame were merged, and only the ligands obtained as a result in more than one 
centroid frame were taking in consideration, giving 2776 compounds (figure 40). 
 
 
Figure 40. Ensemble docking workflow representation. Glide Virtual Screening 
Workflow was used to virtual screening the SPECS library of commercially available 
compounds on the eight centroid frames. MD = Molecular Dynamics simulations. Glide 
HTVS = Glide Virtual Screening algorithm, Glide SP = Glide Standard Precision algorithm. 
Glide XP = Glide Extra Precision algorithm. 
 
The compounds were then clustered using MACCS Fingerprints and Tanimoto similarity 
matrix to select the more different compound structures. From the compounds obtained 
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from the fingerprints clusterisation, only compounds with less than one carboxylic group 
were selected, a log P lower than three and with a molar weight (MW) higher than 250 
Dalton, from which 50 compounds were selected to be visually inspected. In the end, 18 
compounds were selected from the visual inspection on the base of their ability to bind to 
the residues of the Walker A motif with which the triphosphate moiety is interacting. The 
compounds were bought and biological evaluated (see the appendix for the chemical 
structure of the selected compounds). 
 
Figure 41. Selection workflow of the ensemble docking results. Compounds were 
clustered using MACCS Fingerprints and Tanimoto similarity matrix. Then, only compounds 
with less than one carboxylic group were selected, a log P lower than three and with a molar 
weight (MW) higher than 250 Dalton. Finally, 18 compounds were selected after visual 
inspection. 
 
11.3 Antiviral evaluation of the selected compounds 
The selected compounds were evaluated for their antiviral activity on CVB3 and EV-A71 in 
the multicycle-CPE antiviral assay, and only compound 291 showed an EC50 of 15.3 μM 
against CVB3 and an EC50 of 35 μM against EV-A71, with a CC50 higher than 70 μM. 
 
 
 
Figure 42. Chemical structure of compound 291. 
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11.4 Conclusions 
In this part of the project, MD simulations were performed to address the flexibility related 
to the ATPase pocket. The MD trajectories were clustered, and the centroid frames were 
used to perform an ensemble docking, and eighteen compounds were selected. The 
selected compounds were bought and biologically evaluated on CVB3 and EV-A71. One of 
the selected compounds showed antiviral activity against both viruses. Further biological 
investigations are ongoing in order to determine if the compound is targeting the 2C protein. 
If the 2C protein is confirmed to be the target, this compound represents a starting point for 
future structural modifications of the compound. 
  
Part III: Enterovirus 
303 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 12: Experimental section 
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12.1 General information 
All chemicals, reagents and solvents were purchased from Sigma-Aldrich, FluoroChem, 
Apollo Scientific, TCI UK or purified by standard techniques. 
 
Thin Layer Chromatography 
Silica gel plates (Merck Kieselgel 60F254) were used and were developed by the ascending 
method. After solvent evaporation, compounds were visualised by irradiation with UV light 
at 254 nm and 366 nm. 
 
Column Chromatography 
Column Chromatography was performed using an automated Isolera One System 
(Biotage), using Biotage pre-packed silica cartridges (SNAP and KP types). Samples were 
applied as a concentrated solution in the same eluent. Fractions containing the product 
were identified by TLC, combined and the solvent removed in vacuo. 
 
UPLC-MS analysis 
UPLC-MS analysis was conducted on a Waters UPLC system with both Diode Array 
detection and Electrospray (+’ve and –‘ve ion) MS detection. The stationary phase was a 
Waters Acquity UPLC BEH C18 1.7um 2.1x50mm column. The mobile phase was H2O 
containing 0.1% Formic acid (A) and MeCN containing 0.1% Formic acid (B). Column 
temperature: 40°C. Sample diluent: acetonitrile. Sample concentration 10 ug/mL. Injection 
volume 2 uL. Two methods were used: 
Linear gradient standard method A: 90% A (0.1 min), 90%-0% A (2.6 min), 0% A (0.3 
min), 90% A (0.1 min); flow rate 0.5 mL/min.  
Linear gradient standard method B: 90% A (0.1 min), 90%-0% A (2.1 min), 0% A (0.8 
min), 90% A (0.1 min); flow rate 0.5 mL/min.  
Linear gradient standard method C: 90% A (0.1 min), 90%-0% A (1.5 min), 0% A (1.4 
min), 90% A (0.1 min); flow rate 0.5 mL/min. 
 
NMR Spectroscopy 
1H, 13C, 19F NMR spectra were recorded on a Bruker AVANCE 500 spectrometer (500 MHz 
150 MHz and 471 MHz respectively) and auto calibrated to the deuterated solvent reference 
peak. Chemical shifts are given in δ relative to tetramethylsilane (TMS); the coupling 
constants (J) are given in Hertz. TMS was used as an internal standard (δ = 0 ppm) for 1H 
NMR and CDCl3 served as an internal standard (δ = 77.0 ppm) for 13C NMR. 
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Molecular modelling 
A PC equipped with a 1.80 GHz Intel Xeon CPU (8 cores), 32GB of RAM and a GPU Zotac 
GeForce GTX 1080-Ti Mini with 11GB GDDR5X of dedicated RAM, running Ubuntu 14.04 
LTS was used for molecular modelling studies. The molecular dynamics simulations were 
performed using Desmond package (Schrödinger Release 2018-1: Desmond Molecular 
Dynamics System, D. E. Shaw Research, New York, NY, 2018. Maestro-Desmond 
Interoperability Tools, Schrödinger, New York, NY, 2018).76  
The ensemble docking was performed using Glide package (Schrödinger Release 2016-4: 
Glide, Schrödinger, LLC, New York, NY, 2016.)77-79  
VMD software (http://www.ks.uiuc.edu/Research/vmd/) was used to convert the Desmond 
output format of the trajectories into .dcd trajectory format.80 The Jupyter notebook was 
used as interactive command shell Python coding (Python v3.6.8).81 The MD analysis and 
the clustering analysis were performed using the SciKit-learn Python library and SciPy 
Python library. PyPlot Python library was used to generate MD simulation analysis and 
clustering analysis graph. Pictures of molecular modelling were prepared using MOE.82  
 
12.2 Molecular dynamics simulations of Fluoxetine 
enantiomers 
The docking pose of (R)-fluoxetine and (S)-fluoxetine into 2C-site A and 2C-site B of CVB3 
were used to prepare the model systems for the MD simulations. OPLS3 was used as a 
force field. Each of the protein-ligand complex systems was prepared, placing the protein-
ligand complex in a cubic box (buffer 10Å) and filling the space using water molecules. 
TIP3P model was used as a solvent model. The negative charges on the protein were 
neutralized, adding Na+ atoms to the system. Magnesium chloride (10 mM) was added to 
the box to simulate physiological conditions.  
The protein-ligand complex systems were then equilibrated for 112ps at 10 K in an NVT 
ensemble and then simulated for 48 ps at a constant pressure of 1 atm using the NPT 
ensemble. The equilibrated systems were then MD simulated for 100 ns at constant 
temperature (300 K) and pressure recording snapshots every 160 ps. The RMSD values of 
Cα atoms during the simulations were used as an indication of structural stability and 
simulation integrity (figure 43 in the appendix). 
The estimated ΔGbinding was calculated using the Desmond command-line script 
thermal_mmgbsa.py. After splitting the trajectory file of the MD simulation into snapshots, 
the script is calculating the average computed binding energy of the ligand. 
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12.3 Synthesis of Fluoxetine fragments 
 
Synthesis of 1-(3-bromopropoxy)-4-(trifluoromethyl)benzene (217)  
(C10H10BrF3O, M.W.: 283.09) 
 
 
 
 
To a solution of 1,3-dibromopropane (6.17 mmol) and potassium carbonate (4.63 mmol) in 
DMF (3 mL), 4-(trifluoromethyl)phenol 216 (3.08 mmol) in DMF (1.2 mL) were added 
dropwise. The reaction mixture was stirred at room temperature for two hours and then 
heated to 70ºC for another two hours. The mixture was filtrated, diluted with ethyl acetate 
(10 ml) and washed with water (3x10 ml). The organic layer was dried over sodium sulphate 
and evaporated under reduced pressure. The residue was purified by flash column 
chromatography (Biotage Isolera One system, Cartridge: SNAP KP Sil 50g, n-hexane -
EtOAc 100:0 v/v increasing to 70:30 v/v in 20 CV) to give pure 1-(3-bromopropoxy)-4-
(trifluoromethyl)benzene (217) were as a yellow oil.  
T.L.C. System: n-Hexane/EtOAc 80:20 v/v, Rf: 0.7 
Yield: 207 mg (47%) 
Purity: >95% 
UPLC-MS method C: Rt: 2.175, MS (ESI)+: ND 
1H NMR (DMSO) δ: 7.65 (d, J = 8.7 Hz, 2H), 7.14 (d, J = 8.7 Hz, 2H), 4.17 (t, J = 6.0 Hz, 
2H), 3.68 (t, J = 6.6 Hz, 2H), 2.28 (p, J = 6.3 Hz, 2H).  
13C NMR (DMSO) δ: 161.67 (C, C-aromatic), 127.44 (q, J = 3.7 Hz, CH, C-aromatic), 125.02 
(q, J = 271.0 Hz, CF3), 121.73 (q, J = 32.1 Hz, C, C-aromatic), 115.44 (CH, C-aromatic), 
32.08, 31.50 (CH2).  
19F NMR (DMSO) δ: -59.83 (s, 3F).  
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Synthesis of N-methyl-3-(4-(trifluoromethyl) phenoxy) propan-1-amine (211) 
(C11H15ClF3NO, M.W.: 269.69) 
 
 
 
A solution of 1-(3-bromopropoxy)-4-(trifluoromethyl) benzene 171 (0.80mmol) in EtOH 
absolute (0.8mL) were added dropwise at 0ºC to a round bottom flask containing 
methylamine in absolute ethanol (2mL). The reaction mixture was stirred at room 
temperature overnight. The mixture was filtrated. The obtained residue was dissolved in 
DCM (10 ml). The organic layer was washed with sat. aq. NaHCO3 and brine, dried over 
Na2SO4 and concentrated in vacuo. The residue was treated with HCl in diethyl ether. the 
resulting solid was then filtered and washed with diethyl ether to give 131 mg of N-methyl-
3-(4-(trifluoromethyl) phenoxy) propan-1-amine hydrochloride (164) salt as a white powder. 
T.L.C. System: DCM/MeOH 95:5 v/v, Rf: 0.16 
Yield: 131 mg (69%) 
Purity: >95% 
UPLC-MS method C: Rt: 1.521, MS (ESI)+: 234.1 [M+Na]+. 
1H NMR (DMSO) δ: 8.65 (s, 2H), 7.68 (d, J = 8.6 Hz, 2H), 7.13 (d, J = 8.6 Hz, 2H), 4.16 (t, 
J = 6.1 Hz, 2H), 3.06 (d, J = 7.4 Hz, 2H), 2.58 (s, 3H), 2.13 – 2.04 (m, 2H).  
13C NMR (DMSO) δ: 161.58 (C, C-aromatic), 127.43 (q, J = 3.7 Hz, CH, C-aromatic), 125.02 
(q, J = 271.1 Hz, CF3), 121.76 (q, J= 32.2 Hz, C, C-aromatic), 115.48 (CH, C-aromatic), 
65.58, 46.14(CH2), 33.07 (CH3), 25.71 (CH2).  
19F NMR (DMSO) δ: -59.78 (s, 3F). 
 
Synthesis of 1-(benzyloxy)-4-(trifluoromethyl)benzene(214) 
(C14H11F3O, M.W.: 252.24) 
 
 
To a solution of 4-(trifluoromethyl) phenol 216 (1.23 mmol), in DMF (3mL), 
(bromomethyl)benzene 218 (1.55 mmol) and potassium carbonate (4,93 mmol) were 
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added. The obtained mixture was stirred at 105ºC for four hours. After the reaction was 
complete, the mixture was filtrated, diluted with ethyl acetate (10 ml) and washed with water 
(3x10 ml). The organic layer was dried over sodium sulphate and evaporated under reduced 
pressure. The residue was purified by flash column chromatography (Biotage Isolera One 
system, Cartridge: SNAP KP Sil 10g, n-hexane -DCM 100:0 v/v increasing to 0:100 v/v in 
12 CV) to give pure 1-(benzyloxy)-4-(trifluoromethyl)benzene 214 as a white powder.  
T.L.C. System: n-Hexane/EtOAc 80:20 v/v, Rf: 0.77 
Yield: 212 mg (75%) 
Purity: >95% 
UPLC-MS method C: Rt: 2.177, MS (ESI)+: ND 
1H NMR (DMSO) δ: 7.66 (d, J = 8.5 Hz, 2H), 7.49 – 7.44 (m, 2H), 7.44 – 7.38 (m, 2H), 7.38 
– 7.32 (m, 1H), 7.20 (d, J = 8.5 Hz, 2H), 5.20 (s, 2H). 
13C NMR (DMSO) δ: 161.64, 136.88 (C, C-aromatic), 128.98, 128.50, 128.25 (CH, C-
aromatic), 127.42 (q, J = 3.7 Hz, CH, C-aromatic), 125.02 (q, J = 271.1 Hz, CF3), 121.74 
(q, J = 32.1 Hz, (C, C-aromatic)), 115.77 (CH, C-aromatic), 70.00 (CH2). 
19F NMR (DMSO) δ: -59.81 (s, 3F). 
 
Synthesis of N-methyl-3-phenylpropan-1-amine (212) 
(C10H16BrN, M.W.: 230.15) 
 
 
To a round bottom flask containing methylamine in absolute ethanol (2.18 mL), a solution 
of (3-bromopropyl) benzene 219 (1.25 mmol) in EtOH absolute (0.87mL) was added 
dropwise at 0ºC. The reaction mixture was stirred at room temperature overnight. The solid 
residue was filtered and washed with EtOH absolute to give N-methyl-3-phenylpropan-1-
amine 212 as white powder. 
T.L.C. System: DCM/MeOH 95:5 v/v, Rf: 0.42 
Yield: 195 mg (75%) 
Purity: >95% 
1H NMR (DMSO) δ: 8.48 (s, 2H), 7.35 – 7.27 (m, 2H), 7.26 – 7.17 (m, 3H), 2.91 – 2.85 (m, 
2H), 2.65 (t, J = 7.7 Hz, 2H), 2.55 (s, 3H), 1.94 – 1.85 (m, 2H).  
13C NMR (DMSO) δ: 141.13 (C, C-aromatic), 128.92, 128.73, 126.57 (CH, C-aromatic), 
48.30 (CH2), 32.88 (CH3), 32.32, 27.57 (CH2).  
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12.4 Synthesis of Fluoxetine analogues 
 
Synthesis of Boc protected 3-(methylamino)-1-phenylpropan-1-ol (230) 
(C15H23NO3; M.W.: 265.35) 
 
 
To a solution of 3-(methylamino)-1-phenylpropan-1-ol 229 (12.1 mmol) in DCM (48mL), di-
tert-butyl dicarbonate (13.3 mmol) was added, the reaction mixture was stirred at room 
temperature overnight. The reaction mixture was then washed with NH4Cl (3x30ml), brine 
(3x30ml), dried over Na2SO4 and concentrated under reduce pressure to give tert-butyl (3-
hydroxy-3-phenylpropyl) (methyl)carbamate 230 as a colorless oil which, was used without 
further purification.  
T.L.C. System: n-Hex/EtOAc 80:20 v/v, Rf: 0.28 
Yield: 3.16 g (99%) 
Purity: >95% 
UPLC-MS method C: Rt: 1.883, MS (ESI)+: 288.1 [M+Na]+, 192.1[C11H14NO2•]+ 
1H NMR (DMSO-d6), δ: 7.36 – 7.29 (m, 4H), 7.30 – 7.20 (m, 1H), 5.22 (d, J = 4.4 Hz, 1H), 
4.52 (dd, J = 11.0, 6.2 Hz, 1H), 3.18 (br s, 2H), 2.76 (s, 3H), 1.78 (br s, 2H), 1.35 (br s, 9H). 
13C NMR (DMSO-d6), δ: 155.22 (C=O), 146.33 (C, C-aromatic), 128.48, 127.17, 126.13 
(CH, C-aromatic), 78.66 (C), 70.67 (CH), 46.03, 37.91 (CH2), 34.46, 28.53 (CH3). 
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General procedure 11: Synthesis of Boc protected N-methyl-3-phenoxy-3-
phenylpropan-1-amines 
 
 
 
To a solution of triphenylphosphine (1.70 mmol) in diethyl ether (3.39 mL) cooled at 0°C, 
diisopropyl azodicarboxylate (1.14 mmol) in diethyl ether (0.57 mL) was added. After twenty 
minutes 3-(trifluoromethyl)phenol (1.36 mmol) in diethyl ether (2.26 mL) was added before 
adding the solution of tert-butyl (3-hydroxy-3-phenylpropyl)(methyl)carbamate (1,13 mmol) 
in diethyl ether (2.83 mL). The reaction was stirred at room temperature for two hours. The 
organic solvent was evaporated under reduced pressure and the crude residue was purified 
by flash column chromatography to afford tert-butyl (3-(phenoxy)-3-phenylpropyl) 
(methyl)carbamate. 
 
General procedure 12: Synthesis of N-methyl-3-phenoxy-3-phenylpropan-1-amines 
 
 
 
To a solution of tert-butyl (3-phenyl-3-(4-(trifluoromethyl) phenoxy)propyl)carbamate (0.84 
mmol) in DCM (4.2 mL) at 0ºC TFA (4.20 mmol) was added. The reaction was stirred at 
room temperature for two hours. The reaction mixture was diluted with DCM (8 mL) and 
was washed with sat. NaHCO3 solution (3 x 10 mL) and brine (3 x 10 mL). The organic 
layers were then dried over Na2SO4 and concentrated under reduced pressure. The crude 
residue was purified by flash column chromatography to afford 3-phenyl-3-(4-
(trifluoromethyl) phenoxy) propan-1-amine. 
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tert-butyl methyl(3-phenyl-3-(2-(trifluoromethyl)phenoxy)propyl)carbamate (231) 
(C22H26F3NO3; M.W.: 409.45) 
 
General procedure 11 
Colorless oil 
T.L.C. System: n-Hexane/EtOAc 8:2 v/v, Rf: 0.5 
Purification: Purification: Flash column chromatography Isolera One system (Biotage), 
Cartridge: SNAP KP-Sil 50g (n-hexane-DCM 100:0 v/v increasing to 0:100 v/v in 5 CV and 
DCM/MeOH 100:0 v/v increasing to 97:3 v/v in 10 CV). 
Yield: 303 mg (79%) 
Purity: >95% 
UPLC-MS method C: Rt: 2.332, MS (ESI)+: 192.1[C11H14NO2.]+ 
1H NMR (DMSO-d6), δ: 7.59 (dd, 3J = 7.7 Hz, 4J = 1.2 Hz, 1H), 7.44 (t, J = 7.3 Hz, 1H), 
7.42 – 7.34 (m, 4H), 7.29 – 7.25 (m, 1H), 7.04 – 6.96 (m, 2H), 5.52 (br s, 1H), 3.47 – 3.22 
(m, 2H), 2.76 (s, 3H), 2.14 – 1.92 (m, 2H), 1.24 (s, 9H). 
13C NMR (DMSO-d6), δ: 155.50 (C=O), 155.18, 141.01 (C, C-aromatic), 134.29, 129.15, 
128.26 (CH, C-aromatic), 127.26 (q, J = 5.2 Hz, CH, C-aromatic), 126.23 (CH, C-aromatic), 
124.39 (q, J = 272.2 Hz, C, C-aromatic), 120.54 (CH, C-aromatic), 117.84 (q, J = 29.9 Hz, 
C, C-aromatic), 114.85 (CH, C-aromatic), 78.82 (C), 76.70 (CH), 45.30, 36.75 (CH2), 34.10, 
28.35 (CH3). 
19F NMR (DMSO-d6), δ: -60.77 (s, 3F). 
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tert-butyl methyl(3-phenyl-3-(3-(trifluoromethyl)phenoxy)propyl)carbamate (242) 
(C22H26F3NO3; M.W.: 409.45) 
 
 
General procedure 11 
pale yellow oil; 
T.L.C. System: n-Hexane/EtOAc 8:2 v/v, Rf: 0.47 
Purification: Purification: Flash column chromatography Isolera One system (Biotage), 
Cartridge: SNAP KP-Sil 50g (n-hexane-DCM 100:0 v/v increasing to 0:100 v/v in 5 CV and 
DCM/MeOH 100:0 v/v increasing to 97:3 v/v in 10 CV). 
Yield: 280 mg (61%) 
Purity: >90% 
1H NMR (DMSO-d6), δ: 7.46 – 7.39 (m, 3H), 7.36 (t, J = 7.6 Hz, 2H), 7.30 – 7.25 (m, 1H), 
7.20 (d, J = 7.8 Hz, 1H), 7.17 (m, 2H), 5.41 (dd, J = 8.4, 4.2 Hz, 1H), 3.51 – 3.19 (m, 2H), 
2.78 (s, 3H), 2.17 – 1.90 (m, 2H), 1.29 (br s, 9H). 
 
tert-butyl (3-(2-chloro-4-(trifluoromethyl)phenoxy)-3-phenylpropyl)(methyl) 
carbamate (243) 
(C22H25ClF3NO3; M.W.: 443.89) 
 
General procedure 11 
Colorless oil 
T.L.C. System: n-Hexane/EtOAc 8:2 v/v, Rf: 0.5 
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Purification: Purification: Flash column chromatography Isolera One system (Biotage), 
Cartridge: SNAP KP-Sil 50g (n-hexane-DCM 100:0 v/v increasing to 0:100 v/v in 5 CV 
DCM/MeOH 100:0 v/v increasing to 97:3 v/v in 10 CV). 
Yield: 215 mg (48%) 
Purity: >90% 
1H NMR (DMSO-d6), δ: 7.82 (s, 1H), 7.53 (d, J = 8.3 Hz, 1H), 7.43 – 7.34 (m, 4H), 7.31 – 
7.26 (m, 1H), 7.18 – 7.07 (m, 1H), 5.57 (br s, 1H), 3.53 – 3.22 (m, 2H), 2.78 (s, 3H), 2.24 – 
1.94 (m, 2H), 1.27 (br s, 9H). 
 
1-(benzyloxy)-2-methoxy-4-(trifluoromethyl)benzene (246) 
(C15H13F3O2; M.W.: 282.26) 
 
 
Sodium hydride (2.36 mmol) was added to a solution of benzyl alcohol (2.15 mmol) in DMF 
(10 mL). After thirty minutes, 1-fluoro-2-methoxy-4-(trifluoromethyl) benzene 245 (2.58 
mmol) was added dropwise to the mixture. The reaction was stirred at room temperature 
for five hours. The reaction mixture was diluted in ethyl acetate (20 ml) and washed with 
water (3x20 ml), brine (3x20 ml). The organic layer was dried over sodium sulphate, filtrated 
and evaporate at reduced pressure. The residue was purified by flash column 
chromatography (Biotage Isolera One system, Cartridge: SNAP KP-Sil 25g, n-Hexane-
DCM 100:0 v/v increasing to 50:50 v/v in 15 CV) to afford 1-(benzyloxy)-2-methoxy-4-
/trifluoromethyl) benzene 246 as white powder. 
T.L.C. System: n-Hex/EtOAc 8:2v/v, Rf: 0,73 
Yield: 516 mg (85%) 
Purity: >95% 
1H NMR (DMSO-d6), δ: 7.48 – 7.44 (m, 2H), 7.44 – 7.38 (m, 2H), 7.35 (td, 3J = 8.6, 4.5 Hz, 
4J = 1.4 Hz, 1H), 7.29 – 7.19 (m, 3H), 5.18 (s, 1H), 3.84 (s, 2H). 
13C NMR (DMSO-d6), δ: 151.21, 149.72, 136.93 (C, C-aromatic), 128.95, 128.51, 128.34 
(CH, C-aromatic), 124.89 (q, J = 271.4 Hz, CF3), 121.82 (q, J = 32.1 Hz, C, C-aromatic), 
118.54 (q, J = 3.5 Hz, CH, C-aromatic), 113.48 (CH, C-aromatic), 108.89 (q, J = 3.5 Hz, 
CH, C-aromatic), 70.40 (CH2), 56.34 (CH3). 
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19F NMR (DMSO-d6), δ: -59.45 (s, 3F). 
 
2-methoxy-4-(trifluoromethyl)phenol (241) 
(C8H7F3O2; M.W.: 192.14) 
 
 
A solution of 1-(benzyloxy)-2-methoxy-4-/trifluoromethyl) benzene 194 (1.59 mmol) in 
anhydrous EtOAc (0.15 M) was stirred under H2 atmosphere in presence of Pd/C (15%) at 
room temperature overnight. The reaction mixture was filtered on Celite. The filtered 
solution was concentrated under reduced pressure to give 2-methoxy-4-
(trifluoromethyl)phenol (191) as a colorless oil which was used without further purification. 
T.L.C. System: n-Hex/EtOAc 8:2 v/v, Rf: 0.65 
Yield: 257 mg (84%) 
Purity: >95% 
1H NMR (DMSO-d6), δ: 9.88 (s, 1H), 7.17 (s, 1H), 7.14 (d, J = 8.2 Hz, 1H), 6.93 (d, J = 8.2 
Hz, 1H), 3.83 (s, 3H). 
13C NMR (DMSO-d6), δ: 150.58, 148.30 (C, C-aromatic), 125.10 (q, J = 270.9 Hz, CF3), 
120.11 (q, J = 32.0 Hz, C, C-aromatic), 118.83 (q, J = 4.2 Hz, CH, C-aromatic), 115.88 (CH, 
C-aromatic), 109.27 (q, J = 3.5 Hz, CH, C-aromatic), 56.30 (CH3). 
19F NMR (DMSO-d6), δ: -59.45 (s, 3F). 
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tert-butyl (3-(2-methoxy-4-(trifluoromethyl)phenoxy)-3-phenylpropyl)(methyl) 
carbamate (244) 
(C23H28F3NO4; M.W.: 439.48) 
 
 
General procedure 11 
pale yellow oil 
T.L.C. System: n-Hexane/EtOAc 8:2 v/v, Rf: 0.49 
Purification: Purification: Flash column chromatography Isolera One system (Biotage), 
Cartridge: SNAP KP-Sil 50g (n-hexane-DCM 100:0 v/v increasing to 0:100 v/v in 5 CV 
DCM/MeOH 100:0 v/v increasing to 97:3 v/v in 10 CV). 
Yield: 325 mg (64%) 
Purity: >95% 
UPLC-MS method C: Rt: 2.272, MS (ESI)+: 462.3[M+Na]+, 192.1[C11H14NO2•]+ 
1H NMR (DMSO-d6), δ: 7.41 – 7.31 (m, 4H), 7.26 (t, J = 7.2 Hz, 1H), 7.20 (d, 4J = 2.0 Hz, 
1H), 7.10 (d, J = 8.4 Hz, 1H), 6.93 (d, J = 8.5 Hz, 1H), 5.44 – 5.32 (m, 1H), 3.88 (s, 3H), 
3.46 – 3.18 (m, 12H), 2.77 (s, 3H), 2.22 – 2.07 (m, 1H), 2.07 – 1.91 (m, 1H), 1.41 – 1.16 
(m, 9H). 
13C NMR (DMSO-d6), δ: 155.19 (C=O), 150.33, 150.10, 141.19 (C, C-aromatic), 129.08, 
128.22, 126.36 (CH, C-aromatic), 124.79 (q, J = 271.4 Hz, CF3), 121.75 (q, J = 31.9 Hz, C, 
C-aromatic), 118.28 (q, J = 4.2 Hz, CH, C-aromatic), 114.76 (CH, C-aromatic), 109.11 (CH, 
C-aromatic), 78.80 (C), 77.39 (CH), 56.47 (CH3), 45.37, 36.58 (CH2), 34.05, 28.31 (CH3). 
19F NMR (DMSO-d6), δ: -59.90 (s, 3F). 
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N-methyl-3-phenyl-3-(2-(trifluoromethyl)phenoxy)propan-1-amine (220) 
(C17H18F3NO; M.W.: 309.33) 
 
 
 
General procedure 12 
yellow oil 
T.L.C. System: DCM/MeOH 95: v/v, Rf: 0.21 
Purification: Purification: Flash column chromatography Isolera One system (Biotage), 
Cartridge: ZIP KP-Sil 5g (DCM/MeOH 100:0 v/v increasing to 90:10 v/v in 24 CV). 
Yield: 59 mg (83%) 
Purity: >95% 
UPLC-MS method C: Rt: 1.733, MS (ESI)+: 310[M+1]+ 
1H NMR (DMSO-d6), δ: 8.88 (s, 2H), 7.61 (d, J = 6.8 Hz, 1H), 7.48 (t, J = 7.4 Hz, 1H), 7.44 
– 7.37 (m, 4H), 7.34 – 7.28 (m, 1H), 7.06 – 7.00 (m, 2H), 5.81 – 5.73 (m, 1H), 3.05 – 2.92 
(m, 2H), 2.55 (s, 3H), 2.34 – 2.15 (m, 2H). 
13C NMR (DMSO-d6), δ: 13C NMR (126 MHz, DMSO) δ 155.15 (C, C-aromatic), 140.20, 
134.36, 129.34, 128.66 (CH, C-aromatic), 127.32 (q, J = 5.0 Hz, CH, C-aromatic), 126.28 
(CH, C-aromatic), 124.36 (q, J = 272.4 Hz, CF3), 120.89 (CH, C-aromatic), 117.80 (q, J = 
30.0 Hz, C, C-aromatic), 115.14 (CH, C-aromatic), 76.57 (CH), 45.45, 34.50 (CH2), 32.89 
(CH3). 
19F NMR (DMSO-d6), δ: -60.77 (s, 3F). 
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N-methyl-3-phenyl-3-(3-(trifluoromethyl)phenoxy)propan-1-amine (221) 
(C17H18F3NO; M.W.= 309.33) 
 
 
General procedure 12 
yellow oil 
T.L.C. System: DCM/MeOH 95: v/v, Rf: 0.33 
Purification: Purification: Flash column chromatography Isolera One system (Biotage), 
Cartridge: ZIP KP-Sil 5g (DCM/MeOH 100:0 v/v increasing to 90:10 v/v in 24 CV). 
Yield: 46 mg (62%) 
Purity: >95% 
UPLC-MS method C: Rt: 1.77, MS (ESI)+: 310[M+1]+ 
1H NMR (DMSO-d6), δ: 7.46 – 7.38 (m, 3H), 7.35 (t, J = 7.6 Hz, 2H), 7.27 (t, J = 7.3 Hz, 
1H), 7.22 – 7.16 (m, 3H), 5.55 (dd, J = 7.7, 5.4 Hz, 1H), 2.62 – 2.54 (m, 2H), 2.28 (s, 3H), 
2.15 – 2.05 (m, 1H), 1.95 – 1.85 (m, 1H). 
13C NMR (DMSO-d6), δ: 158.46, 141.57 (C, C-aromatic), 131.07, 129.07, 128.16, 126.53, 
120.30 (CH, C-aromatic), 117.56 (q, J = 4.0 Hz, CH, C-aromatic), 112.86 (q, J = 4.0 Hz, 
CH, C-aromatic), 77.95 (CH), 47.92, 38.08 (CH2), 36.36 (CH3). 
19F NMR (DMSO-d6), δ: -61.22 (s, 3F). 
  
Part III: Enterovirus 
318 
3-(2-chloro-4-(trifluoromethyl)phenoxy)-N-methyl-3-phenylpropan-1-amine (222) 
(C17H17ClF3NO; M.W.: 343.77) 
 
 
 
General procedure 12 
Colourless oil 
T.L.C. System: DCM/MeOH 95: v/v, Rf: 0.3 
Purification: Purification: Flash column chromatography Isolera One system (Biotage), 
Cartridge: ZIP KP-Sil 5g (DCM/MeOH 100:0 v/v increasing to 90:10 v/v in 24 CV). 
Yield: 53 mg (63%) 
Purity: >95% 
UPLC-MS method C: Rt: 1.631, MS (ESI)+: 344.2[M+1]+ 
1H NMR (DMSO-d6), δ: 7.81 (d, 4J = 2.0 Hz, 1H), 7.54 (dd, 3J = 8.7, 4J = 2.0 Hz, 1H), 7.42 
– 7.34 (m, 4H), 7.31 – 7.26 (m, 1H), 7.16 (d, J = 8.7 Hz, 1H), 5.71 (dd, J = 7.9, 5.1 Hz, 1H), 
2.69 – 2.58 (m, 2H), 2.30 (s, 3H), 2.21 – 2.10 (m, 1H), 2.00 – 1.96 (m, 1H). 
13C NMR (DMSO-d6), δ: 156.35, 140.78 (C, C-aromatic), 129.19, 128.41 (CH, C-aromatic), 
127.49 (q, J = 3.7 Hz, CH, C-aromatic), 126.31 (CH, C-aromatic), 125.98 (q, J = 3.9 Hz, 
CH, C-aromatic), 124.12 (q, J = 256.5 Hz, C, C-aromatic), 122.36 (q, J = 32.9 Hz, C, C-
aromatic), 115.99 (CH, C-aromatic), 78.95 (CH), 47.65, 37.77 (CH2), 36.17 (CH3). 
19F NMR (DMSO-d6), δ: -60.15 (s, 3F). 
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3-(2-methoxy-4-(trifluoromethyl)phenoxy)-N-methyl-3-phenylpropan-1-amine (223) 
(C18H20F3NO2; M.W.: 339.36) 
 
 
 
General procedure 12 
dark yellow oil 
T.L.C. System: DCM/MeOH 95: v/v, Rf: 0.2 
Purification: Purification: Flash column chromatography Isolera One system (Biotage), 
Cartridge: ZIP KP-Sil 5g (DCM/MeOH 100:0 v/v increasing to 90:10 v/v in 24 CV). 
Yield: 78 mg (64%) 
Purity: >95% 
UPLC-MS method C: Rt: 1.585, MS (ESI)+: 340.2[M+1]+ 
1H NMR (DMSO-d6), δ: 7.41 – 7.33 (m, 4H), 7.29 – 7.24 (m, 1H), 7.20 (d, 4J = 2.0 Hz, 1H), 
7.11 (dd, 3J = 8.4 Hz, 4J = 1.2 Hz, 1H), 6.94 (d, J = 8.4 Hz, 1H), 5.53 (dd, J = 7.8, 5.1 Hz, 
1H), 3.88 (s, 3H), 2.63 (s, 2H), 2.31 (s, 3H), 2.19 – 2.08 (m, 1H), 1.99 – 1.90 (m, 1H). 
13C NMR (DMSO-d6), δ: 150.42, 150.04, 141.47 (C, C-aromatic), 129.06, 128.18, 126.38 
(CH, C-aromatic), 124.80 (q, J = 271.3 Hz, CF3), 121.71 (q, J = 32.2 Hz, C, C-aromatic), 
118.31 (q, J = 4.2 Hz, CH, C-aromatic), 114.94 (CH, C-aromatic), 109.09 (q, J = 3.4 Hz, 
CH, C-aromatic), 78.41 (CH), 56.48 (CH3), 47.76, 37.69 (CH2), 35.97 (CH3). 
19F NMR (DMSO-d6), δ: -59.88 (s, 3F). 
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Synthesis of N-(3-phenyl-3-(4-(trifluoromethyl)phenoxy)propyl)acetamide 247 
 
tert-butyl (3-hydroxy-3-phenylpropyl)carbamate (249) 
(C14H21NO3; M.W.: 251.33) 
 
 
 
To a solution of 3-amino-1-phenylpropan-1-ol 248 (1.65 mmol) in DCM (7 mL), di-tert-butyl 
dicarbonate (1.8 mmol) was added, the reaction mixture was stirred at room temperature 
overnight. The reaction mixture was then washed with NH4Cl (3x30 ml), brine (3x30 ml), 
dried over Na2SO4 and concentrated under reduce pressure to give tert-butyl (3-hydroxy-3-
phenylpropyl) carbamate 249 as a yellow solid which, was used without further purification.  
T.L.C. System: n-Hex/EtOAc 8:2x v/v, Rf: 0.18 
Yield: 1.08 g (87%) 
Purity: >95% 
1H NMR (DMSO-d6), δ: 7.40 – 7.34 (m, 4H), 7.31 – 7.24 (m, 1H), 6.82 (t, J = 5.0 Hz, 1H), 
5.25 (d, J = 4.5 Hz, 1H), 4.60 (dd, J = 11.0, 6.4 Hz, 1H), 3.03 (dd, J = 13.6, 6.3 Hz, 2H), 
1.75 (dd, J = 14.2, 6.8 Hz, 2H), 1.43 (s, 9H). 
13C NMR (DMSO-d6), δ: 156.05 (C=O), 146.55 (C, C-aromatic), 128.45, 127.11, 126.14 
(CH, C-aromatic), 77.87 (CH), 70.68 (C), 39.79, 37.70 (CH2), 28.74 (CH3). 
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tert-butyl (3-phenyl-3-(4-(trifluoromethyl)phenoxy)propyl)carbamate (250) 
(C21H24F3NO3; M.W.: 395.42) 
 
 
To a solution of triphenylphosphine (2.99 mmol) in diethyl ether (5.97 mL) cooled at 0°C, 
diisopropyl azodicarboxylate (2.01 mmol) in diethyl ether (1 mL) was added. After twenty 
minutes 4-(trifluoromethyl)phenol 216 (2.39 mmol) in diethyl ether (4 mL) was added before 
adding the solution of tert-butyl (3-hydroxy-3-phenylpropyl)(methyl)carbamate 249 (1.99 
mmol) in diethyl ether (5 mL).The reaction was stirred at room temperature for two hours. 
The reaction mixture was concentrated under reduced pressure and the residue was 
purified by flash column chromatography (Biotage Isolera One system, Cartridge: SNAP 
KP-Sil 50g, n-hexane-DCM 100:0 v/v increasing to 0:100 v/v in 5 CV and DCM/MeOH 100:0 
v/v increasing to 98:2 v/v in 10 CV) to afford tert-butyl (3-(3-(trifluoromethyl) phenoxy)-3-
phenylpropyl) (methyl)carbamate 250 as a colourless oil. 
T.L.C. System: n-Hex/EtOAc 8:2 v/v, Rf: 0.4 
Yield: 193 mg  
Two species observed. Major/minor species ratio: 4/1. 
1H NMR (DMSO-d6), δ (major species): 7.56 (d, J = 8.8 Hz, 2H), 7.42 – 7.33 (m, 4H), 7.27 
(t, J = 10.0, 4.3 Hz, 1H), 7.05 (d, J = 8.7 Hz, 2H), 6.93 (s, 1H), 5.47 (dd, J = 8.0, 4.9 Hz, 
1H), 3.11 – 3.02 (m, 2H), 2.12 – 2.01 (m, J = 13.8, 7.6 Hz, 1H), 1.95 – 1.85 (m, 1H), 1.31 
(s, 9H). (minor species): 10.28 (s, 1H), 7.53 (d, J = 8.6 Hz, 2H), 6.92 (d, J = 8.6 Hz, 2H). 
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3-phenyl-3-(4-(trifluoromethyl)phenoxy)propan-1-amine (251) 
(C16H16F3NO; M.W.: 295.31) 
 
 
To a solution of tert-butyl (3-phenyl-3-(4-(trifluoromethyl)phenoxy)propyl)carbamate 250 
(0.84 mmol) in DCM (4.2 mL) at 0ºC TFA (4.20 mmol) was added. The reaction was stirred 
at room temperature for two hours. The reaction mixture was diluted with DCM (8 mL) and 
was washed with sat. NaHCO3 solution (3 x 10 mL) and brine (3 x 10 mL). The organic 
layers were then dried over Na2SO4 and concentrated under reduced pressure. The residue 
was purified by flash column chromatography (Biotage Isolera One system, Cartridge: 
SNAP KP-Sil 25g, n-Hexane-DCM 100:0 v/v increasing to 50:50 v/v in 15 CV) to afford 3-
phenyl-3-(4-(trifluoromethyl) phenoxy) propan-1-amine 251 as a yellow oil. 
T.L.C. System: DCM/MeOH 95:5 v/v, Rf: 0,15 
Yield: 160 mg (27% over two steps) 
Purity: >95% 
1H NMR (DMSO-d6), δ: 7.55 (d, J = 8.7 Hz, 2H), 7.42 – 7.32 (m, 4H), 7.26 (t, J = 7.2 Hz, 
1H), 7.06 (d, J = 8.6 Hz, 2H), 5.61 – 5.55 (m, 1H), 2.69 (t, J = 6.8 Hz, 2H), 2.13 – 2.03 (m, 
1H), 1.93 – 1.83 (m, 1H). 
13C NMR (DMSO-d6), δ: 160.99, 141.43 (C, C-aromatic), 129.10, 128.18 (CH, C-aromatic), 
127.27 (q, J = 3.7 Hz, CH, C-aromatic), 126.46 (CH, C-aromatic), 124.92 (q, J = 271.1 Hz, 
CF3), 121.54 (q, J = 32.1 Hz, C, C-aromatic), 116.61 (CH, C-aromatic), 77.48 (CH), 41.01, 
37.95 (CH2). 
19F NMR (DMSO-d6), δ: -59.88 (s, 3F). 
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N-(3-phenyl-3-(4-(trifluoromethyl)phenoxy)propyl)acetamide (247) 
(C18H18F3NO2; M.W.: 337.34) 
 
 
Acetyl chloride was added drop-wise to a solution, at 0°C, of 3-phenyl-3-(4-
(trifluoromethyl)phenoxy)propan-1-amine 251 (0.2 mmol), triethylamine (0.38 mmol) in 
anhydrous DCM (0.4 M) under nitrogen atmosphere. The reaction was allowed to warm-up 
to room temperature and was stirred for 2 hours. The reaction mixture was diluted with DCM 
(8 ml) and extracted with 2N HCl solution (3x10ml). The organic layer was washed with 
brine (3 x 10 mL), dried over Na2SO4 and evaporated at reduced pressure. The residue was 
purified by flash column chromatography (Biotage Isolera One system, Cartridge: ZIP KP-
Sil 5g, DCM-DCM/MeOH 100:0 v/v to 98:2 v/v) to afford pure N- (3-phenyl-3-(4-
(trifluoromethyl)phenoxy) propyl) acetamide 247 as a yellow oil. 
T.L.C. System: DCM/MeOH 95:5 v/v, Rf: 0.5 
Yield: 63 mg (98%) 
Purity: >95% 
UPLC-MS method C: Rt: 1.923, MS (ESI)+: 338.2[M+1]+, 176.1[C11H14NO•]+ 
1H NMR (DMSO-d6), δ: 7.93 (t, J = 5.0 Hz, 1H), 7.56 (d, J = 8.8 Hz, 2H), 7.41 – 7.32 (m, 
5H), 7.27 (t, J = 7.2 Hz, 1H), 7.05 (d, J = 8.7 Hz, 2H), 5.47 (dd, J = 7.9, 5.0 Hz, 1H), 3.21 – 
3.11 (m, 2H), 2.15 – 2.03 (m, 1H), 1.97 – 1.87 (m, 1H), 1.80 (s, 3H). 
13C NMR (DMSO-d6), δ: 169.64 (C=O), 160.91, 141.15 (C, C-aromatic), 129.13, 128.25 
(CH, C-aromatic), 127.29 (q, J = 3.7 Hz, CH, C-aromatic), 126.45 (CH, C-aromatic), 124.92 
(q, J = 271.1 Hz, CF3), 121.60 (q, J = 32.1 Hz, C, C-aromatic), 116.64 (CH, C-aromatic), 
77.53 (CH), 38.20, 35.74 (CH2), 23.09 (CH3). 
19C NMR (DMSO-d6), δ: -59.89 (s, 3F). 
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12.5 synthesis of Guanidine derivatives of fluoxetine 
N,N'-Bis(tert-butoxycarbonyl)-S-methylisothiourea (254) 
(C12H22N2O4S; M.W.: 290.38) 
 
 
To a stirring mixture of methyl carbamimidothioate hemisulfate 253 (7.18 mmol) in sat. 
NaHCO3 (8 mL) and DCM (16 mL) a solution of di-tert-butyl decarbonate (14.37 mmol) in 
DCM (12 mL) was added. The reaction was stirred at room temperature for 48 hours. The 
mixture was diluted in DCM (8 ml) and the organic layer was separated from the aqueous. 
The aqueous phase was extracted with DCM (2x20 ml). The combined organic layers were 
dried over Na2SO4, filtrated and concentrated under reduced pressure. The crude was 
stirred in EtOH/H2O 9:1 for 1h, the resulting precipitate was filtrated under vacuum to give 
1,14 g of 254 as a white powder. 
T.L.C. System: n-Hex/EtOAc 8:2 v/v, Rf: 0.66 
Yield: 1.4 g (55%) 
Purity: >95% 
UPLC-MS method C: Rt: 2.168, MS (ESI)+: 291.1[M+1]+, 313.1[M+Na]+, 
1H NMR (CDCl3-d), δ: 11.60 (s, 1H), 2.40 (s, 3H), 1.53 (s, 9H), 1.51 (s, 9H). 
13C NMR (CDCl3-d), δ: 171.46 (C=N), 160.77, 150.78 (C=O), 83.24, 80.97 (C), 28.04, 14.41 
(CH3). 
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N',N''-Bis(tert-butoxycarbonyl)-(1-(3-phenyl-3-(4-(trifluoromethyl)phenoxy)propyl)) 
guanidine (255) 
(C27H34F3N3O5; M.W.: 537.58) 
 
 
A solution of N, N’-bis(tert-butoxycarbonyl)-S-methylisothiourea 254 (0.28 mmol) in DCM 
(0.5 M) was added dropwise to a solution of 3-phenyl-3-(4-(trifluoromethyl) phenoxy) 
propan-1-amine 251 (0.31 mmol) and DIPEA (0.34 mmol) in DCM (0.5 M) at 0ºC. The 
reaction mixture was stirred at room temperature overnight. A stream of nitrogen gas was 
bubbled through the reaction mixture for 1 hour to purge the gaseous by-product CH3SH. 
The residue was purified by flash column chromatography (Biotage Isolera One system, 
Cartridge: SNAP KP-Sil 10g, n-Hexane-EtOAc 100:0 v/v increasing to 80:20 v/v in 15 CV) 
to afford N, N’-bis(tert-butoxycarbonyl)-N’’-3-phenyl-3-(4-(trifluoromethyl) 
phenoxy)propylguanidine 255 as a white solid. 
T.L.C. System: n-Hex/EtOAc 8:2 v/v, Rf: 0.74 
Yield: 134 mg (81%) 
Purity: >95% 
UPLC-MS method C: Rt: 2.43, MS (ESI)+: 538.2[M+1]+, 560.2[M+Na]+ 
1H NMR (DMSO-d6), δ: 11.46 (s, 1H), 8.49 (t, J = 5.4 Hz, 1H), 7.55 (d, J = 8.7 Hz, 2H), 
7.41 (d, J = 7.2 Hz, 2H), 7.35 (t, J = 7.6 Hz, 2H), 7.27 (t, J = 7.2 Hz, 1H), 7.08 (d, J = 8.7 
Hz, 2H), 5.58 (dd, J = 8.0, 4.3 Hz, 1H), 3.52 – 3.43 (m, 2H), 2.25 – 2.15 (m, 1H), 2.14 – 
2.05 (m, 1H), 1.48 (s, 9H), 1.37 (s, 9H). 
13C NMR (DMSO-d6), δ: 163.50 (C=N), 160.73 (C=O), 155.69 (C=O), 152.44, 140.96 (C, 
C-aromatic), 129.11, 128.25 (CH, C-aromatic), 127.16 (q, J = 3.6 Hz, CH, C-aromatic), 
126.49 (CH, C-aromatic), 121.60 (q, J = 31.9 Hz, C, C-aromatic), 116.64 (CH, C-
aromatic), 83.32, 78.52 (CH2), 78.33 (CH), 38.11, 37.34 (C), 28.42, 28.09 (CH3). 
19F NMR (DMSO-d6), δ: -59.91 (s, 3F).  
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1-(3-phenyl-3-(4-(trifluoromethyl)phenoxy)propyl)guanidine (252) 
(C17H18F3N3O; M.W.: 337.35) 
 
 
Tin(IV) chloride (0.86 mmol) was added to a solution of N',N''-Bis(tert-butoxycarbonyl)-(1-
(3-phenyl-3-(4-(trifluoromethyl) phenoxy)propyl))guanidine 255 (0.22 mmol) in anhydrous 
EtOAc (3 mL) at 0ºC under a N2 atmosphere . The reaction mixture was stirred at room 
temperature for three hours. The reaction mixture was diluted in EtOAc and washed with 
sat. NaHCO3 solution, dried over Na2SO4, filtrate and concentrated under reduced pressure. 
The resulting solid is dissolved in EtOAc and the resulting formed precipitate was filtrated 
under vacuum to give 1-(3-phenyl-3-(4-(trifluoromethyl)phenoxy)propyl)guanidine 252 as a 
white powder. 
Yield: 20 mg (28%) 
Purity: >95% 
UPLC-MS method C: Rt: 1.673, MS (ESI)+: 338.2[M+1]+ 
1H NMR (DMSO-d6), δ: 7.56 (d, J = 8.7 Hz, 2H), 7.42 (d, J = 7.5 Hz, 2H), 7.36 (t, J = 7.5 
Hz, 2H), 7.28 (t, J = 7.3 Hz, 1H), 7.07 (d, J = 8.6 Hz, 2H), 5.53 (dd, J = 8.3, 4.4 Hz, 1H), 
3.28 – 3.23 (m, 2H), 2.21 – 2.09 (m, 1H), 2.07 – 1.95 (m, 1H). 
13C NMR (DMSO-d6), δ: 160.85 (C=N), 160.02, 140.92 (C, C-aromatic), 129.18, 128.33 
(CH, C-aromatic), 127.30 (q, J = 3.7 Hz, CH, C-aromatic), 126.45 (CH, C-aromatic), 124.91 
(q, J = 271.1 Hz, CF3), 121.70 (q, J = 32.0 Hz, C, C-aromatic), 116.66 (CH, C-aromatic), 
77.31 (CH), 38.24, 37.55 (CH2). 
19F NMR (DMSO-d6), δ: -59.90 (s, 3F). 
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tert-butyl (2-hydroxy-2-phenylethyl)carbamate (258) 
(C13H19NO3; M.W.: 237.30) 
 
 
 
To a solution of 2-amino-1-phenylpropan-1-ol 257 (3.64 mmol) in anhydrous DCM (14 mL), 
di-tert-butyl dicarbonate (4 mmol) was added, the reaction mixture was stirred at room 
temperature overnight. The reaction mixture was then washed with 1M HCl solution (3x30 
ml), brine (3x30 ml), dried over Na2SO4, filtered and concentrated under reduce pressure.  
The residue was purified by flash column chromatography (Biotage Isolera One system, 
Cartridge: SNAP KP-Sil 25g, n-Hexane-EtOAc 100:0 v/v increasing to 60:40 v/v in 11 CV) 
to afford to give tert-butyl (2-hydroxy-2-phenylethyl)carbamate 258 as a white solid. 
T.L.C. System: n-Hex/EtOAc 8:2 v/v, Rf: 0.21 
Yield: 808 mg (93%) 
Purity: >95% 
UPLC-MS method C: Rt: 1.668, MS (ESI)+: 164.0[C9H10NO2•]+ 
1H NMR (DMSO-d6), δ: 7.35 – 7.29 (m, 4H), 7.27 – 7.21 (m, 1H), 6.71 (t, J = 5.5 Hz, 1H), 
5.34 (d, J = 4.5 Hz, 1H), 4.61 – 4.55 (m, 1H), 3.16 – 3.08 (m, 1H), 3.05 – 2.94 (m, 1H), 1.36 
(s, 9H). 
13C NMR (DMSO-d6), δ: 156.09 (C=O), 144.16 (C, C-aromatic), 128.41, 127.39, 126.50 
(CH, C-aromatic), 78.04 (C), 71.94 (CH), 48.63 (CH2), 28.71 (CH3). 
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tert-butyl (2-phenyl-2-(4-(trifluoromethyl)phenoxy)ethyl)carbamate (259) 
(C20H22F3NO3; M.W.: 381.40) 
 
To a solution of triphenylphosphine (1.9 mmol) in diethyl ether (3.8 mL) cooled at 0°C, 
diisopropyl azodicarboxylate (1.28 mmol) in diethyl ether (0.6 mL) was added. After twenty 
minutes 4-(trifluoromethyl)phenol 216 (1.52 mmol) in diethyl ether (2.5 mL) was added 
before adding the solution of tert-butyl (2-hydroxy-2-phenylethyl)carbamate 258 (1.27 
mmol) in diethyl ether (3.1 mL).The reaction was stirred overnight at room temperature. The 
reaction mixture was concentrated under reduced pressure and the residue was purified by 
flash column chromatography (Biotage Isolera One system, Cartridge: SNAP KP-Sil 10g, 
n-Hexane-DCM from100:0 v/v increasing to 0:100 v/v in 5 CV and DCM-MeOH from 100:0 
v/v increasing to 98:2 v/v in 8 CV) to afford tert-butyl (2-phenyl-2-(4-
(trifluoromethyl)phenoxy)ethyl)carbamate 259 as a colourless oil. 
T.L.C. System: n-Hex/EtOAc 8:2 v/v, Rf: 0.45 
Yield: 338 mg  
Purity: >95% 
1H NMR (DMSO-d6), δ: (major species) 7.57 (d, J = 8.6 Hz, 2H), 7.41 – 7.27 (m, 5H), 7.16 
(t, J = 5.4 Hz, 1H), 7.06 (d, J = 8.6 Hz, 2H), 5.43 (dd, J = 7.8, 4.4 Hz, 1H), 3.44 – 3.27 (m, 
2H), 1.35 (s, 9H); (minor species) 10.28 (s, 1H), 7.53 (d, J = 8.6 Hz, 2H), 6.92 (d, J = 8.5 
Hz, 2H). 
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2-phenyl-2-(4-(trifluoromethyl)phenoxy)ethan-1-amine hydrochloride (260) 
(C15H14F3NO; M.W.: 281.28) 
 
 
 
A solution of tert-butyl methyl(2-phenyl-2-(4-(trifluoromethyl) phenoxy) ethyl) carbamate 
259 (0.89 mmol) in DCM (2.7 mL) was cooled to 0ºC and HCl (2M) in diethyl ether (3.57 
mmol) was added. The reaction was stirred overnight at room temperature. Formation of a 
precipitate was observed. The precipitate was filtrated under vacuum and washed with DCM 
to give 2-phenyl-2-(4-(trifluoromethyl) phenoxy) ethan-1-amine 259 as a white solid. 
T.L.C. System: DCM/MeOH 95:5 v/v, Rf: 0.36 
Yield: 132 mg (37% over 2 steps) 
Purity: >95% 
UPLC-MS method C: Rt: 1.7, MS (ESI)+: 282.0[M+1]+ 
1H NMR (DMSO-d6), δ: 8.51 (s, 3H), 7.61 (d, J = 8.7 Hz, 2H), 7.48 – 7.39 (m, 4H), 7.35 (t, 
J = 7.2 Hz, 1H), 7.10 (d, J = 8.6 Hz, 2H), 5.76 (dd, J = 9.0, 3.7 Hz, 1H), 3.32 – 3.21 (m, 2H). 
13C NMR (DMSO-d6), δ: 160.21, 137.23 (C, C-aromatic), 129.44, 129.23 (CH, C-aromatic), 
127.35 (q, J = 3.7 Hz, CH, C-aromatic), 126.82 (CH, C-aromatic), 124.84 (q, J = 271.3 Hz, 
CF3), 122.34 (q, J = 32.1 Hz, C, C-aromatic), 117.01 (CH, C-aromatic), 76.83 (CH), 44.94 
(CH2). 
19F NMR (DMSO-d6), δ: -59.99 (s, 3F). 
  
Part III: Enterovirus 
330 
N',N''-Bis(tert-butoxycarbonyl)-(1-(2-phenyl-2-(4-(trifluoromethyl)phenoxy)ethyl)) 
guanidine (261) 
(C26H32F3N3O5; M.W.: 523.55) 
 
 
A solution of N,N’-bis(tert-butoxycarbonyl)-S-methylisothiourea 254 (0.50 mmol) in 
anhydrous DCM (0.5 M) was added dropwise to a solution of 2-phenyl-2-(4-(trifluoromethyl) 
phenoxy)ethan-1-amine 260 (0.48 mmol) and DIPEA (0.86 mmol) in anhydrous DCM (0.5 
M) at 0ºC. The reaction mixture was stirred at room temperature overnight. A stream of 
nitrogen gas was bubbled through the reaction mixture for 1 hour to purge the gaseous by-
product CH3SH. The residue was purified by flash column chromatography (Biotage Isolera 
One system, Cartridge: SNAP KP-Sil 10g, hexane/ EtOAc 100:0 v/v increasing to 90:10 v/v 
in 16 CV) to afford N, N’-bis(tert-butoxycarbonyl)-N’’-2-phenyl-2-(4-(trifluoromethyl) 
phenoxy)ethylguanidine 261 as a white solid. 
T.L.C. System: n-Hex/EtOAc 8:2 v/v, Rf: 0.72 
Yield: 90 mg (46%) 
Purity: >95% 
UPLC-MS method C: Rt: 2.466, MS (ESI)+: 524.2[M+1]+ 
1H NMR (DMSO-d6), δ: 11.44 (s, 1H), 8.55 (t, J = 5.4 Hz, 1H), 7.59 (d, J = 8.7 Hz, 2H), 
7.45 (d, J = 7.2 Hz, 2H), 7.39 (t, J = 7.5 Hz, 2H), 7.32 (t, J = 7.3 Hz, 1H), 7.15 (d, J = 8.7 
Hz, 2H), 5.71 (dd, J = 7.0, 5.0 Hz, 1H), 3.84 – 3.73 (m, 2H), 1.45 (s, 9H), 1.41 (s, 9H). 
13C NMR (DMSO-d6), δ: 163.36 (C=N), 160.66, 155.98 (C=O), 152.51, 138.33 (C, C-
aromatic), 129.15, 128.82 (CH, C-aromatic), 127.40 (q, J = 3.7 Hz, CH, C-aromatic), 126.89 
(CH, C-aromatic), 124.86 (q, J = 271.1 Hz, CF3), 122.05 (q, J = 31.7 Hz, C, C-aromatic), 
116.73 (CH, C-aromatic), 83.67, 78.83 (C), 77.85 (CH), 46.50 (CH2), 28.42, 28.00 (CH3). 
19f NMR (DMSO-d6), δ: -60.00 (s, 3F). 
  
Part III: Enterovirus 
331 
1-(2-phenyl-2-(4-(trifluoromethyl)phenoxy)ethyl)guanidine (256) 
(C16H16F3N3O; M.W.: 323.32) 
 
 
Tin(IV) chloride (0.29 mmol) was added to a solution of N, N’-bis(tert-butoxycarbonyl)-N’’-
3-phenyl-3-(4-(trifluoromethyl) phenoxy)propylguanidine 261 (0.074 mmol) in anhydrous 
EtOAc (1 mL) at 0ºC under a N2 atmosphere . The reaction mixture was stirred at room 
temperature for three hours. The reaction mixture was diluted in EtOAc and washed with 
sat. NaHCO3 solution, dried over Na2SO4, filtrated and concentrated under reduced 
pressure. The resulting solid was dissolved in EtOAc and the resulting formed precipitate 
was filtrated under vacuum to give 1-(3-phenyl-3-(4-
(trifluoromethyl)phenoxy)propyl)guanidine 256 as a white powder. 
T.L.C. System: DCM/MeOH 99:1 v/v, Rf: 0.22 
Yield: 23 mg (95%) 
Purity: >95% 
UPLC-MS method C: Rt: 1.627, MS (ESI)+: 324.2[M+1]+ 
1H NMR (DMSO-d6), δ: 7.58 (d, J = 8.7 Hz, 2H), 7.47 (d, J = 7.3 Hz, 2H), 7.38 (t, J = 7.5 
Hz, 2H), 7.31 (t, J = 7.3 Hz, 1H), 7.08 (d, J = 8.7 Hz, 2H), 5.60 – 5.52 (m, 1H), 3.62 – 3.47 
(m, 2H). 
13C NMR (DMSO-d6), δ: 160.76 (C=N), 157.57 (s), 138.57 (C, C-aromatic), 129.08, 128.70 
(CH, C-aromatic), 127.34 (q, J = 3.5 Hz, CH, C-aromatic), 127.01 (CH, C-aromatic), 124.89 
(q, J = 269.3 Hz, CF3), 121.88 (q, J = 32.8 Hz, C, C-aromatic), 116.69 (CH, C-aromatic), 
78.76 (CH), 57.09 (CH2). 
19F NMR (DMSO-d6), δ: -59.91 (s, 3F). 
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12.6 Synthesis of N-(4-fluorobenzyl)-N-(4-methoxy 
phenyl)furan-2-carboxamide and related analogues 
General procedure 13: synthesis of N-benzylanilines 
 
 
 
4-fluorobenzaldheyde (4.03 mmol) was dissolved in MeOH/THF (4:1, 25 ml) and 4-Methoxy 
aniline (4.43 mmol) was added. The reaction mixture was stirred at room temperature for 6. 
The reaction mixture was cooled 0°C before adding NaBH4 (8.86 mmol). The reaction was 
allowed to warm-up to room temperature and stirred overnight. The reaction mixture was 
concentrated under reduced pressure. The resulting residue was suspended in water and 
extracted with DCM (3x20 ml). The combined organic layers were washed with brine (3x20 
ml), dried over Na2SO4, filtered and concentrated under reduced pressure to give N-(4-
fluorobenzyl)-4-methoxyaniline which, was used next without further purification.  
 
General procedure 14: synthesis of N-benzyl-N-phenylfuran-2-carboxamides 
 
 
 
 
N-(4-fluorobenzyl)-4-methoxyaniline (0.19 mmol) was dissolved in anhydrous DCM (0.2 M) 
and TEA (0.33 mmol) was added. The reaction was cooled to 0°C before adding furan-2-
carbonyl chloride (0.17 mmol).  The reaction was allowed to warm-up to room temperature 
and stirred for 2 hours. The reaction mixture was diluted in DCM (10mL) and washed with 
a sat. NaHCO3 solution (3x8 mL), brine (2 x 20mL), dried over Na2SO4, filtered and 
concentrated under reduced pressure. The crude residue was purified by flash column 
chromatography (Biotage Isolera One system) to give pure N-benzyl-N-phenylfuran-2-
carboxamides. 
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N-(4-fluorobenzyl)-4-methoxyaniline (263) 
(C14H14FNO; M.W.= 231.27) 
 
 
general procedure 13 
yellow oil 
T.L.C. System: n-Hex/EtOAc 8:2 v/v, Rf: 0.61 
Yield: 930 mg (99%) 
Purity: >95% 
UPLC-MS method C: Rt: 1.568, MS (ESI)+: 232.2[M+1]+ 
1H NMR (DMSO-d6), δ: 7.38 (d, J = 8.1 Hz, 2H), 7.13 (t, J = 8.8 Hz, 2H), 6.68 (d, J = 8.8 
Hz, 2H), 6.52 (d, J = 8.7 Hz, 2H), 5.81 (t, J = 6.0 Hz, 1H), 4.19 (d, J = 6.1 Hz, 2H), 3.61 (s, 
3H). 
13C NMR (DMSO-d6), δ: 162.46, 151.22, 143.17, 137.14 (C, C-aromatic), 129.50, 115.36 
(CH, C-aromatic), 115.01, 113.83 (CH, C-aromatic), 55.72 (CH3), 46.96 (CH2). 
19F NMR (DMSO-d6), δ: -116.69 (s, F). 
 
N-(4-(trifluoromethyl)benzyl)aniline (276) 
(C14H12F3N; M.W.= 251.25) 
 
general procedure 13 
yellow oil 
T.L.C. System: n-Hex/DCM 1:1 v/v, Rf: 0.59 
Yield: 300 mg (99%) 
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Purity: >95% 
UPLC-MS method C: Rt: 2.091, MS (ESI)+: 252.1[M+1]+ 
1H NMR (DMSO-d6), δ: 7.68 (d, J = 8.0 Hz, 2H), 7.59 – 7.54 (m, 2H), 7.04 (t, J = 7.7 Hz, 
2H), 6.58 – 6.49 (m, 3H), 6.36 (t, J = 5.5 Hz, 1H), 4.37 (d, J = 5.1 Hz, 2H). 
13C NMR (DMSO-d6), δ: 148.77, 146.04 (C, C-aromatic), 129.36, 128.20 (CH, C-aromatic), 
127.77 (q, J = 31.5 Hz, C, C-aromatic), 125.60 (q, J = 3.8 Hz, CH, C-aromatic), 124.86 (q, 
J = 271.9 Hz, CF3), 116.46, 112.75 (CH, C-aromatic), 46.39 (CH2). 
19F NMR (DMSO-d6), δ: -60.74 (s, 3F). 
 
N-benzyl-4-(trifluoromethyl)aniline (277) 
(C14H12F3N; M.W.= 251.25) 
 
 
general procedure 13 
white solid 
T.L.C. System: n-Hex/EtOAc 8:2 v/v, Rf: 0.59 
Purification: Purification: Flash column chromatography Isolera One system (Biotage), 
Cartridge: SNAP KP-Sil 10g (n-Hex-DCM 50:50 v/v in 6 CV). 
Yield: 102 mg (43%) 
Purity: >95% 
1H NMR (DMSO-d6), δ: 7.39 – 7.29 (m, 6H), 7.27 – 7.22 (m, 1H), 6.99 (t, J = 6.0 Hz, 1H), 
6.67 (d, J = 8.6 Hz, 2H), 4.33 (d, J = 6.0 Hz, 2H). 
13C NMR (DMSO-d6), δ: 152.07, 139.85 (C, C-aromatic), 128.86, 127.59, 127.28 (CH, C-
aromatic), 126.65 (q, J = 3.8 Hz, CH, C-aromatic), 112.06 (CH, C-aromatic), 46.33 (CH2). 
19F NMR (DMSO-d6), δ: -58.88 (s, 3F). 
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N-(4-fluorobenzyl)-N-(4-methoxyphenyl)furan-2-carboxamide (262) 
(C19H16FNO3; M.W.= 325.34) 
 
 
 
A mixture of furan-2-carboxylic acid 264 (0.24mmol), N-(4-fluorobenzyl)-4-methoxyaniline 
263 (0.29 mmol), TBTU (0.29mmol), and DIPEA (0.98 mmol) in anhydrous DMF (0.2 M) 
was stirred at room temperature overnight. The reaction mixture was diluted in EtOAc (10 
mL) and was washed with a HCl (1N) solution (3 x 8 ml), a sat. NaHCO3 solution (3 x 8 mL) 
and brine (3 x 8 mL). The organic layers were then dried over Na2SO4 and concentrated 
under reduced pressure. The crude residue was purified by flash column chromatography 
(Biotage Isolera One system, Cartridge: ZIP KP-Sil 5g, n-Hex - EtOAc 100:0 v/v increasing 
to 70:30 v/v in 24 CV) to give pure N-(4-fluorobenzyl)-N-(4-methoxyphenyl)furan-2-
carboxamide 262 as white solid. 
T.L.C. System: n-Hex/EtOAc 8:2  v/v, Rf: 0.2 
Yield: 58 mg (60%) 
Purity: >95% 
UPLC-MS method C: Rt: 1.92, MS (ESI)+: 326.2[M+1]+, 348.2[M+Na]+ 
1H NMR (DMSO-d6), δ: 7.71 – 7.67 (m, 1H), 7.27 (dd, 3J = 8.7 Hz, 4J = 5.6 Hz, 2H), 7.12 
(t, J = 8.9 Hz, 2H), 7.03 (d, J = 8.9 Hz, 2H), 6.91 (d, J = 8.9 Hz, 2H), 6.39 (dd, 3J = 3.5 Hz, 
4J = 1.7 Hz, 1H), 5.72 (s, J = 17.1 Hz, 1H), 4.93 (s, 2H), 3.74 (s, 3H). 
13C NMR (DMSO-d6), δ: 162.80 (C=O), 159.04, 158.99 (C, C-aromatic), 146.97 (CH, C-
aromatic), 145.64, 134.91, 133.93 (C, C-aromatic), 130.80, 129.85, 116.63, 115.59, 
115.02, 111.78 (CH, C-aromatic), 55.75 (CH3), 52.83 (CH2). 
19F NMR (DMSO-d6), δ: -115.39 (s, F). 
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N-phenyl-N-(4-(trifluoromethyl)benzyl)furan-2-carboxamide (270) 
(C19H14F3NO2; M.W.= 345.32) 
 
 
 
general procedure 14 
pale yellow solid 
T.L.C. System: n-Hex/EtOAc 8:2 v/v, Rf: 0.32 
Purification: Purification: Flash column chromatography Isolera One system (Biotage), 
Cartridge: SNAP KP-Sil 10g (n-Hex -EtOAc 100:0 v/v increasing to 70:30 v/v in 18 CV). 
Yield: 70 mg (88%) 
Purity: >95% 
UPLC-MS method C: Rt: 2.031, MS (ESI)+: 346.2[M+1]+ 
1H NMR (DMSO-d6), δ: 7.72 – 7.64 (m, 3H), 7.50 (d, J = 8.0 Hz, 2H), 7.41 – 7.30 (m, 3H), 
7.20 (d, J = 7.0 Hz, 2H), 6.40 (dd, 3J = 3.5 Hz, 4J = 1.7 Hz, 1H), 5.89 (d, J = 3.3 Hz, 1H), 
5.11 (s, 2H). 
13C NMR (DMSO-d6), δ: 159.13 (C=O), 146.87, 142.53 (C, C-aromatic), 129.97, 129.17, 
128.37, 128.35 (CH, C-aromatic), 125.75 (q, J = 3.7 Hz, CH, C-aromatic), 117.01, 111.83 
(CH, C-aromatic), 53.18 (CH2). 
19F NMR (DMSO-d6), δ: -60.86 (s, 3F). 
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N-benzyl-N-(4-(trifluoromethyl)phenyl)furan-2-carboxamide (271) 
(C19H14F3NO2; M.W.= 345.32) 
 
 
general procedure 14 
yellow solid  
T.L.C. System: n-Hex/EtOAc 8:2 v/v, Rf: 0.33 
Purification: Purification: Flash column chromatography Isolera One system (Biotage), 
Cartridge: SNAP KP-Sil 10g (n-Hex - DCM 100:0 v/v increasing to 0:100 v/v in 18 CV). 
Yield: 80 mg (99%) 
Purity: >95% 
UPLC-MS method C: Rt: 2.059, MS (ESI)+: 346.2[M+1]+ 
1H NMR (DMSO-d6), δ: 7.70 (d, J = 8.4 Hz, 2H), 7.66 (dd, J = 1.7, 0.8 Hz, 1H), 7.38 (d, J 
= 8.2 Hz, 2H), 7.33 – 7.20 (m, 5H), 6.47 (dd, 3J = 3.5 Hz, 4J = 1.7 Hz, 1H), 6.35 (dd, 3J = 3.5 
Hz, 4J = 0.7 Hz, 1H), 5.10 (s, 2H). 
13C NMR (DMSO-d6), δ: 159.17 (C=O), 147.03, 146.47 (C, C-aromatic), 145.94 (CH, C-
aromatic), 137.31 (C, C-aromatic), 128.94, 128.58, 128.34 (CH, C-aromatic), 127.82 (q, J 
= 32.1 Hz, C, C-aromatic), 127.80 (CH, C-aromatic), 126.78 (q, J = 3.7 Hz, CH, C-aromatic), 
124.42 (q, J = 272.2 Hz, CF3), 117.52, 112.05 (CH, C-aromatic), 53.15 (CH2). 
19F NMR (DMSO-d6), δ: -60.81 (s, 3F). 
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12.6.1 Synthesis of N-benzyl-2-(methylamino)-N-phenyl acetamides 
General procedure 15: synthesis of N-benzyl-2-chloro-N-phenylacetamides 
 
 
 
2-bromoacetyl chloride (0.31 mmol) was added drop-wise to a solution of N-(4-
fluorobenzyl)-4-methoxyaniline (0.37 mmol) and TEA (0.62 mmol) in anhydrous DCM (0.2 
M) at 0°C. The resulting mixture was stirred at room temperature for 3 hours. The reaction 
mixture was diluted in DCM (10mL) and washed with a 1M HCl solution (3x8 mL), brine (2 
x 15mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The crude 
residue was purified by flash column chromatography (Biotage Isolera One system) to give 
pure N-benzyl-2-chloro-N-phenylacetamide. 
 
General procedure 16: synthesis of N-benzyl-2-(methylamino)-N-phenylacetamides 
 
 
 
 
N-benzyl-2-chloro-N-phenylacetamide (mmol) was dissolved in absolute EtOH and 
methylamine in EtOH (mmol) was added. The reaction mixture was stirred at room 
temperature overnight. The solvent was evaporated under reduced pressure and the 
resulting residue was purified by flash column chromatography (Biotage Isolera One 
system) to give the desired N-benzyl-2-(methylamino)-N-phenylacetamide. 
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2-chloro-N-(4-fluorobenzyl)-N-(4-methoxyphenyl)acetamide (278) 
(C16H15ClFNO2; M.W.: 307.75) 
 
 
general procedure 15 
yellow oil 
T.L.C. System: DCM, Rf: 0.6 
Purification: Purification: Flash column chromatography Isolera One system (Biotage), 
Cartridge: SNAP KP-Sil 10g (DCM - MeOH 100:0 v/v increasing to 99:1 v/v in 8 CV). 
Yield: 47 mg (87%) 
Purity: >90% 
1H NMR (DMSO-d6), δ: 7.25 – 7.18 (m, 2H), 7.18 – 7.08 (m, 4H), 6.95 – 6.84 (m, 2H), 4.81 
(s, 2H), 4.04 (s, 2H), 3.74 (s, 3H). 
 
2-chloro-N-phenyl-N-(4-(trifluoromethyl)benzyl)acetamide (279) 
(C16H13ClF3NO; M.W.: 327.73) 
 
 
general procedure 15 
yellow/orange oil 
T.L.C. System: DCM, Rf: 0.59 
Purification: Purification: Flash column chromatography Isolera One system (Biotage), 
Cartridge: SNAP KP-Sil 25g (isocratic DCM in 5 CV). 
Yield: 77 mg (68%) 
Purity: >95% 
UPLC-MS method C: Rt: 2.037, MS (ESI)+: 328.2[M+1]+ 
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1H NMR (DMSO-d6), δ: 7.67 (d, J = 8.1 Hz, 2H), 7.49 – 7.39 (m, 4H), 7.35 (dd, 3J = 14.6 
Hz, 4J = 7.7 Hz, 1H), 7.31 (d, J = 7.3 Hz, 2H), 4.99 (s, 2H), 4.11 (s, 1H). 
13C NMR (DMSO-d6), δ: 172.05, 142.70 (C, C-aromatic), 130.10, 129.06, 128.38 (CH, C-
aromatic), 127.97 (q, J = 31.8 Hz, C, C-aromatic), 125.68 (q, J = 3.8 Hz, CH, C-aromatic), 
122.56 (q, J = 272.2 Hz, CF3), 60.62, 52.31 (CH2). 
19F NMR (DMSO-d6), δ: -60.86 (s, 3F). 
 
N-benzyl-2-chloro-N-(4-(trifluoromethyl)phenyl)acetamide(280) 
(C16H13ClF3NO; M.W.: 327.73) 
 
 
general procedure 15 
yellow oil 
T.L.C. System: DCM, Rf: 0.56 
Purification: Purification: Flash column chromatography Isolera One system (Biotage), 
Cartridge: SNAP KP-Sil 10g (n-Hex-DCM 100:0 v/v increasing to 0:100 v/v in 16 CV). 
Yield: 88 mg (76%) 
Purity: >95% 
1H NMR (DMSO-d6), δ: 7.78 (d, J = 8.3 Hz, 2H), 7.52 (d, J = 8.2 Hz, 2H), 7.34 – 7.16 (m, 
5H), 4.96 (s, 2H), 4.19 (s, 2H). 
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N-(4-fluorobenzyl)-N-(4-methoxyphenyl)-2-(methylamino)acetamide (267) 
(C17H19FN2O2; M.W.: 302.35) 
 
 
general procedure 16 
yellow oil 
T.L.C. System: DCM/MeOH 95:5 v/v, Rf: 0.22 
Purification: Purification: Flash column chromatography Isolera One system (Biotage), 
Cartridge: SNAP KP-Sil 10g (DCM - MeOH 100:0 v/v increasing to 95:5 v/v in 18 CV). 
Yield: 18 mg (66%) 
Purity: >95% 
UPLC-MS method C: Rt: 1.452, MS (ESI)+: 303.2[M+1]+ 
1H NMR (DMSO-d6), δ: 7.21 (dd, 3J = 8.5 Hz, 4J = 5.7 Hz, 2H), 7.11 (t, J = 8.9 Hz, 2H), 
7.05 (d, J = 8.9 Hz, 2H), 6.92 (d, J = 8.9 Hz, 2H), 4.81 (s, 2H), 3.74 (s, 3H), 3.03 (s, 2H), 
2.22 (s, 3H). 
13C NMR (DMSO-d6), δ: 170.70 (C=O), 162.75, 160.82, 159.04, 133.96 (C, C-aromatic), 
130.61, 129.76, 115.55, 115.16 (CH, C-aromatic), 55.75 (CH3), 52.51, 51.87 (CH2), 35.98 
(CH3). 
19F NMR (DMSO-d6), δ: -115.53 (s, F). 
 
2-(methylamino)-N-phenyl-N-(4-(trifluoromethyl)benzyl)acetamide (268) 
(C17H17F3N2O; M.W.: 322.33) 
 
 
general procedure 16 
yellow oil 
T.L.C. System: DCM/MeOH 95:5 v/v, Rf: 0.37 
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Purification: Purification: Flash column chromatography Isolera One system (Biotage), 
Cartridge: SNAP KP-Sil 10g (DCM - MeOH 100:0 v/v increasing to 95:5 v/v in 18 CV). 
Yield: 62 mg (64%) 
Purity: >95% 
UPLC-MS method C: Rt: 1.522, MS (ESI)+: 323.3[M+1]+ 
1H NMR (DMSO-d6), δ: 7.66 (d, J = 8.1 Hz, 2H), 7.41 (m, 4H), 7.37 – 7.31 (m, 1H), 7.24 
(d, J = 7.2 Hz, 2H), 4.98 (s, 2H), 3.08 (s, 2H), 2.22 (s, 3H). 
13C NMR (DMSO-d6), δ: 170.94 (C=O), 142.77, 141.45, 130.15 (C, C-aromatic), 129.05, 
128.55, 128.43 (CH, C-aromatic), 128.21 (q, J = 31.6 Hz, C, C-aromatic), 125.69 (q, J = 3.7 
Hz, CH, C-aromatic), 122.56 (q, J = 272.2 Hz, CF3), 52.69, 52.27 (CH2), 36.09 (CH3). 
19F NMR (DMSO-d6), δ: -115.53 (s, 3F). 
 
N-benzyl-2-(methylamino)-N-(4-(trifluoromethyl)phenyl)acetamide (269) 
(C17H17F3N2O; M.W.: 322.33) 
 
general procedure 16 
yellow oil 
T.L.C. System: DCM/MeOH 95:5 v/v, Rf: 0.37 
Purification: Purification: Flash column chromatography Isolera One system (Biotage), 
Cartridge: ZIP KP Sil 5g (DCM - MeOH 100:0 v/v increasing to 97:3 v/v in 11 CV). 
Yield: 52 mg (67%) 
Purity: >95% 
UPLC-MS method C: Rt: 1.565, MS (ESI)+: 323.3[M+1]+ 
1H NMR (DMSO-d6), δ: 7.75 (d, J = 8.4 Hz, 2H), 7.46 (d, J = 8.2 Hz, 2H), 7.34 – 7.16 (m, 
5H), 4.95 (s, 2H), 3.11 (s, 2H), 2.22 (s, 3H). 
13C NMR (DMSO-d6), δ: 176.62 (C=O), 167.48, 137.58 (C, C-aromatic), 128.91, 128.19, 
127.71, 126.99 (q, J = 4.5 Hz, CH, C-aromatic), 53.04, 52.29 (CH2), 36.24 (CH3). 
19F NMR (DMSO-d6), δ: -60.94 (s, 3F). 
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12.6.2 Synthesis of furamide analogues 
 
N-(4-fluorobenzyl)-N-(4-methoxyphenyl)acetamide (282) 
(C16H16FNO2; M.W.: 273.31) 
 
 
Acetyl chloride 286 (0.35 mmol) was added drop-wise to a solution, at 0°C, of N-(4-
fluorobenzyl)-4-methoxyaniline 263 (0.22 mmol), triethylamine (0.43 mmol) in anhydrous 
DCM (0.1 M) under nitrogen atmosphere. The reaction was allowed to warm-up to rt and 
was stirred overnight. The reaction mixture was concentrated at reduced pressure and the 
crude residue was purified by flash column chromatography (Biotage Isolera One system, 
Cartridge: ZIP KP Sil 5g, n-hex - EtOAc 100:0 v/v increasing to 60:40 v/v in 17 CV) to afford 
N-(4-fluorobenzyl)-N-(4-methoxyphenyl)acetamide 282 as a colorless oil. 
T.L.C. System: n-Hex/EtOAc 7:3 v/v, Rf: 0.26 
Yield: 49 mg (83%) 
Purity: >95% 
UPLC-MS method C: Rt: 1.813, MS (ESI)+: 274.1[M+1]+ 
1H NMR (DMSO-d6), δ: 7.20 (dd, 3J = 8.5 Hz, 4J = 5.7 Hz, 2H), 7.10 (t, J = 8.9 Hz, 2H), 
7.06 (d, J = 8.9 Hz, 2H), 6.91 (d, J = 8.9 Hz, 2H), 4.78 (s, 2H), 3.73 (s, 3H), 1.79 (s, 3H). 
13C NMR (DMSO-d6), δ: 170.07, 162.69, 158.73, 135.65, 134.47 (C, C-aromatic), 130.51, 
129.61, 115.48, 115.00 (CH, C-aromatic), 55.71 (CH3), 51.50 (CH2), 22.77 (CH3). 
19F NMR (DMSO-d6), δ: -115.74 (s, F). 
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N-(4-fluorobenzyl)-N-(furan-2-ylmethyl)-4-methoxyaniline (283) 
(C19H18FNO2; M.W.: 311.36) 
 
 
N-(4-fluorobenzyl)-4-methoxyaniline 263 (3.59 mmol) was dissolved in MeOH/THF (4:1, 2 
ml) and furan-2-carbaldehyde 287 (0.33 mmol) was added. The reaction mixture was stirred 
at room temperature for 3 hours. The reaction mixture was cooled 0°C before adding 
Sodium triacetoxyborohydride (0.65 mmol). The reaction was allowed to warm-up to room 
temperature and stirred overnight. The reaction mixture was concentrated under reduced 
pressure. The resulting residue was suspended in water and extracted with DCM (3x20 ml). 
The combined organic layers were washed with brine (3x20 ml), dried over Na2SO4, filtered 
and concentrated under reduced pressure. the crude residue was purified by flash column 
chromatography (Biotage Isolera One system, Cartridge: ZIP KP Sil 5g, n-hex - EtOAc 
100:0 v/v increasing to 60:40 v/v in 17 CV) to afford N-(4-fluorobenzyl)-N-(furan-2-ylmethyl)-
4-methoxyaniline 283 as a yellow oil. 
T.L.C. System: n-Hex/EtOAc 9:1 v/v, Rf: 0.32 
Yield: 31 mg (30%) 
Purity: >95% 
UPLC-MS method C: Rt: 2.13, MS (ESI)+: 312.1[M+1]+ 
1H NMR (DMSO-d6), δ: 7.57 (dd, 3J = 1.8 Hz, 4J = 0.8 Hz, 1H), 7.29 – 7.23 (m, 2H), 7.11 
(ddd, 3J = 9.6, 5.9 Hz, 4J = 2.6 Hz, 2H), 6.74 (s, 4H), 6.37 (dd, 3J = 3.2 Hz, 4J = 1.8 Hz, 1H), 
6.25 (dd, 3J = 3.2 Hz, 4J = 0.7 Hz, 1H), 4.49 (s, 2H), 4.47 (s, 2H), 3.63 (s, 3H). 
13C NMR (DMSO-d6), δ: 162.49, 152.92, 151.95, 142.79 (C, C-aromatic), 142.69 (CH, C-
aromatic), 135.77 (C, C-aromatic), 129.23, 115.64, 115.51, 114.84, 110.79, 108.26 (CH, C-
aromatic), 55.65 (CH3), 54.32, 48.69 (CH2). 
19F NMR (DMSO-d6), δ: -116.47 (s, F). 
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N-(4-fluorobenzyl)-N-(4-methoxyphenyl)furan-2-sulfonamide (284) 
(C18H16FNO4S; M.W.: 361.39) 
 
 
furan-2-sulfonyl chloride 288 (0.49 mmol) was added drop-wise to a solution, at 0°C, of N-
(4-fluorobenzyl)-4-methoxyaniline 263 (0.43 mmol), triethylamine (0.87 mmol) in anhydrous 
DCM (0.1 M) under nitrogen atmosphere. The reaction was allowed to warm-up to rt and 
was stirred overnight. The reaction mixture was diluted with DCM and extracted with 1N 
HCl solution (3x10ml). The organic layer was washed with brine (3 x 10 mL), dried over 
MgSO4 and evaporated at reduced pressure. The crude residue was purified by flash 
column chromatography (Biotage Isolera One system, Cartridge: SNAP KP-Sil 10g, n-Hex 
- EtOAc 100:0 v/v increasing to 70:30 v/v in 18 CV) to N-(4-fluorobenzyl)-N-(4-
methoxyphenyl)furan-2-sulfonamide 284 as a white powder. 
T.L.C. System: n-Hex/EtOAc 8:2v/v, Rf: 0.3 
Yield: 153 mg (99%) 
Purity: >95% 
UPLC-MS method C: Rt: 1.981, MS (ESI)+: 362.3[M+1]+ 
1H NMR (DMSO-d6), δ: 8.09 (dd, 3J = 1.8 Hz, 4J = 0.9 Hz, 1H), 7.29 – 7.24 (m, 2H), 7.15 – 
7.08 (m, 3H), 6.97 – 6.93 (m, 2H), 6.85 – 6.81 (m, 2H), 6.75 (dd, 3J = 3.5 Hz, 4J = 1.8 Hz, 
1H), 4.81 (s, 2H), 3.70 (s, 3H). 
13C NMR (DMSO-d6), δ: 162.96, 161.02, 159.19 (C, C-aromatic), 148.29 (CH, C-aromatic), 
147.41, 132.81, 130.86 (C, C-aromatic), 130.71, 130.51, 118.10, 115.67, 114.68, 112.20 
(CH, C-aromatic), 55.70 (CH3), 54.25 (CH2). 
19F NMR (DMSO-d6), δ: -114.88 (s, F). 
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N-(4-fluorobenzyl)-N-(4-methoxyphenyl)-1H-pyrrole-2-carboxamide (285) 
(C19H17FN2O2; M.W.: 324.36) 
 
 
1H-pyrrole-2-carboxylic acid 289 (0.43 mmol) in Thionyl chloride (0.5 ml) was refluxed for 2 
hours. SOCl2 was eliminated from the reaction mixture under reduced pressure. The 
resulting residue was dissolved in anhydrous DCM (2 ml) and added drop-wise to a solution, 
at 0°C, of N-(4-fluorobenzyl)-4-methoxyaniline 263 (0.43 mmol), triethylamine (0.43 mmol) 
in anhydrous DCM (4 ml) under nitrogen atmosphere. The reaction was allowed to warm-
up to room temperature and was stirred overnight. The reaction mixture was diluted with 
DCM and extracted with 1N HCl solution (3x10ml). The organic layer was washed with brine 
(3 x 10 mL), dried over Na2SO4, filtered and evaporated at reduced pressure. The obtained 
crude residue was purified by flash column chromatography (Biotage Isolera One system, 
Cartridge: SNAP KP-Sil 10g, n-Hex - EtOAc 100:0 v/v increasing to 70:30 v/v in 19 CV) to 
afford N-(4-fluorobenzyl)-N-(4-methoxyphenyl)-1H-pyrrole-2-carboxamide 285 as a white 
solid. 
T.L.C. System: n-Hex/EtOAc 8:2 v/v, Rf: 0.3 
Yield: 89 mg (63%) 
Purity: >95% 
UPLC-MS method C: Rt: 1.924, MS (ESI)+: 325.2[M+1]+ 
1H NMR (DMSO-d6), δ: 11.53 (s, 1H), 7.28 (dd, 3J = 8.7 Hz, 4J = 5.6 Hz, 2H), 7.12 (t, J = 
8.9 Hz, 2H), 7.02 (d, J = 9.0 Hz, 2H), 6.93 (d, J = 9.0 Hz, 2H), 6.80 (td, 3J = 2.8 Hz, 4J = 1.4 
Hz, 1H), 5.81 (dt, 3J = 3.8 Hz, 4J = 2.5 Hz, 1H), 4.92 (s, 2H), 4.80 (ddd, J = 3.7, 2.5, 1.4 Hz, 
1H), 3.76 (s, 3H). 
13C NMR (DMSO-d6), δ: 162.73, 161.42, 159.12, 135.65, 134.57 (C, C-aromatic), 130.73, 
130.43 (CH, C-aromatic), 124.97 (C, C-aromatic), 122.02, 115.51, 115.03, 113.76, 109.21 
(CH, C-aromatic), 55.76 (CH3), 52.91 (CH2). 
19F NMR (DMSO-d6), δ: -115.63 (s, F). 
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N-(4-fluorobenzyl)-N-(4-methoxyphenyl)picolinamide (286) 
(C20H17FN2O2; M.W.: 336.37) 
 
 
 
A mixture of picolinic acid 290 (0.18 mmol), N-(4-fluorobenzyl)-4-methoxyaniline 263 (0.22 
mmol), TBTU (0.22 mmol), and DIPEA (0.72 mmol) in anhydrous DMF (0.2 M) was stirred 
at room temperature overnight. The reaction mixture was diluted in EtOAc (20 mL) and was 
washed with sat. NaHCO3 solution (3 x 20 mL) and brine (3 x 20 mL). The organic layers 
were then dried over Na2SO4 and concentrated under reduced pressure. The crude residue 
was purified by flash column chromatography (Biotage Isolera One system, Cartridge: ZIP 
KP-Sil 5g, DCM - MeOH 100:0 v/v increasing to 99:1 v/v in 11 CV) to give pure N-(4-
fluorobenzyl)-N-(4-methoxyphenyl)picolinamide 286 as white solid. 
T.L.C. System: DCM/MeOH 98:2 v/v, Rf: 0.29 
Yield: 26 mg (37%) 
Purity: >95% 
UPLC-MS method C: Rt: 1.806, MS (ESI)+: 337.3[M+1]+, 359.3[M+Na+]+ 
1H NMR (DMSO-d6), δ: 8.32 (s, 1H), 7.71 (t, J = 6.9 Hz, 1H), 7.45 (d, J = 7.4 Hz, 1H), 7.33 
(dd, 3J = 8.4 Hz, 4J = 5.7 Hz, 2H), 7.23 (s, 1H), 7.15 (t, J = 8.5 Hz, 2H), 6.89 (d, J = 8.0 Hz, 
2H), 6.67 (d, J = 8.0 Hz, 2H), 5.03 (s, 2H), 3.61 (s, 3H). 
13C NMR (DMSO-d6), δ: 168.85, 162.79, 157.93, 155.00 (C, C-aromatic), 148.79, 136.92 
(CH, C-aromatic), 135.08, 133.96 (C, C-aromatic), 130.50, 129.48, 124.29, 123.50, 115.65, 
114.28 (CH, C-aromatic), 55.55 (CH3), 52.04 (CH2). 
19F NMR (DMSO-d6), δ: -115.44 (s, F). 
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12.7 MD simulations of the ATPase pocket  
Molecular Dynamics Simulations 
Chain A and chain F of the EV-A71 2C protein crystal structure (PDB ID:5GRB) were used 
to prepare the system for the MD simulations of the ATPase pocket. OPLS3 was used as a 
force field. The protein-ligand complex system was prepared, placing the protein-ligand 
complex in a cubic box (buffer 10Å) and the system was solvated with water molecules, 
using the TIP3P model as a solvent model. The negative charges on the protein were 
neutralized, adding Na+ atoms to the system. Magnesium chloride (10 mM) was added to 
the box to simulate physiological conditions.  
The protein-ligand complex system was then equilibrated for 112ps at 10 K in an NVT 
ensemble and then simulated for 48 ps at a constant pressure of 1 atm using the NPT 
ensemble. The equilibrated systems were then MD simulated for 500 ns at constant 
temperature (300 K) and pressure recording snapshots every 20 ps. The RMSD values of 
Cα atoms during the simulations were used as an indication of structural stability and 
simulation integrity (see figure 44 in the appendix). 
 
RMSD Clustering analysis 
An RMSD conformational clustering of the MD simulations was performed to obtain a 
reduced number of representative structures for the ATPase pocket of the 2C protein. For 
the clustering analysis of the MD simulations were considered only the last 200ns of each 
trajectory. The structure of the dimer of 2C protein was extracted every 20 ps. The resulting 
10000 trajectory structures for each simulation were superimposed using all Cα atoms. The 
RMSD-clustering was performed on the subset of atoms of the binding pocket surrounding 
the ATP-γ-S (cutoff of 5Å). These atoms were clustered using the atom-positional RMSD of 
all atoms as the similarity criterion with the DBSCAN algorithm. Eight clusters were obtained 
considering all the frames with a neighbouring distance of 1Å (ε=1Å) with 30 as a minimum 
number of neighbouring frames. The cluster centroids were chosen as the representative 
structure of the ATPase pocket.   
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Appendix 
RMSD analysis of the MD simulations of the fluoxetine enantiomers in site A and site B: 
 
 
Figure 43: RMSD of the simulations 
 
RMSD analysis of the MD simulations of 2C dimer: 
 
 
Figure 44: RMSD of the simulations 
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Chapter 13: Conclusions 
  
Conclusions 
362 
During this project, different molecular modelling techniques were applied, to identify new 
potential antiviral compounds able to inhibit RSV and enterovirus replication.  
Two virtual screenings studies were performed on a reported druggable pocket of the RSV 
N protein, among the selected compounds, four hits were able to inhibit the RSV replication 
in the cell-based assay. Two of the four hits, the 2-phenylquinoline-4-carboxylic acid (1) and 
2-(2-(N-phenyl-N-mesyl)acetamido)benzoic acid (2), were further investigated. Both hits 
were synthesised, but the antiviral activity was confirmed only for compound 1.  
Several derivatives were synthesised to explore the importance of the different chemical 
features of the 2-phenylquinoline-4-carboxylic acid. Among the synthesised compounds, 
few compounds showed antiviral activity against both RSV strains in the range of 3-11 μM 
for RSV-A2 and in a range of 11-23 μM for RSV-B. For the second hit compound, the 
antiviral activity was not confirmed. Among the small number of analogues that were 
synthesised the methyl ester derivative of compound 2 showed a comparable antiviral 
activity on both RSV stains to compound 1.  
For the F protein of RSV, several chemoinformatic techniques were used to generate and 
evaluate a focussed virtual library of α-helix mimic compounds for the inhibition of the 
rearrangement of the F protein during the membrane fusion process. One compound was 
selected and synthesis through the development of a highly versatile synthetic route.  
The selected α-helix mimic compound was synthesised, together with a series of analogues. 
Among the synthesised compounds, only the selected compound showed a weak antiviral 
activity against both RSV stains. 
 
For the enterovirus project on the non-structural 2C protein, the already reported antiviral 
activity of the SSRI fluoxetine was further investigated. The enantiospecific antiviral activity 
of (S)-fluoxetine on CVB3 was discovered, and TSA and ITC assays confirmed the 
enantiospecific binding to the 2C protein. Starting from the information acquired on the (S)-
fluoxetine antiviral activity, molecular modelling techniques were used to elucidate the 
binding mode of fluoxetine on 2C protein. Two potential pockets near the 224AGSINA229 loop 
were explored with MD simulations, and the results obtained suggested that only site A was 
able to make a stable interaction with the S-enantiomer, but unfortunately, this was not 
confirmed by mutations study. Different fragments and analogues were synthesised and 
biologically evaluated to explore the chemical features of fluoxetine. 
Two novel guanidine analogues of fluoxetine, 1-(3-phenyl-3-(4-(trifluoromethyl) 
phenoxy)propyl)guanidine 252 and 1-(2-phenyl-2-(4-(trifluoromethyl)phenoxy)ethyl) 
guanidine 256, were designed and synthesised, starting from the information available on 
the antiviral activity of guanidine, and the stereospecific antiviral activity of fluoxetine. 
Conclusions 
363 
Both compounds were found to be active on CVB3 and to have the same trend of antiviral 
activity against other enteroviruses. Compound 252, which was synthesised as a racemic 
mixture, was found to be equipotent against CVB3 in comparison with the (S)-fluoxetine.  
The scaffold of the N-(4-fluorobenzyl)-N-(4-methoxyphenyl)furan-2-carboxamide 262, 
which was reported to inhibit the viral replication of CVB3 by targeting the non-structural 
protein 2C, was chosen to avoid the chiral centre on fluoxetine for further development. 
Different analogues of compound 262 were designed to introduce the relevant features of 
fluoxetine for the antiviral activity into compound 262 and to explore the importance of the 
furamide group for the antiviral activity.  
Interestingly, the replacement of the fluoro group on the benzylic ring of compound 262 by 
the trifluoromethyl group, was associated with pan-inhibitor antiviral activity, suggesting that 
the scaffold of 262 is suitable for the development of a pan-enterovirus inhibitor of the viral 
replication.  
In the last part of the enterovirus project, MD simulations were performed to address the 
flexibility related to the ATPase pocket, and an ensemble docking virtual screening was 
performed. Among the selected compounds, one hit was found activity against CVB3 and 
EV71. 
